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Abstract 
The discovery of antibacterial drugs has been among most significant achievements of mankind in saving 
millions of lives across the planet from infectious diseases. With rise in resistance to almost all existing 
chemotypes, the design of next generation novel antibiotics has become much more challenging and 
difficult. The early 21st century witnessed the advancement of multiple novel chemotypes during golden 
age of antibiotics however the pace of antibiotic drug discovery has slowed down tremendously, 
contributing to life threatening antimicrobial discovery void since 1980’s. Therefore the need to develop 
novel antibiotics with unique mechanism of action to leverage against multi drug resistance pathogens, is 
paramount. In this direction the Caseinolytic Protease P (ClpP) is an emerging drug discovery target with 
significant potential for treatment of recalcitrant biofilm forming infections from pathogens such as 
Methicillin-resistant Staphylococcus aureus (MRSA) This dissertation highlights the ongoing efforts to 
facilitate the discovery of novel non peptidic ClpP activator compounds and improvement of 
pharmacological profile of existing ClpP targeting Acyldepsipeptides (ADEPs) series antibiotics. The 
chapter one discusses the history and synopsis of conventional antibiotics drug discovery screening 
approaches, and transitions to modern era structure or fragment based screening approaches. The merits 
and challenges of such approaches of targeting a well conserved bacterial protease (ClpP) are discussed 
along with dissertation aims toward development of biophysical and biochemical screening approaches. 
Chapter two discusses optimization of thermal shift assay as primary screening assay for ClpP and its 
utility toward screening of fragment collections and buffer conditions. Chapter three discussed the 
development of a site specific Fluorescence Polarization based FP probe based on ADEP scaffold and its 
utility as a robust high throughput capable primary screening assay for screening of diverse collections 
ranging from bioactives to fragments. Chapter four discusses development of a label free Surface 
Plasmon Resonance (SPR) based assay geared toward screening of fragment as well as in house small 
and large (ADEP analogs) series compounds in addition to determining full kinetics for lead prioritization. 
Chapter five discusses the results of multiple screening campaigns utilizing combination of above assays 
to generate multiple hits with superior ligand efficiency and chemical tractability. Chapter six concludes 
with analysis of the best of compounds among individual series or from screening campaigns and 
highlights effectiveness of above screening assays toward hit exploration along with outlook on 
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 The discovery of antibacterial drugs has been among most significant 
achievements of mankind in saving millions of lives across the planet from infectious 
diseases. With rise in resistance to almost all existing chemotypes, the design of next 
generation novel antibiotics has become much more challenging and difficult. The early 
21st century witnessed the advancement of multiple novel chemotypes during golden age 
of antibiotics however the pace of antibiotic drug discovery has slowed down 
tremendously, contributing to life threatening antimicrobial discovery void since 1980’s. 
Therefore the need to develop novel antibiotics with unique mechanism of action to 
leverage against multi drug resistance pathogens, is paramount. In this direction the 
Caseinolytic Protease P (ClpP) is an emerging drug discovery target with significant 
potential for treatment of recalcitrant biofilm forming infections from pathogens such as 
Methicillin-resistant Staphylococcus aureus (MRSA) This dissertation highlights the 
ongoing efforts to facilitate the discovery of novel non peptidic ClpP activator 
compounds and improvement of pharmacological profile of existing ClpP targeting 
Acyldepsipeptides (ADEPs) series antibiotics. The chapter one discusses the history and 
synopsis of conventional antibiotics drug discovery screening approaches, and transitions 
to modern era structure or fragment based screening approaches. The merits and 
challenges of such approaches of targeting a well conserved bacterial protease (ClpP) are 
discussed along with dissertation aims toward development of biophysical and 
biochemical screening approaches. Chapter two discusses optimization of thermal shift 
assay as primary screening assay for ClpP and its utility toward screening of fragment 
collections and buffer conditions. Chapter three discussed the development of a site 
specific Fluorescence Polarization based FP probe based on ADEP scaffold and its utility 
as a robust high throughput capable primary screening assay for screening of diverse 
collections ranging from bioactives to fragments. Chapter four discusses development of 
a label free Surface Plasmon Resonance (SPR) based assay geared toward screening of 
fragment as well as in house small and large (ADEP analogs) series compounds in 
addition to determining full kinetics for lead prioritization. Chapter five discusses the 
results of multiple screening campaigns utilizing combination of above assays to generate 
multiple hits with superior ligand efficiency and chemical tractability. Chapter six 
concludes with analysis of the best of compounds among individual series or from 
screening campaigns and highlights effectiveness of above screening assays toward hit 
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CHAPTER 1.    ANTIBIOTIC DRUG DISCOVERY 
 
 
Introduction to Antibacterial Drug Discovery 
 
The term “Drug Discovery” is defined as a process of identification, optimization 
and application of novel chemotypes (chemical scaffolds) against a disease. The process 
of drug discovery focused on development of antibiotics is referred to as anti-bacterial 
drug discovery. Treatment of infections with antibacterial agents dates back to time 
period of over 2000 years ago during which mixture of plant extracts were used to treat 
wounds1,2. Throughout history of mankind, the treatment of infections with anti-infective 
compounds as a form of chemotherapy is credited with saving countless lives and 
lowering of rate of morbidity or mortality against rising infectious diseases3. The use of 
anti-infective agents such as tetracycline as a preventive measure against infections was 
prevalent in ancient civilizations as suggested by labeling of tetracycline residues in bone 
samples dating back to 350 A.D4,5. In the past, the use of anti-infective agents was often 
derived from serendipitous learnings about their life saving properties as evident by 
numerous anecdotal evidences such as use of anti-infective red soil in Jordan which 
contained Actinomycin6, use of plant extracts with antimalarial properties in Chinese 
traditional medicine practices7, and use of turmeric spice as a general antiseptic or 
antimicrobial product in eastern cultures8. 
 
 
Classification of Antibacterial Compounds and Their Mode of Action 
 
Based on their origin, synthetic (referred to as antimicrobials) or natural (referred 
to as antibiotics) compounds with potential to kill or disrupt the growth (and 
reproduction) of the bacteria, are broadly classified as antibacterial compounds. The 
antibacterial compounds effective against both gram positive and gram negative bacteria 
or with applicability to multiple species of bacteria are classified as broad spectrum (i.e. 
Ampicillin) whereas antibacterial compounds with activity against a particular bacterial 
species are classified as narrow spectrum (i.e. Vancomycin targeting cell wall 
biosynthesis in gram positives)9. Further based on their mechanism of action the 
antibacterial compounds could be classified into bactericidal or bacteriostatic10. The 
bactericidal drugs (such as ß-lactams or Fluoroquinolones) are the chemicals which kill 
the bacteria by interrupting a crucial enzymes or metabolic processes such as DNA/RNA 
replication, or cell wall synthesis. The bacteriostatic drugs (such as Tetracycline or 
Macrolides) reduce rate of metabolism or overall growth rate of the bacteria by disrupting 
processes crucial to survival fitness such as virulence factors, protein synthesis, or 
nutrient uptake. Certain antibiotics such as Rifampicin and Aminoglycosides 
(Streptomycin) are also known to exhibit conditional bactericidal activity11. The 
antibacterial compounds exert their activity by targeting a variety of intracellular as well 
as extracellular targets. Based on their mode of action, the antibacterial can be generally 






Cell Wall Synthesis Inhibitors 
 
The antibiotics such as ß-lactams inhibit either transpeptidases enzymes which 
carry out transport and cross link the structural subunits of cell wall (peptidoglycan 
monomers) across plasma membrane, or block transglycosidase enzymes which link the 
sugars via glycosidic bonds11,12. 
 
 
Cell Membrane Disruptors 
 
Certain non ribosomally translated peptides such as Polymixin-B alter the cell 
permeability by disrupting cytoplasmic membranes13. 
 
 
Protein Synthesis Inhibitors 
 
Antibiotics such as Macrolides, Aminoglycosides and Tetracycline bind to 30S 
subunit of ribosome and block binding of t-RNA whereas Erythromycin blocks peptide 
exit tunnel on 50S subunit essentially blocking synthesis of new proteins14,15,16. 
 
 
Nucleic Acid Replication Inhibitors 
 
Fluoroquinolones inhibit enzymes responsible (Topoisomerases, DNA Gyrases) 





Blocking of RNA polymerase or blocking of mRNA binding to DNA (e.g. 
Rifampicin) is another mechanism of action of antibiotics11. 
 
 
History of Antibiotics Drug Discovery 
 
In the late 16th century, pioneering work of Antony van Leeuwenhoek laid 
foundation to understanding the link between bacteria to occurrence of infections, 
however the relationship of bacteria to infections became clearly understood only in early 
19th century9. Since the discovery of Penicillin by Alexander Fleming in 1928, the 
application area of antibacterial has spread all over the world. The early 20th century 
discovery of Salvarsan to selectively cure then untreatable Syphilis disease by Paul 







Pre-antibiotic Era of Antibiotics Drug Discovery 
 
The history of drug discovery as a process to identify new antibacterial 
compounds however precedes the discovery of penicillin to 1906 in which Nobel laureate 
Paul Ehrlich formulated the process of antibacterial drug discovery now called “drug 
screening” with synthesis of hundreds of organo-arsenic compounds leading to discovery 
of Salvarsan. Paul Ehrlich hypothesized that by systemic screening approaches novel 
chemotypes aka “magic bullet” specifically targeting pathogenic bacteria, could be 
discovered19,20. The idea of magic bullet encompasses selective targeting of a pathogen 
while leaving the host unaffected, originated from observation of differential staining of 
certain microbes by aniline dyes3. Paul and Alfred Bertheim pioneered derivatization of 
Atoxyl, an arsphenamine generating hundreds of chemotypes and screened these 
compounds for their potential to sterilize cultures in infected animals. More than 600 
synthetic organo-arsenic analogs of Atoxyl drug were synthesized and compound 606 
(Salvarsan) was found to be most effective against highly prevalent and almost incurable 
venereal disease models (rabbit) of syphilis3. Indeed the “compound 606” or Salvarsan 
(Figure 1-1A) became the first modern chemotherapeutic agent21. Later, the Salvarsan 
along with its more soluble, less toxic derivative Neosalvarsan became most prescribed 
commercial (by Hoechst) drugs and were more efficacious (and safer) against syphilis 
disease than prevalent inorganic mercury salts which, had severe side effects. The 
pioneering work of Ehrich conceptualized the knowledge based chemotherapy and laid 
out the foundation of modern day antibacterial drug discovery by screening of 
compounds toward drug discovery of drugs against a target 20.Later serendipitous 
discovery of Penicillin by Alexander Fleming in 1928, lead to exponential growth of anti-
infective screening paradigm, marking onset of antibiotic era which has continued at 
varying paces till this date resulting in identification of hundreds of therapeutic agents to 
cure various infectious diseases. 
 
 
Golden Era of Antibacterial Drug Discovery 
 
Since advent of Salvarsan, the synthetic screening approach in early 20thcentury 
lead to discovery of broad spectrum drugs such as Prontosil22. First broad spectrum and 
commercially synthesized antibiotic “Prontosil“ (Figure 1-1B) was a sulfonamide class 
of prodrug which targeted gram positive Streptococcus pyogenes bacteria9,23.The active 
constituent of Pronosil was sulfanilamide whose derivatives were mass produced by 
various pharmaceutical companies. Discovery of penicillin lead to initiation of zone of 
inhibition based mass screening campaigns against pathogenic bacteria3. The realization 
that certain bacteria or fungi produced certain natural metabolites as their survival 
strategy which could be ultimately used to treat bacterial infections in humans resulted in 
discovery of streptomycin by screening soil dwelling actinomycytes for antibacterial 
metabolites24,25. The discovery of Salvarsan, Prontosil, streptomycin and Penicillin set the 
ground rules for modern day drug discovery lead to golden era of antibiotics during early 
1970’s during which number of novel antibiotics with unique mechanism of action were 







Figure 1-1. Chemical Structures of Compounds in Antibacterial Drug Discovery 
Field. 
A: Chemical structure of first modern chemotherapeutic agent. 
B: Chemical structure of first broad spectrum and commercially synthesized antibiotic. 
C: Chemical structure of ClpP targeting indolinone derivative Sclerotiamide. 
D-F: Chemical structure of enopeptin class compound Enopeptin B, ADEP1 and ADEP4  










screening based on inhibition of bacterial growth by natural products or secondary 
metabolites 26.The most important classes of antibiotic classes discovered during golden 
era period of 1940-1970 were Aminoglycosides, Tetracyclines, Macrolides, 
Glycopeptides, Quinolones and Carbapenems26,27. 
 
 
High Throughput Screening Era of Antibacterial Drug Discovery 
 
Following the time period of golden era, the medical chemistry era (1970-90’s) 
came with advancement of medicinal chemistry resources, and target oriented 
repurposing of existing antibiotics became mainstream. Many natural scaffolds were 
successfully improved as more potent drugs with superior efficacy. Since most of the 
initial naturally evolved scaffold were broad spectrum targeting either cell wall synthesis 
or DNA replication and acted on multiple targets ,the frequency of spontaneous 
resistance was lower24. The success of derivatization approach was however, limited as 
any gain in efficacy was shortly overcome by evolution of already existing resistance 
mechanism to a particular antibiotic class scaffold. The time period after 1970, was 
marked with decline in novel antibiotic discovery as despite advances in high throughput 
chemistry, the discovery of novel natural scaffold based zone of inhibition or inhibition 
of cell growth, became increasingly difficult. Following successful completion of 
genomic sequencing in mid-1990’s, several avenues of novel antibacterial target 
discovery opened up and using a target based approaches multiple high through screening 
campaigns using very large collections of semi synthetic compounds, were attempted by 
pharmaceutical companies12. The virulence targets or targets for which function was 
unknown were not included in the screens to reduce complexicity12.The performance of 
such screening campaigns which targeted broad spectrum yet essential bacterial targets 
has been rather disappointing with no new antibiotic class discovered following 7 years 
of high throughput screening12. 
 
 
Antibiotic Resistance and Its History 
 
The history of development of antibiotic resistance predates the cognitive 
discovery of antibiotics. In fact some of antibiotics mechanisms are inherently present in 
nature as a survival strategy among bacteria. The collective diversity of all set of 
resistance genes in microbes dwelling in diverse niches (microbial resistome) suggests 
evolutionary survival advantage of microbes against action of antibiotics28,29,30,31. Several 
phylogenetic studies have revealed natural occurrence of antibiotic resistance genes 
encoding ß-lactamases32 dating millions of years before first antibiotics was 
discovered32,33,34,35. In Year 1946 Alexander Fleming predicted inevitability of resistance 
as an evolutionary survival mechanism of bacteria9. In recent times many pathogens have 
become resistant to original antibiotics as well as their more efficacious synthetic analogs 
as seen in case of Enterobacteriae which have acquired resistance to both original 
penicillin and best in class carbapenems derivatives across different part of the 
world36,37.The rise in resistance is related to malpractices in frequency of usage of 




population of resistant bacteria eventually overgrows escaping effects of used 
antibiotic24. The origin of resistance could be genetic as well as in case of highly 
successful sulfa drugs (sulfonamides) where unique mobile plasmids conferred survival 
fitness to host38. The resistance could also arise from malpractices in food industry in 




Genetic Basis of Acquisition of Resistance 
 
The Bacteria can acquire resistance via multiple strategies including sequential 
accumulation of resistance genes from environment, via horizontal gene transfer from 
other species, spontaneous gene mutations, and up regulation of efflux pump genes 
9,41,42,43. Gene mutations occur randomly as errors in nucleic acid replication process or 
through environment or stress induced damage to bacterial gene repair machinery. At 
certain times the bacteria can transition into mutagenic forms with increased rate of 
mutation (hyper mutations) to evade the selective survival pressure from an antibiotic44. 
The Bacteria can acquire resistance by exchange of plasmids containing resistance genes 
via process of horizontal gene transfer process (conjugation, transformation or 
transduction)45. The process of Horizontal gene transfer is a major route of acquisition of 
resistance in multi-drug resistant pathogens46 and effects almost all of the prevalent 
antibiotic classes including Aminoglycosides and Fluoroquinolones47. 
 
 
Antibiotic Resistance Strategies 
 
The bacteria adopt multiple combination of strategies to acquire resistance to 
enhance its survival fitness and to ultimately evade antibiotics action. Some of the 
strategies are inherent and random as a natural evolutionary processes which are in place 
from millions of years9. Among key strategies are modification of target (i.e. target 
methylation); Target function modification; Target bypass; Target access restriction via 
change in permeability of outer and inner layer or thickening of cell wall; Antibiotics 
modification by phosphorylation, glycosylation, ribosylation, acylation, and 
nucleotidation; Enzyme mediated degradation of antibiotics; Efflux of antibiotics; Kin 




Antibacterial Drug Discovery Efforts in 20th Century 
 
The first generation approaches of antibacterial drug discovery based on natural 
products from fermentation broths or growth inhibiting secondary metabolites, during 
early 1950’s were successful and provided a platform for existence of most of the modern 
day antibiotics26,48,11. The concept of whole cell screening originated from discovery of 
penicillin, where size of zone of inhibition became the standard for selection of colonies 




Later this aspect was expanded to systematic screening (Waksman screening) of extracts 
from soil bacteria (actinomycytes) and fungi leading to discovery of streptomycin48. 
During the golden era period, the empirical whole cell based screening of natural 
products or semi synthetic collections gained popularity27. However rediscovery of 
already discovered scaffolds soon became a bottleneck in discovery of novel antibiotics 
due to increased risk of presence or emergence of resistance mechanism based on original 
compound49,26. Later with advent of high throughput parallel chemistry the focus shifted 
from natural products to fully synthetic libraries as potential sources of antibiotics or at 
least lead like compounds27,50. The underlying expectation was that resistance frequency 
would be lower for unique scaffold in comparison with naturally occurring products51,52. 
The output of whole cell based screening methods have been less than expected due to 
poor design of screening collections lacking conformity to rule of five guidelines, lack of 
bacterial cell wall penetration, identification of compounds with pharmacological 
liabilities such as poor ADME or higher incidences of nonspecific toxicity due higher 
hydrophobicity12,53,54,55. 
 
Following genome sequencing of H.influenzae, the second generation in silico 
and in vitro HTS based approaches became increasingly common identify new targets 
and chemotypes. However despite the ability of HTS to screen millions of compounds in 
a relatively short amount of time the outcomes were rather poor as seen in case of GSK 
which carried out almost a decade long screening campaign on multiple diverse 
antibacterial targets but no promising lead was discovered27. The main reasons for failure 
were attributed to lack of chemical diversity, chemical tractability and poor ADME 
properties in addition to modification of old antibiotics with preexisting resistance 
mechanisms12. Progress of hits with poor membrane permeability to lead candidates was 
hindered due to poor correlation of in vitro activity with whole cell56,11. The design of 
combinatorial libraries with focus on Lipinski’s rule of five (RO5) also contributed to 
failure as antibiotic do not follow RO5 strictly57. Out of millions of screened compounds, 
very few hits (<5-7) were advanced to lead stage and however due to nonspecific toxicity 
to mammalian cell lines, their development was also ceased12. 
 
From molecular size prospective, the ß-Lactams such as penicillin, carbapenems 
constitute the most effective class of antibiotics due to their small molecular size which 
offered chemical tractability. Another class of small sized antibiotics is Fluoroquinolone 
which were derivatized successfully on a commercial scale. The much larger tetracycline, 
macrolides, Aminoglycosides, and rifampin were comparatively less effective or less 
successful due to difficulties in derivatization of their synthetic analogs11. Further the 
derivatization of most natural products based antibiotics was very challenging with poor 
yields and limited scale up capabilities11. The lack of chemical diversity in screening 
collections and selection of targets with low resistance development frequency have been 
linked as rate limiting steps of antibacterial drug discovery26. The vast collections from 
high throughput screening era were biased toward size rather than diversity and favored 
oral bioavailability over membrane permeability i.e. with lead like characteristics obeying 
Lipinski’s rule of five guidelines. Further the intended targets of such collection were 
nonbacterial targets such as G-protein coupled receptors (GPCRs), kinases and ion 




fit for antibacterial drug discovery especially toward requirements of bacterial membrane 
penetration criteria. With development of resistance being inevitable or only point 
mutation (among other resistance mechanisms) away, the approach of identification of 
single bacterial targets with lower resistance potential did not prove to be very fruitful. In 
essence, finding antibacterial “hits” is easier than developing a novel class of antibiotics, 
an aspect realized by large pharmaceutical companies over decades of high throughput 
screening, leading to loss of investment contributing to expansion of existing discovery 
void26. Further in absence of tools for hit prioritization, the development of leads with 
poor pharmacological qualities became increasingly difficult with high rate of attrition 
leading to a discovery void for next three decades24. 
 
 





Development of antibacterial drugs has been one of most remarkable achievement 
of scientific endeavors of the mankind in 20th century and the efforts are still ongoing till 
date. Both challenges and difficulties in design of novel antibiotics have grown due to 
adaptation of multi drug resistance by pathogens. For every known class of antibiotic in 
clinical practice, a resistant strain of bacteria exists, making discovery of newer classes of 
antibiotics as significant as discovery of first antibiotic. Except for introduction of 
carbapenems in 1985,Only 4 newer class of antibiotics were discovered since 1960 as a 
result a discovery void also referred as an innovation gap, exists in the timeline of 
antibiotics development26,10,58. Most of the antibiotic on the markets are either the one 
discovered during golden era of antibiotics or repurposed antibiotics based on same 
parent scaffold. Most likely the resistance mechanism already exist for such antibiotics so 
it is matter of when rather than matter of if the resistance to current antibiotics would 
emerge. Fast forward to 21st century, rate of rise of multi drug resistance to existing 
antibiotics is exceeding the rate at which new antibiotics are being discovered. Thus it is 
important to direct the antibiotics discovery efforts toward discovery of newer classes of 
antibiotics rather than just improving the existing antibiotics while the latter remains an 
important initiative to tackle emerging challenges from pathogens. Thus reducing disease 
burden emanating from increase in nosocomial bacterial infections from multi drug 
resistance pathogens is an increasingly important concern which demands 
implementation of novel antibiotics development strategies. 
 
 
Lower Demand for Newer Antibiotics 
 
The modern practice of antibiotics prescriptions affects pace of discovery of 
newer antibiotics in a subtle way. While it is scientifically accurate to start with therapy 
of existing drugs as first line of defense and move to either combinatorial therapy or 
newer drugs only in case of serious infections, such practices de-incentivises the efforts 




Further shorter duration of antibiotic therapy also exacerbates the situation as results a lot 




Urgent Need for Anti-infective Agents 
 
Across the globe, the alarming trend of rise of bacterial pathogens with resistance 
to every known antibiotic calls for urgent therapeutic intervention59,60. The non-
standardized and often abuse of antibiotics across clinics globally, ineffective antibiotic 
treatment practices and surge in global migration are major contributors toward increased 
risk of infections60. The discovery of penicillin and streptomycin in early years of 20th 
century provided a big relief from infections from staphylococcus and mycobacterium 
tuberculosis respectively61,25. That interim relief has been fast disappeared with 
unprecedented increase in resistance to nearly all exist class of antibiotics and serious 
pathogens have become resistant to multiple drugs. In the 21st century, the development 
of resistance toward existing antibacterial therapeutics have made the possibility of life 
threatening infections real, as a result the arrival of post-antibiotic era of high mortality 
and morbidity, looms around the corner. Increase in the resistance frequency of 
pathogens to original as well as synthetically derived classes of antibiotics due to 
substandard practices of antibiotic use and abuse are fueling the advent of post antibiotic 
era62,63. It is projected that in the foreseeable post antibiotic era success of medical 
procedures will fall dramatically due to increased risk of untreatable secondary infections 
and mortality risk from community acquired infections would rise to levels comparable to 
pre antibiotic era11. 
 
Despite continues efforts to discover antibiotics, the nosocomial infection rates 
from multi-drug resistant strains such as MRSA, VRE and PRSP have increased 
exponentially in united states alone during past two decades64,65,66. This has led to 
tremendous increase in life threating dormant infections arising from gram positives 
especially from genus Staphylococcus and Enterococcus being more prevalent in clinics 
and hospitals among patients undergoing antibiotic therapies67. In particular methicillin 
resistant Staphylococcus aureus (MRSA) has evolved into extremely drug resistant 
variants by acquiring multidrug resistance via interspecies transfer of genes encoding 
resistance to ß-lactams, Aminoglycosides(Penicillin), Trimethoprim and front line 
Vancomycin antibiotics67,68.According to CDC 2013 report, there are estimated 11000 
death annually from MRSA injections and the economic cost of MRSA infections 
exceeds 2 billion dollars a year for USA alone69,70. Increased MRSA incidents are linked 
to spread of Vancomycin resistance Staphylococcus aureus The risk of secondary 
infections expands to patients with other health issues related to cancer, invasive surgery 
and organ transplants11. To combat the threat from such super pathogens development of 
alternative therapeutics strategies with clinically unforeseen and unexploited mechanism 






Discovery of New Antibiotics in 21st Century 
 
The 21st century community has recognized the urgency of the situation and has 
undertaken pledge to improve the situation with multiple initiatives such as introduction 
of 10 new antibiotics by 202073,74,75,76,77. In addition to lack of investment, and 
Improvement of politico-economic as well clinical practice policies, the significant 
challenges toward discovery of novel antibiotics are improvement of drug penetration 
across bacterial membranes especially in gram negatives, high rate of efflux, high rate of 
lead attrition and a host of resistance mechanisms78,56. The conventional rules of 
screening, library selection, hit identification and lead expansion does not apply directly 
to antibacterial drug discovery compared to drug discovery against cancer or other 
diseases. Consequently newer approaches of target identification and novel chemical 
scaffolds have been implemented51,12,78,56. Selection of leads which modulate multiple 
targets over a single target has been proposed to lower risk of quick resistance 
development26. The newer rules for target selection include assessment of target 
druggability, essentiality toward inhibition of bacterial growth, species wide conservation 
to account for broad spectrum activity, and selectivity against mammalian homologs to 
avoid host mechanistic toxicity11,26. A newer whole cell based parallel screening 
approach of using a genetically validated and essential target along with a genetically 
altered (via RNAi knockdown or attenuation of efflux pumps) hypersensitive strain or 
overproduction of same target in a strain which is resistant to effects of potential hits, 
may lead to identification of novel scaffolds11. 
 
Among the key approaches are target based approaches such as structure 
/fragment based drug discovery (SBDD and FBDD) , which are being utilized to extend 
effective sampling of chemical space along with development of highly sensitive 
screening (in silico and in vitro) methodologies27,79. The structure based screening 
approaches have high emphasis on molecular structure of the target, binding pose of the 
ligand and focuses on identification of energy efficient binders as starting point rather 
than potent binders80,79.Till date the SBDD or FBDD approaches have produced more 
anti-viral drugs compared to anti-bacterial counterparts , yet these approaches hold 
promise to push the antibacterial drug discovery to next level by focusing on design of 
screening collections as well as identification of critical interactions within active site of 
the bacterial targets. 
 
 
Process of Antibacterial Drug Discovery 
 
Similar to conventional drug discovery process, the antibacterial drug discovery is 
an iterative and intricate in nature with timelines that exceed 12-15 years at cost of 
millions of dollars to develop a hit in the initial stage to fully validated marketable drug. 
The process of drug discovery begins with identification of a disease relevant target and 
establishing its druggability. A drug target in a broad sense is a biological entity within a 
cell whose modulation by chemicals or drugs can have desired therapeutic effect. 
Proteins by function of their folding have binding pockets to which their substrate 




interactions with their targets (metabolome)81. The ligands (i.e. small molecules or 
fragments) share a complementary similarity to only certain binding pockets on the target 
molecules in terms of physiological properties and surface topologies. Thus only certain 
binding pockets can be perceived as druggable with high affinity interactions by 
compounds with certain physiochemical properties, which are key determinants of oral 
availability of a compounds as defined by Lipinski’s rule of five guidelines57,82,83. 
Various stage of de novo drug discovery of a druggable target are; Development/ 
validation of screening methodologies; Selection of screening strategy via HTS driven 
biochemical/biophysical or whole cell phenotypic assays; Screening of novel scaffolds 
from synthetic to natural products based compound collections; Identification of 
validated hits, procurement or synthesis of hits to expand structure activity relationships 
(SAR) to develop leads; Implementation of lead optimization strategy based on structure 
based information to improve potency, efficacy and pharmacological (ADME) aspects 
including safety; Evaluation of optimized leads efficacy on animal models for preclinical 
development and ultimately clinical testing of drug candidates on human subjects. 
 
 
Characteristics of a Good Antibacterial Target 
 
For purpose of antibiotic drug discovery the selection and suitability of the target 
is essential10.An ideal antibacterial target is a novel and an essential enzyme with 
nonexistent mechanism of resistance whose modulation has profound effect of ability of 
the bacteria to survive. Such target should belong to ribosomal protein classes or certain 
enzymatic classes such as transferases, ligase or hydrolases, and should not be a 
metabolic enzyme10. Targets involved in functions related to bacterial survival such as 
cell wall synthesis or transcription or translation or maintenance of virulence are 
examples of such targets. A good antibacterial target is highly druggable with binding 
pockets suitable for binding of small compounds. Such target is well conserved across 
bacterial species without close human homologs offering prospects for broad spectrum 
yet selective antibiotic discovery26. 
 
The conservation and essentiality of targets has been focus of various genetic 
approaches in post genome sequencing era11. The degree of structural and functional 
conservation of such target across multiple species of bacteria is the determining factor 
for narrow or broad spectrum activity of antibiotics. It is important to differentiate that 
different classes of antibiotics may inhibit a common cellular process however, at 
molecular level the target sites are different. For example translation inhibiting antibiotics 
(such as Macrolides or Aminoglycosides) inhibit the protein synthesis by acting on 
different binding pockets of a common target (ribosomes)11. The presence of homologs in 
human determines the selectivity of the antibiotics which is crucial factor toward success 
of antibiotics to reduce the risk of collateral damage to human host during antibiotic 
treatment11. However it is important to mention that prevalence, cellular location, 
structural or functional similarity at molecular level and ease of access to human 
homologs by a potential antibiotic are important aspects which support discovery of 
antibiotics against bacterial targets with possibility a human homolog. Successful 




possibility of targeting human homologs exists however subtle difference of structural 
hot spots at molecular level enables the safe application of such antibiotics11. 
 
 
Introduction to Fragment-Based Drug Discovery (FBDD) 
 
The discovery and development of a chemical entity into therapeutic drug is a 
route full of challenges to achieve desired pharmacological properties. The key 
challenges include achieving right balance of selectivity and potency, favorable oral 
bioavailability and non-toxicity, duration of therapeutic action and high therapeutic 
index84. Failure to meet above challenges often leads to higher rate of attrition during 
clinical development stages, ultimately resulting in a dead end. 
 
Due to high emphasis on quality of hits in terms of its potency which correlates 
with higher molecular mass or complexity, rather than physical and chemical properties, 
the attrition of leads derived from small molecules has always been the core issue with 
drug discovery efforts85. The attrition during various stages of lead optimization occurs 
during optimization of the physiochemical properties to improve potency of an already 
complex molecule. To resolve the attrition problem guidelines such as Lipinski’s rule of 
five (RO5) are issued to improve physiochemical properties of leads oral availability57,86. 
The concept of fragment based screening stems from identification of target specific 
chemical leads as a starting point with potential to attain physical properties of an orally 
bioavailable drug molecule87. The fragment based screening is based on notion of 
effective sampling of chemical space and focuses on binding efficiency relative to size of 
the fragment hits. The underlying principle of fragment based lead discovery is screening 
of low molecular weight molecules to enable identification of structural subunits (or 
fragments) of drug like molecules with potential for chemical tractability and 
optimization of physical properties. 
 
The key elements of fragment based lead discovery approach are library design, 
screening using sensitive biophysical methods, identification followed by orthogonal 
validation of hits and optimization of selected low molecular weight (MW < 200 Da) hits 
(fragments)as straining point chemical entities to lead molecules with desired 
pharmacological properties. The fragment based lead discovery often utilizes multiple 
screening cascades based on biophysical (NMR, SPR, TSA, X-ray crystallography, MS) 
and high concentration biochemical (FP, TR-FRET) approaches to identify the fragments 
with much weaker affinity. For hit to lead expansion phase, structural information (via 
crystallography) on key interactions or binding pose of ligand to target is critical along 
with sensitive affinity detection methods (such as SPR or NMR) to effectively guide hit 
prioritization and optimization strategies. The success of FBDD relies on designing of 
unique and diverse set of fragment collections with chemical tractability, strategic 







Concepts of FBDD Process 
 
The design of fragment library, screening regimen and medicinal chemistry 
optimization are three primary stages of FBDD. Based on literature comparing physical 
properties of marketed oral drugs, it is apparent that optimization process from hit to lead 
results in increase in molecular mass and lipophillicity82. Additionally increase in number 
of 4-5 heavy atoms increases molecular complexity significantly which tends to reduce 
the quality of physical interactions, thus increasing chances of attrition at later stages88. It 
is important to balance the increase in molecular complexity or lipophilicity to PK/PD 
properties required toward oral availability of lead compounds and bacterial entry 
(permeability) by using rule of three guidelines in the initial phase followed by rule of 
five guidelines during lead optimization phase89,90,57. A study comparing the physical 
properties of marked oral drugs indicated that orally administered drugs are smaller and 
less complex compared to drugs with alternative routes of administration82. Due to 
smaller size and of lower complexity the fragments offer better chances of optimization 
of initial hits toward lead development while obeying above rules. Counterintuitively 
higher number and complexity does not lead to higher chances of hit identification and 
lead progression91. Often the probability of identification of a novel hit with unique 
binding mode is contingent upon sensitivity of the screening method to measure the 
affinity accurately and followed up by identification of binding mode by X-ray 
crystallography. As complexity increases the chances of identification and identification 
of binding mode also goes up. However, the quality of interaction decreases due to higher 
likelihood of miss-matched interactions from inefficient H-bonding or increased 
probability of steric clash between functional groups and target protein (negative 
interactions)88. Thus if the starting hit is simple and less complex the probability of 
successful lead optimization is high with better chances of exploration of chemical space 
through chemical modifications while obeying the rule of five guidelines toward 
development of orally available leads. The affinity based optimization does not favor 
fragments due to much higher cutoffs, and often results in bottle neck at later stages due 
to deterioration of quality interactions per atom as the size of the compound increases. A 
better approach is through ligand efficiency which emphasizes on free energy 
contributions from individual atoms and correlates well with energy contributions from a 
key functional group within a molecule92. Often the key interactions from simple 
functional groups are retained as optimization proceed toward more complexity93. 
 
 
Concept of Chemical Space and Effective Sampling 
 
Chemical space is infinite vastness of chemical structures and their possible 
combinations which are theoretically feasible to exist. The accurate analogy of chemical 
space could be our current universe with countless stars as chemical structures. The cure 
to aliments lies somewhere within the chemical universe and identification of such 
compounds is pursued by screening of compounds, an approach pioneered by Paul 
Ehrlich with discovery of Salvarsan, a drug to treat syphilis disease21,20. Screening of 
compounds is just one aspect of drug discovery while identification and optimization of 




commonly achieved dimension. The fragment screening represents an optimal way to 
effectively sample the chemical space by screening a rather small but unique set of 
compounds of lower complexity and molecular weight. 
 
The discoverable chemical space is vast and it is estimated that total number of 
possible chemical combination for rule of five complaint compounds is between 1020 to 
10200 94,95. The number of drug like compounds with 11 heavy atoms or less is around 109 
compounds 96,97. However, screening of just 1000 fragments with less than 16 heavy 
atoms per compound is more effective way of sampling the chemical space than a million 
compounds with <36 heavy atoms per compound98. The number of compounds 
exponentially increases with increase in heavy atom count along with increase in 
molecular complexity (lower efficiency per atom) or molecular properties such as 
lipophilicity. This illustrates importance of inclusion of lipophilicity and filters to 
molecular weight cut off as without the cLogP and filters, the proportion of compounds 
with higher heavy atom count will represent majority of the collection. For Fragments 
RO3 filter is more suitable than lead like or RO5 filters as later filers allow a lot more 
compounds with complexity to be included. This aspect negatively impacts the equal 
representation of chemical diversity as more common scaffolds (with higher MW) will 
dominate the collection. The chemical space expands as function of number of atoms or 
molecular weight of the compound along with exponential increase in possible 
combination of atoms99. By restricting the molecular weight to certain limit i.e. 250-300 
Da as in case of fragments or scaffolds screening, a much larger proportion of possible 
chemical space for given number of atoms can be explored99. The resulting hit rate of 
compounds with lower complexity is higher than large complex compounds due to lower 
probability of miss-fit with target site which is further due to simplicity of molecular 
structure. Therefore, screening of fragment collections has greater chance to probe the 
fragment like chemical space compared to larger sized compounds collection in HTS 
campaigns which are geared toward probing of drug like chemical space100. 
 
From screening prospective, the sampling of chemical space is poor in HTS 
campaigns as even the combined sum of largest HTS collections with up to million 
compounds constitutes a infinitesimally small fraction of the chemical space of drug like 
molecules at around 1060 molecules95,97. Additionally, the probability of finding hits with 
right combination of ADME properties and potency decreases with increase in molecular 
size resulting in lower hit rates88. A highly lipophilic compound is likely to be rapidly 
metabolized and highly polar compound is unlikely to be absorbed in the gut and a 
compound with reactive functional groups is unlikely to be stable and efficacious due to 
breakdown once within the body. Therefore, it is important to map the chemical 
compounds within certain broad groups defined by presence of certain physiochemical 
properties101,102. The most of the chemical space appears to be sparsely distributed with 
compounds which are not therapeutically interesting. Therefore, it is advantageous to 
map the chemicals specific to broad target groups (i.e. kinases, proteases, phosphatases 
etc.) based on ADME properties and interactions defined by three dimensional 
topological features which determine molecular recognition pattern, within the binding 






Characteristics of Fragments 
 
The fragments can be assumed to be smaller structural sub epitopes like entities of 
a large complex drug like molecules with weak individual affinities due to partial 
interactions to the target binding pockets103,104. Due to small molecular size, the 
fragments have lower complexity and correspondingly form fewer and weaker 
interactions with the target as a result the lower binding affinities are typically in lower 
mM or higher µM range. In general a typical fragment have a chemical handle for later 
stage modifications ,molecular weight between 100-250 Da , and have 8-18 heavy (non-
hydrogen) atoms87,105. Fragments by virtue of their small size bind within sub pockets of 
primary binding pocket and offer the opportunities for expansion (fragment growing) or 
linking two adjacent fragments (fragment linking) via suitable chemical spacer to develop 
a lead like molecule. By strategic combination of such epitopes the overall affinity could 
be exponentially increased due to additivity of free energy of binding103. In contrast to 
fragments, a lead compound is the precursors of drug like molecules with near optimal 
physical or chemical properties along with mechanistic biological activity. The journey 
from initial fragment hit to lead compound is challenging and best accomplished with 
detailed knowledge on physiochemical properties of initial hit, key interactions with 
target acquired via sensitive biophysical and biochemical techniques. 
 
 
Targeted Libraries versus Fragment Collections 
 
Targeted libraries and fragment collections are two most common form of 
screening regimens for discovery of hits which could be later optimized to become leads 
compounds. The targeted libraries are different from fragment collections in the sense 
that its members represent scaffolds which are targeted to exhibit binding interactions to 
a given target with high probability of success. Often targeted collections are screened 
using biological assays at lower concentrations with main focus on binding affinity as hit 
selection criteria. The fragment collections on the other hand contain small and relatively 
simple molecules which could developed into lead compounds based on superior 
efficiency of binding per atom. Due to weak binding affinity, fragments are screened at 
high molar concentrations using sensitive biophysical methods and the hit selection 
criteria is based on ligand efficiency and chemical tractability instead of binding affinity. 
 
 
Fragment Collections versus Drug-Like Collections  
 
The most obvious difference in a fragment collection is that average molecular 
weight of representative chemicals is between 100-300 Da, compared to 300-700 Da for 
drug like collections. Further fragments screening requires utilization of sensitive 
biophysical detection methods compared to biochemical methods for high throughput 
(HTS) drug collection. The solubility of the fragments is yet another factor which is 
critically important at high mM screening concentrations compared to HTS where 




‘rule of three (RO3)’ have been developed specifically for fragment collections to help 
address solubility as well as other important physical or chemical properties such a 
lipophilicity and polar surface area89. According to rule of three guideline the fragments 
within a collection should have molecular weight (MW) <300 Da, number Hydrogen 
atom donors (NHD) ≤3, number Hydrogen atom acceptors (NHA) ≤3, cLogP ≤3, number 
rotatable bonds (NRB) ≤3 and polar surface area (PSA) ≤ 60 Å2, in order to increase the 
probability of survival during the hit to lead optimization trials. To this light the selection 
criteria of Lipinski’s rule of five have been developed which is more geared toward 
improving oral availability of lead compounds106. According to rule of five guidelines, 
the lead compounds should have MW ≤ 500 Da, cLogP ≤5, NHA ≤ 10, NHD ≤5. An 
additional purpose of such guidelines is to help differentiation of drug like compounds 
from non-drug like compounds based upon chemical properties. The rule of five 
guidelines are more applicable to compounds with high affinity and Congreve’s rule of 
three is more useful for fragments with low affinity89,107. The rules of five guidelines are 
geared toward achieving higher oral bioavailability with increased adsorption or 
permeation properties. For an orally bioavailable compound fulfilling Lipinski’s rule of 
five, LE of at least 0.3 is required to achieve the affinity of <10 nM100. 
 
 
Importance of Library Design 
 
A good fragment library contains fragments with molecular weight below 300 da 
with filters using rule of three guidelines107. The success of FBDD campaign is influence 
by number of important criteria in library design such as range of physiochemical 
properties; member count of collection; aqueous solubility; molecular diversity; chemical 
tractability; assessment of drug or lead likeliness; lack of reactive functional groups and 
effective sampling of chemical space. It is important to include fragments with suitable 
chemical handles to allow chemical derivatization108. This allows targeting of same 
fragment collection toward specific screening methods such as fluorine labeled (F19) 
NMR and brominated fragment collections for crystallography, apart from common 
fragment screening methods. The structural features of the fragments are also important 
in context of library design. The central idea is to keep certain structural features to 
balance specificity with promiscuity of fragments to a specific target. A study on 
successful fragment campaigns and known drugs reveals that depending on target certain 
structural features are of more common occurrence than others and such features should 
be used toward lead optimization109,110,88. For example the researches at Weith pharma 
choose those fragments as a core suitable for optimization, which contained at least one 
ring system and at least two distinct analogs in the collection106. 
 
Ideally prior to screening, the compound library should be curated according to 
applicable rules depending on type of screening collection. For example, the rule of three 
guidelines is more suitable for fragment collections whereas rule of five guidelines are 
more suitable for collections with slightly larger lead like compounds. The natural 
compounds collections tend to not follow either of above rules strictly and therefore 
should be curated cautiously otherwise a lot of good compounds might be left out or lot 




of the compounds should be included while designing the library. Only hits which have 
suitable chemical optimization handles for derivatization should be selected to avoid 
scale up issues. High solubility of collections is yet another major consideration 
especially for fragment collections which are often run at high molar concentrations. 
Another equally important aspect of library design is inclusion of filters to exclude 
compounds with reactive moieties such as nitro, thiol groups or the compounds with 
characteristic PAINS activity such as high fluorescence, redox potential and chemical 
aggregation profiles. It is important to remove the bad behaved fragments early in stage 
otherwise the risk of follow-up of hits with little tractability is considerably high. Often 
the order of screening is also important to improve chances of hit identification and later 
stage follow-up. A bottom up approach with screening of up to 10000 compounds should 
be accomplished using combination of biochemical and biophysical assays. The hits with 
at least 2-3 assays should be progressed into X-ray crystallography trials to determine 
target site occupancy and binding mode. Later stage optimization should be based on 
maintenance of LE while improving affinity and other relevant oral ADME properties. 
 
 
Implications of Lipophilicity and Molecular Weight of Lead Compounds 
 
The major cause of attrition of small drugs stems from sub-optimal physical 
properties of leads. One of the most important properties of small molecule drugs is oral 
availability. Lipinski laid out a general criteria (rule of five) of molecular mass <500 Da; 
cLogP(lipophilicity) <5; number of hydrogen bonds ≤5 with number of hydrogen bond 
donors and acceptors ≤10, for a drug to be orally available57. With certain exceptions 
most of the drugs with properties outside the rule of five exhibited poor oral availabil- 
ity 111. It was also observed that as compounds progress through clinical stages the 
molecular weight and lipophilicity decreased gradually, indicating the their implications 
toward ADME properties and increase in molecular weight or lipophilicity were major 
source of attrition98,112,113,114,82,111. Further, the polar compounds with lower lipophilicity 
were found to be less likely to cause toxicity, whereas compounds with higher cLogP 
values (more lipophilic) and lower total surface area were more likely to be more 
promiscuous and toxic115. Therefore it is important to lower molecular weight and 
lipophilicity within acceptable ranges. 
 
 
Ligand Efficiency Matrices 
 
 
Ligand Efficiency (LE) 
 
The ligand efficiency is measure of assessment of free energy contributions of 
each atom toward binding affinity116. The LE is the most simplistic and effective matrix 
in FBDD (compared to affinity) to monitor the optimization of low affinity hit into high 
affinity lead. The concept of ligand efficiency (LE, units (kcal mol-1)/heavy atom) is 
widely applied to FBDD as a guiding criteria for selection and ranking of fragment 




energy per atom118,117. The cutoff of LE is at 0.3 kcal per heavy atom and value of LE 
>0.3 suggests that optimized compound is likely to have higher affinity and vice versa. 
The low affinity fragments are more efficient in binding relative to their size compared to 
higher affinity HTS hits due to the fact that binding energy contributions per atom are 
inversely proportional to molecular weight106. 
 
The primary use of LE in FBDD is as a screening tool for identification of low 
affinity yet efficient fragments. FBDD can be an alternative approach to HTS especially 
for those targets where HTS struggles to generate reliable hits such as protein-protein 
interactions, or proteases. FBDD works best in presence of structural information to 
guide the optimization toward enhancing quality interactions while monitoring the 
progress using ligand efficiency matrices (i.e. LE). Fragments retain the key binding 
interactions in lead optimization process thus provide confidence in assessment of 
potency upon optimization. The LE and potency are influenced by multitude of factors 
including molecular complexity, H bonding, hydrophobic interactions, and energy of 
solvation/desolvation and overall free energy of binding100. At best the maximal 
achievable LE is function of binding site and not of entire fragment and LE could be used 
as measure of druggability of the target with target tractability dependent on 
identifications of hits with LE at minimal 0.3119. 
 
The outcome from a high throughput screening campaign is governed by 
screening strategy, reagent concentrations, stability and criteria for detection of false 
positives or negatives. Reliable detection of low affinity compounds and hit triaging from 
false positives or negatives is contingent on sensitivity of the detection method and hit 
selection criteria, as a result the low affinity binders are often missed. Instead many HTS 
screens tend to be biased toward compounds with observable potency which tracks 
linearly (up till 15 NHA) with higher molecular mass120. A potency driven lead 
optimization process is accompanied with inevitable further increase in molecular 
mass121,122. This upward trend is in sharp contrast with success rate of clinical candidates 
which exhibit high rate of attrition for candidates with higher molecular mass suggesting 
decrease in molecular mass is perhaps right strategy120,111,123. This is due to apparent 
increase in molecular complexity as a result of addition of functional groups to drive 
potency, upsets the balance of pharmacological properties, causing higher degree of 
attrition in lead candidates during clinical stages124. To improve the attrition rate, ligand 
efficiency (LE) is a superior parameter compared to potency. The LE concept normalizes 
the potency of the compounds against its molecular weight by suggesting change of 
potency on a log scale (10 fold) for the maximum change in free energy per non 
hydrogen atom (~-1.5kcalmol-1)120,116. Therefore, for two compounds with same 
potency, the efficiency of compound with lower number of non- hydrogen atoms (i.e. 
lower molecular mass) would be higher and such compound should be prioritized for leas 
selection. This aspect is supported by a study suggesting higher probability of binding for 
compounds with lower molecular mass (or complexity)88. 
 
For a fragment of MW 160-170 Da (HAC 12) , a minimum LE of 0.3 is required 
in order to be detected in high 2mM concentration screen using sensitive biophysical 




screened at lower concentration of 200uM and LE of >0.5 is required if screened at 20uM 
concentration. This suggests that at lower concentrations, fragments with LE at 0.3 will 
not be detected hence missed an opportunity for optimization of lead compounds with 
more desirable chemical properties. Additionally it is rare for fragments to have LE>0.3 
as it would require much higher quality interactions which are rarely seen and highly 
unlikely depending upon robustness of target. For protein-protein interaction targets the 
chances of higher quality of interactions on a relatively flat binding surface are not bright. 
For very simple fragments only X-ray crystallography can detect the binding when 
screened between 2-10 mM ranges. It could be concluded that for HTS or HCS 
campaigns the majority of detectable interactions will be from compounds of higher 
complexity which may not yield promising results given that lead optimization will lead 
to further increase in complexity with increase molecular mass. Also the relation between 
changes in LE to changes in heavy atom count is not linear. At a given potency, for larger 
molecules, the LE decreases slowly as their size increases and for LE increases faster as 
size of fragments decreases. In other words the sensitivity of LE toward small changes in 
potency of fragments is high and sensitivity of LE is low for changes in HAC count or 
potency in larger molecules. Thus for fragments the LE could be a selection as well 
ranking criteria to monitor success of fragment optimization. The strength of FBDD lies 
in screening of fragment collection with MW cutoff between 100-250 Da using sensitive 
biophysical screening approaches , with LE ≥0.3 as selection and ranking criteria. It 
could also be stated that for less tractable targets the FBDD is the best approach as HCS 
or HTS screening of compounds at lower concentrations may not yield fruitful results in 
long run. 
 
Increasingly the LE guidelines are also used in conjunction with tracking of 
lipophilicity and potency. The discovery of CDK inhibitor AT7519 is an example of 
fragment evolution based on utilization of X-ray crystallography as a screen to identify a 
~185 µM affinity fragment with LE of 0.57 which was evolved in to 3nM lead yet 
maintaining the LE at 0.45 and cLogP at 1.3. The discovery of ABT-263 inhibiting BCL-
Xl proteins by Abbott is example of optimization of fragments by linking two weak 
affinity fragments together with a spacer linker. The resulting lead had 0.5nM affinity 
and LE>0.2. The ABT-263 had very high MW at 970 Da and cLogP >5, appearing to be 
an exception to FBDD guidelines, yet this compound have moved into clinical trials. The 
case of ABT-263 was exceptional in the sense that FBDD in this case has enabled 
targeting of protein-protein interactions, an area considered highly challenging for HTS 
to target. It is important to use the LE as guiding criteria during lead optimization so to 
retain the optimal physical properties while improving potency while maintaining LE. 
This can be achieved with help of structural information to retain key binding interactions 




Ligand Lipophilicity Efficiency (LLE or LiPE) 
 
To assess the druggability, it is important to include impact of lipophilicity into 




high lipophilicity as most of their binding affinity is due to desolvation of ligand which is 
higher for lipophilic compounds. This aspect has implications in lipophilic compounds 
being more promiscuous or have nonspecific toxicity than polar compounds especially 
for drug targets lacking distinct binding pockets (proteases, phosphatases and protein-
protein interactions)113. Thus it is important to account for lipophilicity during lead 
optimization phase. The LLE is defined as pIC50 (or pKi)-cLogP (or LogD)
125. For a 
nanomolar lead the ideal LLE is 5-7 or greater. It is has been observed that initial 
fragment hits are often polar and more water soluble with lower cLogP values which is 
indicative of superiority of FBDD approaches with better chance to control cLogP values 
during lead optimization 
 
 
Advantages of FBDD 
 
The basic assumption of HTS is based on higher chances of finding leads by 
screening greater number of compounds per campaign, has not worked so well especially 
in antibacterial drug discovery given the high rate of lead attrition due to lack of optimal 
physiochemical properties126. The high degree of complexity of large molecular sized hits 
in a HTS campaign is the main reason for this weakness. Further the identification of 
potent initial hits require detection of biological activity at lower screening conditions 
which translates into screening of large molecular weight compounds. This practices 
often results in identification of potent hits with poor pharmacological properties and 
leaves little space for further affinity optimization without compromising the ADME 
properties126. The FBDD approach fills into this gap by screening of much smaller yet 
efficient fragments binders. The small size of fragments allows the critical working space 
for chemical modifications while maintaining the optimal physiochemical properties. The 
distinct advantages of FBDD over HTS are as below. 
 
First the FBDD has distinct advantage of effective screening of fewer (107 with 
less than 12 heavy atoms) yet unique scaffolds (diversity sampling) within chemical 
space of estimated 1063 compounds with <30 heavy atoms compared to millions of larger 
compounds in HTS campaign95 ,96. This is due to fact that molecular complexity increase 
exponentially with increase in molecular size yet the number of quality interactions does 
not increase because the possibility of molecular miss-match increases with higher 
complexity121. Therefore, a much smaller yet chemically diverse fragment collection of 
<17 heavy atom compounds can sample the chemical space more effectively on basis on 
quality of interactions due to simplicity in molecular structure106. 
 
Second important contrast is superior ligand efficiency of initial fragment hits 
compared to HTS hits due to higher proportion of atoms directly involved in interaction 
with target for small sized fragments resulting in higher ligand efficiency (LE) or binding 
energy per heavy atom87. The HTS hits are often more potent than fragment hits however 
the higher molecular complexity of HTS hits owing to their larger size reduces the ligand 
efficiency per atom compared to fragments, increasing the risk of attrition at later stages. 
Further, the maximal free energy contribution per heavy atom (~ -1.5 kcal mol-1) has 




and further increase is not significant beyond 15 heavy atom additions116. Thus fragments 
represents the best position to leverage upon binding energy contributions upon 
optimization compared to already complex larger sized compounds. 
 
Third compared to HTS, the FBDD offers greater chances of optimization with 
low molecular weight fragments as higher quality starting point due to higher energy 
contributions relative to their small size98. Often the physical or chemical properties of 
lead like molecules are much difficult to optimize compared to affinity which is largely 
driven by key physical interactions with target. At molecular level, binding of a small 
molecule to a much larger target results in loss of tumbling motion in solution due to loss 
of rigid body entropy of small molecules103,127. The magnitude of rigid body entropy is 
approximately three times the magnitude of binding energy (~15–20 kJ mol–1) and is 
independent of molecular weight128,129. This suggests that contributions of fragment part 
of the potent compound are of high significance even if fragments affinity is exponential 
lower than full sized lead compound as interactions from fragments are often retained 
during optimization process and form a key component of binding interactions. 
 
Fourth low molecular weight compounds offer superior chemical traceability for 
optimization while maintaining the ligand efficiency compared to higher molecular 
weight compounds from a typical HTS campaign122,114,111. The hits from HTS campaign 
are generally large and make surface contact at multiple points within the binding pockets 
of target. This aspect defines higher affinity of HTS hits over fragments which form 
fewer surface contacts comparatively, however the affinity of the HTS hit is often spread 
all over the structure of the hit and without structural information it is increasingly 
difficult to focus on one specific part of molecule to improve potency. Further addition of 
chemical groups upsets the balance of potency and solubility as size of molecule 
increases. One analysis of marketed drugs and their leads suggests that leads on the 
average have lower MW, lower lipophilicity (cLogP), fewer aromatic rings and fewer 
hydrogen donors121. Another analysis suggested that collections with MW 100-350 and 
cLogP value from 1 to 3 are superior to finding leads as compared to collections with 
more drug like compounds with higher lipophilicity121. This could be reasoned on basis 
of addition of MW of 80 Da and 1 log unit of cLogP during optimization phase of the 
lead from its original values82. If the original lead has physical properties close to oral 
drugs then its optimization will likely produce molecule with poorer physical properties. 
This observation suggests that fragments are better starting point for optimization 
compared to hits with large mw and complexity. 
 
 
Hit to Lead Optimization Strategies in FBDD 
 
The success rate in lead identification depends on quality of initial direct binding 
technique and quality of initial hits followed by discovery of binding mode of fragments 
via crystallography. This knowledge enables development of hypothesis on which 
evolution strategy of hit expansion is based. By effectively combining the knowledge 
from different binding assays and X-ray crystallography the affinity of fragments could 




fragment based screening approaches are geared toward binding efficiency and design in 
contrast to HTS approaches which are focused on affinity and number of leads. Therefore 
starting with low MW fragments which are entirely engaged with target due to their small 
size, represents a better chance of lead optimization with desired ADME properties. 
There are multiple strategies for expansion of fragment hits and underlying concepts 
stems from additivity of free energy of binding in protein ligand intreactions103 . The key 





The fragment evolution is the most commonly used and a direct approach of 
growing a fragment via addition of selected functional groups in generate key interactions 
within binding pocket based on structural information. The fragment evolution approach 
can yield leads with superior affinity based on identification of additional interactions as 
fragment hit is grown toward more complexity. Development of ß-Secretase (BACE-1) 





This strategy is less common compared to fragment evolution and contingent on 
precision linking, suitability of linker and its rigid body contributions toward super 
additivity toward increasing overall free energy of binding103. Fragment linking is useful 
in case of two fragments binding to close by but separate binding pockets. In such cases 
theoretically two fragments could be linked together via a tether. The success of this 
strategy relies on occurrence of super additively effect in which free energy of now joint 
molecule is equal or greater then free energy of individual fragments103. Thus two 
fragments with mM affinity can be joint via linker to form a molecule with µM affinity. 
However experimental studies have suggested that entropy loss from a rigid linker effect 
on additively needs to be minimal to limit the high magnitude barrier toward increase of 
binding affinity ,independent of molecular mass of the molecule127,128,98. Optimization of 
pico molar BcL-XL inhibitor (ABT-263) is an example of fragment linking approach of 





This approach focuses on optimization of drug like properties other than binding 
affinity. The fragments despite being small with molecular weight in range of 100-150 
Da and affinities from 100-1000 µM, are efficient binders for their size117. This 
observation is also supported by retention of identical binding pose of lead molecule to 
initial fragment hit indicating that fragments for their size form strong interactions with 
the target87. Discovery of serine protease factor Xa inhibitors is an example of utilization 








This technique employs use of reactive fragments which can be reacted 
chemically to each other in presence of binding template (protein)87. Such fragments 
often carry complementary groups which can react to each other while the enzyme 
backbone acts as catalytic driver leading to formation of lead molecule in the active site. 
The development of sulfonamide derivatives using in situ Click chemistry for carbonic 
anhydrase demonstrates potential of self-linking approach133. 
 
In addition to above approaches other less prevalent approaches of hit 
identification are based on using target binding pocket cysteine as bait catch fragments 
with a thiol group via formation of disulfide bond (fragment tethering) as seen in 
development of caspase-3 inhibitors134,87. In yet another example a known inhibitor of 
STAT3 is broken down (Fragment deconstruction) identify key functional groups to 
generate a new library of fragments which lead identification of another leads with 
superior pharmacological properties135,136. 
 
 
Challenges of FBDD 
 
The first challenge for FBDD operations is implementation of sensitive 
biophysical methods to detect weak interactions reliably. Due to small size of fragments 
the binding affinity is expectedly small and its determination requires multiple sensitive 
biophysical screening methods. Without sound structural and binding affinity 
information, the optimization of initial fragment hit to a high affinity lead is challenging. 
The estimated binding affinity of fragments is between 100 µM to 2mM, therefore 
technique such as NMR, SPR, MS and X-ray crystallography are required in combination 
to identify and optimize fragments hits. Often the fragments are screened at higher 
concentrations to detect a binding response therefore the aqueous solubility of fragments 
at screening concentrations is yet another challenge. Optimization of fragment hits to 
high affinity lead compounds is enormous challenge. The odds of successful hit to lead 
optimization favor fragments with high ligand efficiency and superior quality 
interactions. Therefore successful implementation of structural information 
(crystallography) in combination of sensitive biophysical techniques is required to gain 
knowledge on binding interactions and starting affinity. It is possible to achieve high 
affinity with 20-100 iterations of chemical synthesis provided the structural information 
is found and chemical optimization is directed at retaining ligand efficiency while 
improving affinity yet keeping the molecular weight and lipophilicity of the compounds 
within ranges as suggested by rule of five or three guidelines117,57. Secondly the 
selectivity of fragments against a particular target is not common and presents a potential 
issue toward identification of selective hits. The fragments due to their small size and 
simple molecular structure, bind to multiple targets or multiple fragments can bind to 
same target. The lower selectivity could be turned into advantage by clever chemical 







Challenges of Fragmen-Based Approaches to Discovery of Antibacterial Leads 
 
In context of fragment based anti-bacterial drug discovery, one of main challenges 
is generation of lead compounds with efficacy at clinical level. Second big challenge with 
design of antibacterial is with achieving sufficient selectivity and affinity due to presence 
of homologous proteins in many species including humans. The high resolution protein 
structures are definitely a guiding force for optimization of ligands to improve binding 
potency however the static nature of crystallography presents a gap in knowledge of 
highly dynamic behavior of protein and ligand binding. Focusing the design effort on a 
single target also faces issue of point mutations in target protein which could render the 
designed inhibitor useless. The design of drugs against gram negatives is particularly 
challenging due to issues related to penetration of thick outer layer and prevalence of 
multiple drug efflux pumps. Broad spectrum activity is yet another big challenge in 
which the lead antibiotic would need to inhibit activity of a specific target from multiple 
species of bacteria with different cell wall modifications. Given the spectra of challenges 
it is obvious that such antibacterial agent needs to be a selective, highly efficient binder 
with pharmacological profile in the desired range to balance hydrophobicity with cell 
wall penetration and oral bioavailability with clearance. In this light the fragments are 
promising class of compounds with tractable features like affinity, selectivity and 
ADME. The FBDD approach on antibacterial targets has met a few successes such as in 
case of design of inhibitors of bacterial RNA polymerase and biotin carboxylase137,138. 
However, identification of fragment as good starting points is quire challenging 
specifically in case the binding pocket of the target protein is a protein-protein interface 
with large surface topology. Fragments being small with limited affinity do not have 
initial whole cell antibacterial activity (MIC) to aid selection of good starting hits, 
therefore selection of hits has to be based on other parameters such as efficiency of 
binding or successful formation of crystals in soaking experiments with the target, which 
may or may not correlate to antibacterial activity at later stages. Another major challenge 
is poor penetration of fragments with suboptimal ADME properties. The road of success 
using fragments lies with successful expansion of fragment hits to lead compounds while 
balancing potency with hydrophobicity by careful addition of certain functional groups 
which resist efflux, along with optimal ADME properties to aid penetration139. 
 
 
Proteases as Drug Targets and Their Tractability 
 
Among the macromolecules, proteins are extensions of amino acids joined by 
peptide bonds, and are the fabric of life with multitude of diverse physiological functions. 
The regulation of protein’s structure, function and occurrence is controlled by very 
important class of enzyme called as proteases which cleave the peptide bonds 
(proteolysis) between amino acids with high degree of specificity and catalytic efficiency. 
Proteolysis in general is an important process meant to safeguard the protein folding, 
structural integrity, functionality and cellular homeostasis. The regulatory proteolysis is 




transcription and translation in which certain proteins are up or down regulated by 
proteases mediated degradation140,141,142,143. 
 
Proteases exhibit the protein degradation activity by hydrolysis of amide bonds 
via formation of acyl-enzyme intermediate (tetrahedral intermediate) and their 
degradative activity ranges from simplistic case of cleavage of peptide bond to 
consecutive activation and cleavage of number of substrates in a sequential (i.e. blood 
coagulation) or random fashion. The proteases constitute ~2% of all proteins expressed in 
a human genome144. Major classes of proteases are Serine proteases, Metalloproteases, 
Cysteine proteases, Threonine proteases, and Aspartic acid proteases145.The serine, 
cysteine and threonine proteases perform peptide bond hydrolysis by process of covalent 
catalysis in which tetrahedral intermediate form a covalent bond (hence covalent 
catalysis) within catalytic site with a basic amino acid serving as nucleophile. The 
aspartic and Metalloproteases hydrolyze the peptide bond by generation of reactive water 
molecules (Non covalent or acid base catalysis)146. Based on direction of cleavage of 
scissile peptide bonds on a protein, the proteases are Aminopeptidases (N terminal) or 
Carboxypeptidases (C terminal) and Endopeptidases (middle). 
 
With expansion of knowledge on the role of proteases, the relevance of proteases 
as a drug target has gained considerable traction in recent years. The proteases modulate 
a diverse set of metabolic functions from protein quality control by selective protein 
degradation, complex signaling cascades, and maintenance of homeostasis. The 
difference of normal physiological state to pathological conditions ranging from 
infectious diseases to cancer, hinges on fine balancing of levels of proteases activity. Key 
metabolic processes such as DNA replication, translocation, cell replication and 
physiological processes such as blood clotting, immune response are modulated by 
controlled protease activity. The proteases are enzymes with diverse regulatory functions 
and they interact with multiple binding partners with various degree of affinities which 
indicates multitude of binding pockets with deep as well shallow surface features. This 
aspects represents multiple target locations and higher likely hood of interactions with 
small molecules to produce a therapeutic effect. 
 
Among the protein class, proteases are large, multi-domain entities and most 
suitable for crystallography studies to generate high resolution structural information for 
rational drug design. This feature makes proteases highly tractable drug targets as 
observed from applications of crystallographic data to discovery of leads in a drug 
discovery program147,148,149. About 10% of all the targets pursued by pharmaceutical 
companies are proteases146,150. The discovery of angiotensin converting enzyme (ACE) 
inhibitors (Captopril), Factor Xa inhibitors and HIV protease inhibitors (Tipranavir, 
Ritonavir, Viracept , Kaletra) by pharmaceutical companies are classical examples of 
success stories indicative of druggability of proteases with therapeutic 
effect151,146,152,153,154. This aspect of proteases makes them interesting targets from drug 







Bacterial Proteases as Drug Targets 
 
The bacterial proteases have crucial regulatory roles to maintain vegetative 
growth of bacteria and derailment of quality control machinery in bacteria by targeting 
proteases is an interesting strategy toward eradication of pathogens. Further many 
proteases are indispensable to survival of bacteria during stress or maintenance of 
virulence factors in key gram positive pathogens155,156.The highly conserved nature of 
bacterial proteases is incremental toward development of small molecule modulators with 
broad spectrum activity. Further association of chaperons and multi domain nature of the 
proteases offers abundant druggable sites for targeting, both on the proteases as well as 
its chaperones, thus increasing chances of success in drug discovery efforts. Despite 
obvious applications in drug discovery, targeting of bacterial proteases has not been as 
popular as targeting of proteases of virus. At present no therapeutic drug based on 
bacterial proteases have reached clinical trials however bacterial proteases based drug 
discovery efforts are gaining traction150. Among yet to be explored strategies are 
combinatorial therapy, reduction of survival fitness, and limiting adherence or host 
colonization by targeting bacterial proteases. The inhibition of virulence effects the 
ability of bacteria to survive stress conditions (from antibiotics treatment or from low 
nutrient conditions) especially of drug resistant strains157. For an example inhibition of 
non-essential regulatory protease Clp (Caseinolytic Proteases P) has been linked to 
reduction in biofilm formation capability of urinary tract infection causing pathogen 
S.epidermidis158. Utilization of proteases in a combinatorial therapy could prove effective 
in reducing fitness of bacteria to survive the stress induced by application of a 
conventional antibiotic. 
 
The targeting of bacterial proteases on one hand offers abundant targeting sites 
but on other hand poses challenges to achieve selectivity given the proteases are 
conserved across the species including humans. A major challenge of antibacterial drug 
programs is to prevent unwanted mechanistic toxicity however there are numerous 
examples of safe targeting bacterial enzyme with similar homologs. In such cases subtle 
structural and functional divergence, differences of surface topology at molecular level 
and low probability of antibacterial to access/ bind a human homolog with competing 
efficacy favors the development of antibacterial agents11. 
 
 
Physiological Roles of Bacterial Proteases Complexes 
 
The proteases are well conserved class of enzymes in bacteria along with close 
homologs in humans. The primary role of the bacterial proteases is to clear toxic 
accumulation of abnormal proteins (denatured or nonfunctional) which are produced as a 
result of malfunctioning of transcription or translation machinery, genetic mutations, and 
stress conditions such as nutrient deficiency, competition, or oxidative damage. Events 
promoting mis-folding of the proteins such as heat shock, lead to increase in expression 
of degradative proteases along with heat shock proteins to either refold or eliminate the 
damaged proteins. Numerous stress response modulation factors such as RpoS, RssB and 




order to maintain homeostasis159,150. The proteases recognize the disordered or unfolded 
proteins with high affinity via interactions of their adaptor proteins with exposed 
hydrophobic residues marked by protease recognition motifs such as N-End rule or SsrA 
tags, which otherwise are concealed within well folded proteins150. Lon, HslUV, Clp, 
HtrA and FtsH are the predominant degradative proteases in bacteria with high degree of 
conservation from eubacteria to eukaryotes150. The selective degradation of misfolded or 
malfunctioning proteins (substrates) enables a host of bacterial homeostatic activities 
such as post translation regulation, and stress response150,160. 
 
Most of the protease complexes have a proteolytic chamber made up of assembly 
of multiple subunits with buried catalytic sites whose activity is tightly regulated by 
AAA+ superfamily member cheaperones161. Often the ATP dependent chaperones 
control catalytic chamber access (pore opening) ,selectivity, processivity, unfolding and 
translocation of target substrates to proteolytic chamber in a highly coordinated 
manner161. Structurally the regulatory proteases are compartmentalized entities with their 
active sites protected within a gated proteolytic chamber to avoid nonspecific degradation 
of native proteins162. Although the structural arrangement of subunits, mechanism of 
protein degradation , and substrate specificity varies between proteases complexes from 
species to species, the overall structural layout is similar with a proteolytic chamber 
containing shielded active sites, and regulatory subunits (ATPases) controlling access of 
the targeted proteins to degradation chamber150. Mechanistically all of the proteases 
complexes carry out their functions at expense of ATP with exception of HtrA family 
proteases150. In general the mechanism of action of most of protease complexes involves 
formation of proteolytic chamber by assembly of individual subunits followed by 
interactions with regulatory proteins which select, translocate, unfold and thread the 
proteins through access gates for peptide bond hydrolysis in proteolytic chamber. 
 
 
Regulatory Chaperones from AAA+ Family 
 
Regulation of cellular activities is a highly ordered and complex process in which 
regulatory proteins such as ATP dependent AAA+ family proteins selectively degrade 
and remodel the proteins involved in cellular activities. This regulation is achieved 
through segregation of various cellular components within cytoplasm and sequestering of 
catalytic sites within proteases to regulate unwanted and potentially lethal indiscriminate 
cleavage of proteins163,164,165. The members of AAA+ superfamily are well conserved in 
bacteria as well higher order species including humans and have strikingly similar 
structural or functional similarities164,163. The ATP powered chaperones control vital 
cellular activities ranging from modulation of proteins in signaling cascades, Apoptosis, 
cell division, and macromolecule synthesis (DNA, Proteins)166,150.The AAA+ members 
can be broadly divided into ATP dependent unfoldases and proteases with catalytic sites 
which assemble in a highly regulated manner to selectively recognize, translocate, unfold 
and remodel or degrade the malfunctioning proteins originating from stress response 
(nutrition, heat, oxidation), misfolded or stalled proteins during translation164,163,167,168. 
The specific regulatory proteins such as proteasomes in eukaryotes and eubacterial 




AAA+ family such as heat shock family (HSP) proteins , use ATP hydrolysis to drive 
regulatory functions of protein folding (foldases), preventing aggregation (holdases), 
protein unfolding (unfoldases) and transporting proteins (translocators)169,170,171,172,173. 
The regulatory proteins are often expressed transiently to modulate essential cellular 
activities and are removed by intracellular proteolysis to ensure normal operation of 
signaling pathways173. Aberrations in the intracellular proteolysis are often the leading 
causes of many diseases which results from disruption of signaling pathways due to 
prolonged activity of regulatory proteins or from cellular toxicity due to inefficient 
removal of polypeptides including misfolded or denatured proteins174. 
 
 
Introduction to ClpP Protease 
 
The self-compartmentalized, ATP dependent regulatory Caseinolytic protease P 
(ClpP) is an important member of serine proteases family and is widely conserved among 
multiple species including eubacteria and higher order species (chloroplasts in plants and 
mitochondria in eukaryotes including mammals) as part of essential quality control 
machinery involved in clearing of transition state regulatory proteins with short 
functional life span175,176,177. The ClpP protease complex regulates quality of the proteins 
in general by degrading misfolded or defective proteins and influences the regulation of 
critical developmental pathways by targeting key proteins, selected by regulatory 
chaperones. The regulatory control of ClpP complex extends to key processes such as cell 
sporulation, division, motility, differentiation, and virulence factors expression178,155. The 
regulatory chaperones have been found to be essential for expression of virulence factors 
and biofilm formation for pathogens such as Staphylococcus aureus179,180,181. 
 
The conservation of oligomeric ClpP Protease complex across species is not only 
reflected in sequence similarity of key domains but also in overall structural arrangement 
of monomeric subunits as well as its interactions and mode of regulation by AAA+ 
family member ATPase chaperones ClpA/X/C. Overall the protease complexes are a 
mutually dependent two component system which share remarkable similarity in overall 
functionality (Lon, ClpP, Hs1UV in bacteria and 20S, 26S in eubacteria) with regulatory 
chaperones and a degradation core182,183. The bacterial protease complexes differ from 
each other in structural conformation of their subunits 161. The main difference between 
cross species structurally conserved ClpP protease families is functionality of their 
targets184 in terms of subtle mechanisms governing recognitions of targeted substrates, 
structural orientation of individual subunits forming catalytic site and mechanism of 
protein degradation182,185. Contrary to Lon or FtsH proteases, the ClpP proteases however 
exhibit an exclusive symmetrical mismatch with six membered ClpX or ClpA hexamer 
interacting with seven membered ClpP heptamer, a feature well conserved in ClpP 
proteases across species including humans186. The endogenous ClpP protease exerts its 
proteolytic activity by cleavage of sessile (amide) bond by carrying out nucleophilic 
attack by hydroxyl group on serine in a catalytic triad composed of Aspartic acid (ASP), 






Structure of ClpP Protease 
 
ClpP from Staphylococcus aureus (Sa-ClpP) is a self-compartmentalizing 
protease from the cylindrical serine protease family187.The ClpP protease complex is 
composed (Figure 1-2A)of ClpP as central catalytic core formed by stacking assembly of 
two symmetric seven membered (homo heptamer) rings composed of identical 14 
monomeric units, forming a tetradecameric proteolytic core (90 Å in diameter) along 
with axial hexameric rings of energy dependent AAA+ superfamily members ClpA/X/C 
as ATPase’s chaperone proteins182,188,189. Each ClpP monomer has independent and 
active catalytic site composed of highly conserved (across species) catalytic triad made 
up of Serine, Histidine and Aspartate amino acids161,190. The proximity of catalytic triads 
within proteolytic chamber is key determinant of rate of hydrolysis161,191. The high 
density of catalytic triads in a close proximity results in increased processivity with 
cleavage of substrate at multiple locations into smaller peptides without significant 
buildup of larger intermediates192. The structural arrangement of catalytic triad has 
profound implications of functionality of ClpP. Each monomer has a N-terminal region 
with axial protrusion and hydrophobic residues rich axial pore forming interface, a 
spherical head domain composed of α-helices and ß-sheets which forms the wall of the 
barrel and an elastic α-helical handle region responsible for release of degraded products 
193,194 and interlocking assembly of monomers to stabilize the stacking interactions of 
homoheptamers to from enzymatically active tetradecamic structure161,60,195,196. The role 
of elasticity of α- helix handle region also extends into adaptation of dynamic 
conformation (extended, compressed and compact) by ClpP196. 
 
The axial pores (10Å) on each side of catalytic core are formed by highly 
conserved N-terminal loops regions of monomeric subunits and exist in open or close 
conformations161,197,193. The axial loops exist in outwardly projected “up “configuration 
and a “down “position in which the loops are sequestered within proteolytic chamber via 
axial pore198,199. Upon binding of regulatory chaperones is facilitated by initial up 
configuration leading to opening of axial pores to allow substrate entry , followed 
conformational switching to down position due to allosteric modulation by chaperone 
binding193,200.The axial pores regulate the rate of hydrolysis (input/ output) of targeted 
proteins by opening up upon activation of ClpP due to conformational change imposed 
by binding interactions of axial loops of regulatory chaperones161,190,201,193,202. 
 
 
Role of Regulatory Chaperones in ClpP Activation 
 
The chaperones such as ClpA/C/X and HSP100 are ATP dependent proteins 
belonging to AAA+ protein super family, have critical role of tightly regulating the 
selectivity and specificity of the targeted substrates203,176. These chaperons tag, 
translocate and unfold the proteins at expense of ATP and feed them through the narrow 
axial pores which widens upon simultaneous binding of chaperone to ClpP due to a 
conformational change in protein176,204,205,206. The ClpX and ClpA target unique 







Figure 1-2. Structure of ClpP and Activation of ClpP by ADEP4. 
A: Side view of ClpP and its axial chaperones. 
B: Top view of ClpP and its activation by binding of ADEP4 on axial pockets, resulting 
in opening of axial pore to proteolytic chamber. 
 
Image A and B adapted with permission from Elizabeth Griffith at Saint Jude Children’s 






of multiple protein substrates200,207,197.The standalone ClpP has no proteolytic activity 
toward structured proteins183,201. A fully processed ClpP degrades the proteins into 
smaller residues of 7-8 amino acid length, which later exit from the proteolytic chamber 
through transiently formed lateral pores161,192. In absence of chaperones, the unstructured 
protein are hydrolyzed with very low processivity or only small peptides up to 6 amino 
acids lengths are hydrolyzed based on their ability to squeeze through entrance pore to 
catalytic chamber in ClpP protein208,209,210,205,192,211. It was also determined that N 
terminal His tag interfered with proteolytic activity of ClpP whereas native ClpP 
hydrolyzed the small peptide substrate (N-succinyl-Leu-Tyr-amidomethylcoumarin) 
without assistance of chaperones212. 
 
 
Mechanism of ClpP Activation 
 
Activators of ClpP such as Acyldepsipeptides antibiotics (ADEPs) exert effects 
similar to natural cognates (ClpA/X) and exert widening of axial pore to almost double in 
diameter (20Å) thus facilitating entry of larger proteins for degradation213,161. The 
assembly of heptameric rings of ClpP monomer is mainly governed by inter-subunit 
hydrophobic interactions of adjacent monomers as well as hydrophobic interactions of N-
terminal segments182. Depending upon ClpP functionality, ClpP dynamically exists in 
catalytically active extended form, catalytically inactive compact and compressed forms 
with varying height and structure of handle region161,195. The extended state is marked 
with catalytic triad in proper orientation with Histidine sandwiched between Serine and 
Asparate forming a catalytic triad stabilized by hydrogen bonding161. The handle region 
is oriented in a straight ordered state forming interlocking stacking interactions forming a 
ß-sheet with similar handle regions from adjacent monomers161. The compact state is an 
intermediate sate between fully active ClpP in extended state and completely inactive 
compressed state and is adopted with disordering of handle region and loss of proper 
orientation of catalytic triad resulting into inactive protease. The compressed state is 
adopted by further compressing of tetradecamer leading to vertical reduction of the height 
and increase in the width of proteolytic chamber due to partial refolding of handle region 
resulting in a 80 degree kink formation which leads to in formation of transient side pores 
(6Å)161,190. Another marked change is shifting of histidine reside away from serine and 
Aspartate resulting into inactivity of protease. Overall the mechanism of protein 
degradation is quite complex with confirmatory changes in axial loops modulated by 
allosteric binding of chaperons, facilitating widening of axial pores, ordering of handle 
region, orientation of catalytic triads in proper conformation, processing of substrates 
followed by disordering of handle region along with partial refolding to produce a kink to 
allow formation of transient side pores to release the processed substrates193,214,161. 
 
 
Discovery of ADEPs 
 
The Acyldepsipeptides series compounds belong to enopeptin class antibiotics 
and were discovered from Streptococcus hawaiiensis NRRL 15010 broth as A54556 




Upon further purification and fractionation , the first natural product derivative ‘factor a’ 
later identified as ADEP1 was determined to be active compound within A54556 
complex with antibacterial activity against both representative gram positives(B.subtilis) 
and negatives (E.coli)212,143. ADPE1 and its synthetic congeners were found to be broad 
spectrum antibiotics with activity against gram positives and most importantly against 
multiple drug resistant clinical isolates. For gram negatives the activity of ADEPs was 
diminished due to permeability issues arising from their hydrophobic core. The N-
acylated phenylalanine motif on the ADEPs, is a known recognition motif for efflux 
pumps, resulting in high rate of efflux which further weakens efficacy of ADEPs in Gram 
negatives216,217,218 . The ADEPs were found to active for efflux knockout (∆Tolc) in gram 
nagatives212. The ADEPs were found to outperform the marketed drug linezolid by 
rescuing the mice infected with lethal doses of Vancomycin resistant strain of E.faecalis 
(VRE), penicillin resistant S. pheomoniae (PRSP) and sepsis infection from methicillin 
resistant Staph aureus (MRSA)212. Interestingly the ADEPs also displayed stereo 
selectivity in arrangement of difluorophenylalanine side chain with activity only with S-
isomer while R-isomer was found to be inactive212. Investigatory studies focused on 
incorporation of radiolabeled precursors of macromolecule (DNA/RNA, Proteins, and 
Lipids) biosynthesis revealed that ADEPs potentially inhibit cell division by a unique and 
non-classical antibiotic mechanism212. To tease out the molecular target, genomic library 
of ADEP resistant mutant were created and plasmid contain resistance genes isolated and 
transfected into efflux pump mutant E.coli strain (HN818, ∆acrA)219. The result clones 
had much higher resistance to ADEPs and genomic sequencing of plasmids suggested 
gene encoding a key protease ClpP with an active site single point mutation (Thr182Ala) 
as primary resistance determinant. Later specificity of ADEPs to target ClpP was 
confirmed by determination of high level of ADEP resistance in ClpP knockout strains of 
gram positive B.subtilis, S.aureus, S. pheumonaire, and E.faecalis. The presence of fully 
functional wild type ClpP was found to indispensable for activity of ADEPs and 
mutations in ClpP active site was found to associate with resistance to ADEPs. The N 
terminal sequencing of only protein bound to ADEP saturated affinity column and cross 
linking studies using 3H labeled ADEPs indicated that ADEP physically interact with 
ClpP protein for their activity212.The knock out mutants of ClpP associated chaperone 
proteins were found not to influence ADEPs mediated antibacterial activity. 
 
 
Structure and Characterization of ADEPs 
 
The major structural difference between enopeptins and ADEP-1 is acetylation of 
phenylalanine residue, nitro group substitution of serine analog residue in lactam ring and 
length of hydrophobic alkyl side chain60.The ADEPs consist of a lactam ring with 5 
proteinogenic amino acid residues, a phenyl alanine linker and hydrophobic tail 
containing α-ß unsaturated bonds which in trans configuration are critical for antibacterial 
activity182,60,220. Initially 8 structurally related analogs were synthesized of which ADEP 
1-6 were characterized. An interesting observation was relation of activation potential to 
type of Acyldepsipeptides used. The antibacterial potency against MDR gram positives 
and Gram negatives (in presence of membrane permeabilizing agents) for ADEP2 and 4 




ADEP2) exhibited complete inactivity due to stereo-selectivity resulting from 
unfavorable structural constrains in difluorofenyloalanine group60,212. The potency of 
ADEPs is influenced by conformational constrains within peptidolactone ring as 




Activation of ClpP by ADEPs 
 
Binding of ADEP to ClpP (Figure 1-2B) has multiple effects resulting in 
oligomerization of monomers to form 14mer, disruption of binding of chaperones to ClpP 
and activation of ClpP due to conformation changes in monomer orientation to enable 
sessile bond cleavage. The ADEPs trigger both oligomerization and activation by binding 
to ClpP. The ClpP elutes as a monomer and in its monomeric form ClpP does not possess 
proteolytic activity143. The analytical ultra centrifugation (AUC) experiments suggested 
cooperative oligomerization of ClpP into 14mer upon binding of ADEPs in equi-molar 
concentrations222. The ADEPs in equi-molar concentrations were also found to degrade 
model substrate casein (a structurally disordered protein) by activation of ClpP in absence 
of chaperones and in comparison, the native ClpP did not displayed proteolytic 
activity182. Casein digestion experiments using structurally ordered and compact 
substrates such as GFP-SsrA, GroEL, Tig, DnaK and N-end rule substrate FR-linker-
GFP, suggested lack of proteolytic activity of ADEP activated ClpP143. 
 
The binding of ADEPs significantly enhanced the processivity of ClpP via 
modulation of structural conformational changes leading to opening of entrance pore to 
proteolytic chamber182,222. However, the ADEPs were found to not influence unfolding 
and processing of substrates by chaperon proteins suggesting that ADEPs abolishes the 
binding interactions of chaperones by triggering the dissociation of ClpP from 
chaperones by competing for same binding pockets on ClpP resulting in deregulation of 
ClpP143,182. The efficiency of proteolysis was monitored with FITC labelled casein 
substrate and it was found that although the degradation efficiency (complete degradation 
of substrate) and kinetics (rate of degradation) of ADEP activated ClpP compared to 
ClpP activated by its natural chaperones is identical, however the processivity (ability to 
repetitively degrade the substrate) of ADEP activated ClpP was comparatively slower143. 
This is likely due to stronger binding and hence longer duration of conformational 
changes (residence time of activity) of chaperones compared to ADEPs. 
 
The ADEP mediated functional reprogramming (activation) of ClpP is 
independent of presence of regulatory chaperones and degradation of much larger 
substrate suggests similar opening of axial pores upon competitively binding into axial 
pocket where regulatory chaperones bind. In presence of ADEPs the chaperons lose their 
ability to associate with ClpP, resulting in loss of regulatory functions of ClpP. The 
bactericidal effects of ADEP stems from over activation of ClpP rather than inhibition of 
binding interactions to chaperones or physiological function of regulation of protein 
quality143. The primary targets of ADEP activated ClpP are unfolded nascent 




ribosomes143. ADEP activated ClpP did not exhibited the proteolytic activity on proteins 
with complete folding post translation suggesting preference of semi folded proteins for 
degradation. Thus the rate of folding of nascent proteins appears to have impact on rate of 
degradation of ADEPs activated ClpP. The ADEPs also have preference for degradation 
of proteins from exposed N-terminal regions such as disordered proteins. The folded 
proteins do not have their N-terminal region exposed due to post translations 
modification result in folding based on information decoded from c-terminal regions. 
ADEPs accordingly do not exhibit their activity on preexisting well folded protein and 
exhibit their activity against misfolded, or disordered protein with exposed n terminal 
regions143. Chaperone independent ClpP activity is potentially result of opening of central 
pore to proteolytic chamber which otherwise restricts entry of proteins as part of ClpP 
regulatory function143.The binding of ADEPs to ClpP results in unique outward shift of 
covalently linked hydrophobic cluster on N terminal side of ClpP monomers and this 
structural rearrangement of binding pocket which translates to opening of the pore from 
earlier closed to open position as well as disruption of binding of chaperones due to 
disruption (by hydrophobic tail segment of ADEPs) of hydrophobic interactions in the N-
terminal segment of ClpP monomers, altering the binding pocket symmetry182. The 
potential explanation for this behavior is due to delocalization of hydrophobic patches on 
ClpP surface resulting in structural mismatch or steric hindrance in interaction with 
opposing IGF loops of chaperones183,201,207. Another possibility is that ADEPs could 
disrupt the interaction of N terminal ClpP loops with pore-2 loops on chaperones206,193,143. 
 
In a 2D PAGE experiments ADEP treated cells were found to exhibit induction of 
various stress response (from protein damage) chaperones (ClpA/C, DnaK, GroEL and 
Tig) with accumulation of native proteins as well unique fragments which were later 
found to be from digestion of GroEL, DnaK , Tig and Ef-Tu based on N terminal 
fingerprinting experiments212. This indicated that ADEPs activated ClpP becomes 
deregulated and randomly cleaves any loosely compact proteins as well nascent proteins 
(induced due to stress repair response) resulting in toxic increase of truncated or 
malfunctioning proteins leading to inhibition of cell division and ultimately cell death212. 
 
 
Structural Basis of ADEPs Interactions with ClpP 
 
The crystal of B.Subtilis ClpP with ADEP1 and ADEP2, 3 suggested that there is 
1:1 stoichiometry between ADEPs and ClpP monomers meaning 14 ADEP molecules 
bind to 14 binding pockets on ClpP182. The binding pockets are located both apical and 
proximal sides of the ClpP barrel and binding pocket interface is formed by interactions 
of 2 monomers with many hydrophobic patches to support binding interactions of 
Isoleucine-Glycine-Phenylalanine-Lysine (IGF-L) loops of cheparones182. The N-acyl 
phenylalanine side chain of ADEPs acts as structural mimic of I (L) GF tri-peptide motif 
of chaperone ClpA/X to compete and displace the ClpA/X chaperones from same binding 
pockets on ClpP222,206,201. Standalone IGF tri-peptide motifs can neither displace binding 
of chaperones or activate ClpP, suggesting the importance of interaction over a larger 
surface area183,217. The influence of ADEPs binding to ClpP pockets extend to distantly 




interactions between two monomers) resulting in structural disordering (flexibility) of N-
terminal segments on ClpP monomers which ultimately leads to opening of entrance 
pore182. Based on comparative studies of apo structure with ADEP bound to ClpP, the 
binding of ADEPs influenced N terminal of ClpP more than C-terminal which houses the 
catalytic sites resulting in greater than 4Å outward shift of N terminal segments (with 
some without directly interacting with ADEP) upon binding of ADEPs182. The phenyl 
ring of ADEPs is buried deep within ClpP pockets interacting with Tyr 62, Ile 92, Leu 
114, Leu 189 from one monomer and Phe 182 from adjacent monomer and lactone ring 
interacting with hydrophobic patches of ClpP pocket182. The observed increase in potency 
with meta position fluorination of phenyl ring was due to formation of additional 
hydrophobic and long distance hydrogen bonding interactions and fluorination at para 
position was not tolerated due to steric clashes with Leu 114 and Ile192182. It was also 
found that ADEP binding is facilitated from bulk hydrophobic interactions rather than H 
bonding interactions which explains binding of ADEPs to ClpP with critical Y63 tyrosine 
replaced with Alanine and later substituted to bulkier tryptophan (W) completely disrupts 
the binding of ADEPs182. Structural changes in ADEP binding sites do not influence 
catalytic sites located more than 20Å away where the catalytic triad exist in pre-activated 
form to degrade a substrate without any structural rearrangements from chaperones or 
ADEPs182. Analogous to eukaryotic 26s proteasome, the primary mechanism of ClpP 
activation appears to be through opening of entrance pores rather than allosteric 
activation of catalytic sites182. 
 
 
Issues with ADEPs 
 
The ADEPs are interesting class of antibiotics due to their potent activity toward 
MDR gram positives as well as promising efficacy in animal models of infection212,223,224. 
While a lot of synthetic congeners of ADEPs have been developed with improved 
antibacterial the key issues of poor pharmacology properties are yet to be resolved225. 
With poor solubility, metabolic stability and toxicity at higher doses the transition of 
ADEPs into clinic was hindered despite their exceptionally high antibacterial activity or 
sterilization potential against multiple gram positives. 
 
ADEPs are antibiotics with peptidolactone ring system which are vulnerable to 
pharmacological liabilities226,227,228. The poor solubility of ADEPs stems from large size 
and high lipophilicity from their peptidic nature and despite multiple chemical 
derivatization attempts, the solubility of its synthetic congeners did not improved 
significantly220. Inadequate metabolic stability of ADEPs stems from constrained 
peptidolactam ring which is liable for breakdown at room temperature conditions over 
period of 6-8 weeks. The fragment counter parts without constrained peptidolactam ring 
were shown to exhibit greater stability at room temperature condition suggesting 
weakness in the constrained peptidolactam ring217. Further the ADEPs do not strictly 
follow Lipinski’s rule of five guidelines for lead like compounds (logP>5), therefore 
further optimization is challenging. Apart from pharmacological property issues, an 
important limitation in ADEPs based drug design is that ClpP null mutants showed high 




essential enzymes in bacteria to evade ADEP action184. It is possible that resistance is 
driven by via point mutations in ClpP gene at ADEPs binding site or mutations in ClpP 
promoter gene. Another possibility is target substitution of ClpP with ADEP insensitive 
ClpP version which is otherwise down regulated with regulatory role or activation of 
efflux pumps(Sc1AB) targeting ADEPs184. 
 
 
Discovery of ClpP Modulators Is a Worthy Strategy 
 
 
Essentiality of ClpP and Its Consequence 
 
ClpP is an important regulatory protein however, it is not essential for survival of 
bacteria (gram positive and negative) due to presence of other similar regulatory 
proteolytic complexes and molecular redundancy143. For the species in which ClpP is 
nonessential for vegetative growth the unregulated activation of ClpP has lethal 
consequences due to toxicity induced by excessive proteolysis of native proteins150. The 
ClpP complex has critical role key in smooth functioning of developmental cascades, 
survival during stress conditions and is vital for maintenance of virulence in pathogenic 
bacteria155,176. The bactericidal effects of ADEPs via dispensable ClpP activation 
represent an intriguing strategy of inhibition of normal physiological function of ClpP 
along with over activation (deregulation) of ClpP. This disturbance of normal 
physiological functions of ClpP resulting in reduced fitness of bacteria to spread 
infections and to survive in stress conditions such as during dormant phase, has potential 
implications toward treatment of infections arising from dormant populations specially in 
biofilm related fomite born infections from Staph aureus223. Since ADEPs target the 
nascent polypeptides the damaging effect of ADEPs on growth of bacteria could stem 
from both shortage of essential proteins as well as toxic level abundance of semi 
functional degradation end products leading to oxidative stress and truncated growth143. 
 
The antibacterial activity of ADEPs via allosteric or conformational over 
activation of an otherwise tightly controlled regulatory ClpP represents a unique 
mechanism for a naturally occurring novel antibiotic family. Resistance to newly 
developed antibiotics is unpredictable, perhaps inevitable and is matter of time71. 
However, the unprecedented mode of action of ADEPs brings the much needed 
competitive advantage in the era of multidrug resistant pathogens. A multipronged 
strategy of attacking a pathogen by engaging multiple targets is perhaps the way forward. 
The ADEP resistance frequency is not exceptionally low at 106 , rather is similar to other 
antibiotics such as rifampicin and this aspect might limit use of ADEPs as combinational 
therapy212.However no cross resistance to other antibiotic class has been noticed and 
none of the clinical isolates have shown ADEP resistance suggesting potential uses of 
ADEPs as antibacterial agents with other antibiotic with varying mechanism of action212. 
The combinatorial therapy with ADEPs could also be feasible for pathogen which 
requires presence of ClpP143. For example ClpP is required for virulence of many 
pathogenic bacteria and in case of M.tb Clp inhibition is lethal due to it indispensable role 




antibiotic treatment induces stress response in bacteria enhancing selection pressure to 
retain ClpP protein to mitigate the toxic effects from stress (i.e. protein mis-folding). In 
this light it is less likely that loss of ClpP as a resistance mechanism to ADEPs would 
occur150. 
 
Further the structural conservation of ClpP across species could be exploited to 
design lead compounds with broad spectrum activity. In this light the possibility off 
target effects due to shared structural or functional features in humans is an important 
concern. However, the structural similarity of bacterial and HClpP are less than 40 % and 
with help of structure aided design subtle differences in ClpP modulators could be 
introduced to reduce the risk of substantial toxicity.  
 
 
Effectiveness of ADEPs in Combinatorial Therapy 
 
Utilization of novel ClpP activators in a combinatorial regimen is yet another 
promising approach which could have synergistic effect to eliminate persister populations 
in a manner similar to synergistic effects of trimethoprim with Sulfamethoxazole on 
folate synthesis pathway24 . To this end, the ADEPs in combinational therapy can further 
improve efficacy of treatment by extending the time a pathogen needs to evolve their 
genetic resistome to circumvent the ADEPs activity218. ADEPs act by targeting of 
innocuous proteins in pre translation stage and random degradation of critical proteins 
such as Ef-Tu, Tig, GroEL, and DnaK by ADEP activated ClpP protease212. This 
unconventional mode of action by ADEPs in a combinatorial therapy using a specific 
antibiotics is incremental toward mounting toxic load due to truncated proteins along 
with impairment of the stress response and virulence capabilities of pathogen, leading to 
self-digestion of pathogen143,223. The strategy of attacking pathogens via otherwise benign 
regulatory protease activation rather than conventional target inhibition, is intriguing 
from the fact that ADEPs do not require pathogens to be in growth phase or presence of 
active cellular target to act on230. This is in contrast to conventional antibiotic’s mode of 
action via inhibition of a critical cellular process such as DNA or protein synthesis or 
blocking cell wall synthesis. A recent study further elaborated the potential of ADEPs in 
combinatorial therapy with rifampicin demonstrated significant eradication of 
metabolically dormant biofilm forming pathogens223. The ADEPs have proven to very 
efficacious in achieve complete sterilization of lethal sepsis infection and biofilm models 
of E.faecalis and Staph aureus infections212. This combinatorial approach is gaining 
traction among clinicians due to synergistic effects of different antibiotics toward 
eradication of treat chronic diseases like tuberculosis. 
 
Another novel concept is combination ClpP activators and activators of toxin 
antitoxin system (TA), where enhanced expression of ClpP protease could assist faster 
degradation of antitoxins produced by pathogenic bacteria to counter production of toxins 
(such as ribosome-dependent ribonuclease RelE and MazF factor) as a result of stress 
response due to exposure to a short term antibiotic therapy159,231. Conclusively the 
uniqueness of ADEPs action is advantageous toward building a hypothesis that at very 




MDR pathogens and represents an interesting strategy moving forward toward discovery 
of novel antibiotics143, 218,184,212. 
 
 
Previous Drug Discovery Efforts on ClpP Protease 
 
Modulation of ClpP by two opposing strategies of activation and inhibition has 
implications toward development of therapeutics targeting ClpP. The strategy of selective 
inhibition of ClpP catalytic site by β-lactones met reasonable success with antibacterial 
activity against mycobacteria however encountered issues with poor solubility of β-
lactones and high incidences of cross resistance232.On the other hand strategy based on 
activation of ClpP has gained more traction in the light of potential of activators in 
combinatorial therapy against infections from dormant biofilm forming pathogens223. 
Recently indolinone derivative Sclerotiamide (Figure 1-1C), small molecules based ACP 
series (Figure 1-1G-K) and fragment look alike compounds were identified suggesting 
potential for activation strategy59,218. However these molecules lacked the desired 
antibacterial potency due to weaker binding affinities or poor pharmacological properties, 
therefore the discovery of potent ClpP activators with desirable pharmacological 
properties is still an underexplored objective217,59,218. 
 
 
SAR Lessons from Earlier Drug Discovery Efforts Based on ClpP Activation 
 
A fluorescence screen based activation of ClpP from E.coli was conducted using a 
collection of bacterial and fungal secondary metabolites and a indolinone based natural 
product Sclerotiamide was discovered218. The Sclerotiamide had decent activity against 
EcClpP however did not perform well on ClpP from B.subtilis which may indicate 
differential selectivity of the scaffold among bacterial homologs. Interestingly presence 
of three dimensionally constrained three-dimensional bicyclo[2.2.2]-diazaoctane motif 
appear to guide the activity of the Sclerotiamide218. The compounds was found to not 
exhibit anti-bacterial activity against efflux pump knockout strains of E.coli and 
P.aeroginosa218. 
 
In another study, various fragments of ADEP4 were made and antibacterial 
activity was assessed. It was found that N-E-2-heptenoyldifluorophenylalanine methyl 
ester group was essential for activation of ClpP as well as antibacterial activity whereas 
standalone peptidolactone ring has >16 fold lower potency217. Further elaboration of 
bioactivity of difluorophenylalanine moiety by various substitutions of alkyl side chain 
were made and it was found that extension of polyunsaturated bonds in side chain 
lowered the bioactivity whereas cyclization and branching at least maintained the activity 
to levels similar to difluorophenylalanine moeity217. Consistent with previously published 
SAR of ADEPs, It was also found that elimination of unsaturated bonds also decreased 
the potency with α-ß unsaturated bond in trans configuration remaining most potent and 
removal of difluoro groups resulted loss of H bond interactions with protein backbone 
which leads to decrease of potency whereas complete removal of difluorobenzene moiety 




carboxyl or amide groups did not improved potency and it was found that only aliphatic 
methyl esters retained the potency217. The antibacterial potency of simple ADEP 
fragments and ADEPs was studied in bacteria with slow growth defect associated with 
lack of ClpP and it was found that ADEP fragment target ClpP in similar to ADEPs 
217,233. Further the resistance frequency of ADEP fragments was similar to ADEPs with 
resistance mapping to mutations in ClpP promoter and ORF of ClpP gene217. The In vitro 
activity on synthetic peptide substrate was in narrow range and exhibited positive 
cooperativity as evident from Hill slopes>1217. Further the most active fragment was 
conjugated with biotin azide group and coupled with avidin matric in an affinity pull 
down experiments and it was found that ClpP was found to bind the affinity matrix 
suggesting binding of fragments to ClpP217. 
 
 
Introduction to Human Mitochondrial ClpP (HClpP) 
 
The HClpP protease is ubiquitously expressed in human body including 
mitochondrial rich tissues from Heart / Liver where expression of HClpP is particularly 
high. The ClpP expression is regulated by gene sequences on chromosome 19 whereas 
ClpX expression is regulated by gene sequences at Chromosome 15234,186. Both HClpP 
and HClpX are produced in cytosol in a pro-protein form with additional N terminal 
mitochondrial targeting peptide (mTP) sequences which regulate translocation into 
mitochondria and maturation processing of these proteins by truncation of N-terminal 56 
and 65 amino acid residues form HClpP and HClpX respectively186,169,235,236. 
Additionally both proteins exhibit considerable sequence similarity to E.coli counterparts 
with 56% and 44% for ClpP and ClpX respectively including conserved catalytic triad 
residues and is localized inside mitochondria matrix in close approximation to inner 
mitochondrial membraine186,237,238,169. Each HClpP monomer shares 108 out of 193 
amino acids with EcClpP and is composed of less ordered (or mobile) Cα helix N 
terminal region and a globular proteolytic chamber stabilized with inner hydrogen bonds 
and salt bridge interactions, is made of anti-parallel ß-sheets and a c-terminal 
extension186. Individual monomer subunits are joined by interlocking interactions of αß 
handle regions239. HClpP has its first 7 N terminal amino acids in form of a ß sheet which 
mark the interface of axial channel followed by loosely ordered crown like loop of 8-16 
amino acids with bendable kink followed by anti-parallel ß sheets forming walls of the 
proteolytic chamber containing catalytic triad and a flexible 28 residue long C-terminus 
with role as a anchoring site for other unknown interacting partners and in stabilization of 
HClpP chaperon HClpX186. The N terminal region houses alternating acidic and basic 
stretches of residues with more hydrophobic residues marking the entry pore and 
influences enzymatic activity of HClpP by allosterically modulating binding of 
HClpX186,239. In presence of ATP the HClpX primarily exists as hexameric unit and upon 
interactions with HClpP, triggers the formation of tetradecameric complex186. The 
ATPase activity of HClpX is contingent on thermodynamics of substrate folded or 
unfolded state with higher preference for unfolded subnstrates239,240. 
 
The serine protease family member HClpP in its precursor form is a 227 amino 




charged arginine residues encoding mitochondrial targeting peptide sequence237,241. The 
mTP sequence marks the cleavage site for final processing of the proteases as well as 
signal for the proteins meant to be transported into mitochondria suggesting the final 
destination of the HClpP after expression as a precursor full length protein in the 
cytoplasm237. The transport of the HClpP to mitochondrial matrix is regulated by 
mitochondrial membrane potential and the mature HClpP (~26KDa) is formed after 




Structure of HClpP 
 
The full length HClpP when expressed in eukaryotic system is about 35 kDa whereas 
HClpP expressed in bacteria is about 26 kDa due to processing of HClpP post 
translation169.Electron microscopy experiments suggested that mature HClpP forms a 
tetradecamer (~340 kDa) with two seven membered symmetrical rings composed of 
seven identical monomer units (26 kDa) stacked on each other in manner similar to ClpP 
proteins in other species169,239. In solution HClpP mainly exists as heptamer while HClpX 
predominantly exists as hexamer which binds to HClpP only in presence of ATP and 
pushes HClpP into tetradecameric form in a highly cooperative way239. HClpP in absence 
of ATP loses its binding interactions with HClpX and remodels into a heptamer from 
tetradecamer239. Standalone heptameric HClpP lack activated catalytic triad contrary to 
Clp from E.coli and requires conformational changes leading to HClpX binding 
contingent structural rearrangements leading to activation of catalytic site239. In a manner 
similar to Clp proteases from other species, the regulatory ATP dependent chaperone 
human ClpX bind to HClpP tetradecamer on each sides as homohexameric rings186. On 
the contrary to other Clp proteases unwanted proteolytic activity is regulated by 
sequestering of active sites instead of compartmentalization239. The diameter of HClpP is 
about 90Å and height is about 50Å186. 
 
 
Interactions of HClpP 
 
Standalone HClpP does not possess proteolytic activity and has limited peptidic 
activity186. The proteolytic and peptidic activity is enhanced multifold in presence of 
cognate chaperons ClpX due to enhancement of catalytic efficiency and axial pore 
opening leading to access to catalytic chamber186,239. The in vitro activity of HClpP is 
also exhibited in presence of ClpX from E.coli however ClpA from E.coli does not bind 
or activate HClpP suggesting conservation of binding pocket sequence and binding 
specificity between human and bacterial ClpX186. The HClpP possess an additional c 
terminal extension with potential role in determining binding interaction specificity 
between E.coli ClpX and ClpA toward HClpP. The C terminal extension a unique feature 
of HClpP is not required for binding or activation of HClpP however the C terminal 
mutant of HClpP were found to exhibit increased processivity with E.coli ClpX or 
HClpX while no binding or activity was detected with E.coli ClpA186. Interestingly the 




can degrade targets specific to EcClpP such as GFP-SsrA with higher catalytic activity in 
presence of ATP however the HClpP complex HClpPX cannot degrade GFP-SsrA 
indicating different selectivity of targets between human and E Coli Clp Proteases 186. 
Further the well conserved IGF loops on HClpX are longer than EcClpX thus influencing 
poor or no binding of HClpX to EcClpP however has minimal effect for E.coli ClpX 
interactions to HClpP as corresponding regions on HClpP or EcClpP are well 
conserved186. This indicates that EcClpX can target HClpP substrates however reverse is 
not true as HClpX cannot target EcClpP substrates suggesting tight regulation of 
substrate specificity to control severe consequence of malfunction in mitochondria186. 
The clear mechanism of processivity of HClpP is unknown however it is proposed that 
binding of ATP stabilized HClpX to axial binding pockets is modulated by crown loops 
on N terminal region of HClpP subunits and allosteric conformational changes lead to 
opening of previously closed axial pore239. Mechanism of release of the degraded 
products is not clear with one hypothesis pointing at rotatory and reciprocal movements 
of HClpP and HClpX rings leading to conformational changes in the subunit interface 
resulting in generation of transient side pore for end product exit and second hypothesis 
pointing at release of end products via axial pore opposite to pore of entry186, 239. 
 
 
Aims of the Project 
 
ClpP (Caseinolytic Protease P), a cylindrical serine protease from Staphylococcus 
aureus (MRSA) is an important emerging therapeutic target to stem the rise of drug 
resistance bacterial infections. Despite broad spectrum (Gram +) activity and novel 
mechanism of target engagement, the development of ADEPs into clinical candidates was 
hindered212, 224. The major reasons for retraction were suboptimal key pharmacological 
properties such as solubility, lipophilicity, toxicity, and molecular size. With aims to 
reinvigorate the drug discovery of novel ClpP activators with potent antibacterial activity, 
the major aim of the current project was to adopt a multipronged approach based on (a) 
structure based optimization of ADEP4 derivatives with superior pharmacological 
properties, (b) development of non-peptidic small molecules based activators of ClpP, (c) 
development chemically tractable fragment based leads with tractable pharmacological 
properties and bioactivity potential. 
 
 
Aims of Dissertation Research 
 
The iterative and complex nature of drug discovery process requires carefully 
planned screening and validation regimen to increase prospects of success by reducing 
chances of lead attrition. From antibacterial drug discovery prospective, an important 
lesson learned is that high incidence of lead attrition at later stages of discovery program 
are linked to poor physiochemical properties of leads as well as lack of scaffold diversity 
due to inefficient sampling of chemical space around binding pockets of the target. The 
ClpP is a druggable target as observed from interactions of ADEPs series however 
discovery of non peptidic novel scaffolds based on fragments, targeting ClpP is quite 




historically difficult target sites. Further contrary to discovery of inhibitors of protein 
function, identification and development of “activators” of ClpP which, not only block 
interactions of unfoldase chaperons, but also efficaciously “turn on” the ClpP proteolytic 
activity, is a unique challenge. Therefore in addition to adopting a short term strategy of 
structure guided chemical optimization of ADEP4 analogs to fit desired ADME 
spectrum, discovery of novel scaffolds is crucial to augment chances for successful 
development of non-peptidic novel ClpP lead activators and to sustain ClpP drug 
discovery efforts in long term. The multimeric nature of well conserved ClpP among 
other bacteria on one hand is advantageous toward development of broad spectrum drugs 
but on the other hand, poses issues of site specificity. In addition to above challenges the 
existence of a close human mitochondrial homolog HClpP with 57 % sequence homology 
and 38 % structural similarity to wild type ClpP sets the conditions for development of 
selective leads with preferential activity toward wild type ClpP and minimal off target 
effects. 
 
To realize above aims the central hypothesis, is that careful implementation of 
screening as well as characterization strategy in the beginning phase of hit to lead 
expansion would generate leads with pharmacological tractability and broad spectrum 
activity thus enhancing chances of success. Additional hypothesis of the research strategy 
are (a) Screening of diverse compound collections using sensitive biochemical & 
biophysical detection methods facilitates effective sampling of available chemical space 
which leads to identification/ validation of novel, and efficacious ligands, (b) 
Identification of fragments with high ligand efficiency would enhance chances of 
developing non-peptidic ClpP activators with superior chemical optimization potential; 
(c) counter screening using wild type active site mutants (Y63W, Y63F) with abolished 
ADEP4 affinity as well as human mitochondrial ClpP would offer greater control to 
modulate binding affinity over selectivity. 
 
 





The objective was to develop high throughput primary screening methods capable 
of identification of novel ligands to ultimately generate lead compounds with ClpP 
activation potential. For this purpose three primary screening methods based on thermal 
shift, fluorescence polarization and Surface Plasmon resonance assay were developed for 





The objective was to develop characterization and validation assays to evaluate 
both small molecule and ADEP4 based analogs for SAR exploration based on functional 










The objective was to develop SPR based assays to determine binding affinity, 
kinetics and rank order of specific ClpP activators and contrast against HClpP for 
selectivity assessment. Immobilization and kinetic interaction studies on both wild type 






CHAPTER 2.    OPTIMIZATION OF THERMAL SHIFT ASSAY AND 
ENZYMATIC ASSAY ON CLPP AND HUMAN MITOCHONDRIAL CLPP 
 
 
Optimization of Thermal Shift Assay (TSA) as Primary Screening Method 
 
 
Introduction to Thermal Shift / Differential Scanning Fluorimetry 
 
First introduced in 2001, the fluorescence based thermal shift analysis has gained 
popularity as a fast and easy biophysical platform to aid identification of natural ligands 
or compounds which upon interaction enhance intrinsic stability of the target 
protein242,243. This method has various prevalent acronyms in literature as Differential 
Scanning Fluorimetry (DSF), fluorescence based thermal shift/ Melt assay (FTS/M), or a 
commercial variant as ThermoflourTm 244,245,246. The thermal shift assay is also wrongly 
associated with a pseudo acronym of differential scanning calorimetery (DSC). 
Fluorescence based monitoring of protein denaturation over a temperature gradient is 
distinctly different from DSC assays which monitor phase transitions of protein melting 
by assessing difference of energy required for heat change for sample vs control247. The 
TSA assay is fluorescence based method based on phenomenon of increase in 
fluorescence of certain chemicals upon binding to a ligand248. Certain environmentally 
sensitive dyes such as 1-anilinonaphthalene-8-sulfonic acid (ANS) or SYPRO Orange(TM) 
exhibit exponential increase of fluorescence proportional to increase in hydrophobicity of 
their environment249,250.The TSA determines intrinsic stability of the target proteins by 
measuring changes in fluorescence of a reporter dye which binds to newly exposed 




Significance of Protein Stability Assessment 
 
Generation of pure and stable recombinant proteins is the first critical step to 
develop various characterization assays to advance a drug discovery project. In absence 
of natural stabilizing factors proteins in experimental conditions are prone to aggregation, 
unfolding or denaturation. The successful implementation of various biophysical and 
biochemical assays literally depends proteins stability, solubility and homogeneity in a 
buffer solution. Most of the experimental assays such as crystallography, NMR or SPR 
require proteins which are highly pure and stable at room temperature for extended 
periods of time251.Therefore identification of conditions promoting stability of the 
proteins in vitro is of special significance. There are number of factors which influence 
the stability of the proteins in vitro. Among major determinants of protein stability are 
temperature, salts, pH, additives, metal ions, and surfactants which collectively influence 
thermodynamics, folding, total charge, solubility, adsorption, chelation and aggregation 
of proteins. At physiological conditions, the intrinsic stability of the protein is a function 
of intra molecular interactions which regulate protein folding and unfolding. Most 




temperatures whose thermal stability is a function of amino acid sequence243. In a well 
folded protein the hydrophobic pockets are buried deep within the protein and are 
protected from surrounding aqueous (hydrophilic) environment. Increase in temperature 
results in disruption of intramolecular interactions which leads to exposure of 




Measurement of Protein Stability 
 
The native stability of the proteins or influence of additives on protein stability 
could be assessed by multiple methods such as Circular Diachorism (CD) spectroscopy, 
measuring intrinsic fluorescence from tryptophan/ tyrosine residues, chemifluorescence 
from environmentally sensitive dyes (via TSA), assessment of light scattering properties 
(via DSC), assessment of turbidity, Calorimetry and absorbance252,253. Of all methods, 
steps wise thermal denaturation of proteins is quick, reliable and least resources intensive 
method. The assessment of native stability of a protein or ligand induced increase (or 
decrease) of thermal stability, could be extrapolated by measuring changes in the melting 
temperature of the target protein in presence or absence of ligand. 
 
 
Thermodynamics of Protein Stability and Ligand Binding 
 
The native stability of the proteins is a complex matric with a predominant 
thermodynamic component of Gibbs free energy of unfolding (∆Gu) which is difference 
of Gibbs free energy (∆G) between folded and unfolded state of protein. Stability of a 
protein is inversely related to temperature as increase in entropy leads to decrease in free 
energy of unfolding leading to equilibrium point at which Gibbs free energy of unfolding 
(∆Gu) becomes zero. At the equilibrium point the proportion of folded and unfolded 
protein is equal and the temperature at this equilibrium point (∆Gu=0) is called melting 
temperature (Tm). The binding of natural or synthetic ligands (compounds, cofactors, and 
peptides) leads to increase in thermal stability of the protein due to additivity of free 
energy of protein ligand binding and free energy of uncoupling254. The energy 
contributions from binding of ligands to protein results in increase total Gibbs free energy 
of unfolding thus stabilizing the protein ligand complex against thermal denaturation. The 
increase of protein stability is reflected by higher melting temperature of protein- ligand 
complex , in most cases indicates direct binding of ligand to protein255,256,257. 
 
 
Principle of Fluorescence-Based Protein Thermal Shift (TSA) Assay 
 
Micro plate and HTS compatible TSA assay is based on principle of differential 
scanning fluorimetry (DSF) and is a rapid and inexpensive method to screen protein 
ligand interactions257. The TSA assay employs an environmentally sensitive dyes such as 
SYPRO Orange(TM) with very high signal to noise ratio, to measure increase in 




dye to exposed hydrophobic pockets on a thermal gradient. In a typical thermal shift 
experiment native ligands or test compounds are incubated with protein of interest (in its 
native folded state).As protein is heated in incremental fashion, the protein unfolds, 
exposing hydrophobic pockets to which SYPRO Orange(TM) binds (initially quenched in 
aqueous environment) and emit high fluorescence generating a sigmoidal curve. The 
inflection point (50%) on sigmoidal curve based on Boltzmann algorithm is called 
melting temperature (Tm)
257. The native melting temperature of a protein is indicative of 
its structural compactness, folded state and stability in a given buffer. The well folded 
proteins have higher Tm compared to disordered or partially denatured proteins. The 
stability of three dimensional folded structure of protein depends on surrounding 
environment or buffer system. Thus effects of additives, pH, and Ionic strength could be 
determined by screening of different buffer conditions to identify conditions with highest 
stability. The binding of natural ligands or chemicals stabilizes the tertiary structure of 
the protein resulting in resistance toward thermal denaturation or melting of protein on a 
thermal gradient, an event observed by increase in melting temperature (Tm), shifting the 
sigmoidal melt curve to the right. The differential of melting temperature in presence of 
binder (positive control) to melting temperature in absence of binder (negative control) is 
called ‘delta’ ∆Tm. Depending on extent of shift (∆Tm), multiple ligands can be ranked to 
facilitate selection of ligands with highest shift. 
 
 
Melting Temperature (Tm, oC) 
 
There are multiple definitions of melting temperature (Tm) such as the critical 
temperature at which half of the protein is unfolded, or temperature at which free energy 
of unfolding (∆Gu) is zero, or midpoint of denaturation phase transition curve in presence 
or absence of ligand or 50th percentile point of inflection between lowest to highest 
fluorescence and peak temperature of first derivative plot of fluorescence vs temperature. 
A typical melt profile a.k.a “thermograph” of increase in fluorescence (Y axis) vs 
temperature(X axis) for a well behaved protein is sigmoidal in shape with melting 
temperature at 50% inflection point between top and bottom of the melt curve. The 
melting temperature (Tm) could be considered as a function of protein inherent stability 
and effect of binding of a ligand can be measured as change in melting temperature of the 
protein upon thermal stabilization by ligand257. The shift in apparent melting temperature 
due to coupling of free energy of ligand binding to unfolding energy is proportional to 
binding affinity of the ligand242. Under saturation conditions with 10-20 fold molar 
excess of ligand to protein, the changes in melting temperature correlate proportionally to 
binding affinity, with compounds with high binding affinity producing greater shift in Tm 
and vice versa258. 
 
The Tm could be derived by either fitting the melting curve to model described by 
Boltzmann fit259,260or thermodynamic model254 and high order polynomial 
equations261,262,263. The fitting of raw data to appropriate model is subject to thermal 
denaturation profile of a given protein, which in turn depends on compactness of folding 
in quaternary protein structure. In general well folded proteins have higher native melting 




with higher binding affinity generally produce higher shifts in Tm for well folded 
proteins compared to loosely structured proteins. Often the melt profiles are asymmetrical 
due to dependency of denaturation on net enthalpy/entropy of the system rather than 
heating temperature264. The asymmetric nature of melt profiles require use of nonlinear 
regression fitting using 4 point (Boltzmann) or 5 point sigmoidal curve fitting methods265. 
 
 
Characteristics of Environmentally Sensitive Dyes 
 
There are multiple environmentally sensitive dyes with variable peak excitation or 
emission spectra to fit the needs of exploratory assays. The 1-Anilinonaphthalene-8-
Sulfonic Acid (ANS) is a yellow shifted dye in visible spectra with excitation /emission 
in range of 350/492 nm, the SYPRO Orange(TM) is an orange shifted dye with excitation/ 
emission in range of 492/575 nm, whereas Nile Red is a red shifted dye with 
excitation/emission in range of 585/665 nm. The TSA assay utilizes environmentally 
sensitive dyes whose quantum yield increases exponentially upon interaction with a 
hydrophobic surfaces generated by thermal denaturation of target protein266,242. In the 
aqueous or polar solvents with high dielectric constants, the hydrophobic dye exhibits 
minimal baseline fluorescence due to limited access to hydrophobic patches hidden 
within well folded protein267,268,242. The step wise increase in temperature lowers the free 
energy of unfolding leading to disruption the interactions maintaining the tertiary 
structure of protein, resulting in production of protein’s denaturation globule-dye 
complex intermediates, which exhibits behavior of a non-polar system with low dielectric 
constant, leading to exponential increase in fluorescence269.At certain temperature the 
proteins become irreversibly denatured with all hydrophobic pockets exposed resulting in 
peak fluorescence in a sigmoidal curve fashion followed by decrease due to loss of 




TSA Assay as Prescreening Tool and its Applications 
 
 
Ligand Identification in Drug Discovery 
 
The primary use of TSA assay is identification of natural ligands of a target 
protein by screening natural ligand libraries, thus contributing toward functional 
characterizations of novel drug discovery targets with little information on binding 
partners. Another extended use of TSA assay is detection of binding of novel ligands in 
this case unknown chemicals, to protein of interest. The TSA is a fast, economical and 
medium to high throughput capable primary screening method to quickly identify the 
binding compounds which enhance stability of the target protein by measuring changes in 






Biophysical and Biochemical Assays 
 
The stability of the purified recombinant protein as a drug discovery target is of 
paramount importance toward successful implementation of biophysical and biochemical 
assays. An important requirement for biophysical studies on recombinant protein is 
retention of folded form by recombinant proteins, thus it is important to screen the buffer 
conditions which promote protein stability and retention of folded state. The TSA could 
be used to screen for conditions to aid biophysical techniques such as SPR, X-Ray 
crystallography and NMR which require properly folded, high quality proteins with 
structural homogeneity. Often these experiments are carried over longer time intervals at 
room temperature conditions and thus stability of the protein is the major determinant of 
quality of spectra obtained. A well folded and mono dispersed protein with buffer 
environment favoring long shelf live under experimental conditions is a prerequisite for 
high quality structural data from X-ray crystallography or NMR272. 
 
 
TSA as Primary Screening Tool in FBDD 
 
Identification of small fragments with meaningful biological activity is the 
essence of fragment based drug discovery. Often multitude of biophysical and 
biochemical methods are implemented in a cascade for initial screening and lead 
progression. There are multiple methods which could be used to screen a collection to 
identify weak affinity fragments however cost, ease of implementation and reagent 
consumption are the most often bottlenecks. Often one needs to screen the low molecular 
weight fragments at high molar concentrations, while keeping in mind solubility limit and 
artifacts (pH disturbance, signal quenching, inner filter effects) to determine measurable 
response due to low affinity of the fragments273.Akin to SPR or ITC being gold standard 
of binding interactions measurements, TSA has evolved into gold standard of protein 
stability measurements257,242,271. The higher sensitivity offered by techniques such as SPR 
or ITC is certainly an advantage however it is best suited for lead progression stages. 
Structural techniques such as X-ray crystallography find their best use after extensive 
optimization of crystal conditions specific to a target .Often extensive optimization of 
buffer conditions (pH, Salt) and effect of additives (reducing agents, metal ions, 
detergents), is required before more sensitive techniques could be used reliably. In this 
regard thermal shift emerges as a fast, economic and almost ubiquitously applicable 
primary screening technique which does not require a sophisticated instrumentation or 
prior knowledge of structure or function of the target protein. The TSA has been 
successfully applied to fragment based drug discovery approaches on diverse targets to 
advance identification and prioritization of primary hits274,275,276. Additionally the thermal 
shift assay could be quickly applied to screen the buffer conditions and additives for more 









Another often less used aspect of TSA assay is identification of ligands which 
destabilize the test protein under experimental conditions277,246. Although certain 
fluorescent compound could be falsely identified as destabilizers due to spectral overlap 
with reporter dye, however such compound are more likely to saturate detector 
generating flat denaturation profiles which has no information on melt profile of protein. 
Various unstable, redox cyclers, aggregators, and PAINs category compounds can 
potentially denature protein prematurely generating false negatives especially on assays 
such as SPR where protein is immobilized on chip surface and multiple test compounds 
are passed over same protein. Thus identification of such ligands is very useful toward 






Generation of protein crystals to aid structure guided drug design by identification 
of key binding interactions of the ligands within a binding pocket, is a common goal of 
all drug discovery programs. The TSA assay is commonly used to characterize buffer 
conditions to aid purification of proteins, to determine effect of additives toward 
generation of protein crystals for structural studies278,259,251. The generation of high 
quality protein crystals has been shown to correlate with optimization of crystal 
conditions enhancing protein stability278,259. The TSA assay finds its applications in 
predicting the like hood of formation of crystal based on proteins stability profiles by 
enabling quick screening of stabilizing storage buffer conditions, thus enhancing success 
rate of crystallography279,278. Further comparative thermal shift analysis of a wild type 
against its truncated variants is useful in prioritizing a specific protein constructs to aid 
protein crystallography279,246. Similar comparative assessment of melting temperature of a 
wild type against its mutant protein could be useful in determining specificity of the X-





The TSA is quite handy in guiding affinity optimization by studying binding 
behavior of compounds on a wild type protein and its mutant with key binding 
interactions disrupted. Further transitions in melt profile could indicate positive 
cooperative binding between two ligands or a compound and a protein242. 
 
 
Buffer Components Screening 
 
Another important use of TSA assay is to assess the inherent stability of the 




Phosphate),impact of pH, ionic strength, salts, reducing agents, metal ions, excipients, 
mutations and natural ligands, on native stability of the target proteins281,282,257. 
 
 
Protein Purification and Quality Control 
 
The TSA assay can differentiate effect of purification tags such as Histidine or 
GST tag on purified proteins stability in solution and thus can be used to aid purification 
of proteins. Further based on the melt profile, TSA assay can distinguish between eluted 
protein fractions containing monomeric or oligomeric proteins. The applications of TSA 
have been extended to protein characterization studies by measuring impact of truncation 
or mutations on protein stability and consequently on their function283,284. 
 
 
Formulation and Storage Conditions 
 
The presence of contaminants or generation of protein aggregates over time in 
sensitive therapeutic products such as purified monoclonal antibodies, is a major concern. 
The TSA assay is useful in determining optimal formulations and storage conditions and 
could be used as a quality control measure of protein purity and shelf life. 
 
 
Merits of TSA Assay 
 
The TSA is a simple and easy to implement technique for identification and 
characterization of ligands interactions with target protein for drug discovery 
applications. The most obvious advantage of TSA is its fast, economical and almost 
ubiquitous applicability to diverse drug discovery targets such as proteases or kinases. 
From screening standpoint, the X-ray crystallography based ligand identification first 
requires detailed knowledge about target structure as well extensive optimization of 
crystal conditions to facilitate soaking of putative ligands with target protein, an aspect 
not amenable to every protein target. Contrary to other ligand identification methods, the 
TSA by design is a robust and a minimalistic assay which could be readily implemented 
in mix-read steps without any prior knowledge of target structure or function. For most of 
the proteins the TSA assay is a great substitute or at very least a beginning assay 
especially in absence of a direct activity based output method, thus eliminating need to 
design a dedicated assay for ligand identification. Further the TSA does not require any 
sophisticated instrumentation, expansive reagents, technical knowhow and user expertize 
as often required for successful implementation of other biophysical assays such as SPR, 
NMR, and ITC. The TSA can be configured on any conventional RT-PCR instrument a 
heating block and fluorescence detector to obtain fluorescence data which is sufficient to 
set TSA as a primary screening binding assay. As a ligand identification method, the TSA 
is compatible to both 96 and 384 well format screening formats, offering superior 
throughput compared to techniques such as NMR, ITC or X-ray crystallography. The 
application of TSA extends from monitoring of protein-protein interactions (PPI) as well 




time. The TSA is easy to implement technique and does not require target modification, 
product washing or separation steps. The screening range of TSA extends from peptide 
collections to fragments to natural products including semi pure fractions. 
 
 
Limitations of TSA Assay 
 
The TSA assay despite being a high throughput capable and economic 
biophysical method of detecting potential ligands, is prone to false positives and tells 
very little about specificity of binding. Further the applicability of TSA is however not 
absolute and suitability of the proteins to TSA is contingent on its folded state (globular 
structure), presence of hydrophobic pockets and in vitro stability at room temperature 
conditions. Certain protein such as intrinsically disordered proteins, ion channel 
transporters, and membrane bound proteins, do not have well folded three dimensional 
structure in the in vitro assay conditions and are thermally instable. Exposure to room 
temperature conditions to such protein, results in rapid denaturation. The maximal 
binding of reporter dye to exposed hydrophobic pockets in the beginning phase of 
temperature gradient or at low temperatures , leads to very high fluorescence signal 
resulting in either fluorescent detector saturation or generation of nonlinear (misfit to 
Boltzmann algorithm) complex melt curves with indistinct or non-uniform melting 
transitions, which complicates the analysis. The TSA does not work well with semi pure 
proteins due to masking of target melting curve by denaturation profiles of other 
contaminants. Further the TSA works best when the relative shifts in Tm are larger than 
baseline and when comparing the Tm of related analogs rather than diverse compounds. 
The TSA also cannot distinguish if a ligand is binding inside or outside the binding 
pocket, in other words cannot distinguish allosteric binders from direct binders. In case of 
ClpP protein the TSA assay cannot distinguish between inhibitors vs activators as well. 
The compounds binding to two different pockets on the same protein may appear to be 
more potent due to additivity of binding. This problem can be resolved using dose 
response experiments and orthogonal validation on ITC for stoichiometry. 
 
From drug discovery standpoint, the TSA at its very best is a primary screening 
assay in a single point screening format with yes/no answers for ligand identification. In 
absence of other secondary binding assays (i.e. SPR/ ITC), the TSA is a tool to validate 
and prioritize leads with highest melting temperature shifts, for further optimization. The 
hit rate of TSA is quite low often < 5% however screening of compound libraries with 
poor solubility threshold could lead to increase in number of false positives. The poorly 
soluble test compound could easily form aggregates or interact nonspecifically with 
protein or even denature the protein resulting in generation of spurious data. Another 
source of false positives is the compounds with inherent fluorescence overlapping the 
excitation emission spectra of reporter dye resulting in misleading data due to inner filter 
artifacts. Often such compounds produce large (false) positive shifts and such hits 






Getting Ready for TSA-Based Screening 
 
 
Ideal TSA Experiment 
 
An ideal TSA experiment is shown (in context of ClpP) in Figure 2-1. In the 
beginning of the experiment, apparent hydrophobicity of a well folded protein in a 
solution is low as most of hydrophobic pockets are buried deep in protein folds, as a 
result initial fluorescence signal is also low. As temperature is increased, the apparent 
hydrophobicity increases due to exposure (melting) of buried pockets and consequently 
fluorescence also increases due to binding of SYPRO Orange(TM) to exposed pockets. At 
a certain critical temperature, most of the pockets are exposed and fluorescent signal from 
SYPRO Orange(TM) reaches its maximum, protein starts to break apart and binding 
affinity of dye drops, leading to trailing downwards slope. Certain proteins with partially 
unfolded regions give initial high fluorescence followed by lower minima after which 
maximal signal occur. It is observed often that shape of the curve before and after melting 
transition is mostly nonlinear due to artifacts originating from human or robot errors in 
pipetting (effects fluorescence intensity), optical perspective effects from detector lens, 
air bubbles and quenching of fluorescence by certain ligands. For such proteins, the 
initial part of the melt curve needs to be normalized to minimal point and post peak curve 
needs to be normalized to maximum point before Boltzmann algorithm could be applied. 
It is important to observe slope of the melt curve, Tm of the curve, smooth transition from 
folded to unfolded state. The proteins which are multimeric or having cooperatively in 
their denaturation often produce melt curves with multiple transitions compared to single 
transition of well folded proteins. An ideal curve has low baseline fluorescence, a 




Essential Components of TSA Optimization 
 
The TSA assay can be configured with or without any prior information on 
behavior of target. The choice of instrumentation depends on desired throughput of the 
assay. As such no specialized instrumentation is required as any RT-PCR instrument with 
temperature controlled fluorescence readout facility can be configured to generate melt 
profiles. The first step in TSA assay optimization is determination of suitability of target 
to thermal denaturation. Based on shape of sigmoidal denaturation profile, separation of 
peak signal from baseline (signal window), an estimation on structural integrity (folded 
state or compactness) and hydrophobic character is made. The denaturation profile of a 
well folded protein generates a monophasic and sigmoidal curves with good signal to 
baseline separation of signal, which in turn indicates degree of hydrophobic character of 
target protein. The partially folded proteins have multiphasic, non-sigmoidal curves in 
both pre and post denaturation phase whereas melt profile of unstructured or denatured 
proteins are devoid of typical sigmoidal shape. A characteristic sign of denatured protein 







Figure 2-1. Principle of Thermal Shift Assay (TSA). 
Heating of a protein on a thermal gradient exposes the hidden hydrophobic pockets to 
which the reporter dye binds generating a sigmoidal peak with melting temperature (Tm) 






fluorescence on a temperature gradient. The essential components of TSA assay 
optimization are assessment of suitability of targets to TSA and throughput of instrument; 
Minimum concentration and volume requirements; Optimal buffer conditions (individual 
buffer components, reducing agents, metal ions, reporter dye etc.); Screening range based 
on type of ligands; Order of addition, incubation time ; Work Flow design for screening 
(pin tool drugging) and Data Analysis. 
 
 
Basic Assay Design 
 
The basic scheme of TSA is outlined in Appendix A Figure A-1. The assay is 
configured in single point format for screening of compound collections and in dose 
response format for hit validation. In both formats the well location and concentration of 
test compounds as well as controls is predefined for later stage pipeline pilot processing. 
Unless required otherwise the initial concentration can be set to 2-5 µM for most 
proteins, and 2.5X for SYPRO Orange(TM) dye for both screening as well as 
characterization formats. The final volume can be set to 20 µl per well for ease of 
pipetting although the assay can be carried out in final volume less than 10 µl/well. The 
order of addition is important to ensure assay success. The underlying premise is to 
minimize exposure of protein to reduce chances of protein denaturation due to harsh 
environmental factors before thermal denaturation. In case of fragment screening, often 
high molar concentration of fragments is screened against protein, which can lead to 
denaturation of protein in the beginning of assay. Therefore first a master mix 1 
containing 2 X base buffer conditions is prepared and 10 µl/well pipetted into 384 well 
plates as per plate map. Then selected test compounds and controls for screening or hit 
validation, are pin transferred using automated liquid handling machine (Biomek FX) as 
per screening test range of 10 µM to 2 mM for tight, mediocre and weak binders. Later 
the master mix 2 containing 2X protein and SYPRO Orange(TM) dye is prepared 
immediately prior to final mixing to minimize exposure of protein to environment. Then 
10 µl/well of master mix 2 is pipetted into respective wells while mixing the contents 
gently. The plates are sealed with optically clear plate sealer and following a brief 
incubation time period of 2-5 minutes, the plates are briefly centrifuged to remove air 
bubbles. The fluorescence data is recorded by heating the plate from 25-95 degree with 





Of all methods to get Tm, the most straight forward way is first derivative method, 
in which differential of fluorescence change per unit time is plotted against temperature 
to obtain as bell shaped curve. The melting point is the temperature against highest point 
on the curve, however compared to Boltzmann curve fits, its data quality is rather poor 
and Tm generated using both methods are identical (Figure 2-2A, B).Further the 
derivative method does not work well for biphasic or complex transitions and for dose 







Figure 2-2. Processing of ClpP Thermal Shift Assay Raw Data. 
A: Derivative plot of thermal melt curve with melting temperature at highest point of 
peak 
B: Raw melt curve after pre and post melt phase processing 






screening standpoint the real utility of TSA assay is identification of hits with right 
shifted denaturation profiles (increase in melting temperature) compared to DMSO 
control. However in absence of a dedicated thermal shift evaluation machine or software 
the analysis of raw data from a 384 well plate with varying response per well becomes a 
bottleneck issue while both throughput and reliability of the assay goes down. To resolve 
the issue, a custom pipeline pilot as well as Microsoft excel software scripts were 
developed. For most of the simplistic cases the fitting to Boltzmann algorithm serves as 
quick way to determine Tm. An important requirement for a good fit to Boltzmann 
algorithm is the linear response in both initial and post melting phase. In most of the 
cases the data curves needs to be curated for pre and post melting phase deviations from 
standard sigmoidal curve behavior before curve fitting to generate reliable melting point 
data. The raw fluorescence data is further normalized on a percentage unfolded scale (0-
100%) by baseline subtraction and linearization of pre or post melting curve points. The 
linearization is achieved by first identifying the minimum and maximum signal data point 
in single transition with sigmoidal shape (Complex proteins have multiple transitions) 
and normalizing all data points before minimum to same value and after maximum to 
same value (Figure 2-2C-F). The curated data is fitted to Boltzmann algorithm to 
determine apparent melting temperature. Using pipeline pilot scripts or similar data 
processing algorithms, this procedure can be applied to multiple wells or all wells within 
a plate simultaneously and difference of melting temperature can be readily computed. 
The compounds in Figure 2-3A, B did not exhibited any binding therefore no change in 
Tm was noticeable, whereas compounds in Figure 2-3C, D have noticeable positive shift 
in melting temperature. Additional output data constitutes heat maps, dot plots, and 
sigmoidal plots with Boltzmann’s fit and derivative plots. The performance of assay is 
assessed based on coefficient of variation (% CV), and standard deviations in replicative 
behavior of positive and negative controls. 
 
As a general rule, the hit selection criterion of shift in melting temperature is 
proportional to coefficient of variation (% CV) of baseline response from negative 
controls. The hit selection criteria of at least 1 degree shift or equivalent to 3σ rule (mean 
Tm+3*SD of mean) sufficient when the coefficient of variation of baseline data or 
negative controls is low (<2%) and SEM is below 0.2 degree. It is important to have 
enough replicates (ideally 8-10) of negative controls to have confidence in % CV and 
SEM numbers. For proteins with larger noise in the baseline response the hit criteria 
needs to be increased to 2 or 3 degree or higher. In screening format, based on assessment 
of signal noise from negative controls, the hit selection criteria for tight, mediocre and 
weak affinity binders can be set to >10 degree , >5 degree and at least 1-2 degree of 
positive shift in melting temperature respectively. Further it is important to pay attention 
to both positive as well negative shifts as in certain cases the ligand binding favors the 
denatured state of the protein. For typical fragments any positive shift greater than 10 
degree and negative shift greater than 4-5 degree is likely an artifact either from spectral 
interference or protein aggregation respectively. Peak fluorescence in the initial phase of 
the denaturation experiment is indicative of either highly fluorescent test compound with 
overlapping emission spectrum or maximum fluorescence from reporter dye upon 







Figure 2-3. Detection of Yes/ No Binding of Ligands to ClpP in Dose Response 
Format. 
A-B: Raw and processed thermal shift data from a non-binding compound in dose 
response format. 
C-D: Raw and processed thermal shift data from a binding compound in dose response 







positive Tm shifts in a close range and greater than set criteria, making their competitive 
ranking assessment difficult. Further given similar solubility of ligands, the shift in Tm is 
proportional to concentration of the ligands. Therefore to differentiate such compounds 
maximum Tm achieved at a given concentration (∆Tmax) is much better criteria than mere 
shift in Tm compared to baseline Tm. This criteria also works well in hit validation format 
as well for compounds with tight or mediocre binding affinity. 
 
 
Optimization of ClpP TSA Assay as a High Throughput Primary Screening Tool 
 
The underlying objective of ClpP TSA assay optimization was to optimize 
conditions for high throughput screening to facilitate rapid identification of potential 
binders to ClpP. For purpose of identification of binders specific to wild type ClpP, two 
mutants with substitution of essential tyrosine 63 with phenylalanine and tryptophan were 
purified. Additionally, human mitochondrial homolog of wild type ClpP was also 
purified to aid species selectivity differentiation. All optimization trails for wild type 
ClpP, its mutants (Y63W, Y63F) and human mitochondrial HClpP were carried in 




Initial Characterization of Wild Type ClpP 
 
The purified wild type ClpP from Staph aureus was initially tested in its storage 
buffer (Tris buffer pH 8.0) to observe its denaturation profile nature and to determine 
minimum concentration required over a temperature gradient. The wild type ClpP 
displayed (Figure 2-4A) proper sigmoidal denaturation profile suggesting its excellent 
stability under experimental conditions. The wild type ClpP is a multimeric protein with 
majority of its species population as tetradecameric complex (14 subunits) in solution and 
the generation of sharp melt profile indicates that melting of individual subunits is 
energetically coupled in a cooperative manner. Above experiments suggested suitability 
of wild type ClpP for ligand identification on a high through screening format. 
 
 
Determination of Optimal Screening Conditions 
 
The buffer conditions were explored (Figure 2-4B) to identify individual buffer 
components with stabilizing effect on wild type ClpP stability. First effect of pH and 
buffering capacity of Tris or Phosphate buffer on stability of ClpP was monitored. It was 
found that change of pH from 8.0 to 7.5 for both Tris and phosphate buffer enhanced 
thermal stability of ClpP. Additionally, effect of change of primary buffer component 
from Tris to Phosphate or Sulphates under constant pH and salt concentration was 
evaluated using a small molecule (2164) as positive control. The change in melting 
temperature between DMSO and positive control was lowest at 8.7 degree for Tris buffer, 






Figure 2-4. Optimization of ClpP Thermal Shift Assay. 
A: ClpP showing proper sigmoidal denaturation profile. 
B: Assessment of protein stability under various buffers and pH ranges. 
C: Comparison of ClpP stabilization by small molecule positive control 2164 to melting 






The Tris buffer is known to lose its buffering capacity at higher temperatures and 
phosphate buffer was found to be superior than Tris buffer at given pH. Next, effect of 
salt concentration was determined in a matrix experiment with varying concentration of 
NaCl and Na2SO4 salt. For a given concentration of Phosphate buffer (Figure 2-5A), 
Na2SO4 enhanced stability of the ClpP compared to NaCl, however due to instability of 
sulphates, NaCl was preferred. Further effects of detergents which are often added to 
screening assays to aid solubility of test compounds or certain proteins, was tested by 
using nonionic detergent Triton X-100. Addition of Triton X-100 (Figure 2-5B) lowered 
the melting temperature of ClpP significantly. This however was not due to 
destabilization of ClpP by Triton X-100, instead it is likely due to preferential binding of 
reporter dye to aggregates or micelles of Triton X-100, masking actual signal of protein 
denaturation, thus generating a false negative. Then addition of reducing agents such as 
DTT or TCEP was found to not affect ClpP stability significantly. Lastly, stability of 
ClpP stored at 4 degree over period of seven days was measured in selected phosphate 
buffer and protein was found (Figure 2-5C) to be very stable with reproducible 
denaturation profiles (%CV<1). 
 
 





To determine minimum concentration of ClpP required to generate sufficient 
signal, melting temperature of ClpP titration (0.2-200 µM) was obtained (Figure 2-6A). 
At concentration up till 10 µM the apparent melting temperature of ClpP was in close 
range of +/- 1 degree with proper sigmoidal transitions and at concentration greater than 
20 µM the melt profiles exhibited complexity in melting transitions. Therefore final 
concentration of 5 µM (v/v) was determined to be sufficient for screening experiments. 




SYPRO Orange(TM) Titration 
 
The effect of reporter dye concentrations at set protein concentrations was also 
monitored in a titration experiment with up to 10X (v/v) SYPRO Orange(TM) and up to 
0.3-2.5X SYPRO Orange(TM) was found (Figure 2-6B) to give reproducible denaturation 
profiles of wild type ClpP. The final concentration of SYPRO Orange(TM) was set to 2.5X 









Figure 2-5. Determination of Best Buffer Conditions for ClpP. 
A: Evaluation of native melting temperature of ClpP under varying buffer or salt 
conditions. 
B: Assessment of impact of detergent on ClpP stability in Tris or Phosphate buffer. 








Figure 2-6. Optimization of High Throughput Screening Conditions for ClpP 
Thermal Shift Assay. 
A: Determination of minimum ClpP concentration required for a 384 well format assay. 
B: Determination of minimum SYPRO Orange(TM) concentration. 
C-D: Assessment of ClpP tolerance of DMSO and variability from plate to plate. 








To adapt TSA to high molar concentration screening format, DMSO tolerance of 
ClpP was determined and it was found (Figure 2-6C) addition of DMSO greater than 
10% introduced complexity in phase transitions. Therefore the maximum tolerated 
DMSO % was set to 5% DMSO (v/v), in which ClpP protein exhibited reproducible melt 
profiles. The DMSO only wells were set to be the negative control representing native 
stability of protein in absence of a ligand. Later well to well, plate to plate and day to day 
variations in baseline response of DMSO only wells were found to be highly reproducible 
within ±1 degree (Figure 2-6D). 
 
 
Assessment of Controls 
 
The selection of controls for screening experiments was based on degree of shift 
in Tm. The large molecule sized ADEPs have higher binding affinity toward ClpP and 
therefore exhibit larger shift (25-30 oC) and correspondingly the smaller sized 
compounds with mediocre binding affinity introduce comparatively smaller (10-15 oC) 
shifts (Figure 2-6E). The underlying purpose of TSA assay was to provide ranking for 
both large and small molecule analogs. Therefore ADEP4 and its more soluble analog 
2378 were selected as large molecule positive control and 2164 and 2599 were selected 
as a small molecule controls. 
 
 
Screening Concentration Ranges 
 
The selection of screening range for different compound collections was based on 
average molecular weight of the collection. This was due to fact that smaller compounds 
have much weaker affinity and often signal is hard to distinguish from baseline. In case 
of TSA, the shift in melting temperature from an average binding fragment is between 1-
2 degree at a mill molar concentration and the signal from the same fragment would be 
indistinguishable from the baseline at ½ or 1/3rd concentration. While it is true that a 
smaller sized fragment can have larger shift provided its binding affinity is high however 
later is largely not true. Most of the fragments have much weaker binding interactions 
compared to larger sized compounds, therefore their detection demands higher dose and 
higher detector sensitivity. The ClpP is a large multimeric protein with large interaction 
area within binding pockets. Therefore to increase the chances of reliable detection of 
signal the screening range for fragment sized collections was extended up to 2 mM while 
taking note of solubility limit of collections. For collections with larger average 
molecular weight (~500 Da) the screening range was set to be around 500 µM. For 
collections with even larger molecular weight the screening concentrations were set at 
200 µM or lower. For known binders of ClpP the final screening ranges were similarly 
determined based on anticipated response. Further the titration experiments with ADEP4 
suggested that up to 20 µM ADEP4 (4 time ClpP molar volume) induces as much as 
thermal shift as ADEP4 at 100 µM or higher. For ADEP4 analogs the ∆Tmax screening 






For fragment binders the baseline response was highly reproducible with minimal 
variations (% CV<2, SEM < 0.2 degree), therefore the hit criteria was set to +1 degree 
shift from average Tm of baseline response. For small molecules series #1 (2164 
derivatives) and 2 (3421 derivatives), the hit cut off for binding was set at greater than 5 
degree Tm shift whereas for large molecules series the hit cutoff was set at greater than 10 
degree Tm shift. The shift in Tm is proportional to concentration of the compounds up till 
a saturation point where further increase in compound concentration starts destabilizes 
protein through aggregation or change of environment (pH, hydrophobicity) of the 
solution. Therefore for both large and small molecule based analogs, the maximum Tm at 
a given concentration (Tmax) was selected as selection or competitive ranking criteria 
instead of mere shift in Tm. This is due to limited resolution power of TSA for analogs 
with similar binding affinity. The shift in Tm for high affinity ADEP analogs and in many 
cases mediocre affinity small molecules was in very close proximity of set cutoff criteria 
as a result the analogs could not be distinguished against a set criteria of 10 or 20 degree 
shift. Therefore the maximum response concentration was set at 500 µM for small 
molecules series #1 , 50 µM (solubility limit ~100 µM) for comparatively higher affinity 
small molecule series#2 and 5 µM for large molecules to compensate for 10-100 fold 
difference of affinity between small and large molecules. In case of small molecules 2164 
and 2599 the apparent Tm shift is greater than 10 degree for both compounds however 
maximum shift (∆Tmax =Tmax test compound-Tmax negative control) at 500 µM 
concentration is higher for 2599 compared to 2164. Similarly for larger molecule 2378, 
the Tmax at 5 µM was lower than Tmax for 1999, aiding in their ranking (Figure 2-7A). 
The cut off criteria best small molecules series was set at Tmax of 10 degree and 20 degree 
for best large molecule series. For selectivity assessment the minimum of 2X maximum 
shift cut off was selected for small molecules series and 4X for large molecule series. 
 
 
Characterization of ClpP Mutants (Y63W, Y63F) 
 
The purpose of the Y63 mutants is to validate specificity of ligand binding within 
ADEP4 binding pocket. Based on wild type ClpP response the essential tyrosine mutants 
(Y63F, Y63W) were tested for their thermal denaturation profile and were found (Figure 
2-7C-F) to exhibit stable denaturation profiles similar to wild type ClpP. However 
comparison of hill slope of mutant’s denaturation profiles against wild type ClpP 
suggested subtle destabilizing effect of essential tyrosine substitutions on protein stability 
with phenylalanine substitution more destabilizing (steeper slope) than tryptophan 
substitution. This observation was further corroborated in an experiment (Figure 2-7B) 
with known binder ADEP4. As expected both Y63W and Y63F mutations had profound 
effect on binding pocket geometry, and ADEP4 binding was completely abolished. 
Compared to ∆Tm of ADEP4 for wild type at 22 degree, the ∆Tm for Y63W was at 1.5 







Figure 2-7. Determination of Maximum Response Control Concentrations and 
Optimization of ClpP Mutants on Thermal Shift Assay. 
A: Determination of control concentration for maximum response from small and large 
molecules. 
B: Assessment of control binding interactions with ClpP and its mutants. 
C-F: Assessment of native melting temperature of wild type (WT) ClpP and its Mutants 






Characterization of Human Mitochondrial ClpP (HClpP) 
 
The HClpP was purified to provide validation for preferential selectivity of the 
potential hits toward wild type ClpP compared to HClpP. The thermal denaturation of 
HClpP produced normal sigmoidal melt profiles suggesting its stability and suitability as 
a counter screen to wild type ClpP. The minimal concentration of HClpP required per 
well was determined to be identical to wild type ClpP at 5 µM. The HClpP melting 
temperature was found to be higher (Figure 2-8A, B) than wild type ClpP owing to 
difference of physiological occurrence of HClpP as majority of heptameric species in 
solution compared to tetradecameric form of wild type ClpP. Further known activators 
(2164, 2599, 2378, and 1999) of wild type ClpP were screened at selected concentrations 
against HClpP to determine if TSA on HClpP can reveal species specific differences in 
binding. All compounds except 2378 were found (Figure 2-8C) to bind to HClpP 
suggesting overall similarity of binding pocket. The shift in melting temperature for small 
molecules 2164, 2599 was higher for HClpP at a given concentration (500 µM) compared 
to bacterial ClpP. The lack of selectivity of small molecules was understandable given 
both proteins share structural topology within binding pockets. Most likely the selectivity 
is influenced by molecular size of the molecules and its multi-point interactions with 
protein backbone. The ADEP4 on the other hand, produced much larger shift in wild type 
compared to HClpP suggesting selectivity or preference for wild type ClpP. Interestingly 
2378, an ADEP with truncated hydrophobic chain and lack of difluoro moieties on 
phenyl ring was found to exhibit no binding to HClpP compared to much larger Tm shift 
in wild type. This observation suggested that key to building selectivity lies in parts of 
pocket housing di-fluoro moieties and alkyl chain. 
 
 
Utilization of TSA as a Buffer Screen for ClpP SPR Assay 
 
One of the important concern during buffer optimization on SPR is impact of 
buffer additives on immobilized ligand. Often initial buffer scouting is time consuming 
therefore TSA assay was selected for preliminary buffer scouting. Addition of DMSO is a 
requirement for SPR buffers to match the refractive index of running buffer to injected 
analytes, therefore all buffers systems contained 4% DMSO. Next impact of EDTA, a 
common additive added in SPR buffers to chelate contaminating metals, was assessed in 
respective buffers. To this effect in a matrix setting within single experiment, first 
melting temperature of ClpP protein in selected SPR screening buffers at pH 8.0 (Tris, 
Phosphate, Hepes and PBS) was assessed. Regardless of the buffer conditions the ClpP 
exhibited proper sigmoidal melt profiles indicating its tolerance to chosen buffer 
conditions. As expected the Tm for Tris buffer (Figure 2-9A, B) was slightly lower 
compared to other buffers due to thermal instability of Tris buffer. The Tm for HEPES 
buffer was practically same as phosphate buffer suggesting suitability of either of the two 
buffers SPR experiments. Addition of ~3 mM (v/v) EDTA in either buffer destabilized 
ClpP slightly in all test buffers suggesting potential implications on its use. This 







Figure 2-8. Optimization of Human Mitochondrial ClpP (HClpP) on Thermal 
Shift Assay. 
A: Assessment of native melting temperature of HClpP. 
B: Determination of minimum concentration of HClpP required for robust signal. 








Figure 2-9. Utilization of Thermal Shift Assay (TSA) in Buffer Exploration for 
Surface Plasmon Resonance Assay (SPR) and Determination of Binding Affinity 
from TSA. 
A: Determination of ClpP native melting temperature on SPR compatible buffers. 
B: Determination of effect of EDTA on ClpP stability under various buffers. 







EDTA to running buffer decreased stability of immobilized ClpP (increased drift rate) on 
Ni-NTA likely by chelation of Ni ions thus destabilizing immobilization conditions. 
 
 
Calculation of Affinity Constants Based on TSA 
 
There is essentially no limit of detection for TSA as depending on ligand 
concentration higher Tm shifts are produced
246. In an ideal situation, increase in thermal 
shift is proportional to increase in concentration of binding ligand and in theory binding 
affinity of the ligand can be estimated by plotting meting temperature differential against 
compound concentration. The TSA experiments could be used to determine binding 
affinity contents (KD) and various algorithms have been published to calculate binding 
affinity of the ligand at Tm
282,247,242. Often thermodynamic data on enthalpy (∆H) and heat 
capacity (∆C) from ITC or DSC experiments is required to supplement KD determination 
based on TSA melt profiles. A few studies have further derivatized the TSA as a 
secondary screen to measure binding affinity and stoichiometry in lieu of traditional gold 
standard yet resources intensive techniques such as ITC285,282. In absence of any ITC 
data, a standard value of ∆H at -15 Kcal Mol-1 could be used as an average for most 
protein ligand interactions242. The machines dedicated to thermal denaturation analysis 
which provides both fluorescence and thermodynamic data are commercially available, 
however in TSA proteins are irreversibly denatured on a temperature gradient, so 
determination of accurate thermodynamic parameters such as enthalpy or heat capacity is 
challenging. Given the fact that most of common RT-PCR based instruments do not 
generate accurate thermodynamic parameters such as enthalpy and heat capacity, the best 
utility of TSA is in ligand identification from screening standpoint, rather than 
calculation of affinity constants. Additionally in absence of a dedicated thermal shift 
machine and associated software, the data analysis is the most rate limiting step besides 
limitation of machine output of one plate at a time. This is especially true for screening of 
fragment collections with thousands of test compounds with primary objective of the 
screen is to identify ligands which interact with target protein. 
 
Further the estimation of binding affinity from TSA is less accurate compared to 
SPR or ITC and at its very best, is in agreement with affinity constants from SPR or ITC 
in trend rather than absolute values. This is due to inability of TSA to distinguish 
specificity of binding. The TSA observes the shift in melting temperature as function of 
total binding (specific + nonspecific) of the reporter dye as well as ligand. Further 
thermal denaturation is an asymmetric, nonlinear process as results the denaturation curve 
do not fit the signature of sigmoidal shape and have poorly defined max denaturation 
(saturation) regions. To compensate for specific and non-specific binding, a new matric 
based on maximal thermal shift (∆Tmax) can be utilized to estimate binding affinity. The 
∆Tmax can be calculated as maximum shift in melting temperature induced by a ligand at 
a given concentration and is defined by one site total binding model, which assumes total 
binding (specific + nonspecific) is larger than specific binding from ligand286. 
 
The response of larger tight binding molecules expectedly reaches saturation stage 




affinities. However the binding response of both large and small molecules in general is 
nonlinear with increase in concentration especially at lower concentrations. The TSA 
based KD is 50% is defined by concentration at which the half of maximum shift in 
melting temperature is achieved. Due to observed non linearity in both initial and post 
saturation part of the curve, the TSA based bind affinity a close estimate. Further both 
Tmax and KD however are useful in rank ordering the compounds during SAR expansion 
studies. For example (Figure 2-9C) evaluation of ADEP4 derivatives 2420, 2421 on TSA 
suggests a contrast difference of affinity with 2420 as much more potent compared to 
2421. The binding affinity of ADEP4 urea derivative 2428 is higher than 2420 as 
suggested by faster saturation rate and higher Tmax. For small molecule analogs (Figure 
2-9D) similar ranking order could be achieved with 2567 as most potent. 
 
 
Conclusions- Thermal Shift Assay 
 
The performance (assay quality) of TSA on a high throughput screening platform 
is limited by standard deviations in the background noise. For a well folded protein the 
SD is lower than 1 % which helps in determining a suitable cutoff at 3 times the SD. 
Correspondingly for proteins which are less behaved on the system the variability of the 
background noise makes cutoff determination rather difficult or less accurate resulting in 
increase in fast positives. Since TSA measures the melt temperature as a function of 
inherent stability of the protein , the variability in Tm could originated from buffer 
components, pH, ionic concentration, hydrophobicity, purity, multimeric nature, 
cooperative unfolding patterns and human or machine error. Evaluation of hits below 1-2 
degree of shift is difficult and run the risk of identification of false positives. The 
Screening of fragments on TSA requires high molar concentrations (below solubility 
limit) and shift in Tm by real fragment binders is 1-2 degree given that fragments are 
weak binders. The detection of real binders depends more on the variability of baseline 
noise or variability of Tm of the negative control rather than actual Tm of the protein. In 
such scenario distinction of positive or negative hits from noise is challenging. To 
improve the chances of successful TSA based screen it is important to optimize buffer 
components such as pH, salt, additives and detergents if any before actual screen. Unless 
curated on basis of high aqueous solubility at mM ranges, most compound collections 
especially fragment libraries unavoidable have compounds which are not soluble at high 
molar screening concentrations. To aid the solubility of the test compounds, addition of 
detergents is recommended however most detergents increase the hydrophobicity of the 
solution, resulting in masking of the signal of actual protein denaturation. In many cases 
addition of detergent to the assay leads to saturation of signal due to maximal binding of 
SYPRO Orange(TM) to local hydrophobic detergent micelles even before thermal gradient 
is applied, rendering the assay completely unusable for data analysis. Utilization of 
detergents well under their CMC values may be of limited use in certain cases where 
protein is exceptionally stable and net increase in hydrophobicity upon melting is much 
larger than the baseline with detergent. 
 
Based on the above observations the final buffer conditions for characterization or 




2mM DTT, 2% DMSO (v/v). The final screening conditions as well as test ranges for 
Y63 mutants were kept identical to wild type ClpP whereas for hClpP the final salt 
content was increases to 200mM to match its storage conditions. The screening range for 
large, small and fragment size molecules was set to up to 200, 500 and 2000 µM. The hit 
selection criterion for fragments was based on % CV and SD of negative controls and 
maximum Tm achieved at 500 µM for small molecules and at 5 µM for large molecules. 
 
 
Optimization of Functional Assay on Bacterial ClpP and HClpP 
 
To meet the objectives of aim 2 toward optimization of a functional assay capable 
of measuring activation potential for ClpP (from Staph) activator compounds, enzymatic 
degradation of a fluorescent substrate by ClpP was selected as suitable assay format. To 
determine selectivity of activators toward bacterial ClpP, the HClpP functional assay was 
also developed in parallel using same substrate. The underlying premise of dual assay 
design was to determine impact of structural modifications on ADEP or small molecule 
analogs on their activation speed (Vmax), or Potency (EC50 or KM) and to generate a rank 
ordering parameter based on overall catalytic efficiency (kcat) of bacterial ClpP to 
differentiate various analogs from one another. 
 
 
Design Principle of Enzymatic Assay 
 
The basic design of ClpP functional assay was based on measurement of 
fluorescence signal upon degradation of initially quenched fluorescently labeled substrate 
by ClpP upon activation by either its natural chaperons (ClpA/X) or by compounds 
(ADEPs)212. A fixed concentration of protease under linear velocity conditions and 
substrate below its KM (concentration of substrate at half maximum initial velocity value, 
is incubated at 37o C and titration of the ligand (activator) added at time 0 and increase in 
fluorescence (RFU) counts over a time course of 1 hour is measured. The activity (initial 
velocity, V0) of enzyme (Slope or RFU per unit time) is plotted against titration range of 
activator to generate a sigmoidal curve from which max velocity of enzyme (Vmax) and 
EC50 (concentration of activator to achieve 50 % maximum velocity) or KM is computed. 
The EC50 value gives estimate of potency of ligands as their activation potential (ability 
of ligand to turn on the ClpP proteolytic function). 
 
 
Critical Parameters of Enzymatic Assay Design 
 
The ClpP due to its multimeric assembly and cooperatively between individual 
monomers each containing an active site, exhibits complex behavior from enzymatic 
assay standpoint. Although the active site within individual monomers can degrade the 
substrate however the processivity is quite low, therefore complete assembly of the 
tetradecamer with 14 active sites is required for full activation. According to in house 
AUC experiments the assembly of the ClpP protein is concentration dependent with 




on the concentration, different population of ClpP exists within the system, complicating 
the response in an assay setting. In addition to above complexity, the binding of ADEP4 
is through positive cooperative mechanism, with binding of one ADEP4 molecule 
facilitating binding of additional ADEP4 molecules along with speeding up the assembly 
of ClpP tetradecamer. Therefore from enzymatic assay standpoint the concentration of 
ClpP needs to be kept low to facilitate linear velocity conditions in order to get accurate 
results. The HClpP also exhibits similar complexity during its assembly although not 
much is known about effects of ADEP4 binding on its behavior. 
 
The sensitivity of enzymatic assays is function of linearity of enzyme response at 
a given concentration287. At higher concentrations the activity of the enzyme does not 
stay linear due to rapid depletion of the substrate or from complex (non Michaelis–
Menten kinetics) behavior of enzyme due to formation of aggregates or higher order 
species. Further the lower limit of detection (assay floor) is proportional to half of the 
concentration of the enzyme below which determination of potency becomes nonlinear 
and increasingly inaccurate287,288. Therefore detection of linear range of the enzyme 
activity is critical to establish a robust assay. Next critical parameter in development of 
enzymatic assays is determination of initial velocity conditions in which response of the 
enzyme does not change with time (or is linear) within 10 % of substrate depletion or 
product formation288. The basic assumption of linear velocity conditions is that substrate 
is present in excess and its concentration is not rate limiting parameter288. The 
measurement of the initial velocity conditions ≤ KM of the substrate ensures achievement 
of Michaelis–Menten equilibrium (steady state) conditions. Product or substrate based 
inhibition is yet another critical parameter which could affect accuracy of potency 
measurements for competitor compounds. Therefore concentration of substrate should be 
below its KM
288. The turn over number or catalytic efficiency kcat is a measure of enzymes 
efficiency and can be computed based on value of Vmax and enzyme concentration under 
initial velocity conditions. 
 
 
Choice of Enzymatic Assay Substrate 
 
Previous studies reported use of a synthetic dipeptide substrate SUC-LY-AMC 
(N-Succinyl-Leu-Tyr-7-amido-4-methylcoµMarin) and its variants with varying peptide 
lengths based on substrate cleavage specificity of proteases208,289. However from 
screening assay standpoint the lower wavelength spectrum of SUC-LY-AMC at (Ex/Em 
360/460 nm) was suboptimal due to higher chances of fluorescent interference from 
compounds from screening collections. Further the reported KM of the SUC-LY-AMC 
was quite high requiring up to molar concentration of substrate, an aspect with potential 
implications toward substrate mediated inhibition enzyme activity and assay cost. 
Additionally the ClpP protein exhibits low level of processivity for peptides up to 6 
amino acid length without requiring activation, as aspect which could complicate the data 
analysis, therefore the selection of a larger substrate was sought209,205. The FITC 
(Fluorescein isothiocyanate) labeled casein substrates (Ex/Em 485/538 nm) were an 
attractive alternative due to their linear response to common proteolytic enzymes and 




photo bleaching over time was an issue therefore a relatively pH and light insensitive 




Test of Enzyme Activity and Detection Limit 
 
The selection of BODIPY-FL as a fluorophore for substrate conjugation was also 
incremental for high signal quality owing to its high extinction coefficient (EC >80,000 
cm-1M-1). The functional activation of ClpP with ADEP4 and degradation of substrate 
was confirmed by observing (Figure 2-10A) increase in fluorescence due to degradation 
of substrate titration by activated fixed concentration of ClpP pre-incubated with molar 
excess of ADEP4. The activated ClpP below 100 nM concentration exhibited small 
signal increase in signal due to inhibition by saturating concentrations of substrate. The 
ClpP at 1 µM concentration exhibited proper response with linear increase in signal along 
increase in substrate concentration. Further the detection limits of instrument (BMG 




Determination of KM under Linear Velocity Conditions 
 
For ClpP functional assay conditions close to linear velocity conditions (~10% of 
product formation) were chosen given complex behavior of the protein at higher 
concentrations. To determine KM the titrations up to 100µM BODIPY-FL substrate were 
added to fixed concentrations (1µM, 5 µM) of pre-activated ClpP and response was 
measured at 37 degree for a period of 1 hour. The initial velocity of ClpP was measured 
by observing slope of signal increase curve against substrate concentration. Using 
standard Michaelis–Menten equation, the KM of the BODIPY-FL substrate was 
determined. For 5X increase in ClpP concentration, the maximal generated signal 
(Figure 2-10B) was almost twice the value for 1 µM ClpP suggesting nonlinear response 
of ClpP at higher concentrations. The KM of substrate was determined to be practically 
same for both test concentrations. Further similar to ClpP from bacteria, HClpP was 
found to be functionally active upon binding of ADEP4 (Figure 2-10C). The maximal 
activity (Vmax) of HClpP increased linearly along with increase in protein concentration 
up till 1µM and thereafter was found to exhibit nonlinear response at higher protein 
concentrations. Based on above results the final concentration of both bacterial ClpP and 
HClpP was determined to be 1µM. In accordance with linear velocity conditions for 
enzymatic assays, the final concentration of substrate was kept below its respective KM, at 
~ 1 µM and 0.5µM for bacterial and HClpP respectively for future characterization. 
 
 
Determination of Controls and Final Buffer Conditions 
 
The ADEP4 was selected as primary control for both ClpP proteins as a 






Figure 2-10. Optimization of ClpP and HClpP Enzymatic Activation Assay. 
A: Determination of ADEP4 mediated ClpP activation by monitoring degradation of 
BODIPY-FL labeled casein substrate. 
B: Determination of ClpP linear velocity assay conditions. 






ADEP4 was titrated against 1 and 5 µM of ClpP to observe the reaction kinetics. The 
kinetics of ADEP4 mediated substrate digestion were complex, with very fast initial 
velocity profiles, which did not followed classical Michaelis–Menten velocity curves 
(Figure 2-11A, B).For both proteins, the max velocity of substrate digestion was 
achieved within first 5-10 minute of incubation at 37 degree followed by decrease in 
fluorescence signal indicating differential processivity depending on quantity of 
undigested substrate in solution. The difference of processivity may have originated from 
different sub population of heptameric to tetradecameric ClpP which upon binding by 
ADEP4, cleaved the substrate to different extent. Further similar to earlier observations, 
the maximal velocity of casein degradation by activated ClpP and respective ADEP4 KM 
was nonlinear above ClpP concentration of 1 µM, reaffirming earlier results of non-
linearity in ClpP activity above 1µM concentration. Slight variations in kinetics of 
substrate digestion by ADEP4 activated ClpP were observed due to differences of assay 
conditions and different lots of synthetic substrate. On the average the both bacterial and 
HClpP exhibited sub micro molar activation potency (ADEP4 KM < 1 µM). The initial KM 
of ADEP4 for bacterial ClpP was determined to be in the range of 0.432±0.1 µM, and 
based on this data the turnover number or catalytic efficiency (kcat/.KM) of the ClpP was 
determined to be 6244.4 Sec-1 (Figure 2-11D). 
 
Further a Lineweaver Burk plot of inverse of initial velocity vs inverse of 
substrate concentration was parabolic contrary to expected straight line suggesting 
(Figure 2-11C) positive cooperivity in ADEP4 mediated activation of ClpP. The ability 
of the enzymatic assay to differentiate between ADEP4 analogs was tested by 
determining activity of more soluble yet weaker affinity analog 2378 on both bacterial as 
well as HClpP. As seen in Figure 2-12A, the KM of 2378 was 10 time higher than 
ADEP4 suggesting 10 fold weaker bacterial ClpP activation potency of 2378 compared to 
ADEP4. This observation was in accordance to earlier published SAR of ADEP4 activity 
highlighting contributions of difluoro groups and α-ß poly unsaturated chain toward 
ADEP4 activity220,217. Although with increasingly nonlinear velocity curves, the HClpP 
exhibited higher activation rates (Vmax, Figure 2-12C) with ADEP4 compared to bacterial 
ClpP. Interestingly the activity of 2378 on HClpP was more than 100 fold lower than 
bacterial ClpP suggesting selectivity of 2378 toward bacterial ClpP. This observation 
suggested that structural key to developing selective ClpP activators lies around 
interactions of aliphatic chain and difluorophenyl group on ADEP4. 
 
The choice of buffers and additives were based on observations from TSA assay. 
First influence of varying pH on substrate kinetics of BODIPY-FL was determined by 
measuring the KM of ADEP4 and 2378 against bacterial ClpP. As seen in Figure 2-13A, 
the decrease in pH increased the overall signal due to generation of higher fluorescence at 
lower pH however the rate of catalysis stayed the same as suggested by similar KM of 
ADEP4 and 2378 between varying pH. To test the DMSO tolerance, 2378 was titrated 
against bacterial ClpP at 2, 5 and 10% (v/v) final DMSO concentrations. As shown in 
Figure 2-13B, the effect of up to 10% DMSO was marginal on enzyme kinetics owing to 
good stability of ClpP in solution. To limit changes to system hydrophobicity and pH, the 
DMSO % was set to 2%. Additionally to aid the solubility of test compounds, 0.01% 






Figure 2-11. Determination of ClpP Enzymatic Rate Constants. 
A-B: Assessment of rate of enzymatic reaction of substrate digestion under different 
ClpP concentrations. 
C: Lineweaver Burk plot suggesting positive cooperivity in ADEP4 mediated activation 
of ClpP. 








Figure 2-12. Assessment of Michaelis Menten Constant (KM) and Enzymatic 
Activation Potency (EC50) and % Activation (Top or Vmax) using Positive Controls. 
A-B: Assessment of ClpP KM and EC50 values of ADEP4 and 2378. 








Figure 2-13.. Optimization of ClpP Enzymatic Assay. 
A: Determination of effect of varying pH on substrate kinetics. 






Experiment Design and Data Analysis 
 
The ClpP exhibited extremely fast kinetics in presence of tight binding 
compounds such as ADEP4, such that accurate measurement of enzymatic reaction from 
time point zero became an issue despite availability of automated injectors in the plate 
reader. Further the volume requirements (dead volume and tubing) for automated 
injections using plate reader were considerably higher raising the consumable cost per 
assay. To resolve the problem, order of addition of components was altered (Appendix A 
Figure A-2). First the test compounds were added to assay buffer first using an 
automated liquid handler (Biomek FX) in a 384 well format. Then master mix of ClpP 
with BODIPY-FL labelled ß-casein (substrate) was applied manually just prior to reading 
on pre-equilibrated plate reader at 37 degree. In order to measure the activity of potential 
ClpP activators (ADEP4 or small molecule analogs) with accuracy, the ClpP substrate 
master mix was kept cold to compensate for time delay toward manual addition above 
master mix (minimal quantity) to respective wells on a 384 well plate. During data 
analysis, the data from initial few minutes was skipped to generate slope linearity for 
respective test concentrations. The assay plate was read using optical filters specific to 
BODIPY-FL fluorophore for time period of 45 minutes with incremental readings every 
minute. 
 
In general the data from bacterial ClpP was more uniform in fitting than HClpP 
for any given experiment using Michaelis–Menten equation293. To accommodate for 
complexity in protein behavior a nonlinear regression based approach with fitting to four 
parameter agonist binding equation with variable slopes, was adopted. The resulting 
sigmoidal curves were a better fit compared to fits generated from Michaelis–Menten 
equation (Figure 2-12B, D). The time period during which the linear rate of ADEP4 
activated ClpP action (reaction velocity slopes) reach its maximum value, was 
determined and generated slope values were plotted against concentration of ADEP4 to 
determine EC50 values and % activation. The generated EC50 values perfectly correlated 
(Figure 2-14) with the KM values, similar to % activation and Vmax values for ADEP4 
using Michaelis–Menten equation. To compare the enzymatic activity of the analogs the 
slope were normalized against maximal activity of ADEP4 as 100 % activation of ClpP 
and corresponding % activation score and EC50 value were generated to rank order the 
analogs. As seen in Figure 2-12A the 2378 caused about 75 % of bacterial ClpP 
activation compared to ADEP4, while its potency was10 fold lower than ADEP4. On 
HClpP the activation by 2378 was below 10% of ADEP4 activation suggesting its 
selectivity toward bacterial ClpP. This observation was orthogonally validated on TSA 
assay where shift in melting temperature for binding of 2378 to bacterial ClpP is much 





Both ClpP and HClpP enzymatic assays were optimized under linear velocity 







Figure 2-14. Correlation of Enzymatic Assay Parameters. 
A: Correlation of KM to EC50. 






8.0, 100mM NaCl, 2mM DTT, matching its native storage conditions. Except for 200mM 
NaCl the buffer conditions for HClpP were kept identical to bacterial ClpP. The test 
controls for both proteins were set identical (1999, 2378) to contrast the activity as well 






CHAPTER 3.    DEVELOPMENT OF FLUORESCENCE POLARIZATION 
ASSAY AS PRIMARY SCREENING ASSAY 
 
 
Introduction to Fluorescence Polarization (FP) 
 
The 21st century drug discovery efforts are fueled by continuously evolving high 
throughput screening (HTS) capabilities which conceptualized in 1990’s to modern day 
ultra-high throughput (µHTS) screening294,295. Along with this revolution the diversity of 
assay readout formats has expanded to screen diverse drug discovery targets ranging from 
proteomic targets such as protein kinases, proteases, G-Protein Coupled Receptors 
(GPCRs), Ion channels, membrane transporters, to nucleic acids296,86,297,298. Among the 
popular screening reads outs from absorbance , luminescence (Alpha screen 
,Electrochemicluminiscence) and radiometric (Scintillation proximity) assays, the 
Fluorescence based read outs are most high throughput ,economic, robust and offer 
increased sensitivity299. Fluorescence based methods are applicable to most of the drug 
discovery targets300. The superior speed, dynamic range and mix-read type format of 
fluorescence based methods is justifiably a distinct advantage to low throughput, costly, 
hazardous yet with higher sensitivity radioactive label based assays295. The throughput 
and economic of fluorescence based assays is driven by their suitability for 
miniaturization to high density micro plate formats (384 or 1536 well plates)301. The high 
sensitivity and robustness are attributes of high quantum yield and photo stability of 
fluorophores requiring only a nano-molar quantities of fluorophore to repeatedly deliver 
high quality signal for long periods of time301. 
 
The common variations of fluorescence based assays are Fluorescent Intensity 
(FI), fluorescence life time (FLT), Fluorescence polarization/anisotropy (FP/FA) 
,fluorescence resonance energy transfer (FRET) and Time resolved fluorescence 
(TRF)302,303. The simplistic fluorescence intensity (FI) based assays are ideal for certain 
targets such as kinases or proteases, for which the formation of end product is 
accompanied by amplification or reduction of fluorescence signal. The major drawbacks 
of fluorescent intensity assays are their dependence on measurement of total 
fluorescence, higher sensitivity to spectral interference (auto fluorescence) from test 
compounds, and to inner filter effects at higher fluorophore concentrations, resulting in 
generation of false positives or negatives302. Additionally quantum yield of commonly 
used fluorophores such as FITC (fluorescein isothiocyanate) or Dansyl or Coumarin is 
dependent on system buffer conditions (ionic strength, pH), lowering their robustness due 
to higher signal variability295. Lastly the FI methods are not truly homogenous due to 
requirements of time based reagent additions or product separation steps295. The 
homogeneous fluorescence based energy transfer (FRET) based assay offer attractive 
alternative to FI-based assays by employing a dual fluorophore system as a donor–
acceptor pair based on transmission of energy over a short distance302. The FRET system 
however had limited applications due to relatively short fluorescence life time, 
susceptibility to inner filter effects and restriction of efficient energy transfer over a 
distance greater than 5 nm295,302,303. The issues related to shorter fluorescence life time, 




fluorophores (lanthanide chelates or europium cryptates) with much longer fluorescence 
life time in highly sensitive Time resolved fluoresce energy transfer (TR-FRET) assays. 
The underlying concept of allowing the interfering signal with shorter fluorescence life 
time to cease before measurement of signal from fluorophore is incremental toward 
reduction of assay inferences, however the limited choice of suitable donor acceptor 
pairs, distance restrictions and complexity in ligand labeling and possibility of 
nonspecific energy transfer are significant issues restricting their proper utility303,295,304. 
 
Fluorescence polarization is based on measurement of change (or depolarization) 
of plane of polarization of incident plane polarized light on a fluorophore due to its 
Brownian motion driven molecular rotation upon absorption of excitation energy 
(photons)303. The essence of fluorescence polarization (FP) or inter changeably used term 
Anisotropy (FA) based assays is to quantify the protein ligand interactions through study 
of molecular motion of a fluorophore. The underlying concept behind FP assay is 
measurement of binding isotherms by detection of changes in molecular motion of a 
fluorophore upon binding to a target (protein, DNA, RNA etc.). The FP is a 
homogeneous and solution based technique for real time ratio metric detection of 
molecular interactions of receptor/ ligand, protein/peptide, antibody/antigen & 
DNA/protein interactions305. The most important characteristic of fluorescence 
polarization based methods are their adaptability to true homogenous format which do 
not require any washing or product separation steps, therefore eliminating bottleneck of 
speed , precision and sensitivity295. The single wavelength based fluorescence 
polarization or Anisotropy (FP/FA), is relatively immune to inner filter effects due to its 
ratio metric format which allows self-normalization or cancelling out of artifacts 
influencing the degree of polarization of emitted to plane of excitation polarized light. 
The FP being a versatile method with applications to variety of drug discovery targets 
and is highly amenable to high throughput screening formats306,307,308. 
 
 
History of Fluorescence Polarization 
 
The concept of fluorescence polarization originated from studies of polarized 
nature of fluorescence emitted from fluorescent dyes309. The pioneering work of Weigert, 
laid the concept of changes in degree of polarization with increase or decrease in 
molecular mass, viscosity, temperature of the system309. The changes in polarization were 
linked to increase or decrease in molecular motion of species in a solution310. Later 
Francis Perrin developed theoretical concepts of interrelation fluorescence polarization of 
a molecule in solution to its molecular mass, rotation and time duration of fluorescence 
(fluorescent life time)311. The concept of fluorescence polarization was extended to 
macromolecule interactions by Gregorio Weber who laid down fundamentals of coupling 
of small molecule based fluorophores to larger non-fluorescent proteins as a way to study 







Principle of Fluorescence Polarization 
 
The theoretical basis of polarization are discussed in explicit details in the 
literature303,314,315,316. Briefly, the FP is based on measurement of shift in polarization 
state of emitted fluorescence by free or bound fluorophore upon excitation by plane 
polarized light. The shift in polarization state is proportional to molecular rotation which 
in turn depends on molecular volume or size of fluorophore302. The resolving limit of FP 
assays is independent of concentration of fluorophore and total system volume however 
depends on duration of total fluorescence life time and molecular mass (size) of the 
ligand295,302,311. According to equations derived by Perrin, at constant viscosity and 
temperature ,the relationship between molecular volume and hence the mass of 
fluorophore to rotational correctional time and total fluorescence life time is linear and 
changes in mass of fluorophore affects the FP signal proportionally311,314. 
Mathematically, the fluorescence polarization (FP) of a molecule is ratio of difference 
between parallel fluorescence emission intensity and perpendicular fluorescence emission 
intensity to total fluorescence emission intensity317,315,318. The FP assay is based on 
inverse relation of degree of polarization (relaxation time for 68.5o rotation of molecule) 
to Brownian movements driven molecular motion of a fluorophore311,315,318. The extent 
and speed of Brownian motion depends on molecular size of the molecule as a smaller 
size molecule (i.e. fluorophore) have higher speed compared to a larger size molecule 
(i.e. proteins or DNA)316. 
 
The design principle of a typical FP assay is shown (In context of ClpP) in Figure 
3-1. The sample containing unbound probe (fluorophore labeled ligand) or probe-receptor 
complex is illuminated with a plane polarized light at fluorophore specific excitation 
wavelength and after the brief fluorescence life time period (𝛕) , the change in plane of 
polarization in emitted fluorescence is sampled by polarizing filters set in perpendicular 
and parallel direction to plan of excitation polarized light. For the sample with only 
unbound probe, the angle of rotation (rotational diffusion or rotational correctional time 
ɵ) for small sized molecule is higher after fixed fluorescent life time of photon emission, 
following initial excitation by plane polarized light. Overall the plane of incident 
polarized light changes to a larger degree for a small size molecule compared to a large 
size molecule with slower speed of rotation due to its larger molecular mass316. Hence the 
extent of polarization (change in plan of light) is inversely related to molecular size 
which in turn affects the tumbling speed. In other words, upon excitation of relatively 
stationary probe-receptor complex by plane polarized light , the emitted light is in same 
plane as excitation light, on the other hand if probe is rapidly tumbling (unbound) the 
emitted light is in different planes (Horizontal (P) & Vertical (S)) to excitation light. This 
change is measured as a dimensionless units of milli-polarization (mP)319. The unbound 
probe have higher rate of tumbling owning to small size, as a result, have lower 
polarization values (low mP) whereas probe-receptor complex tumbles at much slower 









Figure 3-1. Principle of ClpP Fluorescence Polarization (FP) Assay. 
Binding of protein to fast tumbling free probe results in slowing of tumbling rate of probe 
bound to protein (Red curve), a change detected as increase in FP signal. Addition of a 
competitive ligand leads to displacement of bound probe resulting increase in tumbling 






Applications of FP to Drug Discovery 
 
The FP assays in high throughput formats have been applied as a primary as well 
as orthogonal validation technique to variety of drug discovery targets including GPCRs; 
kinases; proteases; Ion channels and nuclear receptors320,321,322,323,324. In particular FP 
assays can be readily adopted to proteases using fluorophore labeled substrates, as signal 
increase or decrease assays to measure protein-substrate interactions325,326. The suitability 
of FP assays to proteases comes from basic protease action of degradation a larger 
molecular weight (labeled) substrate with high polarization values into smaller molecular 
weight peptides with low polarization values320,327,328. The FP assays can be readily 
configured as direct binding assays by direct labeled of one of interaction partner and 
protein-protein or peptide, Protein DNA type interactions can directly quantified on basis 
of changes in polarization329,330. The FP assays are also directly applicable to drug 
discovery projects as competition binding assays and novel protein-ligand interactions 
(inhibition or activation of activity) based on displacement of a known (labeled probe or 
tracer) binder, can be identified by screening large collections of test compounds331. 
Based on the fluorescence life time and molecular size cutoff for the ligands, the FP 
assays can be configured to screen wide range of collections including natural peptides, 
small molecules and fragments320,318,332. 
 
 
Advantages of FP-Based Assays 
 
Among the fluorescence based assays the FP based assays offer fast, real time, 
economical and robust ways to quantitatively measure bimolecular interactions318. The 
FP assays can be configured as simple mix-read assays in single point or competition 
formats, as a result the % inhibition of primary hits and potency of competing inhibitors 
can be quantified quickly as IC50 or Ki values
333,334. The FP readout (polarization change) 
is proportional to bound to free probe percentage measured through ratio of difference of 
light intensity in different plane of emission to total fluorescence emission intensity. This 
ratio metric format allows cancellation of disturbances in emission output to both 
perpendicular vs parallel intensity as a result the FP assays (with red shifted fluorophore) 
are relatively immune to inner filter effects arising from fluorescent nature of test 
compounds or probe itself314. One of the major advantage of solution based FP based 
assays is the true homogeneous format which does not require extra washing or product 
separation steps. This feature makes the FP assays highly amenable to high speed 
automated screening platforms. Further the ratio-metric nature of FP assays allows 
miniaturization as observed polarization signal is independent of concentration as well as 
volume requirements of probe or probe receptor complex. The fluorescence nature and 
polarization based readout of FP assays enables ultra-high speed readout without 
sacrificing precision, therefore the FP assays can be quickly adopted to high throughput 
screens using 384 or increasingly common 1536 well formats. Additionally the FP assays 
provide an attractive alternative to hazardous, time consuming and resource extensive 
radio isotope based methods for quantification of binding interactions. The slight loss of 
extreme sensitivity of radioisotopes is compensated via higher throughput and robustness 




proximity as in TRET (time resolved energy transfer) based assay is advantageous from 
assay design standpoint. Further the FP readouts are nondestructive in nature as a result, 
readouts can be taken repeatedly over time without loss of signal quality. 
 
 
Limitations of FP-Based Assays 
 
Similar to any technique the FP assays have few disadvantages. One of the main 
disadvantages of FP assays is the sensitivity to autofluoroscence artifacts from test 
compounds with overlapping fluorescence emission spectra which either supplement or 
reduce the ligand intensity causing false negatives or false positives respectively335,314,303. 
The additive nature of background fluorescence due to its variation from one test 
compound to another , does not get canceled out by ratio metric format of FP which is 
effective in canceling out changes in overall signal intensity314. This limitation can be 
overcome to some extent by selection of red shift fluorophore or fluorophore with 
extended life time and prescreening of compound collection followed by subsequence 
background subtractions336,337,338,302. 
 
The ability of the FP assays to detect weak binders can become an issue if binding 
affinity of the probe to protein is weak339. This limitation can be resolved by either 
improvement of binding affinity of the probe or by converting the FP assay into TR-
FRET format340,335. From assay design standpoint the successful optimization of FP 
assays depends on knowledge of molecular properties of fluorophore such as quantum 
yield, fluorescence life time etc. Additionally the structural information on proper 
attachment site is required to minimize loss of binding affinity of fluorophore upon 
coupling to ligand. Next the length and rigidity of the linker between fluorophore and 
ligand needs to addressed to avoid occurrence of local motion or propeller effects303,316. 
 
 
Key Concepts in Fluorescence Polarization Optimization 
 
 
Assessment of Assay Conditions 
 
For consistency of FP readouts, it is important to maintain constant conditions of 
temperature, viscosity, ionic strength and pH especially if quantum yield of a fluorophore 
such as fluorescein is known to be susceptible to its environment316. Further proper 
judgment on use of reducing agents (DTT, TCEP), metal ion cheaters (EDTA) could lead 
to increase in assay stability and overall assay performance. Further the influence of 
DMSO % on signal stability of unbound or bound probe over time should be carefully 
evaluated. The molecular crowing reagents such as glycerol, or appropriate detergents 
(Triton X-100, Tween 20, and NP 40) could be used to aid the solubility of a probe or to 
aid poor solubility of test compounds at high molar screening conditions. Depending on 
affinity of the probe to the protein, the time required for achievement of equilibrium may 
vary from minutes to hours, therefore it is important to measure the time requirements for 




the similar note, contingent upon high to low inhibition potency specific to type of test 
compounds (close analogs to fragments), the time requirements for complete 
displacement of the bound probe should be determined to get accurate assessment of % 
inhibition or IC50/ Ki values. 
 
 
Homogenous Assay Format and Assay Miniaturization 
 
Most of the fluorescence based methods can be optimized to homogenous format, 
however come with certain limitations in photo stability and susceptibility to 
fluorescence quenching or interference depending on fluorescence life time or quantum 
yield of the fluorophore314,331,342. The FP based assays can be optimized to a truly 
homogeneous format based on simple mix and read steps without requirements of time 
dependent reagent addition, washing or product separation to obtain assay 
readout343,325.The homogeneous nature of FP assays is very receptive to assay 
miniaturization as the changes in polarization are independent of assay volume. The 
miniaturization of an assay is contingent on excellent photo stability fluorophore to 
ensure repeatability, sensitivity of assay readout using minimal volumes and 
homogeneous format without requirements of product separation or additional steps302. 
According to a study the 1536 well format was the most preferred for high throughput 
applications based on FP assay320,344. While shift from 96 or 384 well format to 1536 well 
format is economically favorable due to reduction in assay volumes, and reagent costs, 
the impact on dynamic range of the assay should be carefully assessed320. In addition to 
reduction is assay volume, the miniaturization also favors reduction overall rate of false 
positive or negatives arising from interferences based on signal quenching320,314. 
 
 
Optimal Fluorophore and Protein Concentrations 
 
Selection of optimal concentration of protein and fluorophore coupled ligands is 
important to ensure maximum dynamic range and screening range340. To determine the 
affinity (KD) of the ligand to protein with accuracy, the labeled ligand and protein 
concentrations should be set in nonstoichiometric manner with total ligand concentration 
lower than twice its affinity to the protein and total protein concentration be set between 
50-80 % of binding saturation level339. Under nonstoichiometric titration conditions, the 
probe with high binding affinity to proteins delivers wider screening range339,340. Overall 
the final concentration of the protein should be higher (> 2 fold) than KD of the labeled 
ligand to generate non stoichiometric binding conditions and final concentration of the 
labeled ligand should be sufficiently high to generate total fluorescent intensity in higher 
magnitude order of background fluorescence level from test compounds, in order to 
effectively mask the background fluorescence345,340. Additionally the practice of 
increasing probe (above its KD) or enzyme concentrations to improve the assay quality 
should be avoided as it could leads identification of false positives from overestimation 







Binding Affinity of Fluorophore to Protein 
 
Besides quantum yield, the binding affinity of the probe is the most important 
criteria for successful assay design. The labelled ligand with higher binding affinity to 
protein is preferred over ligand with weaker affinity to increase assay sensitivity, 
resolving range and detection (assay bottom) limit for inhibitor potencies339,340. For 
ligands with high binding affinity to protein, the requirements for probe concentration are 
low as long as probe is labeled with a red shifted fluorophore with high quantum yield, as 
at low concentrations the noise from background fluorescence becomes high320. In 
contrast to a ligand with higher binding affinity, a weaker affinity ligand requires much 
higher concentration of protein/probe to generate similar dynamic range, a requirement 
counterintuitive to high throughput screening conditions340. Further in a competition 
format, inhibitor potencies are best resolved by inhibition constant (Ki) compared to 
commonly used parameter of IC50 values. The dependence of IC50 values on 
concentration of ligand, protein and compounds makes it less attractive potency 
parameter than (Ki) which is independent of test conditions (except temperature)
340. The 
inhibition constants for competitive FP assays can be computed using correctional 
version of original enzyme substrate interactions based Cheng-Prusoff equation340,333,346. 
 
 
FP Probe Design Considerations 
 
A variety of fluorophores with range of molecular properties such as total 
fluorescence life time, correctional time, Quantum yield etc. are available for 
development of FP assays320,347. Among the most available fluorophores the Fluorescein, 
Rhodamines, Texas Red, and CY5 derivatives in green, yellow and orange and red 
shifted spectrum respectively, are the most commonly used fluorophores (in that 
order)320,344. The design of FP probes requires complex design considerations contrary to 
simple labeling (random) of proteins. Following labeling the probe must retain most of 
binding affinity although some modulation (mostly drop, rarely increase) in affinity is 
expected. Further the non-stoichiometric labeling of ligands with fluorophores can result 
in smaller dynamic range, therefore one fluorophore per ligand is best303. Next extensive 
knowledge on appropriate linking site as well linker length is required to avoid local 
motion or propeller effects which results in lower polarization shift due to insufficient 
reduction in rotational rate of fluorophore upon binding to enzyme302,303,316. For best 
results the linker between fluorophore and ligand should be short and rigid, however care 
should be taken to prevent loss of binding affinity due to steric hindrance from 
fluorophore302. The fluorescence based assays work best when wavelength of fluorophore 
is above 400 nM, otherwise spectral interference becomes an overwhelming problem. 
The concentration of fluorophore has direct (linear) influences on total fluorescent 
intensity (FI) and above absorbance factor 0.5, the relationship become increasingly 
nonlinear303. At concentration higher than 1µM, the inner filter effects from fluorophore 
itself significantly mask the actual signal287. Therefore ideally the fluorophore should be 





The dynamic range of the FP assays depends upon molecular properties of the 
fluorophore. In particular for larger dynamic range the total fluorescence life time of the 
fluorophore should be greater than its molecular correction time320. For most commonly 
used fluorophores such as Fluorescein or rhodamines (fluorescent life time <4 ns), 
attachment to a ligand greater than 10KDa results in very small change in FP values as 
the duration of rotational correctional time of the ligand exceeds the fluorescence life 
time of fluorophore314,303. Therefore the molecular size of the ligand must be small 
(<1500 Da) in order to resolve the change in rotatory motion of unbound or bound 
ligand314,315,342. To resolve the rotational rate of larger ligands such as in case of protein-




Resolution Limits of FP Assays 
 
The theoretical lower and upper limit of polarization is 0 mP and 500 mP and 
values outside the ranges are indicative of poorly configured assay295. For most of the 
biological interactions, a change of 50-100 mP is significant as long as the Z` score is 
high (>0.6) and variations (noise) in low and high fluorescent signal (from 
negative/positive controls) are small, otherwise the assay lacks its resolving power and 
should be re-optimized314. The resolving power of a FP assay depends on fluorescence 
life time of the fluorophore (Fluorescein/ Rhodamines 𝛕= 4ns) and molecular size of the 
ligand. The upper limit of resolving power of FP assays is up to 5 KDa for test screening 
collections due to its dependence on fluorescent lifetime of probe295,314.The polarization 
increases with Increase in molecular weight of the ligand up to a plateau point beyond 
which the fluorescence correctional time exceed the fluorescence life time of fluorophore 
as a result any further increase in molecular weight in size of the ligand has minimal 
effect on polarization314. By decreasing the size of ligand and by selection of 
fluorophores with longer fluorescent life time (𝛕>10 ns), the range of polarization can be 
maximized without disturbing signal window and extended to screening of larger 
molecular weight peptide collections295. 
 
 
Sources of Artifacts in FP Assays 
 
Often artifacts in high throughput fluorescence based techniques arise from 
inherent physiochemical properties of certain test compounds (i.e. heterocyclic 
compounds) causing spectral interference with fluorophore in a manner similar to actual 
response from biological activity of real hits, resulting in identification of false 
positives349,342. In a similar scenario, the masking of signal of fluorophore as result of 
quenching effect from absorption of emitted light, can lead to generation false negatives 
in which the response from potent hit might appear weaker or indistinguishable from 
baseline response. Quenching of the FP signal often results from binding interactions of 
test compounds to fluorophore leading to its fluorescence deactivation or sapping of 




emission in blue range of spectrum are more susceptible to interference, compared to red 
shifted fluorophores342,350. 
 
Aggregation is often caused by poor solubility of the test compounds under 
screening conditions. The changes in light scattering properties of aggregates compared 
to soluble test compounds interfere with optical detection of polarization as a result the 
background fluorescence becomes more noisy314. The interactions of compound 
aggregates with fluorophore or protein are another source of artifacts which could result 
in generation of false positives due to partial or full denaturation of enzyme or masking 
of emission properties of fluorophore351. Often addition of a suitable nonionic detergent 
(below its CMC values) can resolve the aggregation dependent response from actual 
biological response of a real hit compound351,342. However the suitability of a detergent 
addition to performance of a particular assay type must be examined before actual 
screening. For an example addition of detergents in assays (such as thermal shift) based 
on interaction of reporter dye to hydrophobic regions of target enzyme is a potential issue 
due to likelihood of binding of dye to hydrophobic detergent micelles itself, resulting 
generation of false negatives. On the other hand, addition of detergent in certain assays  
(such as FP) is useful in sequestering of probe-enzyme complex under equilibrium 
binding conditions in addition to aiding solubility of test compounds, resulting in 




Identification of Interference Compounds 
 
In addition to spectral overlap the fluorescence interference can arise from various 
sources such as aggregation of probe or test compounds, receptor precipitation, and 
presence of impurities or PAINs320,318,352. Generally the absorption of fluorescence 
emission and chemical inactivation leads to quenching of FP signal, whereas spectral 
overlap and light scattering due to aggregation leads to increase in FP signal316. In this 
light the raw data from parallel and perpendicular fluorescent intensity and overall FP 
signal can be evaluated for identification of outliers from a normal range of response 
from high or low controls353. 
 
 
Assay Quality and Performance Parameters 
 
There are multiple parameters to assess the assay sensitivity as well as 






The unit less Z` score defines the quality of the assay and its repeatability over 




with Z` at 0 , can only deliver yes/no binding answers, whereas at Z`>0.6 the assay is 
considered as acceptable, while Z`>0.8 is excellent assay and Z` =1 is a perfect assay354. 
The Z score is different from interchangeably used Z factor which is based on 





The Sensitivity of the assay is defined as repeatable precision in measurement of 
an activity355. An optimal assay has right balance of sensitivity to performance. A highly 





The resolution is defined as ability of an assay to resolve or accurately measure 





The signal window is defined signal separation between maximum and minimum 
(baseline) response and signal window >2 is considered statistically significant342. 
 
 
Signal to Noise Ratio(S/N) 
 
S/N ratio is parameter to assess strength of the signal and to assess acceptable 
ranges for raw data354. Ideally the S/N ratio should be >= 10342. 
 
 
Signal to Baseline Ratio (S/B) 
 
The S/B ratio is the dynamic range of difference of signal between low and high 





The % CV is the ratio of average of maximum value to its standard deviation and 
is a measure of precision of assay measurements relative to controls342. The acceptable 







Minimum Significant Ratio 
 
The minimum Significant ratio is measure of statistically significant range of 
potency which could be measured with reproducibility between assay runs356. 
 
 
Getting Ready for FP-Based Screening 
 
 
Ideal Fluorescence Polarization Experiment 
 
In an ideal fluorescence polarization experiment, unbound probe (ligand labeled 
with fluorophore) and probe-receptor complex are the only two molecular species, which 
could be detected by photo sensors. In absence of protein, the probe is completely 
unbound and exhibits unimpeded fast molecular rotation (tumbling motion) based on its 
small molecular volume. The excitation of unbound probe by plane polarized light does 
not change the plane of incident light as a result the polarization values stay low (baseline 
signal). Upon addition of protein or the receptor, the binding of the probe to the target is 
driven by random molecular collisions between the two species till achievement of 
equilibrium at which amount of bound probe equals unbound probe. At this stage the rate 
of molecular rotation slows down due to net increase in molecular volume (size) of 
protein-probe complex, causing depolarization in the plane of incident light, a change 
measured as increase in polarization values. At equilibrium the maximum change in 
polarization compared to completely unbound probe defines the dynamic range (signal 
window) of the assay. The tests compounds compete for binding to specific protein 
surface (binding pocket) against the probe and based on their inhibition potencies 
displace the probe to various extents. The displacement of the probe may happen as a 
result of direct completion or through allosteric site (rare) occupancy. 
 
The FP assays provide quantitative measure of binding interactions and sensitivity 
of the assay depends on affinity of the probe, its excitation emission spectra, solubility of 
test compounds and optimal buffer conditions. Given all criteria is met, the selection of 
optical filters with bandwidth ±5-10 nm to excitation emission spectrum of the 
fluorophore ensures accuracy (precision) of FP measurements. Further the FP data from 
one instrument to other is not directly comparable due to difference of optical 
sensitivities toward measurement of fluorescence emission, therefore G (grating) factor 




Basic Assay Design 
 
The basic design scheme of FP assay is shown in Appendix B Figure B-1. In a 
single point screening or titration based competition format, the probe is added to a 





upon the size of the screen, selected volume (10 or 20 µl/well) of protein probe mixture is 
added to 384 well plates and system is incubated (protected from light) at room 
temperature for a brief period of time (1 hour) to achieve saturating binding equilibrium 
between protein and probe. At this stage, the test compounds and respective positive or 
negative (DMSO only) controls are added (pin tool transfer) to the system either in single 
point format or as titrations, at selected concentrations specific to type of screening 
collection. For low molecular weight compounds such as fragments the screening 
concentration is keep at high (mM range), whereas for larger molecular weight 
compounds or analogs of positive controls the screening concentration is kept low (µM 
range). Following pin tool transfer, light protected plates are incubated at room 
temperature conditions for period of 2 hours to allow complete displacement of FP probe. 
Depending on their inhibition potency test compounds /controls compete and displace the 
bound probe to various extent (% inhibition or displacement). Plates are briefly 
centrifuged to remove any air bubbles and read on a suitable plate reader (with stacker) 
using narrow bandwidth optical filters specific to excitation emission wavelength of 
fluorophore. As a result of displacement of bound probe by test compound the net change 
in polarization level is measured in milli polarization (mP) units. 
 
 
Hit Selection Criteria and Data Analysis 
 
For single point screening format the net change in polarization is measured as % 
inhibition or displacement. The high polarization level (baseline) is defined by 
polarization values for negative controls with 0% displacement of bound probe and low 
polarization level (maximum signal) is defined by polarization values for positive 
controls with 100% displacement. Raw data is normalized to respective controls and hit 
compounds are identified based on 25-50% displacement cutoff, a variable parameter 
based dynamic range of the assay. In competition binding format, the IC50 values are 
determined as measure of inhibition or displacement potency, at test concentrations of 
titrated compounds at which 50 % displacement of bound probe is achieved. The cut off 
criteria for potency varies according to compound type. The potency cutoff for best 
compounds within small molecule series #1, 2, and large molecule series is set at IC50 
values at 50, 25, and 5 µM respectively. For assessment of selectivity, the criteria is set to 
at least 3-4X higher IC50 values for staph protein in contrast to HClpP. Further a more 
absolute and quantitative parameter of inhibition potency, the inhibition constant (Ki) can 
be measured based on generated IC50 values
334. The common assumptions behind 
calculation of inhibitor potencies or inhibition constants are reversibility of binding 
interactions and 1:1 stoichiometry between protein and inhibitors. For systems with 
complexities in binding interactions between protein and inhibitors or FP probe, the 
interpretation of data is subjective to system characteristics. For proteins with cooperivity 
(positive or negative), multisite ligand binding with mixed modes (competitive or 
uncompetitive) the evaluation of inhibition potency data in absence of appropriate model 
equations is quantitatively less pure and more suitable as generic ranking criteria. In this 
light the IC50 values were used instead of more informative inhibition constants (Ki) as a 




(14) binding pockets and cooperative mechanism of interactions between monomers as 
well as with test compounds. 
 
 
Optimization of ClpP FP Assay as a High Throughput Primary Screening Tool 
 
 
Challenges Associated with ClpP FP Assay Development 
 
Development of a assays based on binding interactions with ClpP protease is quite 
challenging due to multimeric nature of ClpP along with highly complex mechanisms of 
binding interactions. The targeting of proteases in general toward antimicrobial drug 
discovery endeavors have generated very few lead candidates358,359,360. The biggest 
challenge in targeting of proteases is achievement of sufficient binding affinity toward 
active sites146. Additional challenge is achievement of species selectivity due to presence 
of close structural homolog (mitochondrial ClpP) in humans. In this light, the widely 
conserved ClpP protease is no exception, with 14 identical axial binding pockets in 
addition to 14 endogenous catalytic domains. The self-assembly of monomer ClpP into 
tetradecameric (14mer) active form in solution is through concentration based 
cooperative mechanisms. The known ClpP activators (binders) ADEPs also exhibit 
highly complex (non/super stoichiometric) interactions through positive cooperivity 
based mechanisms. Therefore accurate measurement of binding response of ligands to 
ClpP is challenging and is based on certain assumptions specific to a particular assay. 
 
 
Design of ClpP FP Probe 
 
The Development of ClpP fluorescence polarization based assay was sought to 
accelerate discovery of novel ClpP activators (especially non peptidic) at higher pace and 
throughput by screening of large chemical collections. Previously reported high 
throughput screening assays targeting ClpP were based on degradation of (Fluorescein) 
labeled substrate (ß-casein) or a synthetic decapeptide substrate59,361. From assay design 
standpoint the major draw backs of these assays were lack of site specificity, dependence 
of substrates on pH for fluorescence emission and relatively poor photo stability316. The 
assay were susceptible to significant fluorescence interference, resulting in false 
positives, due to selection of fluorophores at lower (blue) end of excitation/emission 
spectrum (FITC Ex/Em:490 /520 nm and Amino Benzoic acid Ex/Em: 320/430 nm). 
Additionally assays based on degradation of substrates have requirement of specific 
temperature (37 degree for most enzymes), an aspect which restricts the throughput to 
one plate at a time. To address these potential issues, a design strategy of attachment of 
longer wavelength fluorophore to a ClpP site specific ligand (modified ADEP core) was 
sought to develop a miniaturized, high throughput capable competition based FP assay 
capable of screening wide (MW) range of compound collections at room temperature 
conditions. The ClpP FP assay was developed as both primary screening tool (Aim1) as 





Based on initial goals of design of high affinity site specific ClpP FP probe, the 
Acyldepsipeptides core of ADEPs with reported high affinity was selected212,59. Further 
based on available co-crystal structure of first isolated ADEP1 bound to E.coli ClpP 
(Figure 3-2A), the solvent exposed N-methyl Alanine on the cyclopeptide ring of a 
modified ADEP core was selected as optimal site of probe attachment via conjugation 
chemistry222. The selection of fluorophore was based on good photo stability and high 
quantum yield of the fluorophore along with its suitability to conjugation to modified 
ADEP core via a spacer linker of optimal length and rigidity. Based on commercial 
availability and synthesis accessibility, multiple iterations of probes (Appendix B Figure 
B-2) spanning the visible to far red spectrum (Dansyl, Bodipy, Fluorescein isothiocyanate 
(FITC), Rhodamine (TAMRA), Texas Red, in that order) were synthesized and attached 
to modified ADEP core via “click” chemistry. The linker length was varied from 3 to 22 
carbon chain among fluorophores depending upon ease of attachment. Over the course of 
evacuation of various probes for binding to ClpP, number of obstacles related to 
solubility of ADEP core, signal stability, quantum yield, propeller effects, and signal 
window were encountered toward selection of optimum probe. 
The binding affinity of probe 1 based on Dansyl fluorophore (Ex/Em: 330 nm/524 nm) 
was measured at FP-EC50 at 16.2 µM (Appendix B Table B-1) however probe 1 
exhibited incomplete binding saturation (Figure 3-2C) largely due to spectral 
interference from modified ADEP core with overlap of emission at 340 nm with 
excitation wavelengths of probe 1 at 334 nm. 
 
The ADEP4 was used a competitive displacement control , however despite its 
high affinity to ClpP, ADEP4 did not displaced the bound probe owing to its own poor 
solubility59. To overcome the spectral interference issues, a far red shifted probe 2 with 
Texas Red fluorophore (Ex/Em: 592 nm/612 nm) was designed. The probe 2 had high 
quantum yield (detector saturation above 40nM) but displayed poor binding to ClpP at 
IC50 >75 µM (Appendix B Table B-1), with a very short signal window of ≤ 50 mP 
(Figure 3-2B) and incomplete displacement upon treatment with competitive inhibitor 
titration series. This was in part due to exacerbated solubility issues with underlying 
ADEP core upon addition of a hefty Texas Red fluorophore and in part due to propeller 
effect imposed by much longer (22 carbon) linker318,362,363. With propeller effect issues, 
the binding of probe to protein does not result in usual reduction in tumbling rate of probe 
due to projection of fluorophore away from protein due to longer spacer linker, thus 
compounding the accurate measurement of binding or displacement. Next the linker 
length was reduced to 11 carbons and probe 3 based on FITC (Ex/Em: 495nm/520 nm) 
and probe 4 based on Bodipy FL (Ex/Em: 503 nm/512 nm) fluorophores were generated. 
The probe 3 and 4 had also had high quantum yield with good signal stability over course 
of time and considerably lower propeller effect related issues, however binding affinity 
(FP-IC50) of probe 3 and 4 was found to be >100µM (Appendix B Table B-1). As a 
result both probe 3 and 4 failed to achieve the binding equilibrium (Figure 3-2B) at low 
ClpP concentrations, another important requirement toward developing FP assay in high 
throughput screening format. 
 
Based on observations from above probes, balancing of probe solubility and 






Figure 3-2. Probe Design and Superior Binding of ADEP-FP Probe 6. 
A: X-ray complex of ADEP1 with E. Coli ClpP. 
B: Structure of ADEP4 with modification sites (Red arrows), structure of modified 
intermediate ADEP and structure of Probe 6. 






optimal probe. First important consideration was to fine tune the binding affinity of the 
probe in such a way that both high and low affinity compounds could be reliably 
screened. According to published reports the screening range of a probe with high 
binding affinity is wider than a probe with lower binding affinity340. This aspect of FP 
probe design suggested that displacement of the tightly bound probe by competing 
compounds is a function of their concentration and time with high affinity compounds 
displacing the bound probe relatively quickly compared to weaker affinity compounds. 
On the other hand, a probe with lower affinity would not resolve the tight binders 
reliably, due to capping of resolution limit (assay floor) at binding affinity (KD) of the 
probe to protein339. Given a decent probe affinity, the effective screening concentration 
for ADEP4 analogs needed to be much lower than weak affinity compounds such as 
fragments for which screening concentration needs to high (mM range). At high molar 
screening concentrations, the issues (light scattering, precipitation, aggregation etc.) 
related to solubility of test compounds became significant, therefore optimum balance of 
probe binding affinity, solubility and detection limit was critical toward extension of 
screening range of the FP assay. Second important consideration was solubility issue of 
ADEP core based probes. The poor solubility of ADEP4 derivatives restricted selection 
of ligands with superior binding affinity toward optimization of probe with higher 
resolution power. The improvement in probe solubility was sought by reducing the 
overall molecular weight (and apparent hydrophobicity) of the probe with shortening of 
ADEP4’s hydrophobic alkyl chain length. Third consideration was balancing distance of 
fluorophore to the ADEP core (linker length) to avoid steric hindrance in case of too 
short linker and propeller effect in case of long linker. Fourth consideration was selection 
of far red shifted fluorophore to help separate hits from false positives or negatives 
arising from fluorescence interference and inner filter effects. 
 
Above challenges were addressed by first resolving the poor solubility of ADEP 
core which primarily restricted equilibrium binding experiments. As suggested in 
previously published SAR of ADEPs, the balance of potency and solubility hinges on 
hydrophobicity and length of the alkyl chain of ADEPs220. We proceeded to shorten the 
alkyl chain of ADEP4 by 2 carbons length while maintaining α, β-unsaturated double 
bond in trans-configuration (Figure 3-2B, Red Arrows) and removed the di-fluoro group 
from phenyl ring of ADEP4 to improve the solubility of the ADEP core. The removal of 
di-fluoro group however, came at cost of loss of activity which correlated to loss of 
binding affinity as suggested by previously published literature220. The resulting ADEP 
modified scaffold (Appendix B Figure B-2G, 7) had improved solubility at 39.6 µM , 
good enzymatic activity as suggested by in house enzymatic activation assay at EC50 =3.5 
µM and a decent ITC based binding affinity (KD) at 2.1 µM (Appendix B Figure B-3B, 
C,D). The enzymatic activity of ADEP4 at EC50 at 0.41±0.03 µM correlated well with 
ITC driven KD estimate at 0.32 µM, further validating the loss of activity in compound 7 
as suggest by published literature. 
 
Next the FITC fluorophore (Ex/Em :490nm/525nm) was attached to methyl ester 
side chain of Alanine on the cyclopeptide ring of modified ADEP and resulting probe 5 
was tested for binding saturation. Although probe 5 had very high quantum yield 




2C) and based on binding curve response the estimated binding affinity of the probe 5 
based on FP binding assay was in excess of 200 µM (Appendix B Table B-1) , making it 
unfavorable for further optimization. We finally acquired the right balance of solubility, 
binding affinity, and linker length in probe 6 by selecting modified ADEP as core and 
conjugating a near red shifted tetramethylrhodamine (TMR) based TAMRA fluorophore 
(Ex/Em: 540nm/575 nm) via a short 3 carbon alkyl linker . The resulting probe 6 (Figure 
4-2, B) was tested for signal stability, quantum yield, and binding affinity. It was 
pleasantly found that compared to other probes, the probe 6 had much improved binding 
affinity (FP-IC50) at 3.8 µM (Appendix B Table B-1) which correlated well with ITC 
based binding affinity (KD) at 1.96 µM (Appendix B FigureB-3). The Probe 6 exhibited 
robust signal stability and excellent signal to baseline ratio with maximal binding signal 9 
times higher (Figure 3-2C) than signal from unbound probe suggesting that it was 
suitable for screen development. 
 
 
Initial Buffer Conditions Optimization 
 
To establish FP assay as robust and sensitive assay, the first objectives were to 
achieve a stable signal from free probe over course of several hours, and high signal to 
baseline (S/B) ratio following probe binding to ClpP. The titration experiments with 
probe 6 in various buffers (Tris, Phosphate, and Hepes) under varying pH at room 
temperature, suggested (a)Tris pH 8.0 buffer was optimum, (b) probe concentration 
above 150 nM saturated instrument detectors indicating high quantum yield of probe 6. 
The stability of the baseline signal from unbound (free) probe 6 was monitored in various 
combinations of buffer additives (DTT, BSA, and Detergents). A non-ionic surfactant 
Triton X-100 (0.01 % final v/v) was found to significantly improve the stability of signal 
as indicated by steady baseline (red line) over course of 16 hours (Figure 3-3A). 
 
 
Probe 6 Equilibrium Binding Constant (KD) Determination 
 
Next to determine binding affinity (KD) of probe 6 with ClpP, the objectives were 
set to determine (a) minimum concentration of probe 6 required to achieve stabilization 
of binding (at equilibrium) with ClpP protein, (b) impact of concentrations of probe 6 on 
its binding affinity. Binding of probe 6 to saturating concentrations of ClpP protein over 
time period of 4 hours suggested that maximum signal stability was achieved following 
one hour of incubation of 6 to ClpP at room temperature. The probe 6 was found (Figure 
3-3B) to bind to ClpP with high binding affinity (EC50 = 3.51±0.1µM) under equilibrium 
conditions following incubation period of 1 hour. With baseline at 23 mP for unbound 
probe 6, the binding of probe 6 to ClpP resulted in maximum binding signal at 216 mP 
units suggesting excellent signal window of 193 mP with a high signal to baseline ratio 
with maximum binding signal 9 times higher than the baseline signal from unbound 
probe 6. Further the binding signal at saturation was found to be stable for additional 6 
hours owing to exceptional stability of ClpP in solution and increase in probe 







Figure 3-3. Optimization of ClpP FP Assay. 
A: Increase in signal stability of unbound probe 6 upon addition of Triton X-100. 
B: ClpP binding saturation of probe 6 after 1 hour incubation. 
C: Dose dependent displacement of bound 6 by competitor compound 7 
D: Site specificity of probe 6 to ClpP compared to ClpP mutants Y63W, and Y63F. 
E: Activation of ClpP by ADEP4 analogs. 







to ClpP was orthogonally validated using isothermal titration Calorimetry (ITC). It was 
found that probe 6 has thermodynamically favorable (H = -1261 cal/mol) interactions. 
The FP-IC50 estimate of binding affinity of probe 6 was found to be in good correlation 
with orthogonal ITC experiments which estimated its binding affinity (KD) to be at 1.96 
µM (Appendix B Figure B-3A). 
 
 
Determination of Probe 6 Displacement Conditions 
 
The next step in FP screening assay development was establishment of 
displacement conditions for a bound probe 6 to ClpP with higher affinity competitor 
compounds. ADEP4 and compound 7 were selected as positive control based on 
previously reported binding affinity at 300 nM for ADEP4 and 2.1 µM for compound 7 
as determined by in house ITC (Appendix B Figure B-3B-C)59. Titration of positive 
controls and negative control (DMSO) (in triplicate) into wells containing previously 
bound probe 6 to ClpP, resulted in concentration dependent displacement of probe 6 as 
observed by decrease in mP units to the baseline levels equivalent to levels observed 
from unbound probe 6. It was also observed that a minimum of 2 hour incubation period 
was required for 100% displacement of previously bound probe 6. Both ADEP4 and 
compound 7 was found to completely displace previously bound 6 with ADEP4 
displacing probe 6 earlier in time compared to compound 7. This was due to much higher 
binding affinity of ADEP4 at 300 nM compared to binding affinity of compound 7 at 2.1 
µM. However aggregation of ADEP4 beyond its solubility limit resulted in upward re-
curving of displacement curve for previously bound 6 to ClpP. This was likely due to 
quenching of FP signal as a result of fluorescence interference or partial denaturation of 
ClpP by ADEP4 aggregates. Based on this observation we selected compound 7 with 
improved solubility over ADEP4 as primary positive control for future displacement 
experiments of probe 6. As shown in Figure 3-3C the compound 7 completely displaced 
previous bound 6 in a concentration dependent manner (FP-IC50 =20.7±0.44µM) 
following 2 hours of incubation. A Slight decrease in assay window from 193 mP to 173 
mP was due to quenching of FP signal by likely aggregation of compound 7 at 
concentration >200 µM. The displacement signal was found to be stable up to at least 6 
hours which indicates excellent robustness of the assay. The excellent stability of FP 
signal at room temperature for long time periods was incremental toward setting up 




Site Specificity of Probe 6 
 
To investigate if binding of probe 6 was indeed site specific, a critical amino acid 
tyrosine at position 63 within ADEP4 binding pocket of ClpP was mutated to Tryptophan 
and Phenylalanine, to disrupt the binding of probe 6. The resulting mutants of ClpP were 
expressed and purified in manner similar to purification strategy for wild type ClpP. The 




wild type and mutant protein (n=3) as per established buffer conditions. As shown in 
Figure 3-3D the probe 6 binds specifically to the active site on WT ClpP with EC50 at 
3.18 ±0.02 µM whereas the binding affinity of probe 6 to ClpP (Y63F) and ClpP (Y63W) 
was significantly reduced (EC50 > 150 µM), suggesting binding specificity of probe 6 to 
WT ClpP. This observation was independently confirmed by SDS-PAGE based 
unlabeled casein digestion assay (Appendix B Figure B-3, E). The gradient (molar 
equivalent at 5,2.5, &1.25 times) of ADEP4, compound 7 and probe 6 show digestion of 
unlabeled casein in an identical manner suggesting probe 6 binds and activate ClpP in 
manner similar to ADEP4 or compound 7. 
 
 
Validation as Competitive Ranking Assay 
 
The utilization of current FP assay was further extended as a ranking assay to aid 
SAR studies by setting the assay in a competition format to determine displacement 
potencies of synthetic analogs. A series of compounds based on ADEP4 were synthesized 
in the lab and tested for their competitive ability to displace the previously bound probe 
6. To test the hypothesis that compounds with superior displacement potency (higher 
IC50) should also have higher potency to activate ClpP, same set of FP- IC50 ranked 
compounds were tested on an orthogonal enzymatic assay to measure ability (EC50) of 
test compounds to activate ClpP. A high degree of correlation (R2 at 0.96) was found 
between two assays (Appendix B FigureB-4, B). Compared to compound 7, the 
compounds with higher FP-IC50 values also exhibited higher activation potency and vice 
versa for compound 23, 25, and 26 (Figure 3-3E, F). The compound 26, an ADEP4 
analog with methyl substitution displaced probe 6 with FP-IC50 at 6.41±0.24 µM, similar 
to displacement potency of ADEP4 at FP-IC50 5.87±0.3 µM (Appendix B Table B-1). 
This observation was corroborated by an orthogonal enzymatic assay with similar EC50 
values for compound 26 and ADEP4 at 0.46±0.04 and 0.33±0.02 µM respectively. The 
FP-IC50 values for all compounds with binding affinity higher than binding affinity of 
probe 6 were a close approximation due to limit of detection (assay floor) being set at 
binding affinity of probe 6 to ClpP around 3µM339. The poor solubility of ADEPs as 
reflected by upward shift in displacement curves (data not shown) around 10-12 µM 
mark potentially interferes with accurate determination of binding affinities which are 
likely in sub nM range as shown by ITC (Appendix B FigureB-3, C) for ADEP4 at KD 
of 322 nM. The FP-IC50 of more soluble ADEP analog, compound 7 at 8.50±0.34 µM, is 
within limit of detection and is expectedly lower than ADEP4 as reflected by orthogonal 
enzymatic assay EC50 at 2.42±0.24 µM and ITC KD at 2.1 µM. Interestingly compound 
23 displaced bound probe with IC50 of 13.88±0.44µM whereas its close analog 
compound 24 which has additional propenyl-benzene group was completely inactive with 
IC50 >200 µM (Figure 3-3E, F). This observation was also reflected in enzymatic assay 
with EC50 values for compound 23 and 24 at 3.10±0.15 µM and >200 µM respectively 
(Appendix B Table B-1). The sensitivity of FP assay toward structural changes in 
synthesized analogs as reflected from comparative FP-IC50 values, was found to be very 
useful not only in affinity ranking of the compounds against compound 7 or ADEP4 but 
also contributed significantly in shaping the direction of SAR evaluations of ongoing 






Determination of High Throughput Screening (HTS) Parameters 
 
Next the FP assay was optimized to high throughput screening format by 
determining the minimum volume and concentrations requirements for protein and probe 
without sacrificing robustness and sensitivity. To reduce the volume requirements per 
well, the Greiner black, flat bottom, low volume (384 well) plates were selected over 
regular 384 well plates. The low volume plates by virtue of their design, deliver relatively 
flat meniscus, accommodate up to 25 µL/ well and have elevated bed floor which helps in 
bringing the buffer mixture close to fluorescence detector, thus increasing the sensitivity. 
The excellent miniaturization ability of the current FP assay was further demonstrated by 
consistent IC50 values from positive controls between final assay volume at 10, and 20 
µl/well (Appendix B FigureB-4A).The minimum concentration requirement for the 
ClpP were determined to be at 15 µM by titrating the protein against fixed concentration 
of probe 6 with a signal window of 195 mP units for extended time period of 6 hours. 
Next the positive control compound 7 was found to displace previously bound probe 6 
with IC50 at 7.1±0.2 µM (Appendix B Figure B-4C). 
 
Next performance of FP assay as a primary high through screening assay was 
assessed by measuring DMSO tolerance, Z` score, Signal to noise ratio (S/N), Signal to 
baseline ratio (S/B), Signal window (dynamic range), and assay test range. DMSO is the 
most common organic solvent used to dissolve the compounds and is known to alter the 
local environment in solvent system resulting in protein precipitation and denaturation 
364. Depending on its concentration, DMSO can cause formation of local hydrophobic 
pockets within solvent system which could result in local aggregation of unbound probe, 
therefore making the mP calculations difficult to interpret365. To determine impact of 
DMSO % on stability of FP signal, varying percentages of DMSO (2, 5, & 10 %) was 
added to wells (n=12) following established testing conditions for binding and 
displacement. No significant change was found in corresponding signal (mP) for bound 
probe 6 and displacement curve by 7 for 2 and 5 % DMSO however 10 % DMSO leads 
to increase in background noise in bound probe 6 signal as well as significant increase in 
quenching of signal during displacement of probe 6 by compound 7 as indicted by 
decrease in signal window from 173 to 137 mP units (Appendix B Figure B-4D). This 
effect was likely caused by aggregation of unbound probe within hydrophobic pockets 
from DMSO at higher concentration resulting in decrease of % unbound probe available 
for binding to ClpP, thereby perturbing the equilibrium between two which is observed as 
decrease in signal window. Based on these result the final DMSO % was set to be at 2 % 
(v/v). 
 
Another important factor for high through format screening is excellent 
reproducibility of the assay. Z` score is a dimensionless measure of assay quality and is 
the accepted statistical standard to assess the quality (robustness) and fitness of the assay 
to HTS standards366,354. An experiment with replica (n=80) wells of unbound probe 6, 
bound probe 6 and displaced probe 6 was set as per established conditions to measure the 




6 by compound 7 (Appendix B FigureB-5A). The maximum signal for bound probe 6, 
unbound probe 6 and displaced probe 6 was observed to average at 215.8±4.6, 32.5±6.9, 
33.4±5.8 mP units respectively. The Z` factor was computed to be at 0.82,signal to 
background (S/B) ratio, and signal to noise (S/N) ratio was determined to be 6.45 & 24.5 
respectively. This data suggests that the current assay system has large dynamic range 
(signal window =183 mP), has large separation between baseline signal and maximum 
signal (S/B= 6.45 or S/N= 24.5). In a separate experiment variability in assay quality and 
reproducibility (Z` factor) on plate to plate or day to day basis was measured under 
established conditions. The Z` factor for each plate was measured to be in range of 0.87- 
0.92 (Appendix B FigureB-5B) and showed practically no variation over period of 
several days, indicating that the current FP assay is highly reproducible. 
 
 
Validation as Primary HTS Assay and Discovery of ICG-001 as Novel ClpP 
Activator 
 
Next the ability of the FP assay to screen compounds with wide range of affinities 
including very weak affinity compounds was determined by screening a commercially 
available bioactive chemicals library (Selleckchem, TX) of 1840 unique compounds in 
single point format in 384 well plates as per established conditions. The bioactive 
collection was selected as screening library as it represents collection of unique, 
medicinally active, structurally diverse compounds including small molecules and larger 
FDA (Federal Approved Drugs) collection with compound molecular weight ranging 
from 100-1600 Da. The bioactive collection was supplemented by with previously known 
ClpP activators, which were placed within the plates as external controls to test ability of 
FP assay to identify these compounds as hits. These controls included compounds 
representing wide range of molecular weight and affinities with in house ADEP4 
derivatives (Appendix B Figure B-2G, 19-26) representing tight binding affinity large 
compounds with MW>650 Da, ACP1 series (compound 27-28) representing low affinity 
small molecules compounds with MW 350-450 Da and a previously published ADEP 
fragment derived from ADEP4 (compound 29) representing weak binding affinity 
compounds with MW <350 Da59,217. The compound 7 (positive control) and DMSO 
(negative control) were also added to control wells to measure robustness (Z` factor) of 
the assay. 
 
At hit rate of 1.1 %, corresponding to 20 compounds out of 1840 test compounds, 
displaced bound probe 6 to greater than 75 % of the signal from 100% bound probe 6 and 
were identified as primary hits (Figure 3-4A). The test results indicated minimal plate to 
plate variation (Appendix B FigureB-5C, D) of positive control 7 and produced 
excellent Z` of 0.9, while delivering average signal window of 193 mP units across all 6 
plates. The selected 20 compounds were tested in a dose response (1:2) format and top 4 
compounds with FP-IC50 in range of 50-100 µM were selected for orthogonal validation 
experiments (Figure 3-4B). Later three compounds out of tested four were found to be 
highly fluorescent with emission wavelength at 570 nm which overlapped with emission 
wavelength of probe 6 (Ex/Em: 540nm/575 nm) resulting in false positives due to inner 






Figure 3-4. Discovery and Validation of ICG001 as Novel Small Molecule ClpP 
Activator. 
A: Single point screening of bioactive collection with hit cut off at 25% displacement 
compared to positive control. 
B: Dose response confirmation of top 5 hits on FP assay. 
C: Structure of the lead compound, ICG001 or SJ000773156-4. 
D: Orthogonal validation of ICG001 suggesting its ClpP activation potential. 
E: Confirmation of ClpP activation potential on in gel casein digestion assay. 
F: Binding confirmation of ICG001 with ClpP by X-ray crystallography. 
 
Image F adapted with permission from Elizabeth Griffith at Saint Jude Children’s 






SDS-PAGE based unlabeled casein digestion assay. As expected all false positive hits 
were found to be inactive whereas a novel compound SJ000773156-4 or ICG-001 
(Figure 3-4C), activated the ClpP resulting in degradation of ß-casein in manner similar 
to ADEP4. The displacement potency (FP-IC50) of the validated hit at 62.52±2.83 µM 
was expectedly weaker than ADEP4 or compound 7 potency at 3.76±0.2 and 7.64±0.2 
µM respectively (Appendix B Table B-1). This observation was reconfirmed on ClpP 
functional (enzymatic) assay (Figure 3-4D) on which ICG-001 activated ClpP with EC50 
at 9.67±0.58 µM to an extent comparable to compound 7 with EC50 at 2.42±0.24 µM, 
although the rate of enzyme digestion (Vmax) was slower than ADEP4. The orthogonal 
validation of ICG-001 as a ClpP activator in addition to being a binder, was also 
confirmed on unlabeled casein digestion (proteolytic activation) assay (Figure 3-4E) on 
which ICG-001 activated ClpP and degraded casein in manner similar to ADEP4. The 
above observations were structurally backed up by X-ray co-crystal structure of ICG001 
with ClpP (Figure 3-4F). 
 
 
Optimization of HClpP FP Assay 
 
Given the structural similarity between axial binding pockets between bacterial 
and HClpP and similarity in binding of ADEP4 analogs and small molecule series 
compounds to both proteins in TSA assay, the wild type ClpP FP probe (2591) was tested 
for binding to HClpP. The overall binding conditions (protein or probe concentrations) 
were kept identical to wild type ClpP except higher salt content for HClpP to match its 
storage conditions. The FP probe was found to bind to HClpP with EC50 of ~3 µM 
following incubation time period of 60 minutes and found to exhibit stable binding over 
time (Figure 3-5A). Further matching the displacement conditions of wild type ClpP, the 
2378 was used as displacement control. Following equilibrium binding of FP probe to 
HClpP, the 2378 was titrated into wells and allowed to incubate for 2 hours before 
measurement of IC50 curves. The 2378 was found (Figure 3-5B) to completely displace 
bound FP probe with relatively much weaker IC50 of 28.6±0.8 µM (green curve) 
compared to 2378 IC50 of 7.34±0.2 µM (blue curve) on wild type ClpP. Finally the assay 
robustness, its stability over time and signal window was determined by setting up 
repetitive (n=16) unbound, bound and displacement reactions in single well format and 
taking two measurements over time period of 16 hours. The overall Z` score (Figure 3-
5C) was measured to be >0.8 suggesting excellent reproducibility, the signal window was 
>190 mP suggesting excellent signal separation between baseline and positive response 





In conclusion a FP based assay with site-specificity to ClpP activation domain 
was developed as a high throughput primary screen to enable discovery of new and 
highly tractable chemical scaffold for the development of non-peptidic ClpP activators. 







Figure 3-5. Optimization of HClpP FP Assay. 
A: Determination of saturation binding condition for probe 6 (2591) to HClpP. 
B: Assessment of displacement conditions of previously bound probe 6 by positive 
controls. 







specific, high binding affinity and reversible binding ADEP probe of ClpP, (b) robust 
(Z`=0.91) nature of the FP screen with the ability to screen diverse chemical libraries in 
high throughput manner, (c) ranking of compounds based on their inhibition potency and 
(d) the discovery of ICG-001 as a novel ClpP activator. For selectivity determination 









CHAPTER 4.    DEVELOPMENT OF SURFACE PLASMON RESONANCE AS 




Introduction to Surface Plasmon Resonance (SPR) 
 
At cellular level the interactions of biomolecules (DNA, RNA, Proteins, Sugars 
and Lipids) are the driving force behind all biological activity. The measurement of 
bimolecular interactions is the key to understand their occurrence and mechanism of 
interaction. Various biochemical or biophysical characterization methods have been 
devised based on principles of fluorescence, luminescence, and radiometric detection to 
enable measurement of bimolecular interactions. These methods often require 
modification of interacting molecules or use of certain functional groups or labels to 
indirectly measure the interactions as a function of modulation of label activity (i.e. 
fluorescence or luminescence). The utilization of label based assays makes sense from 
high throughput screening standpoint, however the higher throughput often comes at 
expense of sensitivity and resolving power. In this context the label free characterization 
methods based on thermodynamics (ITC) or photometric detection (SPR) are superior in 
contrast to label based methods, both in terms of sensitivity or resolution. Among the 
label free methods, the Surface Plasmon Resonance (SPR) is a powerful, real time and 
highly sensitive technique to analyze interactions of biomolecules367,368. In simplistic 
terms the SPR is based on measurement of changes in refractive index of incident light 
on a sensor surface with chemically immobilized ligand (interactant 1), when an analyte 




History of SPR 
  
In the 1960s the surface plasmons were explained for very first time as non-
radiative surface plasma waves (SPW) emerging across the surface of a metal (silver) 
when a plane polarized light was focused on the metal under total internal reflection 
conditions using a prism metal interface spaced by a medium of lower refractive index 
369. The concept of SPR was formally conceptualized by arranging a prism coupled photo 
detector in what is known as Kretschmann configuration in which thin metal layer is 
seated on top of prism’s total internal reflection interface370. At a particular angle (SPR 
angle) of incident light under total internal reflection conditions , an evanescent wave of 
surface plasmons is formed at prism metal interface which transverses through the 
interface up to certain distance (~300 nm). The extreme sensitivity of evanescent wave to 
any mass changes within its traverse space enabled detection of such events in real 
time371. This configuration formed the basis of optical design in most of the modern day 
SPR instruments. The technology was commercially introduced by Pharmacia Biosensors 






Principle of Surface Plasmon Resonance 
 
Surface Plasmon Resonance is an actual physical phenomenon of wave like 
oscillations of outer shell electron constellations across the “Surface” of an inert , yet 
highly conductive metal (gold) coated at reflective interface of a prism, when a plane 
polarized light is incident at a critical angel of total internal reflection372. The total 
internal reflection angle is an angle of incident light at which light do not escape the 
prism and completely bends (refraction) inward at glass air interface of prism. At a 
specific surface plasmon angle (angle of incidence) the energy of incident light (photos) 
is absorbed by outer shell electrons of the metal creating electromagnetic waves of 
electron density referred to as “Plasmon” which oscillate parallel to metal air interface at 
a specific “Resonance” frequency at which momentum (and energy) of the incident light 
and surface plasmons is equal373.The surface nature of plasmons at negative dielectric 
interface of metal against air or buffer or vacuum, makes plasmons very sensitive to mass 
changes within the “evanescent” wave region which extend 50-300nm on either side of 
the interface374,373. Thus binding of an analyte to an immobilized ligand within 
evanescent field perturbs the momentum of surface plasmons, which alters the SPR angle 
of resonance. This change is measured in real time by a prism coupled detector as direct 
evidence of binding interaction between ligand and analyte. The refractive index shift is 
proportional to concentration to binding molecules and is quantified in arbitrary units 
called Resonance Units (RU)375,368. The intensity of evanescent wave region decreases 
exponentially with distance from the surface and correspondingly the sensitivity of the 
detection also decreases373. 
 
 
Applications of SPR 
 
In the world of label free bimolecular analysis, the Surface Plasmon Resonance 
(SPR) holds a pivotal position as a real time, analytical method with information on 
kinetic rates as well as affinity constants376,377. In simplistic terms the SPR is a highly 
sensitive mass detection technique with binding response proportional to increase in mass 
as result of direct binding of interacting partners within evanescent field of surface 
plasmon wave. This features makes SPR highly suitable to detection of low molecular 
weight analytes such as fragments as a result the SPR has emerged as a powerful tool to 
probe the low binding affinity interactions of fragments378,379. In addition to providing 
affirmation of binding between two interacting species, the SPR can quantitatively 
measure association as well dissociation rates in real time to generate information on the 
binding affinity constants, dissociative half-life of ligand analyte complex (residence 
time) , analyte concentration and stoichiometry of binding interactions380. 
 
The application of SPR-based bimolecular analysis extends far beyond 
assessment of binding interactions between key macromolecules (proteins, DNA/RNA, 
lipids) and their combinations (protein to DNA/RNA or Protein to Lipids)381,382,383,384. 
The SPR-based biosensors have very wide gamut of applications in SPR-based high 
contrast microscopy, detection of toxins, diagnostic biomedical research, and drug 




characterization extend from epitope mapping of antigens, aptamer selection to antibody 
profiling from crude extracts (serum)384. Further the SPR-based biosensors are highly 
applicable as quality control methods of detection of drug residues within clinical 
samples387,70. In the area of drug discovery the SPR-based biosensors are employed in 
target validation, lead characterization, pharmacokinetic profiling of drugs, drug-protein 
binding and ADME interactions388,389. Recently the off rates analysis was shown as an 
lead prioritization tool through identification of fractions with slower off rate from 
mixture of crude natural product fractions390. In terms of throughput the SPR technology 
now matches the pace of conventional high throughput screening platforms through 
advancement of microarray format based SPR microscopy or Imaging (SPRM/I) systems 
capable of measuring full kinetics of > 1000 bio molecular interactions simultaneously391. 
 
 
Advantages of SPR 
 
The label free detection of bio molecular interactions is one of the biggest 
advantages of SPR-based methods as a result the reliability of bio molecular 
measurement is quite high compared to fluorescence based platforms. The label free 
nature also extends the applicability of SPR-based measurements to wide variety of the 
drug discovery targets392,393,394,395. The SPR assays are highly qualitative in nature and 
provide real time assessment of bimolecular interactions without any requirements of 
product separation or wash steps. The SPR enables true referencing by measurement of 
changes in refractive index with extreme sensitivity, as a result the influence of changes 
in buffer conditions, temperature etc. can be reliably subtracted from measured responses. 
The affinity detection range of SPR assays is quite wide and it extends from mill molar to 
Pico molar ranges for variety of targets392. Further the screening range of SPR technology 
is quite large as it extends from very small (i.e. fragments, <100Da) to very large analytes 
such as antigens or antibodies (>100KDa)384. 
 
The next big advantage of SPR is relatively high throughput and lower reagent 
consumption. The reagent requirements of SPR-based assays are minuscule compared to 
other label free methods such as ITC or DSC. The targets with very low yield (<0.1 
mg/mL) can be immobilized on SPR chip to generate sufficient ligand density to perform 
bio molecular studies. Further the multi-channel configuration of SPR Chips enables 
immobilization of functional mutants and wild type protein on the same chip. The 
analytes response to either protein can be monitored in real time to assess specificity of 
the binding. In an alternative experiment, multiple analytes could be injected over on an 
immobilized target and analytes with distinctive on or off rate could be identified. 
 
 
Limitations of SPR 
 
One of the limitation of SPR-based methods is requirement of immobilization of 
one of the interacting partner (mostly ligands), therefore the quantification of bio 
molecular interactions at best are very close approximation of same interactions in 




the reliability of the binding kinetics could be affected. In certain cases the kinetics 
become skewed due to partial inactivation of binding sites as a result the observed 
kinetics or binding stoichiometry are lower than actual391. Another limitation of SPR-
based assays is its extreme sensitivity buffer components with high refractive index. For 
example the mismatch of buffer components or DMSO to running buffer may become a 
significant issue in analysis of test analytes. Although the Self assembling monolayer 
(SAM) acts as barrier between metal surface and biomolecules, its effectiveness is not 
absolute as a result the issues related to nonspecific adsorption of ligands or analytes to 
sensor surface still exist. 
 
 
Basic Elements of SPR Analysis 
 
The biosensor based SPR is a label free, real time optical spectroscopy method 
based on analysis of changes in refractive index in immediate vicinity of sensor surface 
upon adsorption or binding of an interacting species391. The basic elements of biosensor 





The biosensor surface is composed of an optically clear glass surface coated with 
thin layer (~50 nm) of metal (gold) to measure perturbations of charge density 
oscillations or surface plasmons396,397. Gold is metal of choice due to its excellent 
conductivity, high adsorption properties and inertness to most of the chemicals. On the 
gold coated surface, a self-assembling mono layer (SAM) of ω-hydroxyalkanethiol is 
deposited to provide an anchor to a dextran layer which provides the sensing 
surface 398,399. A thin, hydrophilic hydrogel layer (100nm) of non-crossed linked 
carboxymethylated dextran (1,6 linked glucose) provides reactive carboxyl groups, which 
act as anchor for immobilization of ligand by various surface chemistry 
modifications397,400. The hydrogel dextran layer is negatively charged and could be 
chemically activated to covalently bind to positively charged ligands of interest 
generating high ligand density on the sensor surface396. The poly dextran surface could be 
further derivatized to support additional immobilization chemistries such as nickle-
nitriloacetic acid (Ni-NTA) for histidine tagged ligands, Streptavidin or neutravidin 
(Biocap) for biotinylated ligands, and n-octyl-glucoside for liposome capture. The 
biosensor surface is embedded on to a disposable biosensor chip which is docked in a 






The ligand in bimolecular analysis is the one of interacting partner which is 
immobilized on dextran coated surface of SPR chips. Most commonly used ligands are 




interactions between protein and antibody, immobilization of proteins with single binding 
pocket is advantages compared to immobilization of antibody which typically have two 
or more binding pockets. In other words, homogeneity of ligand (binding pockets) is 
incremental toward data analysis using simple 1:1 interaction model compared to 2:1 or 
multivalent data analysis which tends to very complex with poor data fits with available 





The analyte in bimolecular analysis is one of the binding partner in solution which 
is flown over immobilized ligand by mechanically controlled buffer flow. In general 
analytes are either chemicals (small molecules, fragments) or in some cases natural 
peptides or antigens. In an SPR experiment the concentration, flow rate, contact time, 
steady state and dissociation rate of analyte has direct impact on kinetics of the 
interaction. Similar to ligand homogeneity, purity of analyte is one of critical aspect 
toward successful kinetics determination. For small molecules work, high solubility of 
the analyte in buffer is paramount to avoid artifacts from nonspecific binding of analyte 





A sensograms is a real time visual representation of biomolecule interaction 
occurring on a flow cell. In an SPR experiment, the changes in optical density of 
biosensor due to binding or adsorption of molecules (ligands or analyte) to metal surface 
greatly perturb the charge density oscillations (surface plasmons) at prism-metal surface 
interface which result in difference in refractive index of bound to free metal surface397. 
Correspondingly the angle (SPR angle) at which physical phenomenon of SPR occurs, a 
change reflected as alteration of sharp dip angle on computer monitor. These change are 
converted into arbitrary units called Resonance Units (RU), with a change of 1000 RU 
equivalent to change of 1 ng/mm2 in protein concentration on the chip surface368, 375. 
During a biosensor experiment, as an analyte flows over a sensor surface with 
immobilized ligand, increase in response units (Y axis) vs time (X axis) due to mass 
change brought by binding of analyte to ligand, are produced in real time on a graph 
(sensogram) reflecting association followed by steady state at which change in response 
plateaus followed by dissociation phase of downward decay of signal during which 
analyte diffuses away from ligand397. The hallmark of a good sensogram is observed 
curvature in the association phase and exponential decay in the dissociation phase. The 
sensograms with linear association phase profile do not provide accurate kinetic 
information and indicate a sub optimal assay. The most commonly observed sensogram 
shapes are biphasic in nature with appearance of two separate association or dissociation 
profiles and are indicative of system complexity or issues related to ligand density and 
mass transport limitation. The sensogram shape for fragments is square shaped due to by 
virtue of their low affinity the fragments acquire steady state rapidly and have fast 








Key Concepts in Optimization of SPR Assays 
 
 
Kinetics of Bio-Molecular Interactions 
 
In its most elementary form the bimolecular interactions between analyte and 
ligand in solution could be seen as interactions governed by constant (and random) 
Brownian motion during which analyte binds to and dissociate from a ligand at a certain 
pace. The reversible binding or dissociation events of physical interaction, and time of 
contact (ligand occupancy) of ligand analyte complex are contingent on law of mass 
action or chemical equilibrium, rate of diffusion, proper orientation and energy of impact 
between analyte and ligand401,402. In SPR experiments, immobilization of ligand restricts 
its degrees of freedom to some extent as a result the law of mass action does not apply. 
Thus at the very best the measured binding responses in SPR experiment are close 
approximation of actual responses in solution. During a kinetic experiment, a molar 
excess (5-10 times estimated KD) concentration of analyte is flown over immobilized 
ligand in a continuous stream of buffer. On the chip surface, concentration of 
immobilized ligand is constant assuming zero drift from dissociation of bound ligand 
over time. The above interactions between analyte and ligands are best described by 
single exponential process as simple pseudo first order kinetics403,404. During initial stages 
of interaction, the analyte approaches the ligand at a specific rate called rate of 
association. The association rate is a measure of number of ligand analyte complexes 
formed per unit time (sec) and is expressed as kon or more quantitatively as ka [M
-1s-1]. 
The association rate depends on total number of available binding sites as well as on 
concentration of the analyte. The association phase profile is best described by simple 
exponential binding profile rather than a parabola or sigmoidal shape. At the end of the 
analyte injection, the continues buffer stream replaces the analyte sample plug causing 
concentration of free analyte to decease exponentially to zero, perturbing the steady state 
and analyte begins to diffuse away from ligand under continues buffer flow, at a rate 
called dissociation rate, expressed as koff or more accurately kd [s
-1]. The rate of 
dissociation is independent of analyte concentration or number of binding pockets instead 
it depends only on its rate of diffusion. Similar to association, the dissociation phase 
profile is also best described by exponential dissociation profile. 
 
Overall the time course of single exponential process under steady state is 
described in. As the sample plug of analyte is pushed over ligand, the occupancy of 
analyte maximizes to saturation point referred to as steady state equilibrium at which the 
rate of change of the concentration of the analyte –ligand complex is equal to the 
difference between its rate of formation and dissociation. Due to the continues injection 
the analyte is added and removed away from ligand at a steady rate, the overall rate of 
change of ligand complex formation is zero. This situation closely resembles the 




Under equilibrium conditions the strength of interaction is defined by term equilibrium 
dissociation constant KD as ratio of dissociation to association rate constant (inverse of 
equilibrium association constant KA), expressed in units of molarity. The equilibrium 
dissociation constant is independent of concentration of both analyte and ligand as a 
result two analytes can have same KD at different concentrations and vice versa. 
 
 
Type of SPR Experiments 
 
Various injection methodologies could be used depending on type of analysis. For 
analytes with fast dissociation time or weak affinity, fixed concentration injections in 
replica of three could be injected both manually and with automation starting with low 
concentration to high concentration. Later the different curves are overlaid in data 
evaluation software to generate one sensogram and binding affinity measured by plotting 
response at steady state (close to injection end) at respective concentration against 
concentration. For analytes with tight binding affinity the length of dissociation phase is 
increased to observe complete dissociation at various concentrations before appropriate 
model fitting. Alternatively low to high concentrations of analyte could be injected in a 
single experiment using machine controlled dispersion injection (i.e. OneStep) method 
while keeping dissociation phase sufficiently long to allow complete dissociation of 
analyte. For analytes with very tight affinity the achievement of steady state is completely 
governed by their very slow dissociation rates due to which length of association phase of 
the injection has to be prolonged before steady state equilibrium could be achieved. For 
weak affinity analytes such as fragments, the dissociation rates are very fast and steady 
state is achieved quickly. Often accurate determination of very fast on or off rates is 
problematic, therefore steady state experiments or equilibrium affinity analysis could be 
used to inject fixed concentrations of analyte from low to high concentration in replicates. 
An important requirement for equilibrium affinity experiments is that for a given 
concentration the steady state must be achieved before model fitting however 100% 
saturation of the ligand binding sites is not required. 
 
 
SPR Data Analysis 
 
The interactions between analyte and ligand are best described by simplest one to 
one model for binding interaction proposed by Langmuir isotherm405,406. However unlike 
interactions of completely mobile gas particles in Langmuir isotherm, only analyte in 
solution has complete degree of freedom while immobilized ligand is slightly restricted 
due to tethering to dextran hydrogel. Therefore the best model to describe the analyte 
ligand interactions is pseudo first order kinetics model according to which difference of 
rate of formation and dissociation of analyte equals to rate of change in ligand analyte 
complex concentration407,403. However due to restraints from nature of ligand or analyte 
not all interactions could be described by simple one to one binding. The experimental 
variables such as ligand heterogeneity, mass transport, nonspecific binding and rebinding 
effects introduce additional complexity which requires integration to more complex 




interactions arising from mass transport limitation or multi-valancy of ligand or 
analyte408,409,410,411. The basic assumptions of theories of bimolecular interactions are that 
both ligand and analyte are pure and homogeneous in composition and their interaction is 
completely reversible with ligand and analyte returning to their pre binding stage after 
dissociation. The ligand concentration does not change by virtue of immobilization 
(assuming zero drift) and analyte is in saturating concentrations such that analyte 
depletion is not a factor. Further association event is a function of affinity between 
analyte and ligand whereas dissociation is only dependent on analyte diffusion. Another 
assumption is that affinity of all ligand binding pockets is equivalent to each other and 
binding is not mutually dependent412. Any binding interaction outside above set of 
assumptions constitutes a complex system, which would require complex models to fit 
the data. 
 
The key to good data fit is robust experimental conditions along with double 
referenced high quality data free from artifacts or spikes413. For the experiments in which 
multiple concentrations of same analyte are injected over immobilized the kinetic 
parameters such as ka, kd, km KD and Rmax generate best fits to global rather than local 
analysis413. When multiple analytes are injected over same ligand then the Rmax should be 
fitted to local analysis due to dependence of Rmax on molecular size of the analyte. Other 
parameters such as Req or RI differences are also fitted locally as their response is 
proportional to concentration of analyte injected. 
 
 
Typical SPR Instrument Configuration 
 
Most of the conventional SPR instruments employ mechanically controlled 
microfluidic system with disposable gold coated poly-dextran SPR chips with 3 or 4 
surface channels. Different ligands can be immobilized on each surface depending on 
various immobilization strategies and analytes injected with variable flow rates across 





Term immobilization in SPR field refers to tethering of a ligand to dextran 
hydrogel layer on a poly dextran gold chip. A typical Immobilization is performed by 
activating the surface (EDTA for His capture, NHS-EDC for amine coupling) followed 
by ligand coupling and inactivation or capping of remaining functional groups. in The 
essence of immobilization is hold one of interactant referred to as ligand (proteins or 
antibodies) close to negatively charged dextran hydrogel layer within measurable 
evanescent plasmon field of gold chip to generate a stable baseline while second 
interactant referred to as analyte (small molecule, antigen) is flown over immobilized 
ligand to generate binding signal. The immobilized ligand contrary to the term is not 
completely immobile instead it maintains sufficient degree of freedom to allow binding 
interactions similar to interaction in solution408. The term coupling is referred to as 




(strap or neutra) Avidin tethering or amine coupling. The term capturing refers to 
temporary form of immobilization based on affinity as in case of Ni-NTA-Histidine 
capture. Another transient term capture couple is used when above two type of 
immobilization strategies are mixed. A ligand could be immobilized by exploiting 
various functional groups (primary amines, aldehydes, thiol etc.) on proteins or dextran 
hydrogel and by engineering certain tags such as poly histidine tag or biotin tag to 
recombinant proteins407. Among the most popular methods for immobilization is affinity 
capturing based on chelation of metal ion (Ni+2) with polyhistidine tagged ligands on 
“His-chips” with Ni+2-Nitrilotriacetic acid moiety tethered to dextran matrix. Despite 
mediocre affinity of histidine tags to Ni-NTA at 10-6M, the Ni-NTA chips produce a 
stable surface due high level of rebinding of histidine to Ni-NTA surface414. 
 
Immobilization by amine coupling is yet another common method in which 
carboxyl groups on dextran layer are esterified (activated) by mixture of NHS-EDC into 
N-hydroxy-succinimide esters which form covalent bond with primary amine functional 
groups on ligand407,415. The immobilization by exploiting very high affinity between 
biotin and Strap(neutra)-avidin (10-14M) on streptavidin sensor chips could also be 
performed407,416. The 15 amino acid long biotin (BAP) tag sequence can engineered into 
N or C terminus of recombinant protein or minimal biotinylation could be performed in 
vitro to covalently bind the ligand on surface chip to generate very steady baseline417. 
Further depending on type of immobilization the generated ligand surface could be 
uniformly orientated as in case of poly his or biotin tag based immobilization and 
randomly oriented as in case of amine or thiol coupling. 
 
The choice of immobilization type is based on certain characteristics of ligand 
such as stability in buffer, pH, Isoelectric point (PI), molecular weight, valancy, amino 
acid sequence, functional groups and presence/ location of tethering tags. For proteins 
with PI<4, amine coupling is not suitable instead thiol based coupling is recommended 
whereas for proteins with PI=> 5 both amine and thiol coupling could be performed. 
Immobilization by using tags such as Histidine or biotin tag have more diverse range of 
pH tolerance but require engineering of tags at a location distant to binding pocket. The 
GST tag is not recommended due to its ability to form dimers while on the surface, 
complicating the kinetic parameters409. The extreme sensitivity of surface plasmons to 
mass changes governs the type of bio molecular analysis which could be performed at a 
given surface density. The SPR is a mass detection technique so size of analytes in 
comparison to ligand is important. For small molecule or fragment screen, the ligand 
must be immobilized to high densities in order to generate a measurable signal. However 
the level of ligand density should be carefully selected to avoid higher ligand density 
artifacts such as mass transport limitation, volume exclusion and steric hindrance. To 
determine specificity or selectivity of the binding of same analyte against two different 
ligands, it is required that both ligands are of similar size (homologs) are immobilized to 
same level. For protein antibody type of experiments, it is possible to measure 
concentration of analytes by purposely facilitating mass transport limitation with high 
ligand density. Kinetic parameters are best determined at lower surface density however a 
due care must be taken to ensure that signal from interaction is above the noise from 




in baseline signal and retention of functionality of ligand binding pockets are absolute 





For SPR sensor chips with carboxyl dextran layer, pre-concentration procedure is 
performed to aid assessment of ligand immobilization level based on electrostatic 
interactions between protein and dextran matrix396. During amine coupling procedure 
ligand is injected over negatively charged dextran layer under varying pH (4.5-6.5) 
conditions in low salt buffer conditions. At pH below isoelectric point of the protein (PI) 
the proteins become positively charged and bind to negatively charged dextran layer396. 
Replacing the buffer with high slat and with neutral or slightly basic pH disrupts the 
electrostatic interactions resulting in dissociation of bound ligand. This way maximum 
binding of the ligand is obtained at a specific pH point below PI point of the ligand. 
However using pH much below PI point (pH <3) causes protonation of the carboxyl 
groups of the dextran resulting loss of signal. So it is important to balance the pH. 
Combination of NHS-EDC is used for activation of the dextran layer at higher pH 
following pre concentration at lower pH to achieve maximal binding of the ligand. 
 
 
The Concept of Rmax and Req 
 
The Rmax is the maximal binding response at equilibrium under saturating 
conditions at which when all available binding pockets are saturated with the analyte. The 
maximum response depends on maximum number of available binding sites and size 
(molecular mass) of analyte. At saturating conditions the maximal response (Rmax) 
becomes independent of concentration of analyte i.e. Rmax does not increase upon 
increasing concentration of analyte. The maximum response at saturating condition is 
however different from response at equilibrium (Req). Depending on injection length of 
the analyte, the Req is the maximum response at a given concentration of analyte when 
steady state is achieved under which rate of complex formation becomes equal to rate of 
complex dissociation. This is true for very low concentrations of analyte which would 
take far longer to reach steady state compared to analyte at higher concentrations for 
which length of injection would be shorter418. Thus the Req shifts with increase in 
concentration of analyte till saturating conditions are achieved at which Req becomes 
equal to Rmax. When concentration of analyte becomes equal to equilibrium dissociation 
constant KD, the percentage occupancy is at half (50%) of the maximal available binding 
pockets419. Therefore concentration range up to 10 time higher than KD is sufficient to 
generate Req equal or very similar to maximal response Rmax. For generation of accurate 
kinetic parameters the length of injection should be long enough to reach steady state, 







Significance of Dissociation Rate 
 
The dissociation rate contains useful information on association phase and overall 
affinity KD. The equilibrium dissociation constant (KD) is often used as a parameter for 
deciding strength of binding interaction however the off rate is the true measure of the 
strength of binding as it describes the time duration of interaction compared to 
equilibrium dissociation constant KD which describes the concentration of analyte at 
equilibrium conditions, required to achieve 50% saturation of binding pockets. Further 
the shape of binding curve in a sensogram is entirely governed by dissociation rate. The 
analytes with very slow dissociation rate tends to have long association phase and low KD 
(more potency). This is due to considerably longer time required by analytes with slow 
dissociation rate to reach steady state compared to analytes with faster dissociation. 
Additionally the dissociation constant describes rate at which the ligand analyte complex 
decays per sec. This information is useful in computing half-life of complex dissociation 
(t1/2). The t1/2 is the time it takes to dissociate half of the maximum bound analyte or time 
duration to 50% occupancy of all available binding pockets. The t1/2 is often confused 
with residence time which is the total time during which analyte occupied ligand binding 
pockets. The residence time is inverse of dissociation rate. The residence time is often in 
consensus with t1/2 as analytes with longer residence time would also have longer t1/2 due 
to slow dissociation rate. Both t1/2 and residence time are of special significance from 
therapeutic efficacy standpoint as analytes with longer residence time or t1/2 have longer 
time window of therapeutic action420. From drug discovery stand point the analytes with 
longer dissociation rates hence longer residence time are most potent and prioritized for 
lead optimization421. Therefore the accuracy in determination of dissociation constant is 
critically important. Due to mass transport limitation at higher ligand density, 
immobilization induced heterogeneity, and rebinding effects of dissociated analyte, the 
dissociation becomes nonlinear with double exponential decay, generating lower 
dissociation constants than actual value411,410,422. 
 
 
Mass Transport Limitation 
 
Mass transport limitation is phenomenon of time it takes for analyte to reach the 
reactive surface. In a flow cell (in form of a tube) the buffer carrying sample plug 
(analyte) moves in a laminar (layered) acquiring parabolic shape due to frictional forces 
between layers of buffer as well as at interface of flow cell walls against buffer. The 
shape of parabolic buffer flow is dependent on over all flow rate of buffer with flow 
velocity highest in the middle and minimal at walls which results in relatively unstirred 
layer close to wall. At the interface of parabola the rate of sample diffusion into buffer 
generates another concentration gradient. As a result a two dimensional concentration 
gradient is formed with more concentrated analyte at center and back end of sample plug 
compared to sides as well as front end of the sample plug423. Another force creating the 
gradient is relatively faster depletion of analyte binding to ligand closer to flow cell walls 
compared to center of the sample plug. Following the gradient the analyte molecules in 
the center of flow cell travel toward surface till saturation equilibrium is reached over 




the analyte molecules at center of stream might not get a chance to reach the surface and 
only analytes close to wall can passively diffuse (proportional to its mass) to surface. In 
other words the transport of the analytes is limited by flow speed and mass of the analyte. 
To overcome the mass transport limitation, the flow speed of buffer is increased to 
eliminate the concentration gradient to generate a more uniform sample plug. 
 
The second factor contributing to mass transport limitation is density of the 
immobilized ligand. Contrary to the belief that immobilized surfaces are uniform with 
ligand attached to top layer of dextran, the ligand binds throughout the poly dextran 
extensions. At higher ligand densities there are higher number of binding pockets which 
creates a sort of affinity sink for analyte molecules which diffuse at a relatively slower 
rate from relatively unstirred layer close to surface till saturation in analyte concentration 
is achieved423. Once the analyte is bound to one of the ligands then neighboring ligand 
might still have to wait for the next analyte to diffuse through the unstirred layer. In this 
case the rate of association becomes transport limited. At higher ligand density surface 
the association rates appears to be faster than actual rates, with linear profiles (lacking 
characteristic curvature) compared to lower ligand density surface424. Mass transport 
limitation also influences the dissociation rate at higher ligand densities due to rebinding 
of already dissociated analyte from one ligand to neighboring ligand before it could be 
diffused away. As a result the apparent dissociation rates appear to be slower than actual 
rates, leading to skewed equilibrium dissociation constant (KD) calculations. To avoid 
possibility of mass transport limitation, ligand density should be lowered to reduce 
competition on the surface and flow rates should be increased to ensure uniform sample 
lug with minimal concentration gradient as well as reducing the likelihood of rebinding 
effects424,425. 
 
To analyte a mass transport limited data, two compartment model could be used. 
The km (mass transport coefficient) is dependent on flow rate, diffusion coefficient, 
height and length of the flow cell423. So mass transport limitation coefficient km differs 
from one point in the flow cell to a point later in flow cell. A hallmark of mass transport 
is linear binding at higher concentrations and binding with curvature at lower 
concentrations and slows off rates at all concentrations (due to rebinding effects). 
Another sign is same starting on rate at various ligand immobilization levels. To test 
mass transport, change the flow rate, lower the viscosity of the buffer, vary flow cell 
height. The dextran layer at surface interface is relatively very thin (100nm)compared to 
height of the flow cell (~50µM) so it do not impede diffusion or gradient to a significant 
extent however the density of ligand does403. If a mass transport model is applied to a 
system which does not have mass transport issue then kinetics parameters will not change 
however the system with mass transport will show better fits and different kinetic 
numbers. The linear binding curves do not have any kinetic information as it does not 
follow simple exponential equations of mass action. The mass transport is also different 
from one channel to another because channels are connected in series. The limit of 








The affinity between analyte and ligand arises due to combination of electrostatic, 
Van der Walls, hydrogen bonding, and hydrophobic interactions. The term regeneration 
refers to removal of bound analyte from ligand binding pockets by disruption of all 
underlying interactions426,427. The essence of regeneration procedures is based on the fact 
that binding of analyte to ligand is reversible and binding pockets could be safely 
regenerated before next analyte is injected to observe a binding response426. The primary 
purpose of regeneration procedure is to disrupt all interactions (specific or nonspecific) of 
analyte by using combination of solutions with varying ionic strength (pH , Salt) to 
“regenerate” or recover the binding pockets of the ligand428. Regeneration of the surface 
is more relevant for analytes with slow dissociation rate (high affinity) or certain 
compounds with nonspecific binding behavior which could cause carry over effects into 
association phase of next analyte, thus compromising entire experiment or all analyte 
binding profiles following such compounds. 
 
A very important consideration of regeneration is that functionality of the ligand 
must not be compromised either in physical conformation or affinity of bind pockets427. 
The utilization of harsh regeneration procedures could easily cause loss of ligand function 
which could be observed from loss of maximum binding response of same analyte after 
each regeneration injection. Further strong regeneration conditions such as sudden pH 
changes could induce non replicative matrix memory effects in which each regeneration 
injection causes random re-orientation of the dextran hydrogel layer causing shift in 
orientation of the ligand429. Further conformation changes in the ligand binding pockets 
could arise from exposure to extreme pH or ionic strength of regeneration solutions, 
resulting in partial or complete inactivation of ligand. Last but not the least effect of 
regeneration procedures is introduction of nonspecific binding and baseline drift from 
regeneration solution itself. The determination of successful regeneration conditions 
however, is strictly dependent on stability and behavior of a particular immobilized 
ligand. Therefore a strategic approach of using regeneration conditions ranging from 
weak to strong ionic strength, acidic to basic pH and combination of solutions 
(detergents, chelating agents, nonpolar solvents) is required to identify best regeneration 
conditions. 
 
Various regeneration strategies using solutions from low to high pH (2.5-10), 
ionic strength (up to 1mM Salt) and cocktails of various acidic or basic solutions have 
been recommended to safely break interactions of analyte and ligands400,428,427,426. Among 
the common procedures for regeneration are use of low ionic strength (10 mM) glycine 
solution (pH 2.5) to reversibly and partially unfold proteins (binding pockets) via mutual 
repulsion due to added positive charge (for proteins with PI >5)427. Another common 
strategy for regeneration is by injecting a brief pulse of low affinity competitor binding 









Residuals represent fitness of the data to applied model. A data which fits well to 
selected model, generates very low Chi2 values which suggest accuracy of the data fit. 




Instrument Maintenance and Data Quality 
 
The quality of the data depends on condition of SPR instrument and test system 
(ligand, analytes) characteristics. It is important to pay attention to mechanical moving 
parts as well as optics of the SPR instrument. Since typical SPR experiments use salts in 
running buffers, gradual buildup of salt in the microfluidics of SPR instrument is not 
uncommon. A due care should be taken to ensure optimal performance of the SPR 
instrument by inspection of the injection needle to keep it clear of any salt deposits in 
addition to periodic checks to ensure proper well positioning of needle to ensure smooth 
injections. Further the performance of optical detection system should also be checked by 
periodically by monitoring the normal dip angle. A broad shallow dip angle with waving 
signatures is indicative of malfunctioning optics or optics requiring expensive repairs. 
The buffer tubing and microfluidics of SPR instruments should be kept clear of dust or 
salt deposits by leaving system under continue water flow. Further the proteins can 
naturally adsorb on the tubing and later desorb randomly therefore periodic desorb or 
sanitization procedures are highly recommended. 
 
 
Limits of SPR Analysis 
 
The resolving limit of most of the modern SPR instruments for the association 
rate (ka) is between 1e
3 to 1e8 M-1s-1 and 1e-1 to 1e-6 for dissociation rate392. The 
measurement limit for association rate is largely proportional to size of the analyte, with 
larger analytes faster association rates could be measured with more confidence 
compared to smaller analytes. This dependency stems from mass transport limitation 
which becomes issues for smaller analytes which require higher ligand density to 
generate a measurable response422. Accuracy in measurement of dissociation rate is 
dependent on capability of instrument to record responses in a fraction of second. Most 
modern SPR instruments takes multiple reading (up to 20Hz) per sec however 
measurement of ultra-fast dissociation rate of 1-2 s-1 is just outside of calibration range 
for most instruments. Therefore the reactions with association rate higher than 1e8 and 
dissociation rate faster than 1 s-1 cannot be resolved with confidence. 
 
 
Sources of SPR Artifacts 
 
The sources of errors in reproducibility of sensograms could originate from 




are systemic which occur frequently (buffer mismatch, DMSO mismatch), while some of 
errors are random and due to contaminant metals in buffers or very sticky compounds 





The duration of artifacts could be small (dextran matrix effects) to very long 
(contamination) depending on type of sensor chip and level of ligand immobilization. 
The flow rate of the analyte injections must be sufficiently faster to minimize artifacts 
such as mass transport limitation which tend to skew the kinetic parameters413. A sudden 
change in flow rate can alter microenvironment of dextran hydrogel around ligand 
resulting in a drift in the baseline. Similarly change of one buffer to another can cause 
baseline drift. Therefore overnight stabilization of the surface with repeat buffer 
injections before and after ligand immobilization is highly recommended to ensure proper 





For the long experiments with many analytes such as a fragment screen, the 
injection order of analytes should be randomized with frequent buffer injections to 





Depending on composition of buffer (with detergents) , temperature and flow rate 
of the experiment, air bubbles can get introduced in microfluidics of the SPR instruments 
and could take very long time to clear. The air bubbles produce very sharp spikes in the 
baseline due to very high difference of refractivity of air vs buffer containing DMSO, 
making interpretation of data very difficult. Therefore the running buffer as well as 
sample buffer should be degassed thoroughly and in built degasser function of the 





Typical SPR instruments inject the sample by introducing air bubbles around 
analyte sample plus to minimize diffusion of sample into running buffer before injection 
over flow cell. This process is however not precisely controlled and could generate spikes 
at start and end of the injection. Further density of the ligand and flow rate can cause a 
sample diffusion gradient which could complicate the data analysis. Further all reference 
cells on the chip are in series and there is a delay in introduction of sample plug from one 




sample dispersion, use of special injection methods such as OneStep or Kinject at higher 
flow rates could help alleviate dispersion issue. 
 
 
Refractive Index Bulk Shifts (RI) 
 
The spikes due to RI jumps at the beginning and end of analyte injection are 
caused during switching between buffer streams to analyte solution during an injection. 
The source of RI jumps is the high refractive index of one of component (analyte) which 
differs significantly from running buffer, causing spikes in data which in turn causes poor 





The ligand heterogeneity refers to existence of multiple forms of ligand within 
solution and on chip surface. The best ligands for SPR are monovalent ligands due to 
ease of fitting the data to simple interaction models such as Langmuir model of 1:1 
interaction406. Certain ligands such as protein complexes with multiple monomers 
populations in solution or on chip could still be studied on SPR however the kinetic data 
is unlikely to fit into simple interaction models and would require complex models to 





The surface heterogeneity is similar to concept of ligand heterogeneity in term of 
presence of multiple forms of the protein on the surface however it differs in reference to 
presence of contaminants and orientation issues. Surface heterogeneity is primarily 
driven by purity of the ligand and immobilization method. An impure ligand could lead 
to generation of surface with varying level of affinities for analytes, resulting in uneven 
analyte responses complicating the data analysis. Further immobilization methods such as 
amine coupling could cause decrease in stability of ligand on chip surface alone with 
random orientation of ligand on the surface with possibility of inactivation of ligand from 
disruptive covalent modification of primary amine groups within binding pocket395. The 
solution to avoid surface heterogeneity is by engineering of histidine or biotin tags in 
recombinant proteins to generate a homogeneous surface with uniform ligand orientation. 
The use of larger tags such as GST is not recommended due to their ability to form 
dimers on the surface409. Further the % integrity or functionality of the ligand after 
immobilization must be determined to rationalize complicity of kinetic data. 
 
 
Immobilization Level of Ligand 
 
The density of ligand on the chip surface has profound effect on kinetic 




hindrance) and mass transport limitation432,423. The best kinetic data is generated at low 
surface densities however the response of the analyte also decreases proportionally due to 
mass dependency of SPR detection. Evaluation of binding data at low surface densities 
requires use of higher analyte concentrations which in turn cause increase in bulk shift 
artifacts. Further detection of analytes at low surface density of ligand require detection 




Behavior of Reference Surface 
 
Often in SPR experiments, reference flow cell is used to make adjustments for 
differential binding behavior of analytes or buffer components toward a surface with 
immobilized ligand in comparison to surface without ligand. The data from reference cell 
is subtracted from data generated from surfaces with ligand to differentiate specific 
binding response of analyte to ligand from nonspecific binding of analyte to sensor 
surface (dextran layer)433,435. During immobilization, ligands occupies small physical 
space on the chip surface excluding corresponding small buffer volume compared to 
reference channel with no ligand. When analyte sample containing co-solvents with high 
refractive index such as DMSO is injected on reference cell, the proportional bulk signal 
response is much higher for reference masking the signal of analyte binding during 
reference subtraction. This phenomenon is referred to as excluded volume effect and it 
could complicate the data analysis especially at lower ligand densities422. Depending on 
type of SPR experiment, the reference surfaces are either deactivated to prevent 
nonspecific interactions or a non-binding protein is immobilized to same level as surface 
with active ligand. In certain cases the reference surface is left unmodified if above 





The concentration of injected analyte can directly influence the rate of association 
and therefore the equilibrium dissociation constant (KD). The variations between analyte 
concentrations due to pipetting error or sample evaporation could lead to reporting of 
lower equilibrium constants than actual due to corresponding erroneous increase in 
association rate. Further high concentrations could introduce artifacts from larger bulk 
shifts as well as carry over effects which can alter the quality of the data. The most 
pronounced effect is increase in baseline line level before injection of next analyte, 
making the sensograms unfit to any reliable data evaluation. Yet another artifact from 
high concentrations of analyte is rebinding effects especially for analytes with low 
affinity. For compounds with lower affinity the steady state equilibrium is achieved 
rather quickly, as a result, at high concentrations, more analyte is available to bind to 
adjacent ligand sites. As a result the dissociation rate appears to be slower than actual 
rate. Further at higher concentrations the association curves appears to have biphasic 
behavior with initial faster association rates followed by slower association rate. The 




steady state equilibrium and complete dissociation of analyte at end of the injection, 
hence impact accuracy of kinetic parameters. 
 
 
Nonspecific Binding (NSB) 
 
Nonspecific binding is a critical but often overlooked aspect of bimolecular 
analysis on SPR instruments with serious implications toward accuracy of results. The 
nonspecific interactions arise from random ionic, hydrophobic or electrostatic 
interactions analyte or contaminants with dextran matrix and to ligand itself. The 
nonspecific interactions if not resolved could obscure the actual binding response as often 
the binding profile of nonspecific binding is similar to actual (specific) interactions of 
analyte to ligand. Therefore it is important to test interactions of either partner to an 
unmodified surface to predict if nonspecific binding will influence accurate determination 
of kinetics. The characteristic features of nonspecific binding are upward slope in signal 
at equilibrium phase of interactions. Generally smaller degree of nonspecific interactions 
could be compensated with reference subtraction from active surface data as long as 
response from protein channel is much greater than reference channel. If nonspecific 
binding is significant, then lowering of surface density of ligand followed by addition of 
higher concentration of salt (NaCl up to 0.5 M) , chelating agents (EDTA), certain 
nonionic surfactants such as Tween 20 (0.05%) or Triton X-100 (0.01%) and dextran 
(0.1-10 mg/mL) to running buffer could lower the nonspecific binding. Further capping 
of unreacted carboxyl groups by BSA (0.1-10, mg/mL) could help reduce possibility of 
nonspecific binding. Inclusion of chemicals with high net negative charge such as 
ethanolamine or ethyldiamine could be used in running buffer to neutralize nonspecific 
electrostatic interactions. Occasionally some degree of nonspecific binding is inevitable 
owing to nature of interactant (analyte insolubility or lipophilic behavior) and in such 
cases change of immobilization chemistry or substitution of chips with lower dextran 
content could be useful. 
 
 
Dextran Matrix Effects 
 
The orientation of dextran hydrogel on SPR chip surface is not static, instead the 
dextran polymers exhibit considerable dynamic mobility allowing sufficient degree of 
freedom to immobilized ligands mimicking natural binding interactions in solution. The 
orientation of dextran polymers is influenced by sudden changes in pH, ionic strength 
(during regeneration conditions), with increase in intensity of effect proportional to 





Kinetics of binding interactions is affected due to variations in refractive indices 
of buffer and samples which in turn depend on variations in temperature. Increase or 




the rate of Brownian motion, alerting kinetics of association or dissociation436. At higher 
temperatures the rate of association or dissociation is usually faster and decrease in 





In certain cases the sensograms are produced in inverse orientation. Inverse 
sensograms could result from higher degree of nonspecific interactions of analytes to 
reference channel compared to active surface with ligand. As a result a reference 
subtracted data is produced in upside down orientation. Another source of inverse 
sensograms is due to high affinity of certain analytes especially small molecules to 
dextran matrix. Differences of DMSO or buffer mismatch or in some cases high 
difference of ligand immobilization between sensor surface and reference surface can 
give rise to volume exclusion effect which can produce differential response between 
sensors causing inverse sensograms437. A solution to this issue is careful match of DMSO 
and salts between analyte and running buffers. Further nonspecific interactions should be 




Getting Ready for ClpP SPR-Based Screening 
 
 
Ideal ClpP SPR Experiment 
 
An ideal SPR experiment is described by simple 1:1 binding interactions between 
analyte and immobilized ligand. The basic SPR experimental setup consists of a parallel 
multiflow cells with biosensor embedded on their floors. The ClpP sensor surface consist 
of three parallel flow cells with sensing surface as channel 1, channel 2 and channel 3, 
embedded on a sensor chip in a continuous serpentine shape. Depending on type of 
injection method, the direction of flow can be altered in various configurations (1-2-3 or 
3-2-1 or 1-2 or3-2 etc.) by switching between exit values placed at end of each channel. 
Each sensor surface consist of gold monolayer (~50 nm) on a glass slide, which houses a 
very thin (1-3 nm) self-assembling monolayer (SAM) which anchors the dextran 
hydrogel layer (~50-100 nm) with reactive carboxyl groups for immobilization of a 
ligand (i.e. ClpP) in a sensor specific orientation. 
 
To simply describe the ClpP biosensor experiment, the ligand (in this case ClpP) 
is immobilized (Figure 4-1, blue curve) on a gold coated surface made of dextran 
polymer using various coupling chemistries438. The running buffer without analyte is 
flown through the flow cell, over the ClpP surface (channel 1 or 3) as well as over 
reference surface (channel 2) without immobilized ClpP and a baseline signal is obtained. 
The running buffer is then switched to a buffer containing analyte as a sample plug 







Figure 4-1. Principle of ClpP Surface Plasmon Resonance Assay. 
Different analytes are injected over immobilized ClpP using dynamic injection methods 
and response of analyte binding to ClpP is measured in a sensogram revealing kinetics of 
binding interaction (on/ off rate, Binding Affinity and residence time). 
 
Adapted with permission from Macmillan Publishers Ltd: Nature Reviews Drug 
Discovery 1, 515-528, 2002, doi:10.1038/nrd838 and Cooper, M. A., Optical biosensors 







green) within sample plug as a result of parabolic buffer flow and diffusion of analyte. As 
sample plug reaches the flow cell with immobilized ClpP, an upward change in baseline 
is observed which results from changes in refractive index of the surface upon binding of 
the analyte to the immobilized ClpP is observed. This phase is called association phase in 
which increasing number of binding pockets get occupied due to random collisions 
(driven by diffusion), with analyte occur (double arrows). During association phase, the 
structural alignment of ClpP monomers along with opening of ClpP central pore occurs 
potentially as a mechanism of ClpP activation (hence the complexity in binding 
interactions) especially for ADEP series analytes. The association phase is followed by 
steady state (equilibrium) phase in which all binding pockets of the ligand have been 
occupied by the analyte which results in plateau in the signal at maximum binding. 
During steady state the net association rate equals net dissociation rate. After all of the 
analyte is injected, the buffer flow switches back to running buffer again and the bound 
analyte starts to dissociate producing dissociation phase which results in downward 
sloping of signal to original baseline position when no analyte was bound. At the end of 
dissociation time period, regeneration buffer (Red line) is injected to free or regenerate 
the binding surface or pockets on the immobilized ligand in order to make surface ready 
for next analyte. The interactions of analyte to ClpP during association, steady state and 
dissociation phase are quantified into kinetic parameters such as association and 
dissociation rates (ka, kd) from which equilibrium dissociation constant (KD) also referred 
to as binding affinity (KD=kd/ka) and dissociation half time or residency time (1/kd) by 




Basic Assay Design 
 
The basic SPR design scheme for low throughput kinetic analysis and higher 
throughput library screening is shown in Appendix C Figure C-1 along with important 
steps and estimated timing for execution. First the immobilization chemistry is selected 
on basis of ligand characteristics such as presence of tags (histidine or biotin) or 
requirement of specific orientation (homogeneous vs random). Prior to chip installation 
the SPR instrument is thoroughly washed using either through desorption or sanitization 
protocols following manufacturer instructions. For SensiQ FE instrument the flow cell 
and microfluidics are soaked in 10% Bleach, 0.5% SDS, 0.5 M NaOH and 1M Tris pH 
8.0 (in that order) for set period of time (5-6 min), followed by multiple cleaning runs 
(prime) of filtered Milliq water. Following chip installation procedure it is important to 
monitor the dips reflecting observed SPR angle. The Appendix C Figure C-2A, 1 shows 
variations in dips from three sensing channels prior to normalization of the sensor. The 
dips are streamlined by normalization procedure during which a solution of high 
refractive index (100% DMSO or 70% glycerol) is injected over all sensors and 
maximum response is linearized to 100% (Appendix C Figure C-2A, 2). Following 
normalization a sharp dip at a certain SPR angle (Appendix C Figure C-2A, 3) reflects a 
fully normalized sensor with perfectly aligned response from all three sensor surfaces 




smoothened by chip hydration procedure (short injections of 10 mM HCl, 50 mM NaOH, 
& 0.1% SDS) to ensure a drift free homogeneous response across all sensor surfaces. The 
Appendix C Figure C-2B shows the heterogeneity (black circle) in blank surface 
responses from channel 1 and Appendix C Figure C-2C shows the smoothening of 
blank surface responses from repeat buffer injections (n=10). 
 
Finally to restore the pH of dextran hydrogel, chip neutralization procedure is 
performed by injections of a buffer at appropriate pH (pH 7.5 or 8.0). Next depending 
upon type of sensor surface appropriate conditioning /activation procedure such as 
injections of EDTA/ NiCl2 for Ni-NTA chips or NHS: EDC for COOH chips, are 
performed in appropriate 1.0X buffer without DMSO to generate the reactive surface 
functional groups for immobilization of ligands. The immobilization level for the ligands 
is determined on basis of type of experiment, molecular size of analytes and desired Rmax. 
For kinetic measurement the immobilization level is kept low (to avoid mass transport 
limitation and other artifacts) by aiming at theoretical Rmax between 50-100 RU and for 
library screening the immobilization level is kept higher depending on size of analyte and 
desired Rmax. For most experiments, the reference channel is intentionally kept blank for 
purpose of subtraction of native response of analyte to sensor surface from surface with 
ligand however an active mutant or a different ligand of similar molecular mass 
compared to active ligand, can be used as reference surface as well. The immobilization 
procedure depends on type of sensor chip, desired ligand orientation and nature of the 
ligand. For example the his-tagged proteins are immobilized by a manually controlled or 
automated injection of predefined length, whereas for immobilization of proteins without 
tags can be performed by implementing pre-concentration procedure at low salt buffer 
conditions prior to ligand injection for a covalent coupling via primary amines. Upon 
immobilization of ligand to certain RU levels on channel 1 or 3 the corresponding dips 
shift to right (Appendix C Figure C-2A, 4) compared to dip from reference channel 2, 
suggesting observed change in SPR angle from ligand immobilization. Following 
immobilization, any unbound functional groups on the sensor surface can be capped by 
injection of 0.1 mg/mL BSA or through hydroxylation (of COOH groups) via 
Ethanolamine or Tris buffer injection and in case of expectation of low nonspecific 
binding, can be left uncapped. Next stability of baseline response or % drift from all 
surfaces is monitored for a period of time (3-4 hours to overnight) in a buffer with DMSO 
to ensure a drift free system for upcoming analyte injections. The Appendix C Figure C-
2, D shows the blank buffer responses from both channels with ligand (red, and blue) on 
a properly conditioned and stable system with minimal drift. 
 
The high sensitivity of SPR assays requires high accuracy and precision during 
preparation of running buffer and analyte solutions to lower the chances of DMSO or 
buffer mismatch which may affect the data quality significantly. The golden rule for 
consistency of data is to prepare the fresh buffer every time before experiment run to 
lower chances of variation in buffer pH or ionic strength over time. Further to aid the 
solubility of test analytes, addition of a non-ionic detergent is highly recommended 
however care must be exercised to determine effects of a particular detergent to baseline 
response and % drift. To reduce the occurrence of air bubble, both running buffer and 




degasser in most of SPR instruments. It is critically important to match the final DMSO 
% of analytes to DMSO% of running buffer as a mere difference of 0.1% can produce the 
bulk shift response in excess of 100RU, rendering the data uninterpretable. Therefore the 
best practice is to first prepare a large volume of pH adjusted buffer as 1.0X % to 
accommodate the dilution of buffer components due to addition of DMSO or analytes. 
Later carefully measured volume of DMSO is added to larger part of 1.04X buffer to 
achieve desired final DMSO% of running buffer and analytes added to remaining 1.0X 
buffer to matching DMSO % to running buffer. All internal controls (DMSO calibration), 
assay controls (ligand functionality & known binder), regeneration solutions, blank buffer 
vials (for base response) and test analytes are mixed and spun before actual injections. 
With selection of a relevant injection method (Fast or OneStep or standard), the binding 




Challenges Associated with Optimization of ClpP SPR Assays 
 
The first challenge in any SPR assay is achievement of stable baseline with 
minimal drift following ligand immobilization, for duration of the experiment. Second 
equally significant challenge is retention of functional activity of ligand upon 
immobilization. In this context the indirect capture methods are superior in preserving the 
orientation (& functionality) of the ligand compared to direct coupling methods. The 
hexa-his tagged wild type ClpP, its mutants and HClpP were suitable for capturing with 
enhanced stability on Ni-NTA chip surface owing to presence of multiple his tags for 
(indirect capture) fully assembled ClpP. However the multimeric nature of wild type 
ClpP contributes toward ligand heterogeneity on the chip surface, as a result attaining a 
drift free system after immobilization is challenging. This is due to likely presence of 
multiple ClpP forms with tetradecameric form as dominant species compared to minor 
fractions of heptameric or lower order ClpP oligomers. The electrostatic interactions 
between Ni-NTA and histidine functional groups are weaker in comparison to a covalent 
bond and presence of multiple species of ClpP leads to proportionally higher variability 
in affinity of hexameric his tags toward Ni-NTA groups at higher immobilization levels. 
As a result the ClpP protein exhibits a small net % drift (5-10% dissociation over time) 
on Ni-NTA chips. The HClpP also exhibit similar drift pattern however to a lesser extent 
than wild type ClpP primarily due to dominant heptameric form as a major species 
therefore the ligand heterogeneity on chip surface is proportionally lower. Further the 
binding response of an analyte at a given concentration is proportional to number of 
available binding pockets on immobilized ligand. In this context at same level of 
immobilization the binding response of an analyte is higher (almost 2x) for wild type 
ClpP compared to HClpP. This is due to higher number of available binding pockets on 
wild type ClpP compared to HClpP owing to their predominant tetradecameric (14 sites) 
or heptameric (7 sites) forms respectively. 
 
The presence of drift on a protein surface complicates the data analysis 
significantly due to referencing procedure (during data analysis) of subtraction of 




immobilized ligand. As a result the kinetic model fit to distorted binding response 
becomes less precise, leading to generation of inaccurate kinetic parameters. The 
selection of different immobilization strategies such as amine (via lysine), thiol (via 
cysteine) coupling or biotinylation can help lower the drift by directly coupling the 
protein to carboxymethyl groups on chip surface via stronger affinity covalent bonds. 
However utilization of primary amines or thiol groups as a hook to immobilize the ligand 
brings in challenges of surface heterogeneity. The surface heterogeneity originates from 
coupling of ligands in random orientations resulting in complete or partial loss of 
functional activity especially if the location of captured primary amines (such as lysine) 
is within active site or in close proximity to active site. The biotinylation of ligand via 
primary amines (lysine) for a capture on streptavidin coated sensor chips offers a very 
stable ligand surface due to extremely high affinity between biotin and streptavidin 
however retention of ligand functionality and attainment of sufficiently high ligand 
density is challenging. 
 
The successful optimization of any assay is contingent on complexity of the key 
system constituents. An optimum ClpP SPR response on a given sensor surface would 
require identification of similar buffer conditions, immobilization levels, baseline 
stability and %drift for both wild type and HClpP simultaneously. The ideal ClpP SPR 
assay would require a highly pure mono dispersed ClpP monomers in selected buffer 
conditions. The purity of ClpP was not an issue with > 98% purity as measured by SDS 
PAGE however retention of ClpP in monomeric form in solution is quite difficult due to 
natural affinity of ClpP monomers to self-assemble into higher order oligomers. Further 
the self-assembly of ClpP is concentration dependent with dominant tetradecameric form 
(14mer) at higher protein concentrations. The SPR chips are capable to accumulating 
very high surface densities with just 1000 RU equivalent to ~10 mg/mL concentration in 
solution. Based on this aspect the bulk of immobilized ClpP can be assumed to be of 
tetradecameric nature however presence of other lower order oligomers cannot be ruled 
out. Further binding of known binders (ADEPs) to ClpP monomer has been reported to 
aid its assembly into tetradecamer along with facilitating cooperative binding of other 
ADEPs molecules in solution. This complexity in ClpP assembly and its binding 
interactions affects SPR optimization route and assay performance. The underlying 
assumptions of SPR-based assays are simple 1: 1 interactions defined by pseudo first 
order exponential process. For systems with complex binding interactions such as ClpP 
with multiple binding sites of potentially different affinities or with cooperivity driven 
affinities, the precise fitting of available 1:1 interactions based models is quite 
challenging. In absence of dedicated models describing binding behavior of the ClpP, the 
accuracy of generated kinetic parameters requires orthogonal validation. In addition to 
above challenges, generation of a drift free, homogenous and functional ClpP surface on 
SPR chips requires extensive optimization of assay conditions. 
 
 
Optimization of ClpP SPR Assay as a High Throughput Primary Screening Tool 
 
The Surface Plasmon Resonance based primary screening (Aim 1) as well as 




orthogonal validation alternative to assess validity of primary screening hits along with 
determination of their binding characteristics. The label free nature of SPR-based assays 
is ideal to further separate those false positives which inevitably pass the scrutiny filters 
of original assay. The label free nature of SPR is inherently immune to common 
fluorescence interference based artifacts as result the hit rates are lower than any 
fluorescence based assays. The SPR assays can be optimized to get yes/no binding 
answers as well as binding kinetics of both weak affinity (fragments) and tight affinity 
binders at a relatively high throughput pace. Additionally the SPR assay supplements 
other binding assays by extending the detection range from mM to nM affinity. In this 
light, the SPR assays for ClpP were developed to support fragment based screening as 
well as real time kinetics evolution assay for determination of binding kinetics (ka, kd, KD 
and residence time) toward generating affinity based ranking of small molecule series as 
well as ADEP analogs. To determine site specificity of a potential binders the active site 
mutants of ClpP (Y63F, Y63W) were used against wild type (bacterial) ClpP whereas to 
determine species selectivity human mitochondrial ClpP (HClpP)was used to help 
differentiate the ClpP binders on basis of binding rates (ka, kd) as well as affinity (KD) 
parameters. All experiments were performed on SensiQ Pioneer FE (fragment edition) 
instrument which offers a range of surface chemistries on disposable chips housing 2 
sensing channels or surfaces for immobilization of two different proteins and a reference 
channel in a continues flow (serpentine S shaped) configuration. 
 
 
Determination of Immobilization Conditions for Wild Type ClpP and HClpP 
 
The ClpP SPR assays were developed to meet requirements of both primary 
screening assay as well as kinetic screening assay. To meet the objectives of developing a 
kinetic screening SPR assay capable of determining site specificity as well as species 
selectivity of potential ClpP binders, the immobilization conditions of wild type, its 
active site mutants (Y63W, Y63F) and human mitochondrial ClpP were evaluated on all 
available surface chemistries. The choice of immobilization methods included indirect 
capturing via Ni-NTA Chips, direct capturing via amine coupling or in vitro biotinylation 
and via capture couple (combination of Ni-NTA and amine coupling) methods. The end 
goal of the optimization efforts was to find the right balance of ligand functionality with 
stability of baseline drift following protein immobilization. 
 
 
Selection of Assay Buffer Conditions 
 
To determine optimum buffer conditions, the TSA assay was used to observe the 
stability of the ClpP in Tris, Phosphate and HEPES buffer. The assay pH was kept at 8 in 
order to keep the pH at native storage conditions of the proteins. As seen in Figure 2-9A, 
B, in Chapter 2, the stability of ClpP was higher in both HEPES and phosphate buffers 
than Tris based buffer. The HEPES buffer at pH 8.0 was selected as primary ClpP SPR 
running buffer, over phosphate buffer due to its higher buffering capacity over long 
periods of time. The Tris buffer was not selected due to its incompatibility with 




coupling). In a parallel experiment, the EDTA was found to affect protein stability 
negatively. Further EDTA (at 50 µM or higher) was found to increase the drift of ClpP on 
Ni-NTA sensor surface and was excluded from SPR buffers. 
 
 
Detection of Nonspecific Binding to Sensor Surface 
 
For optimum performance of the assay, assessment of nonspecific binding (NSB) 
behavior of ligands as well analytes is important prior to final optimization of 
immobilization conditions. The NSB behavior can occur due to electrostatic interactions 
of ligands or analytes to negatively charged poly dextran coating on the sensor chips or 
due to adsorption to inner lining of microfluidic channels and pump tubing. Ligands with 
NSB behavior tend to stick to the sensor surface and have major drift issues, 
complicating the data analysis. Similarly analytes with NSB can complicate the data 
analysis by dissociating in a highly non-replicative and random manner. Both wild type 
ClpP and HClpP were assessed for NSB behavior on a non-derivatized Ni-NTA sensor 
surface by a injecting a brief pulse of buffer containing respective proteins. As shown in 
Figure 4-2A, red line, the wild type ClpP exhibited minimal NSB behavior and got 
washed off the surface without requiring EDTA (Ni ion chelator). The HClpP on the 
other hand, exhibited high level of NSB (Figure 4-2A, blue line) and displayed up to 
10000 RU of immobilization on a non derivatized surface. However as seen in Figure 4-
2B, following pulse of EDTA, the HClpP was found to be non-sticky and completely 
washed off sensor surface. Next the ADEP4 (1999) was tested on same chip surface for 
NSB. Owing to known solubility issues the ADEP4 did exhibit (Figure 4-2C) low degree 
of transient (concentration/time dependent) NSB behavior as seen from elevated (black 
arrow) baseline response from all sensor channels. Based on this observation, the salt 




Selection of Immobilization Chemistry 
 
Next performance of ClpP proteins on all available surface chemistries were 
monitored by conditioning of the sensor surface following of immobilization of ClpP 
proteins. First ClpP was biotinylated in vitro under minimal biotinylation conditions as 
per established protocols and following conditioning, was injected (50 µg/mL) over 
Biocap sensor surface. Despite the ultra-strong affinity of pre-immobilized streptavidin to 
biotin, the ClpP immobilization levels were very low (Figure 4-2D) rendering the 
immobilization strategy unsuccessful. Next the commonly used immobilization strategy 
based on formation of amide (covalent) bonds between carboxyl groups on sensor surface 
and primary amine groups on proteins. Pre-concentration experiments were performed on 
ClpP as per established protocols by injecting ClpP at varying pH levels in low salt buffer 
conditions. The underlying objective was to establish the right pH conditions for highest 
level of binding and to monitor quick dissociation of ClpP as a sign of non-sticky (NSB) 
behavior to COOH sensor surface. As seen in Figure 4-3A, the injection of ClpP at pH 






Figure 4-2. Detection of Non Specific Binding. 
A: Sensor response from injection of ClpP and HClpP on an un-derivatized surface 
suggesting nonspecific binding of HClpP to sensor chip. 
B: Stripping of nonspecifically bound HClpP by EDTA. 
C: Sensor response from injection of ADEP4 (1999) on an un-derivatized surface. 







Figure 4-3. Immobilization of ClpP on Carboxyl (COOH5) Sensor Chip via 
Amine Coupling. 
A: Preconcentration procedure at varying pH conditions to determine optimum 
conditions for ClpP immobilization. 
B: Conditioning of COOH5 sensor (blue) followed by immobilization of ClpP. 






exhibited slow binding profile up to 2500 RU. The ClpP at pH 5.0 (pink line) exhibited 
highest level of binding expectedly below its PI followed by rapid dissociation, whereas 
ClpP injection at pH 4.5 displayed much lower immobilization levels with signs of 
stickiness to sensor surface (elevated baseline (Orange line)). Following pre-
concentration, the COOH sensor surface was activated using NHS:EDC mixture and 
ClpP was successfully immobilized to set level(Figure 4-3B, red line).Next stability of 
immobilized ClpP was monitored by observing the rate of drift over time. The ClpP was 
found to exhibit significant drift (>15 %) over course of 2 hours (Figure 4-3C) 
suggesting unsuitability of the amine coupling based immobilization method. 
 
Next immobilization of ClpP proteins on Ni-NTA sensor surface was attempted 
based on expectations of achieving stable baselines owing to presence of multiple His 
tags on ClpP. Following conditioning of sensor surface with EDTA and activation by 
NiCl2 injection, both wild type and HClpP exhibited (Figure 4-4A) sufficiently high 
level of immobilization. Both proteins exhibited stability in baseline after immobilization 
with much lower drift (~1-2%) compared to COOH sensors over the period of 3 hours 
(Figure 4-4B). Overall the Ni-NTA surface was found to be suitable for ClpP SPR 
experiments. The non-covalent interactions between Ni-NTA and histidine also meant 
that Ni-NTA surface could be potential reused, therefore the regeneration potential of Ni-
NTA surface was tested by stripping of immobilized proteins by injecting EDTA. As 
seen in Figure 4-4C both proteins were found to dissociate to lower levels for new 
immobilization attempts. The Ni-NTA surface was found to be reusable as it was possible 
to achieve original immobilization levels after additional conditioning of surface. 
However to lower the chances of ligand heterogeneity due to small amount of residual 
(sticky) protein, the derivatized Ni-NTA surface were not reused. All further initial ClpP 
optimization experiments were performed on single use Ni-NTA sensors using 2378 an 
ADEP4 derivative with improved solubility. 
 
The small drift% of ClpP on Ni-NTA sensors did not perturbed the data quality 
for short experiments however for experiments with time period >4 hours such as 
fragment screening (time >24 hours), the drift on Ni-NTA surface became a significant 
issue affecting alignment of response from ligand surface after subtraction of baseline 
response (baseline referencing). To resolve the issue, a novel strategy (capture couple) of 
combining Ni-NTA and amine coupling immobilization method (Figure 4-4D) was 
adopted. First the Ni-NTA sensor surface was conditioned and activated by EDTA/Ni 
injection followed by derivatization of surface carboxyl groups to reactive amine esters 
by injection of NHS: EDC mixture (blue line). Then ClpP was injected (green line) till 
desired immobilization level was reached and any remaining carboxyl groups were 
capped by injection (Red line) of 100mM Tris (pH 8.0). Due to additional anchoring of 
the ClpP the baseline stability of ClpP was substantially improved (Figure 4-4E) and 
drift% was reduced below 1% over long time period. To test the strength of 
immobilization over time, the stripping of protein surface with EDTA (Figure 4-4F) was 
attempted the following day. Both wild type and HClpP were found to hold on to surface 
with minimal dissociation suggesting excellent baseline stability and suitability of capture 







Figure 4-4. Immobilization of ClpP and HClpP on Hiscap (Ni-NTA) Sensor Chip 
via His Tag Capture. 
A: Immobilization of ClpP (blue) and HClpP (red) on Hiscap sensor chip. 
B: Determination of ClpP stability upon immobilization on Hiscap sensor chip. 
C: Stripping of ClpP and HClpP by EDTA. 
D: Conditioning of Hiscap sensor chip (blue) followed by Immobilization of ClpP 
(green), followed by capping of sensor surface (red). 
E: Determination of ClpP stability upon immobilization via capture couple method on 
Hiscap sensor chip. 







Determination of Ligand Functionality 
 
The next important aspect of SPR assay is functionality of ligand after 
immobilization on sensor surface. All immobilization methods cause loss of some 
functionality by virtue of anchoring the protein in a specific orientation. The key is to 
find the best balance of ligand functionality with excellent baseline stability. The 
functionality of ClpP protein immobilized on Ni-NTA surface was assessed by setting up 
kinetic experiment of measuring response of 2378 interactions using dispersion based 
gradient injection (OneStep) method. The quick OneStep method was preferred over 
lengthier standard injection method which required injections of multiple analyte 
concentrations. An additional hypothesis of the experiment was to test if increase in ClpP 
immobilization levels (2000-5000 RU) impacts the binding kinetics of 2378. As seen in 
Figure 4-5, the immobilized ClpP was found to be functionally active and kinetics of 
binding interactions of 2378 with ClpP was recorded in sensograms at each 
immobilization level. The binding affinity constant of 2378 to ClpP was determined to be 
close to ~4 µM and 2378 was observed to be a medium affinity binder based on its 
modest on rate of ~10x E4 M-1S-1,fast off rate at 0.34 sec-1 and short residence time at 
2.2sec. The binding kinetics of 2378 appears to be slightly slow (expected) at 
immobilization level of 5000 RU, potentially due to mass transport limitation at high 
ligand density. The data quality of 2378 interactions at each level was excellent owing to 
its superior solubility as a result the model fitting (Orange line) to 2378 binding response 
(Black line) was very good and residual standard deviation was low (<2% of Rmax). 
 
The experimental Rmax for 2378 at each level of ClpP immobilization (Figure  
4-6) was found to be about 60-70 % of theoretical Rmax for the respective level. At 
2000 RU the loss of ClpP functionality upon immobilization on Ni-NTA surface was 
determined to be in range of 25-30 %, with additional decrease in protein functionality 
with increase immobilization level. Overall the fractional occupancy of 2378 was found 
to be in range of 70-85% due to inaccessibility to few sites as virtue of immobilization 
scheme. Further analysis of the binding data suggested sub-stoichiometric (0.6) binding 
interactions between 2378 and immobilized ClpP. It is likely due to varying degree of 
cooperativity in binding interactions of 2378 or ADEP4 derivatives to ClpP, and based on 
their binding affinity, binding of one molecule facilitating binding of another. This 
observation also reflects upon known complexity of multimeric ClpP binding interactions 
and indicates likelihood of both low and high affinity binding sites on ClpP. 
 
 
Impact of Immobilization Strategy on Ligand Functionality 
 
The choice immobilization strategy can alter the binding kinetics depending on 
orientation and physical anchoring induced ligand heterogeneity on the chip surface. The 
functionality of the ClpP protein using standard his capture and hybrid capture couple 
method was assessed by immobilizing ClpP to similar levels in two separate experiments 
on Ni-NTA chips. Additionally utilizing availability of three sensing surfaces per chip, 







Figure 4-5. Assessment of Positive Control 2378 Binding Response on Varying 
Level of ClpP Immobilization. 
A-D: Determination of binding kinetics of 2378 on varying levels of ClpP immobilized 








Figure 4-6. Determination of Experimental Maximal Response (Rmax) at Varying 
ClpP Immobilization Levels. 
A-D: Assessment of ClpP (ligand) functionality, experimental Rmax, and fractional 






immobilizing different (Figure 4-7A, B) 2014 (green)and 2015 (blue) ClpP batches of 
ClpP stored at -80 oC. The 2378 was injected using gradient injection method and binding 
kinetics were evaluated using same model fit (2 site). The ClpP was found to functional 
on both immobilization methods to similar extent although the storage conditions of 2015 
ClpP batch appeared to impact the % ligand functionality for both methods (Figure 4-7C, 
F). The overall fractional occupancy of the 2378 on immobilized ClpP was similar 
between Ni-NTA and capture couple methods. Finally the binding kinetics of 2378 were 




Impact of Detergents on Binding Kinetics 
 
The binding response of analyte is proportional to number of available binding 
pockets on the ligand however measurement of kinetics does not depend on maximum 
possible response. In other words measurement of kinetics is possible at low surface 
densities as long as steady state conditions are achieved. However certain additives such 
as detergents can impact the steady state by altering the binding characteristics of 
analytes. To observe impact of different non-ionic detergents on the binding kinetics, 
ClpP was immobilized at 2000 RU and 4000 RU on parallel surfaces on Ni-NTA sensor. 
The response of 2378 to ClpP was tested under six different buffer conditions while 
keeping the rest of the buffer conditions same. 
 
Following an overnight incubation period in a buffer with Triton X-100 (0.01% 
v/v), a relatively stable baseline was obtained and binding response from 2378 gradient 
injection was recorded (Figure 4-8A). Under buffer conditions with Triton X-100, the 
2378 displayed excellent reproducibility in the binding profiles at high low ClpP densities 
with corresponding fractional occupancy at 65 % and 86% respectively. The off rates (kd) 
were similar however the on rate (ka) of 2378 at high density of ClpP appeared to be at 
least 3 time slower than same rate at lower ligand density as a result the KD of 2378 at 
low surface density was 3 time higher than KD at higher ligand density. This observation 
suggested that the apparent slower kinetics were likely due to increase in mass transport 
limitation at higher ligand densities as a result the diffusion rate of 2378 on sensor 
surface was affected causing lower fractional occupancy and the corresponding binding 
kinetics appears to be slower than actual. Therefore lower ligand density was more 
suitable for kinetics experiments compared to higher ligand density. 
 
Next the same experiment was repeated while replacing Triton x-100 with 
alternative detergents at selected concentration below their respective CMC (critical 
micelle concentration) values. With exception of Tween-20, all other detergents 
conditions replicated earlier observations of slower kinetics at higher ligand density 
compared to lower ligand density. The different detergents appeared to affect the binding 
kinetics to some extent by virtue of their detergent like properties in aiding solubility of 
2378 in solution however none of the added detergents appeared to be superior to Triton 
X-100. On the contrary Tween 80 and Octyl-D-Glucoside appeared to cause more 






Figure 4-7. Comparison of ClpP Functionality via His Capture and Capture 
Coupling Method. 
A: Assessment of 2378 response on different ClpP batches immobilized using His 
capture method. 









Figure 4-8. Effects of Detergents on 2378 Binding Response on High and Low 
Level ClpP Immobilization. 
A: Assessment of Effect of Triton X-100 on 2378 kinetics on high and low level of ClpP  
B: Assessment of Effect of Brij-35 on 2378 kinetics on high and low level of ClpP. 
C: Assessment of Effect of NP40 on 2378 kinetics on high and low level of ClpP. 
D: Assessment of Effect of Octyl-D-Glucoside on 2378 kinetics on high and low level of 
ClpP. 
E: Assessment of Effect of Tween-20 on 2378 kinetics on high and low level of ClpP. 






Selection of Model Fits 
 
Next the model fit of above binding data to all available models within SensiQ 
data evaluation program (QDAT) was evaluated to find the best model for kinetic 
evaluations. The binding interactions between two species are best described by simple 
exponential equations under the assumptions of simple 1:1 binding interactions without 
additional complexity. However fitting of binding data from a multimeric ClpP with 
known complexity, to such models is entirely subjective to complexity of system. For 
mild affinity 2378 the two site model fits slightly better than one site model especially in 
dissociation part of the curve (Figure 4-9A). Overall the binding parameters generated by 
both models were similar with 2-3 fold difference of binding affinity (1st affinity 
component of 2 site model) as well as kon rates. The better fits to two site model does not 
correlate to presence of two sites per analyte instead it point to presence of both low and 
high affinity sites on wild type ClpP (Figure 4-9A, B, C, blue curve) as well as HClpP 
(green curve).The difference of model fits between models to binding data was more 
apparent for tight affinity binders than mild or weak affinity binders. A number of 
parameters such as mass transport limitation, diffusion rates of analytes, sample 
dispersion and immobilization method can affect the quality of the model fit. To rule out 
artifacts related to mass transport limitation, analyte diffusion and injection method, the 
immobilization level of ClpP was lowered to ~2000 RU, flow rates were increased to 150 
µl/min from earlier 75 µl/min and analytes injected using standard injection method. The 
data was fitted to mass transport model and no significant difference of kinetic 
parameters was observed suggesting mass transport limitation was not involved. The 
Figure 4-9D, E, F shows issues (black arrow) related to model fitting of a high binding 
affinity analyte 3371 injected over ClpP surface using standard injection method. The 
data did not fit one site model or km model and only two site model showed reasonable 
fits (Figure 4-9F, inset equilibrium fit) with two apparent affinity constants for high 
(~13 nM) and relatively lower affinity (~254 nM) binding sites. 
 
 
Species Selectivity Assessment 
 
In addition to comparing the binding affinity (KD) of an analyte between wild type 
and HClpP for selectivity, the association and dissociation rate constants were also 
evaluated. Both wild type and HClpP were immobilized to similar levels on Ni-NTA 
surface in parallel on channel 1 and 3 respectively. After double referencing the response 
of blank surface (channel 2) as well as blank buffer from response from protein surfaces 
the binding affinity the 2378 was found (Figure 4-9A) to be at least 4 times more potent 
on wild ClpP against HClpP. This observation was in line with observations from 
orthogonal FP and TSA assays, which suggested preferential binding of 2378 to wild type 
ClpP. The dissociation rate (koff or kd) and residence time of 2378 on both proteins was 
short as observed from dissociation at rapid pace however the association rate (kon or ka) 
of 2378 on wild type ClpP was at least 4 times higher than HClpP suggesting selective 
preference of 2378 toward wild type ClpP. This observation suggested that developing 







Figure 4-9. Comparison of Different Model Fits and Injection Methods on 
Binding Kinetics of ClpP and HClpP  
A-C: Assessment of 1:1, mass transport limited, and 2:1 Model Fit on dispersion based 
injection (oneStep) of 2378 on ClpP and HClpP. 
D-F: Assessment of 1:1, mass transport limited, and 2:1 Model Fit on standard multiple 






to increase the binding selectivity greater than 10-50 fold between two proteins and 
assessment on basis of affinity (KD) alone was not sufficient. The binding of 2378 to both 
proteins was justifiably due to ~60% structural similarity between two proteins. 
Assuming same level of immobilization, the maximum binding response(Y axis) of 2378 
on HClpP was less than half of wild type ClpP due to lower number of available binding 
pockets owing to nature of structural assembly of two proteins. This observation was 
consistently observed for all ADEP4 derivatives tested at time. 
 
 
Site Specificity Assessment 
 
The site specificity of the ClpP activators was assessed by immobilization of ClpP 
active site mutant (Y63W) in parallel to wild type ClpP. The 2378 was injected over both 
surfaces and binding response was evaluated. The maximum observed response Rmax 
(~80 RU) of 2378 binding to wild type ClpP was much higher than active mutant which 
displayed Rmax around 5RU. Further the binding affinity of active mutant was 
expectedly abrogated in comparison to wild type ClpP (Figure 4-10) and this observation 
suggested that 2378 binds directly within binding pockets of ClpP. This observation was 
independently supported by lack of binding response of analytes to ClpP mutants on site 




Determination of Kinetic Experiment Conditions 
 
Next the ClpP SPR assay for determination of binding kinetics of both large 
(ADEP4 derivatives) and small molecules series, was optimized in 96 well format. The 
capture couple immobilization method was selected for kinetic experiments due to lower 
drift % than his capture. As mentioned before drift in baseline can become significant 
issue especially for titration experiments with long run time. Depending on the surface 
chemistry, drift normally slows down with time as most of nonspecifically bound protein 
get washed away under continues buffer flow. To minimize the time bound drift related 
issues, the immobilization of ClpP proteins was performed at least 12-16 hours prior to 
actual run time to ensure a steady baseline for duration of experiment. The ligand density 
for kinetic evaluations was kept low to avoid high ligand density related artifacts such as 
mass transport limitation. The ClpP protein exhibited poor binding behavior at lower 
immobilization levels (i.e. 100-400 RU), therefore the ligand density was kept around 
1000-2000 RU to get the maximum response in range of 20-30 RU given loss of 25-30 % 
ligand functionality upon immobilization. Based on response of high affinity ADEP4 
derivatives the anticipated dissociation time for complete dissociation was determined to 
be in excess of > 1000 sec (~15 minute) and about 200-250 sec for compound with 
comparatively weaker affinity (i.e. 2378). For small molecule series the dissociation time 
was set at 120 sec. The concentration of analytes was kept up to 10 fold higher than 
anticipated KD to achieve steady state conditions as 100% saturation of immobilized 







Figure 4-10. Site Specificity Assessment on ClpP and ClpP Mutant. 
Assessment of site specificity and binding kinetics of 2378 by injection of 2378 on ClpP 






and for small molecules the final concentration was set at 100 µM. The above test 
concentrations were also selected to lower the risk of carry over artifacts which were a 
major obstacle due to limited solubility of large molecule series. Based on the solubility 
profile, 2795 and 3371 were selected as representative controls for small molecules and 
large molecule series respectively. The replicate injections of 2795 and 3371 were first 
injected using gradient injection method either as independent assay per analyte or in 
sequential and random manner as combined assay. In an attempt to shorten the time 
requirements for future kinetic experiments , the dissociation time for high affinity 
analyte 3371 was set at 300 sec under the assumption of minimal carry over effect (with 
improved solubility), contrary to previously observed time period of 1000sec. The 
analyte dissociation up to 5 % of saturation level is generally enough to get reasonably 
accurate idea of dissociation rate441. Both 2795 and 3371 exhibited good repeatable 
binding response (Figure 4-11A) with their binding affinities measured at 42µM and 
15.4 nM respectively. With higher on rate and lower off rates, the kinetics of 3371 were 
expectedly superior to 2795, however both 2795 and 3371 still exhibited (to some degree) 
carry over issues as observed from slight difference in Rmax / off rates for repeat injection 
of 2795 and 3371 respectively. 
 
Additional runs with multiple ADEP4 analogs with varying solubility profiles, 
displayed exacerbated carry over effects, which in many cases completely deteriorated 
data quality of following analytes especially during association phase. The carry over 
effects were attributed to concentration dependent aggregation behavior of analytes with 
solubility issues at selected buffer (with detergent) conditions and potentially due to 
nonspecific interactions of analyte aggregates with dextran matrix or tubing resulting in 
irregular, multiphasic and non-replicative binding responses with abnormally high Rmax. 
The addition of negatively charged carboxyl poly dextran (up to 10 mg/mL) to buffer to 
reduce nonspecific interactions did not resolved the carry over issues and data quality of 
3371 and 2795 (Figure 4-11B) was unaffected. An important observation made from 
above experiments was that it was better to run analytes with close range of affinities as 
independent assay with injection order randomized to minimize the carry over issues. In 
assays with combination of high and low affinity analytes, the dissociation time period 
needed to extend significantly longer to minimize carry over effects which affected the 
association phase of low affinity analytes more severely than high affinity analytes. 
 
Finally changes in DMSO % from 3% to 4% were sought to reduce compound 
crashing and DMSO pipetting errors during automated (via Integra work station) 
pipetting of high concentration stock compounds into small volume sample vials. The 
data quality of controls was unaffected (Figure 4-11C, D) and binding parameters were 
found to be in close range. The excellent repeatability of the 3371 and 2795 over different 
experiments conducted on different days indicated robustness of kinetic experiments and 
that the dissociation time of 300 sec and 120 sec was enough to acquire quality data, 








Figure 4-11. Determination of Optimum Kinetic Experiment Conditions. 
A-B: Assessment of reproducibility of low affinity small molecule (2795) binder kinetics 
and high affinity large molecule (3371) binder kinetics in regular buffer and buffer with 
Dextran. 
C-D: Assessment of reproducibility of low affinity small molecule (2795) binder kinetics 







Assessment of Regeneration Conditions 
 
The carry over effects are manifestation of inadequate regeneration of binding 
pockets before next analyte injection and progressively worsens in absence of correct 
regeneration strategy. The carry over effects from large molecule series were a significant 
issue impeding assay optimization, therefore multiple regeneration solutions of varying 
ionic strength were tested. This included injections of 10 mM glycine at low pH (acidic) 
ranges (1.5-3), up to 100 mM Phosphoric acid, up to 10mM Hepes/ NaOH at high pH 
(basic) ranges (9-11), 0.5-3 mM EDTA, and up to 2 M NaCl/ MgCl2 (ionic) solutions. 
However the in either combination the regeneration of the ClpP binding pockets was 
either incomplete or the regeneration conditions deteriorated the ligand functionality 
itself. In worse case the EDTA and phosphoric acid triggered dissociation of ClpP by 
surface deactivation rendering the chip useless. The strategy of competing the slowly 
dissociating high affinity analyte with saturating concentration injection of lower affinity 
analyte with rapid dissociation profile, was also adopted. In this case 2795 was used as a 
regeneration agent however the successful regeneration was limiting due to longer time 
requirements to wash off the 2795 and more significant carry over effects from 2795 
itself on HClpP. Finally yet another strategy of using 50% DMSO solution along with 
additional pulse of running buffer after each analyte injection, reduced the carry over 
effects significantly for both wild type and HClpP. As seen in Figure 4-12A the binding 
response of high affinity control analyte 3371 was highly reproducible in both association 
and dissociation phase of injection for both proteins. Later the above strategy was also 
found to be effective in reducing carry over effects from analytes with low solubility 
profile such as parent ADEP4 (Figure 4-12B, 1999). This strategy was ultimately 
extended to kinetic screening of multiple high affinity analytes ran in duplicate while 
randomizing the injection order. The resulting data had excellent model fits with 
residuals signal within ± 1 RU (Figure 4-12C, inset, red dots), as well as good 
reproducibility. The carry over issues were significantly decreases as evident from clean 
and compact baseline in the pre-injection phase. The high binding affinity (Green arrow) 
analytes were easily distinguishable from medium (Magenta arrow), weak (black arrow) 
and completely inactive (Red arrow) analytes. 
 
 
Determination of High Throughput Screening Conditions 
 
The second objective of optimization of ClpP SPR as a high throughput (384 
well) screening was achieved by altering the immobilization conditions for ClpP 
according to molecular weight of the analyte. The mass detection nature of SPR demands 
higher immobilization level of the ligand when screening low molecular weight analytes. 
The Appendix C Figure C-3A shows the expected ligand density level (x axis) 
according to desired analyte response (y axis). Further the Appendix C Figure C-3B 
shows expected ligand density levels (y axis) to achieve the theoretical Rmax of 100RU 
for analytes of different molecular weight (x axis), with desired level of ligand density 
much lower for large molecular weight compounds compared to low molecular weight 







Figure 4-12. Determination of Tandem Kinetic Experiment Conditions with 
Ligand Regeneration. 
A-B: Assessment of binding kinetics of 3371 and 1999 on ClpP and HClpP. 
C: Assessment of reproducibility with minimal baseline (inset)of tandem kinetic 






levels were adjusted to achieve target Rmax of 20-50 RU, given the % ligand functionally 
of the ClpP protein was 65-70 %. The regeneration strategy was kept same as for high 
affinity binders although the length of blank buffer wash was reduced to lower total time 
per run. 
 
The success of SPR fragment screening depends on careful selection of controls, 
screening concentrations, minimal interference from buffer or DMSO mismatches, 
library curation, identification of nonspecific binders, type of injection method and data 
evaluation expertise442,443,444,445. The focus of screening format ClpP SPR assays was to 
identify the binding hits at higher throughput pace compared to kinetic format assays by 
evaluating the % activity (response) based on selected cut off above the baseline noise. 
Therefore the control compound should represent the type of collection being screening 
and should generate response at selected screening concentrations. Among the most 
important properties for a relatively high throughput SPR screening control is its good 
solubility profile at representative screening concentration, its repeatability over time, 
relatively fast off rate with no carry over related issues to validate the observed activity of 
test compounds as real response rather than an artifact from carry over related issues. In 
this context a compound with poor solubility profile or with slow off rate (i.e. high 
affinity) makes a poor control especially for screening of fragments. The 2378, 2795 and 
3027 (Appendix C Figure C-3E, F, G) were selected as representative controls for 
compound libraries with large (>600 Da), small (>350 <600Da), and fragment sized 
(MW <300 Da) compounds. The Figure 4-13 shows the response of 2378 (blue), 2795 
(Red) and 3027 (Brown) as representative controls due to their relatively fast off rate (in 
that order) and robust response with excellent repeatability over multiple injections 
(n=16). The Figure 4-13, inset, top right shows the result of a 400 fragment screen 
using Taylor dispersion based gradient OneStep injection method which brings in 
additional advantage of determination of kinetics as well as affinity compared to standard 
single concentration injections440. As shown in Figure 4-13, top, inset the hit cut off 
response (Red dots) of fragments from Maybridge collection was based on normalization 
of fragment responses (multi-color sensograms) to binding response (at 100%) of 
fragment control (3027) by using locally weighed regression model (LOESS) within 
Box-Whisker plots in QDAT software (Qualitative data analysis tool) provided by 
SensiQ [www.sensiqtech.com]. The resulting fragments hits (Figure 4-13, top Inset, 
green dots) can be quickly prioritized based on binding affinity(KD) or ligand efficiency 
(LE) parameters (Bottom insets) without requiring traditional follow-up dose response 
experiments, saving both valuable time and resources. 
 
The current SPR instrument (SensiQ Pioneer FE) can accommodate up to 2 X 384 
well plates, therefore about 768 test compounds (including controls) can be ran within 
time period up to 60 hours. The low affinity fragments are purposely screened at 
relatively higher concentrations to generate a measurable response however at high 
concentration the probability of nonspecific or promiscuous binders with abnormally high 
Rmax, ligand deactivation and artifacts such as rebinding effects becomes higher. The 
Appendix C Figure C-3C show a commonly encountered issue with uneven stock 







Figure 4-13. ClpP SPR Screening Controls and Assay Performance. 
Excellent reproducibility of binding of large molecule (2378), small molecule (2795) and 
fragment control (3027) on ClpP under high throughput screening conditions. Selection 
and efficiency based ranking of hits (lowest inset) is performed by comparing the 







with poor solubility or quality control issues despite best practices using molecular 
property based filtering algorithms for library curation. A direct transfer of such unevenly 
distributed fragments even using sophisticated pipetting robots (i.e. Biomek stations), to 
assay plates inevitably produces final concentrations beyond their solubility limits 
resulting in crashing of fragments. Such fragments and their aggregates cause a lot more 
downstream troubles by exhibiting abnormal binding profiles and interfering with activity 
of other test compounds. In worse cases, the deactivation of ligand may occur rendering 
the entire screen interpretable and may even damage the instrument by clogging the 
microfluidic channels. The Appendix C Figure C-4E shows results of fragment screen 
with solubility issues (from unevenly high stock concentrations), as a result the hit rate 
was abnormally high at >40%. However due to exceptional in vitro stability of ClpP its 
functionality was not affected as shown by 2378 activity but the activity of fragment 
control 3027 was completely diminished (green) rendering the screen uninterpretable 
(Appendix C Figure C-4B, E). For ClpP SPR assay the above issues were resolved by 
setting the target screening concentration Appendix C Figure C-3D, shaded area in the 
range of 75-150 µM per fragment. The stock plates were specially reformatted as per 
concentration from high to low and were carefully diluted into daughter plates by altering 
amount of stock or diluent (DMSO) to stock concentration at which the selected final 
screen range per screening plate could be achieved. As shown in Appendix C Figure C-
4B, the screening of fragment collection with concentrations within set screening range, 
against ClpP resulted in a very clean screen with just 6 hits (hit rate ~1%) along with 
excellent reproducibility of fragment control (3027) and ligand functionality control 
(2378). 
 
The high sensitivity of SPR to changes in refractive index of the buffer also meant 
that DMSO and buffer mismatches between running buffer and test fragments were 
closely matched. This requirement demands high pipetting accuracy of liquid handling 
robot or a person in case of manual pipetting. Further to keep the buffer and sample 
volume requirements low, test compounds are pipetted into deep (384) well plates with 
volume capacity up to 150 µl/ well. The Appendix C Figure C-4D shows (v shaped) 
DMSO mismatch extending greater than -50 RU, between double referenced fragment 
responses from assay buffer generated baseline, and the carry over effect from a 
heterogeneous sample plug. The hand mixed fragment (Green) and ligand functionality 
(Blue) controls on the other hand, generated smooth baseline response during pre-
injection and association phases. The root cause of large DMSO mismatches was 
inefficient mixing of fragments as well as errors in pipetting very small quantities (often 
µL or nL volumes) of stocks close to error margin of pipetting accuracy. It was also 
found that overnight mixing on conventional plate shakers was inefficient in mixing the 
buffer solutions within narrow perpendicular columns of deep well SPR screening plates. 
This problem was resolved by increasing the final DMSO % to 4% to allow increase in 
the minimum stock transfer volume above the pipetting accuracy range of liquid handing 
robot from adjusted stock daughter plates and implementation of manual (30-40 times) 
mixing steps. To avoid the generation of air bubbles which can causes massive air spikes, 
the sealed screening plates were spun at 4000 RPM for period of at least 30 minutes to 




improvement in data output with minimal DMSO mismatches and carry over effects, 
along with repeatable controls. 
  
The SPR assays cannot distinguish between sites specific or allosteric binders as 
the recorded response is sum total of mass increase on ligand surface regardless of 
binding specificity. However by screening two functionally different ligands (i.e. wild 
type and active site mutant) the site specificity can be established. The choice of 
immobilization of two different ligands on current SensiQ pioneer instrument was 
incremental toward developing a screening assay capable of determining site specificity 
of binding. Ideally ClpP, its active site mutants (Y63W/F) or HClpP can be immobilized 
in parallel to measure binding kinetics along with site specificity or species selectivity of 
ClpP binders. However for small molecular weight fragments, both ClpP mutants and 
HClpP are not ideal controls due to their structural similarity to wild type ClpP, instead a 
completely (structurally) different ligand makes a better orthogonal control. The 
Appendix C Figure C-4C, F contrasts the validation of site specificity of ligand 
functionality control 2378 (top, blue dotted line) to ClpP as 2378 did not exhibit any 
binding activity to orthogonal DHPS ligand. However the same contrast could not be 
drawn for fragment control 3027 (bottom, dark blue dotted line) and it appears to bind to 
both ClpP and DHPS. Further it is possible that a fragment due to its small size can bind 
to two completely different proteins with similar affinity making segregation of 
promiscuous binders from specific binders difficult. The Appendix C Figure C-4C, F 
also highlight the presence of nonspecific or sticky fragments (red circles) with identical 
binding behavior (promiscuous) to both proteins. Certain fragments by virtue of their 
molecular properties such as hydrophobicity can interact nonspecifically with dextran 
matric and can dissociate randomly affecting functionality of entire screen. The 
Appendix C Figure C-4C also highlighted that interactions of non-specific sticky 
fragments in the beginning of the screen can generate a drifty baseline along with 
diminished binding activity of fragment control 3027 below baseline, rendering entire 
screen fruitless. Such promiscuous fragments may appear as hits in absence of an 
orthogonal ligand control however their abnormally high signal response compared to 
fragment control highlighted that their interactions were rather non-specific. This issue 
was resolved by pre-screening of fragment collections on TSA (Chapter 2) assay as an 
alternative binding assay and elimination of fragments which displayed promiscuous 





The ClpP SPR assays were configured in both screening and kinetics 
determination format to allow screening of compound collections of diverse molecular 
weights as well to kinetically characterize the analogs from ADEP4 and small molecule 
series for lead prioritization. Based on the observations from optimization, the key 
recommendations are summed up below. 
 
Following chip installment the sensor surface should be properly normalized, 




system should be allowed to equilibrate for couple of hours and its stability should be 
asses over multiple prime cycles and blank buffer injections. After ligand immobilization, 
the drift % should be monitored over a period of time preferably overnight. The 
preparation of samples solutions should be carried out carefully using freshly made 
degassed 1.0X buffer at assay specific pH. It is also important to ensure that sample 
evaporation is minimum to lower the chances of bulk refractive spikes due to changes in 
buffer composition. The required immobilization level should be decided on basis of type 
of analysis sought. For kinetics, the immobilization levels should be low whereas for 
affinity determination the level can be high. Further for low molecular weight analytes, 
the immobilization level should be high and vice versa. In reality is almost impossible to 
achieve the theoretical Rmax due to immobilization limitations. An observed response 
lower than theoretical Rmax, is indicative of loss of ligand functionality due to lower 
number of available sites after immobilization. On the other hand the observed response 
higher than theoretical Rmax is indicative of nonspecific binding or analyte behavior from 
analyte. The proper orientation of ligands is also important to generate reliable kinetic 
data therefore homogenous immobilization methods (Ni-NTA or Biocap) are preferable 
over random immobilization methods (amine/ thiol coupling). Additionally high and low 
affinity sites can be introduced as a result of physical distortion of binding sites during 
immobilization as a result the kinetics can become skewed from typical single 
exponential binding or decay. 
 
The concentration range between lowest and highest analyte concentrations 
should be >100X to ensure maximum occupancy of available binding sites. Therefore the 
low and high analyte concentration should be set at 0.1-10X of estimated (orthogonally) 
KD or IC50 values. This approach helps to generate response close to 100% of theoretical 
R max specially if the affinity of the analyte is low (i.e. fragments). For analytes with 
high binding affinity (i.e. tight binders with kd < 10
-4 sec) the concentration range should 
be increased between 100-1000 X of estimated KD due to additional time required by 
virtue of their slow off rates, to achieve steady state equilibrium. For standard injection 
method, minimum five concentrations should be run in triplicate or double dilutions 
series and for oneStep injection method a minimum of 2 or 3 injections runs should be 
carried out. Additionally blank buffer injections should be including after each analyte 
injection to lower the chances of carry over artifacts. The observed kinetic parameters 
should be tested for validity on a separate time while using the analytes prepared from 
same stock solution. In case of multiple (different) analytes the order of injections should 
be randomized. The association time required to achieve steady state should be observed 
carefully and injection length adjusted accordingly per analyte (longer for high affinity 
binders). The dissociation time length is also equally important and should be long 
enough to achieve greater than 90% of analyte dissociation. Depending on affinity of an 
analyte, for a high affinity analytes the length of dissociation time could be extend from 
short 10 minute to over a day. The strategy of lowering flow rates could be applied to 
adjust for long dissociation time while keeping in mind the mass transport limitations. 
The nonspecific binding interactions can be reduced by addition of salt (ionic strength) to 
running buffer in addition to Carboxyl methyl dextran or BSA at 0.1-10 mg/mL. 
However a compatibility check for such additives to surface chemistry of sensor chip 




not great toward reduction of nonspecific binding as analytes can bind to BSA itself and 
dissociate randomly. Finally the regeneration conditions should be carefully optimized 
while ensuring functionality of the ligand. To lower the risk, extra wash steps should be 










Screening and Characterization Scheme for ClpP Activators 
 
The results from various screening campaigns as well as characterization of 
compounds from small/ large molecules series with best affinity and best selectivity are 
presented in this chapter. The Figure 5-1 shows various screening and characterization 
methodologies implemented for discovery of ClpP activators. The high yield and stability 
of ClpP protein, its mutants and human homolog HClpP allowed us to explore multiple 
screening and characterization methods. Three parallel structure guided approaches 
(Figure 5-2) of (a) development of non peptidic small molecule based activators with 
tractable pharmacological properties such as oral bioavailability, (b) medicinal chemistry 
aided derivatization of ADEP4 analogs to improve its existing properties and (c) 
identification of novel scaffolds through screening of diverse compound collections 
including fragments were initiated. To identify unique ClpP ligands with superior binding 
efficiency (LE/ LiPE) and pharmacological tractability, a wide variety of compounds 
from Fragments, lead like, FDA, and bioactive collections were screened against ClpP. 
The molecular properties of screening collections, screening hits and in house small or 
large molecules series are discussed in detail in Supplemental Data for Chapter 5. The 
overall screening strategy was to conduct a high (single) concentration screens using 
combination of primary screening assays on diverse libraries, with goals to augment 
chances of successful discovery of novel and chemically tractable scaffolds with 
measurable biological activity (activation) against ClpP. All hits from primary screening 
were orthogonally validated in dose response format on combination of secondary assays. 
The Figure 5-3 showcases detailed biochemical and biophysical screening cascade 
implemented for discovery of novel ClpP activators. 
 
For primary screening purposes, the fluorescence polarization (FP), thermal shift 
(TSA) and SPR assays were used in combination (Yes/No format) depending upon size, 
concentration and type of compound collection. Due to much higher throughput owing to 
simple mix and read format, the FP assay was used as first choice screening tool for 
larger collections. The main advantage of FP-based screening was identification of site 
specific competitive ligands which displaced the bound FP probe from ADEP4 binding 
pockets of ClpP. Additionally ease of operation, wide screening range, and exceptional 
stability of FP probe, enabled screening of diverse compound collections such as 
fragments (5020), bioactives (8618), FDA approved drugs (2125), and representative set 
of lead like compounds (10041). Next based on ease of applicability, the low cost 
minimalistic TSA assay was used primarily for screening of fragment collections at high 
molar concentration conditions owing to high DMSO tolerance of ClpP. The TSA assay 
was also advantageous in buffer scouting experiments to determine optimal buffer 
conditions as well as identification of fragments with destabilization effects on ClpP, 
particularly for SPR assays. The TSA assay in addition to primary screening assay, also 
served as confirmatory assay for validation of ligand binding in combination with other 






Figure 5-1. Biophysical and Biochemical Screening Techniques for Discovery of 
ClpP Activators. 
The assay methods are color coded based on throughput with FP and SPR being fast and 
ITC and X-Ray being slow. The thickness of the bars represents information content. X-
ray has most information content, followed by ITC/NMR/SPR followed by Enzymatic or 
FP and TSA as least information assay. The solid border of the bar indicates sensitivity 
based on detection of both high and low potency chemicals. SPR and ITC are very 
sensitive and FP/Enzymatic assay/NMR has mediocre sensitivity and TSA has least 
sensitivity. The bars with stars are methods with labelled fluorophore and bars without 








Figure 5-2. ClpP Activators Drug Discovery Pipeline. 
The multi-pronged iterative pipeline of ClpP drug discovery utilizing combination of 
screening methods complemented with X-ray crystallography mediate structure based 










Figure 5-3. Biophysical and Biochemical Screening Cascade for ClpP Activator 
Discovery. 
Screening work flow of primary screening in yes/no answer format followed by dose 
response confirmation to generate hits, later assessed on secondary screening assays for 







ssays was for screening of fragment collections to provide orthogonal validation. The key 
advantage of using SPR assays is simultaneous determination of binding affinity and 
binding kinetics (on rate, off rate, residence time) due to choice of dispersion based 
gradient (oneStep) injections offered by SPR instrument. The resulting hits were 
validated in dose response format by tweaking FP, thermal shift and SPR assays to 
determine IC50, Tm and affinity constants (KD) respectively. The hits with activity on at 
least two orthogonal assays were retested on respective assays over dose response 
experiments for validity and removal of false positives. The selected hits were evaluated 
for orthogonal validation on a functional assay measuring in vitro ClpP activation (EC50, 
KM, Vmax, % activation, catalytic efficiency) through ClpP substrate (labeled B-casein) 
digestion, binding kinetics on SPR (kon / koff, residency time) before their selection for X 
ray co-crystallization studies. 
 
 
Screening Controls, Concentrations, and Hit Selection Criteria 
 
Different controls were used for each screening or characterization format per 
given method to standardize the observed activity to a comparable scale. The Figure 5-4 
sums up the hit selection criteria, screening ranges for primary screening (i.e. Fragments, 
FDA, and bioactives etc.) and small or large molecule series based on type of compound 
per given assay. The final screening concentrations for compounds collections were 
adjusted to according to representative molecular weight per collection and anticipated 
response per given assay. For both TSA and FP assays, the low molecular weight 
fragment collections were screened at high molar (0.5-2 mM) concentration, whereas the 
screening concentrations were lowered (100-500 µM) for high molecular weight FDA or 
bioactive collections. On high sensitivity SPR assays the low molecular weight fragments 
were screened at much lower concentrations (150-200µM) compared to other assays and 
larger molecular weight compounds were screened at even lower concentrations (25-100 
µM). For primary screening on TSA assay the cut off criteria (Chapter 2) of increase in 
melting temperature (∆Tm) by 1 degree, was based on average baseline response from 
negative controls (DMSO). The small molecules series #1, 2 and ADEP4 analogs were 
characterized based on maximum shift (Tmax) at final concentration of 500 µM, 50 µM 
and 5µM respectively with lead selection cut off criteria at >10 degree for all small 
molecules and >25 degree for large molecules. On SPR in screening format the selection 
of hits was based on binding response >40% of fragment control (3027) response (RU) 
with estimated KD in range of 0.25-1 mM. The screening of the fragments was carried out 
in presence of an off target protein or ClpP mutants (Y63F, Y63W) immobilized on a 
parallel channel to wild type ClpP to aid identification of ClpP specific hits. Based on 
best solubility and affinity profile, the small molecule derivative (2795) and large 
molecule derivative (3371) were used as control for kinetic experiments on SPR assays. 
The kinetics (KD, on/off rates, residence time) parameters cut off for leads compounds 
from small and large molecules series was set at <50 µM or <1µM respectively. 
 
For the FP assay the selection of primary screening hits was based on >25% 






Figure 5-4. Preliminary Results of Purified ClpP, ClpP Mutants and HClpP and 
Analytical Ultra Centrifugation (AUC) Results. 
A-D: SDS-PAGE gel of purified ClpP, ClpP Mutants (Y63F) (Y63W), and HClpP 
indicating high yield and purity of proteins. 
E: AUC based characterization suggesting distribution (Svedberg sedimentation 
constants) of heptameric (7 monomers) and tetradecameric (14 monomers) population of 






superior solubility. For characterization of lead compounds from small or large molecule 
series the cut off criteria (compared to positive control) was at >50% probe displacement 
(IC50 <25-50 µM) and >70 % probe displacement (IC50< 20 µM) respectively. The 
primary screening hit validation criteria on FP assay was based on >25% displacement 
and IC50 ≤250µM compared to displacement potency of FP probe by 2378 or ADEP4. 
Finally the main use of functional assay was determination of enzyme activity (activation 
potential) of leads via degradation of fluorogenic substrate (Bodipy FL labeled ß-casein) 
under linear velocity conditions. Only orthogonally validated hits or compounds from 
small/large molecule series were tested on enzymatic assay. The low affinity fragment 
collections yielded partial curves so hit selection cutoff was based on the >25 % 
activation (Vmax) of ClpP instead of EC50 values, compared to normalized maximum 
(100%) activation of positive control ADEP4. The leads from small or large molecules 
series were selected based on >30 % activation (EC50 <30 µM) and >70% activation 
(EC50 <5 µM) respectively. Finally, the assessment of selectivity to wild type ClpP was 
performed on FP, enzymatic and TSA assays using HClpP in parallel experimental 
conditions to wild ClpP whereas on SPR assays the selectivity was evaluated by 
examining bio molecular interactions (of selective compounds) with HClpP immobilized 






Purification of WT ClpP, Mutants and HClpP 
 
The gene sequence of ClpP (Staphylococcus aureus strain NCTC 8325) was 
obtained through examining reference literature and PubMed gene database search. The 
primers for expression of 6-His tagged Sa-ClpP were designed using CLC workbench 
and Sa-ClpP gene construct was amplified from Sa-genomic DNA using PCR and later 
cloned into pET28a+ vector. The pET28 a vector containing ClpP gene was transformed 
in chemically competent DH5α™ E.coli cells. The transformed E.coli culture was grown 
to mid log phase (OD600=0.4-0.7) and ClpP expression was induced using 1 mM IPTG 
at 18°C overnight. Pelleted E.coli were suspended in lysis buffer [ 50mM Tris pH8.0, 100 
mM NaCl , 1 mg/mL Lysozyme and protease inhibitor cocktail tablets for period of 45 
minutes on Ice and later the E.coli were disrupted via sonication. The resulting lysate was 
spun at 14000 x g, and supernatant containing ClpP was collected. Supernatant was 
passed through a 0.22µm filter, and then loaded on to Ni column pre-equilibrated with 50 
mM Tris pH 8.0, NaCl 100, 50 mM Imidazole for affinity chromatography. The Ni 
Column was subjected to 3X Column volumes of wash cycles using wash buffer (50 mM 
Tris pH8.0, 100 mM NaCl, 100 mM Imidazole) to get rid of nonspecifically bound 
proteins. The 6 his tagged ClpP bound Ni Column was eluted using gradient 3 column 
volume cycles of elution buffer (50 mM Tris , pH 8.0, 100 mM NaCl, 500 mM 
Imidazole) and analyzed on SDS Page for assessment of purity. The resulting fractions 
were pooled and concentrated before loading on to Superdex 200 columns pre-
equilibrated with 50 mM Tris pH8.0, 100mM NaCl. The collected fractions were found 




mapping. The purification strategy for ClpP mutants (W/F) and human homolog HClpP 
was similar to bacterial ClpP except truncation of first 55 amino acids from HClpP gene 
sequence to generate a functional (mature) HClpP. The Figure 5-5 shows SDS PAGE gel 
images of purified ClpP, Y63W, Y63F, and HClpP respectively. 
 
 
Circular Dichroism (CD) 
 
To ensure that expressed ClpP protein is structurally stable and properly folded, 
Circular Dichroism spectroscopy experiment was conducted and Sa-ClpP was found to 
exist primarily as α-Helix with few β-Sheets which correlated well with existing literature 
on structure of cylindrical proteases187. 
 
 
Analytical Ultra Centrifugation (AUC) 
 
To determine exact molecular weight and mass purity of tetradecameric ClpP, 
Analytical centrifugation experiments (Sedimentation equilibrium) were performed and 
ClpP was found (Figure 5-5E) to exist in concentration dependent reversible equilibrium 
between tetradecameric (MW 297 kDa) and heptameric forms (MW 138 kDa). The 
dissociation constant (KD) between tetradecamer and heptamer was found to be >6 µM 
which suggested that at a concentration higher than 6µM, the ClpP predominantly exists 




In vitro Characterization of Virtual Screen Collection 
 
To initiate discovery of non peptidic activators of ClpP, a virtual screening based 
approach was adopted based on available crystal structure of ADEP (PDB ID 3MT6) 
bound to E.coli ClpP. Using molecular dynamics software suit, a pharmacophore model 
of ligand (ADEPs) interaction was developed which predicted a bi-dimensional hydrogen 
bonding with Tyrosine (T62) and π-π stacking interactions of benzyl ring of ADEP as 
critical component of largest free energy contributions of ADEP binding to ClpP. The 
underlying hypothesis of design was to identify small molecules based novel scaffold 
with superior oral bioavailability optimization potential, a key issue with larger ADEP 
based scaffolds. Further multiple ligand or structural constraints based on molecular 
weight cutoff around 350 Da, minimal energy binding conformation and essentiality of 
hydrogen bonding interactions with essential Tyrosine were applied in Glide docking 
experiments while screening against commercially available compound databases (ZINC, 
Chembridge, Enamine and Maybridge). A total of 95 lead like and structurally diverse 









Figure 5-5. Preliminary Results of Purified ClpP, ClpP Mutants and HClpP and 
Analytical Ultra Centrifugation (AUC) Results. 
A-D: SDS-PAGE gel of purified ClpP, ClpP Mutants (Y63F) (Y63W), and HClpP 
indicating high yield and purity of proteins. 
E: AUC based characterization suggesting distribution (Svedberg sedimentation 
constants) of heptameric (7 monomers) and tetradecameric (14 monomers) population of 






Primary Screening of Virtual Screening Compounds 
 
For initial binding experiments, the set of 95 compounds were tested on TSA and 
SPR in a Yes/No binding format. TSA was the first choice for detection to answer if 
compounds exhibit binding as a measure of increase in thermal stabilization. Given the 
binding response from small molecular weight compounds was expected to be close to 
lower end of TSA detection range, SPR-based primary screening experiments were 
carried out to generate consensus in separation of hits from false positives. The hits from 
each binding assay were cross checked for repeat validation on respective assays in dose 
response format and later tested on enzymatic assay for functional activity. 
 
 
TSA-Based Primary Screening 
 
95 compounds were tested for thermal stabilization of ClpP as a measure of 
binding to ClpP and three compounds 21 (2025), 24(2028), and 80 (2084) (Figure 5-6A) 
were identified as distinct hits along with known small molecule ClpP activator ACP1b. 
Based on positive control ACP1b response, the cut off criteria was set to 1 oC and 
compound 21 was found (Figure 5-6B) to stabilize ClpP to greatest extent with melting 
temperature (Tm) at 59.5±0.09 
oC (∆Tm= 14.4 
oC), closely followed by compound 2028 
with Tm at 58.3±0.09
 oC (∆Tm= 13.2
oC). The compound 80 displayed much weaker 
affinity with Tm at 48.3±0.05
 oC (∆Tm= 3.1
oC). The rest of compounds (Appendix D 
Table D-1) were either inactive or has very little binding (Tm <1 
oC). Based on structural 
similarity (Figure 5-6C) to positive control ACP1b or prominent hits, compound 03 
(2007), and 52 (2056) were selected along with compound 21, 24 and 80 for re-synthesis. 
 
 
SPR-Based Primary Screening 
 
All virtual screening compounds were screened for binding activity on SPR 
(Figure 5-7). To determine selectivity of the potential hits an unrelated off target protein 
(wild type DHPS) was immobilized Ni-NTA sensor chip to similar density along with 
wild type ClpP. Of all 95 compound screened, only 2025 was a clear hit on wild type 
ClpP with greater than 20 % of fragment control (3027) response compared to a known 
small molecule binder (positive control). The 2025 did not exhibited any binding 
response to DHPS protein suggesting selectivity of 2025 toward ClpP. 
 
 
Characterization of Virtual Screening Hits 
 
 
Characterization of Hits Based on TSA 
 
The resynthesized compound 2007 and its analogs (2230-2236, 2480-83) were 







Figure 5-6. ClpP TSA Assay: Assessment of Virtual Screening Compounds. 
A: Identification of 3 virtual screening hits (21, 24, 80) with positive shift in ClpP 
stability. 
B: Reconfirmation of binding activity of initial hits along with control (ACP1b). 
C: Chemical Structure of TSA hits (03, 21, 24, 52, 80), controls (ACP11, b) and stereo 







Figure 5-7. ClpP SPR Assay: Assessment of Virtual Screening Compounds. 
Identification of racemic virtual screening hit (21 or 2025) and it’s S-isomer (2164) with 
normalized binding response compared to positive control (3027) response. The 2025 






and analogs of its structural mimic 2084 (2316-19,32) were also found to be inactive in 
dose response experiments, suggesting initial activity of compound 2028 and 2084 was 
likely an assay artifact. Interestingly compound 2025, was determined to be racemic and 
was re-purified into its R isomer 2163 and S isomer 2164. Repeat dose response test 
(Figure 5-8A) on TSA revealed that R isomer was completely inactive whereas S isomer 
(Red star) retained the activity suggesting stereo-selectivity of ClpP binding pocket. Both 
compound 2055 and 2056 with para (mono) substituted benzyl rings displayed 2-3 degree 
of thermal shift suggesting very weak binding interactions. This observation suggested 
importance of Meta (di) substitution of benzyl group to binding interactions on 
compound 2025. Further the di substituted benzyl group on compound 2025 appeared to 
mimic the difluorophenyl group on ADEP4, suggesting the structural basis of its binding. 
 
 
Characterization of Hits Based on FP Assay 
 
Of all selected virtual screening hits, only compound 2164 exhibited (Figure 5-
8B) significant displacement (IC50 of 168.8±10.7 µM) of FP probe in a competition 
format assay whereas its R isomer 2163 was completely inactive. The parent racemic 
2025 and 2056 displaced FP probe partially whereas 2028, 2084 were completely 
inactive reaffirming observations on TSA assay. 
 
 
Characterization of Hits Based on Enzymatic Assay 
 
The racemic compound 2025, its enantiomer 2163 (R), 2164 (S), along with 2028, 
2056 and 2084 were retrospectively tested for functional activity on enzymatic assay 
based on fluorescently tagged casein digestion. Compound 2028 and 2056 were found 
(Figure 5-8C) to be inactive while compound 2084 were confirmed to be a false positive 
with inner filter effects due to its fluorescent nature. The activity of racemic 2025 was 
borderline at (Vmax ~10 % compared to ADEP4), and without any discernable EC50 curve. 
Expectedly the 2163 was inactive and 2164 displayed weak ClpP activation potency at 
EC50 of 208.3 ±28.4 µM. 
 
 
Characterization of Hits Based on SPR Assay 
 
To estimate binding affinity, wild type ClpP was immobilized on separate 
channels on Ni-NTA chip at two different surface densities (Figure 5-8D) and 2025, 
2163, 2164 were injected using dispersion based oneStep injection method. The 2025, 
2164 showed binding affinity (KD) in range of ~100-150 µM on both surface densities 
whereas binding affinity of 2025 was expectedly lower (KD~ 200µM) than 2164. The 
binding affinity for 2163 was estimated to be in mill molar range (~1mM) validating 
stereo selectivity of 2164 to ClpP. 
 
In conclusion the compound 2164 (Table 5-1) was found to be active on 4 






Figure 5-8. Orthogonal Validation of Virtual Screening Hits. 
A: Positive shift in ClpP stability by racemic 2025 and its stereo selective S-isomer 2164 
(red star) on ClpP TSA assay. 
B: Superior dose dependent displacement of previously bound probe 6 by 2164 on ClpP 
FP assay. 
C: Higher ClpP activation by 2164 compared to other hits on ClpP enzymatic assay. 





Table 5-1. Validation of 2164 on Multiple Orthogonal Assays as a True Hit. 
 










2163 0.0 0.0±0.0 0.0±0.0 990.0±0.3 







chemistry optimization to gain potency in in vitro assays. The molecular dynamic 
experiments on 2163 (R isomer and 2164 (S-isomer) supported the in vitro assays with S 
isomer exhibiting stability with minimal energy conformations. The modelling study was 
further substantiated by successful co-crystallization of 2164 with wild type ClpP which 
suggested its structural overlap with similar key interactions (with essential Tyrosine 63) 
with urea analogs of ADEP4. 
 
 
In vitro Characterization of Small Molecule-Based Activators of ClpP 
 
The small molecule series is a hit optimization series derived from sole validated 
hit (2025) from virtual screen compounds. The optimization was geared toward 
optimization of potency (enzymatic activity and MIC) of the initial hit through structural 
modifications. The validation of 2164 as a true binder to ClpP laid the platform for 
optimization of non peptidic small molecules based series #1 as ClpP activators. Over the 
course of 2 years over 200 small molecules were synthesized to expand the SAR by 
targeted substitutions and analyzed for in vitro activity on FP, TSA, enzymatic, SPR 
assays. More recently the new small molecules series #2 based on a validated novel 
scaffold (3421 a Wnt pathway inhibitor, ICG-001) discovered during FP assay validation 
was also expanded to explore its unique SAR within ClpP binding pockets. 
 
 
Characterization on TSA Assay 
 
All compounds within small molecules series # 1 were tested in at least duplicate 
runs in a dose response format and maximum response (∆Tmax) at 500 µM final 
concentration was determined (Figure 5-9A). For small molecules series #2 the 
maximum response was set at 50 µM final concentration (Figure 5-9B) due to solubility 
issues above 100µM concentration. The series #2 compound had higher Tmax values due 
to comparatively superior affinities than series #1. The series #2 parent compound 3421 
showed higher binding response with ∆Tmax 7.5 
oC at 50µM final concentration whereas 
no activity was detectable at same concentration for series# 1 compounds. The Appendix 
D Table D-2 shows respective ∆Tmax values of all compounds within small molecule 
series # 1 and 2. From ClpP TSA assay standpoint the 10 small molecules out of 202 
compounds from series #1 displayed maximum shift greater than 10 degree at 500µM 
final concentration and 12 small molecules out of 48 compounds from series #2 displayed 
maximum shift greater than 10 degree at 50 µM final concentration. Finally to assess the 
selectivity, all small molecules were screened against human homolog HClpP under 
identical dose response conditions. The Figure 5-9C, D shows the respective HClpP 
∆Tmax values for small molecules series #1 and 2 in comparison to corresponding values 
against ClpP. Most of the small molecules series #1 or 2 compounds exhibited higher 
∆Tmax shifts for HClpP contrary to expectations. This aspects highlights the difficulty in 
achieving species selectivity due to structural similarity between two proteins. The 
Figure 5-9E, F contrast the maximum response of both series between HClpP (Y axis) 







Figure 5-9. ClpP TSA Assay: Best of Small Molecules Series # 1, 2 Compounds. 
A: Collective bar plot of 202 small molecules series # 1 compounds with maximum 
positive shift in ClpP stability (Tmax) at screening concentration of 500µM. 
B: Collective bar plot of 48 small molecules series # 2 compounds with maximum 
positive shift in ClpP stability (Tmax) at screening concentration of 50µM. 
C: Collective bar plot of 202 small molecules series # 1 compounds with maximum 
positive shift in HClpP stability (Tmax) at screening concentration of 500µM. 
D: Collective bar plot of 48 small molecules series # 2 compounds with maximum 
positive shift in HClpP stability (Tmax) at screening concentration of 50µM. 
E: Selectivity comparison of maximum positive shift of small molecules series # 1 ClpP 
and HClpP binders. 
F: Selectivity comparison of maximum positive shift of small molecules series # 2 ClpP 






response on ClpP compared to HClpP. Only 2 compounds from series #1 and 7 
compounds from series #2 exhibited at least 2-3 fold selectivity (Black dot rectangle) for 
ClpP in contrast to HClpP. Overall small molecules compounds appeared to be non-
selective in general given their small size which could easily fit within similar binding 
pockets on both protein. There were few exclusive compounds as well to each protein. 
One compound from series #2 and 17 compounds from series #1 were found (Appendix 
D Table D-2) to be exclusive to HClpP (∆Tmax HClpP >10, ∆Tmax ClpP <1 degree) 
whereas for ClpP only 1 compound (2623) exhibited exclusive binding (∆Tmax ClpP >10, 
∆Tmax HClpP <1 degree). 
 
 
Characterization on FP Assay 
 
The competitive FP probe displacement activity (IC50) of all compounds from 
small molecules series #1, 2 was determined in triplicate in a dose response format. The 
selection of best compounds from each series was based on % probe displacement and 
IC50 values as per criteria described above. 12 (out of 193) compounds from small 
molecules series #1 had IC50 <30 µM, whereas about 30% (15 out of 48) compounds 
from small molecules series #2 had IC50 <25 µM (Figure 5-10A, B, Appendix D Table 
D-2), highlighting superior displacement potencies of series #2 over series #1. The 
selectivity of each series toward ClpP was determined by observing the displacement of 
same FP probe bound to HClpP under assay conditions similar to ClpP. None of the 
compounds from either small molecules series had more than 4 fold lower IC50 value for 
HClpP compared to ClpP, therefore the selectivity criteria was set at 3X. Only two 
compounds from series # 1 and 6 compounds from series #2 were found to exhibit 3 fold 
selectivity (Figure 5-10C, D) for ClpP over HClpP. 
 
 
Characterization on Enzymatic Assay 
 
Of 202 compounds from small molecules series # 1, 7 (3.5%) compounds (Figure 
5-11A, Appendix D Table D-2) activated ClpP to >30 % of observed maximum velocity 
from positive control ADEP4 (1999). Similar to observation on FP assay, the small 
molecules series # 2 displayed better ClpP activation profile with 10 out of 48 (~21%) 
compounds (Figure 5-11B, Appendix D Table D-2) exhibiting >40% activation and 
EC50 < 5µM. Further the selectivity of the each series was determined by observing 
activation of HClpP under assay conditions similar to ClpP. Following elimination of 
compounds inactive on both ClpP and HClpP the % activation of HClpP was compared 
against % activation of ClpP (Figure 5-11C) for both series # 1 and 2. Most of the 
compounds from series #1 had higher % activation (>50% of positive control 1999) on 
HClpP contrary to expected % activation on ClpP reaffirming observations of non-
selectivity of series #1 from thermal shift and FP assays. Interestingly the multiple 
compounds from series #2 exhibited no activation on HClpP while their % activation on 







Figure 5-10. ClpP FP Assay: Best of Small Molecules Series # 1, 2 Compounds. 
A: Best 12 small molecules series # 1 compounds with >90% probe 6 (2591) 
displacement and IC50 values <30µM. 
B: Best 15 small molecules series # 2 compounds with 100% probe 6 (2591) 
displacement and IC50 values <25µM. 
C: 2 small molecule series # 1 compounds with greater than 3 fold ClpP binding 
selectivity compared to HClpP. 
D: 6 small molecule series # 2 compounds with greater than 3 fold ClpP binding 








Figure 5-11. ClpP Enzymatic Assay: Best of Small Molecules Series # 1, 2 
Compounds. 
A: Best 7 small molecule series # 1 compounds with ClpP enzymatic activity compared 
to ADEP4 (EC50 <30µM and % activation >30%). 
B: Best 9 small molecule series # 2 compounds with ClpP enzymatic activity compared 
to ADEP4 (EC50 <40µM and % activation >40%). 
C: Comparison of % activation of 48 small molecules series # 2 compounds on ClpP and 
HClpP. 







from series # 2 were found to exhibit >10 fold selectivity toward ClpP. The Figure 
5-11D shows overlay comparison of ClpP selective compounds from small molecules 
series # 2, over HClpP. 
 
 
Characterization on SPR Assay 
 
The assessment of binding activity of small molecules series #1,2 was carried out 
based on optimized kinetic assay conditions (Chapter 4) using 2795 as a positive binding 
control for all small molecule series compounds. Based on the observation from FP and 
enzymatic assay, small molecules were expected to binding to HClpP to a similar extent 
as with ClpP. Therefore testing of small molecules activity against HClpP was restricted 
to only best compounds with binding response above selection criteria (Figure 5-4). The 
detection of small molecules series # 1 was initially carried out against ClpP immobilized 
at two different (high / low) levels to generate measurable binding signal. The data 
between high (~4500 RU) and low (~2200 RU) surface densities was overall very 
comparable, with higher artifacts on high surface density, therefore data from low ClpP 
surface density was evaluated for binding kinetics. The testing of small molecules series 
# 2 compounds was carried at ClpP surface density levels (~2000 RU) comparable to 
small molecules series # 1. Of 202 compounds from series #1 and 48 compounds from 
series #2, tested in tandem, about 29 out of 202 (14 %) exhibited binding to ClpP 
(Appendix D Table D-2) with measurable kinetics (KD <200 µM), whereas 23 out of 48 
(~ 48%) of series #2 compounds displayed measurable binding kinetics (KD <100µM) 
.The binding response of remaining compound was either lower than 50% of control 
compound (i.e. KD > 200µM) or was close to baseline buffer response levels (completely 
inactive). As shown in Figure 5-12A, B, C the best compounds from series #1 and series 
#2 with KD above the best fit criteria (series #1 KD < 50µM , Series #2 KD <15 µM) were 
retested against both ClpP and HClpP to reaffirm their binding as well as to determine 
selectivity. 
 
Unsurprisingly with exception of 2881 and 2796, all selected compounds from 
series #1 (Figure 5-12D, E) displayed higher binding affinity to HClpP (Green curves) 
compared to ClpP (Blue curves) reaffirming observations from orthogonal (FP and 
enzymatic) assays. Interestingly the positive control (2795) exhibited (Table 5-2) much 
slower off rate on HClpP (residence time ~58 sec) compared to main target ClpP 
(residence time 2.4 sec). Overall the series #1 compounds were found to non-selective 
with very similar on or off rates to both ClpP and HClpP. Further series # 1 compounds 
had relatively fast off rates, therefore the residency time was quite low (2-3 sec) with 
mediocre binding affinities. Similar to observations in other ClpP assays the series # 2 
compound performed better with consistently superior binding affinities compared to best 
of series # 1 compounds. The on rates of top 3 selected compounds were >8 times higher 
on ClpP compared to HClpP while off rates were fast (& similar, residence time ~2 sec) 
on both proteins. Further these compounds were also found to exhibit at least 3 fold 







Figure 5-12. ClpP SPR Assay: Best of Small Molecules Series # 1, 2 Compounds. 
A: Best 29 compounds out of 202 small molecules series # 1 with ClpP binding affinity < 
200 µM 
B-C: Best 12 compounds out of 48 small molecules series # 2 with ClpP binding affinity 
< 100 µM. 
D-E: Selectivity comparison of select small molecules series # 1 compounds on ClpP and 
HClpP. 






























2795 1 1.8±0.001E+4 0.4±0.001 23.3±0.1 2.4 1.9±0.00E+4 1.7±0.002E-2 0.9±0.0 58.8 
2796 1 2.0±0.03E+4 0.3±0.001 16.4±0.3 3.0 6.0±0.06E+3 0.6±0.003 93.0±1.0 1.8 
2881 1 5.9±0.04E+4 1.9±0.01 33.2±0.3 0.5 1.6±8.0E+4 1.6±0.003 96.2±0.2 0.6 
3496 2 3.1±0.0E+5 3.7±0.0 12.1±0.0 0.3 2.8±0.02E+4 1.1±0.008 39.5±0.4 0.9 
3498 2 2.1±0.0E+5 2.8±0.0 13.5±0.0 0.4 2.6±0.03E+4 1.8±0.02 70.0±1.0 0.6 








Finally the compounds with best affinity were selected by assessing their 
performance on at least 3 or more orthogonal assays and compounds with best selectivity 
toward ClpP were evaluated for their performance on at least 2 orthogonal assays. The 
Figure 5-13A, C shows the best affinity compounds from series #1 and series #2 and 
Figure 5-13B, D shows compounds with at least 3 fold selectivity toward ClpP. 
 
 
In vitro Characterization of Large Molecule-Based Activators of ClpP 
 
Over the course of 4 years, ~225 analogs of parent compound ADEP4 were 
synthesized with aims to improve the antibacterial activity along with key 
pharmacological properties. All large molecules series compounds were tested in dose 
response format (n=3) on multiple assays to support the ongoing structure based SAR 
exploration. The screening concentration of ADEP4 analogs for FP, TSA and enzymatic 
assays were lowered up to 200µM (v/v) to accommodate the limited solubility of ADEP4 
analogs. The underlying objective of large molecule series characterization was to 




Characterization on TSA Assay 
 
For large molecules series compounds, the expected shift in melting temperature 
of ClpP was rather large due to much higher potency of ADEP4 and its analogs compared 
to small molecules series compounds. The results of dose response experiments were 
rather indistinguishable as almost all of the large molecules exhibited Tm shift in excess 
of initial selection criteria of >10 degree shift. To accommodate the ~100 fold difference 
in potency between small molecules series and large molecule series compounds, the 
target test concentration was lowered to 5 µM. The resulting maximum shift (∆Tmax) of 
positive control ADEP4 (1999) at 25.9 degree (Appendix D Table D-3) was clearly 
distinguishable from corresponding shift at 12.3 degree for its weaker analogs 2378. This 
analysis was extended to remaining compounds within the series and 41 out of 192 (21 
%) compounds exhibited ∆Tmax greater than ADEP4 indicating their superior binding 
affinity to ClpP. To observe if ADEP4 and 2378 also exhibited binding to HClpP, their 
activity was tested for corresponding shift in melting temperature under assay conditions 
similar to ClpP. As expected the ADEP4 was found to bind and stabilize the HClpP and 
the ∆Tmax was considerably lower at 13.2 degree compared to ∆Tmax of ADEP4 at 25.9 
degree for ClpP. Interestingly the 2378 was found to exhibit no binding activity toward 
HClpP (∆Tmax below baseline) compared to 13 degree shift on ClpP, generating first clue 
of selectivity toward HClpP. This analysis was extended to all compounds (Figure  
5-14A, B) within large molecule series to observe the selectivity on basis of thermal 
stabilization. The selection criteria for ClpP selectivity was set at > 10 degree 
stabilization of ClpP. As shown in the Figure 5-14C, D the corresponding Tmax values for 







Figure 5-13. Chemical Structures of Best of Small Molecule Series# 1 and 2 
Compounds. 
A: Best small molecules series #1 compounds with <50µM SPR binding affinity (KD) on 
ClpP. 
B: Best selective small series #1 compounds with at least 3 fold selectivity for ClpP. 
C: Best small molecules series #2 compounds with <15µM SPR binding affinity (KD) on 
ClpP. 








Figure 5-14. ClpP TSA Assay: Best of Large Molecules Series Compounds. 
A: Collective bar plot of 225 large molecules series compounds with maximum positive 
shift in ClpP stability (Tmax) at screening concentration of 5µM. 
B: Collective bar plot of 225 large molecules series compounds with maximum positive 
shift in HClpP stability (Tmax) at screening concentration of 5µM. 
C: Selectivity comparison of maximum positive shift of ClpP and HClpP binders. 






of the compounds stabilized both ClpP and HClpP to similar extent and were non 
selective (Green shaded area), 26 compounds were found to exhibit >5 fold selectivity of 
which 9 compounds had > 10 fold selectivity. 
 
 
Characterization on FP Assay 
 
A total of 220 large molecules series compounds were evaluated for their FP 
probe displacement activity in a dose response format (n=3) up to 200µM top 
concentration. Most of the test compounds were potent and completely displaced 
(Appendix D Table D-3) the previously bound FP probe similar to parent 
ADEP4.However a significant number of compounds displayed an upward shift in the 
displacement curves indicating their limited solubility. The upward shift in displacement 
curves were result of partial displacement of FP probe by test compounds up till their 
solubility limit beyond which the test compounds either precipitated out of solution or 
formed inactive aggregates. Since the resolving power of FP assay was limited (detection 
limit) at the binding affinity of the FP probe at 3.5 µM , therefore the IC50 values of 
compounds with higher potency (than 3 µM) were clustered around the detection limit, 
even though the actual numbers were perhaps considerably lower (in nM range). The 
selection criteria (Figure 5-4) for best compounds was set at >70% of probe 
displacement (& IC50 ≤5 µM). The Figure 5-15A, shows the best 15 compounds with 
100% probe displacement with IC50 values lower than the detection limit around FP assay 
floor and corresponding displacement curves of positive controls 2378 and ADEP4. 
Based on observations during optimization of FP probe (Chapter 3), on partial 
displacement activity of 2378 on HClpP, all compounds were tested for selectivity based 
on probe displacement against HClpP. Due to similarity in binding pockets between ClpP 
and HClpP, only 13 compounds exhibited selectivity toward ClpP. As shown in Figure 
5-15B, C, D with overlay of displacement activity on ClpP and HClpP, 3 compounds 
exhibited greater than 10 fold selectivity, 6 compounds had 5-8 fold selectivity followed 
by 4 compounds with 3-5 fold selectivity. 
 
 
Characterization on Enzymatic Assay 
 
The characterization of large molecules series compounds was based on the 
activity of positive control ADEP4 as 100% ClpP activation (at EC50 0.32 µM). The 
resulting % activation values of all test compounds (total of 225) were normalized 
(Appendix D Table D-3) to ADEP4 activity. As a general trend the compounds with 
higher % activation were observed to be more potent however many compounds 
exhibited lower % activation around 60-80% while their reported potency values were 
within 2 fold of ADEP4. Of all compounds tested, 17 exhibited % activation higher than 
positive control ADEP4 while their respective EC50 values were within 1-2 fold of EC50 
value of ADEP4. The selection cut off criteria (Figure 5-4) was set at EC50 < 0.35µM (& 
% activation >60%) and 32 compounds were identified as best compounds (Figure  







Figure 5-15. ClpP FP Assay: Best of Large Molecules Series Compounds. 
A: Best 15 large molecules series compounds with 100% probe 6 (2591) displacement 
and IC50 values lower than the ClpP FP assay detection limit at 3µM. 
B: 3 large molecule series compounds with greater than 10 fold binding selectivity 
compared to HClpP. 
C: 6 large molecule series compounds with higher ClpP binding selectivity in range of 5-
8 fold compared to HClpP. 
D: 4 large molecule series compounds with higher ClpP binding selectivity in range of 5-








Figure 5-16. ClpP Enzymatic Assay: Best of Large Molecules Series Compounds. 
A: Best 32 large molecule series compounds with ClpP enzymatic activity higher than 
ADEP4 (EC50>0.35µM and % activation >60%). 
B: Comparison of % activation of 225 ADEP4 analogs on ClpP and HClpP. 
C: Determination of fold selectivity to ClpP. 
D-F: Best 8 large molecule series compounds with > 20 fold selectivity to ClpP and next 






susceptibility of labeled substrate to changes in assay conditions (i.e. pH), the differential 
net % activation from different compounds appeared to be linked to extent and duration 
of ClpP pore opening event in vitro. Further all available compounds were evaluated on 
HClpP activation assay to determine selectivity on basis of activation potency. Similar to 
observations from FP assay, most of the compounds appeared to be non-selective 
(Appendix D Table D-3) as they activated both proteins to similar extent. A contrast of 
% activation values from all active compounds on ClpP and HClpP (Figure 5-16B, C) 
suggested at least 22 compounds with HClpP % activation less than 50% of 
corresponding ClpP activation. Based on ratio of EC50 values, 22 compounds were 
identified to exhibit > than 10 fold selectivity for ClpP over HClpP. The Figure 5-16D, E 
shows the overlay of enzymatic activity (degradation of labeled substrate) of >20 fold 




Characterization on SPR Assay 
 
The binding kinetics of large molecules was assessed in tandem on a low density 
(~1200-1500 RU) ClpP surface to avoid mass transport limitation artifacts. The large 
molecules series compounds, were potent binders and ClpP activators as observed from 
TSA and enzymatic assay, therefore the screening concentrations were kept at much 
lower levels at 1 µM or below compared to small molecules series. Further the off rates 
for large molecules series were expectedly much slower, therefore dissociation time per 
compound was extended to >5 min to reduce the carry over artifacts. The poor solubility 
of the ADEP4 analogs was a major hurdle toward their kinetic characterization, therefore 
> 100 compounds (out of 225) with poor solubility profiles, were eliminated from kinetic 
characterization experiments. About 51 % of compounds (59 out of remaining 115) 
exhibited binding (Appendix D Table D-3) to ClpP with measurable kinetics (KD <100 
nM). As per expectations from multisite ClpP the binding profiles of ADEP4 derivatives 
exhibited complexity and were found to not fit well with simple 1:1 kinetic interaction 
models. Therefore the determination of binding parameters of large molecules was based 
on 2 site model which suggested presence of both high (~low nM) and low affinity 
(~high µM) binding sites on ClpP. The Appendix D Table D-3 shows the parameters 
from high affinity sites only while parameters from low affinity sites were assumed to be 
either with insignificant contributions to overall affinity or were assimilated within high 
affinity parameters. 
 
The 22 best compounds (Figures 5-17, -18, and -19) with binding affinity <10 
nM were tested for binding to HClpP at similar immobilization density to ClpP, to 
determine apparent selectivity to ClpP. The immobilized HClpP was found to have lower 
functional activity and lower corresponding fractional occupancy per compound, 
compared to ClpP, therefore the representative kinetic parameters for HClpP are at very 
best close estimates based on common assumptions of model fitting and complex binding 
as with ClpP. On a comparative scale the maximum response from each compound was 
expectedly higher for ClpP than HClpP due to higher number of available binding 






Figure 5-17. ClpP SPR Assay: Best of Large Molecules Series Compounds (Set1). 
Best 1-8 compounds out of 22 large molecules with binding affinity <10 nM for ClpP 







Figure 5-18. ClpP SPR Assay: Best of Large Molecules Series Compounds (Set2). 
Best 9-16 compounds out of 22 large molecules with binding affinity <10 nM for ClpP 








Figure 5-19. ClpP SPR Assay: Best of Large Molecules Series Compounds (Set3). 
Best 17-22 compounds out of 22 large molecules with binding affinity <10 nM for ClpP 






(tetradecamer vs heptameric HClpP) per given surface density level. The on rates of 
compounds were found to be consistently higher and off rates were found to be slower 
for ClpP compared to HClpP. Only 5 compounds (2849, 2921, 2965, 2968, 2969) were 
found to exhibit >20 fold higher binding affinity (or selectivity) to ClpP compared to 
HClpP. Overall the binding affinity (KD) was found to rather inconclusive determinant of 
selectivity as most of the test compounds exhibited the binding affinity to HClpP within 
1-10 fold of ClpP binding affinity. However comparison of on rates of compounds for 
ClpP and HClpP provided clues to apparent selectivity. The 5 fold higher on rate of 
ADEP4 on ClpP compared to HClpP suggested higher probability of ClpP activation over 
HClpP under conditions of equal access of ADEP4 to both proteins. 
 
Extending the analysis, at least 12 compounds were found to have 6-28 fold 
higher on rates for ClpP compared to HClpP. Based on off rate data, a comparative 
evaluation of residence time suggested 14 compounds (Table 5-3) with residence time > 
that of ADEP4 (t=115 sec). At least 10 compounds out of above 14 also had superior on 
rates for ClpP compared to HClpP, reaffirming the observation of selectivity based on 
kinetic rates. The cross comparison of large molecules series over different assays was 
performed to select the best large molecules with highest binding affinity as well 
selectivity toward ClpP. The Figure 5-20A shows best ADEP4 analogs with nM 
affinities and longer residence time on ClpP. The Figure 5-20B shows the best ClpP 
selective compounds with better kinetics compared to HClpP. 
 
 
Primary Screening Results 
 
For primary screening purposes, a three pronged strategy of characterization of a 
collections using three different techniques of TSA, FP and SPR was implemented. The 
enzymatic assay was not selected based on lower throughput and requirement of 
incubation at 37 degree. Further the observed % activation of primary hits (especially low 
affinity fragments) was below 25% of ADEP4, as a result the enzymatic activity curves 
were incomplete and determination of EC50 values was inconclusive. The FP assay based 
screening was performed on basis of availability of individual fragment collections, 
whereas the TSA and SPR-based screening were performed (in that order) on an 
assembled set of same fragments as one library. The negative hits which were identified 
as destabilizers on TSA assay were removed from SPR-based screens to avoid 
denaturation of immobilized ClpP on SPR chips. Based in higher throughput or ease of 
screening, the FDA collection#2 was screened by FP and TSA assay only whereas 
bioactive #1, 2, FDA#1 and lead like collections were only screened on FP assay only. 
The bioactive collection #1, 2 and FDA collection #1, 2 were found to have many 
duplicate compounds which originated from earlier compound sorting attempts on 
respective libraries. The primary screening hits from all assays (and collections) were 
curated by removing duplicates, and highly fluorescent compounds. The resulting unique 
primary screening hits were tested on dose response validation experiments in 





























2968 3.4±0.02e5 3.6±0.002e-3 10.7±0.06 277.1 2.6±0.005e5 6.7±0.01e-2 253.8±0.7 15.0 
1999 3.5±0.008e5 8.71±0.002e-3 24.4±0.06 115.5 6.9±0.007e4 2.6±0.002e-2 377.2±0.5 38.5 
2921 4.7±0.01e5 3.9±0.001e-3 8.3±0.02 257.1 2.1±0.008e4 5.4±0.02e-2 2.5±0.0 18.4 
3120 5.9±0.03e5 3.1±0.006e-3 5.3±0.03 319.7 4.3±0.1e5 4.5±0.006e-3 10.3±0.3 223.5 
2869 2.1±0.06e6 6.1±0.001e-3 2.92±0.08 165.3 2.3±0.008e5 4.2±0.003e-3 17.7±0.1 239.7 
2969 1.8±0.05e6 2.6±0.0006e-3 1.5±0.04 381.7 1.5±0.005e5 4.7±0.006e-3 31.3±0.1 211.8 
3023 5.9±0.5e6 1.4±0.0005e-2 2.4±0.2 71.2 3.6±0.05e5 4.7±0.005e-3 13.2±0.2 211.4 
3173 1.0±0.02e6 6.6±0.002e-3 6.6±0.2 151.2 6.5±0.3e5 7.7±0.01e-3 11.9±0.6 129.3 
2867 2.3±0.04e6 1.8±0.0004e-2 7.9±0.1 55.0 3.8±0.1e5 4.8±0.007e-3 12.7±0.4 206.9 
2777 9.0±0.2e5 5.9±0.003e-3 6.6±0.1 167.9 4.8±0.005e4 2.5±0.004e-3 52.4±0.1 393.8 
2873 1.9±0.05e6 4.7±0.001e-3 2.5±0.07 213.4 2.6±0.02e5 3.5±0.003e-3 13.4±0.1 282.4 
3176 3.6±0.009e6 2.9±0.0005e-3 0.8±2 339.4 1.2±0.003e5 4.5±0.005e-3 36.8±0.1 221.1 
3090 9.0±0.1e5 5.9±0.002e-3 6.5±0.1 170.1 5.2±0.01e4 1.9±0.007e-3 37.0±0.2 524.3 
3416 8.9±0.06e5 6.9±0.003e-3 7.7±0.05 146.1 4.4±0.06e6 5.7±0.006e-3 1.3±0.02 175.3 
2849 1.7±0.09e6 2.8±0.001e-3 1.6±0.08 361.9 1.6±0.007e5 5.8±0.008e-3 36.0±0.2 173.1 
2965 1.2±0.01e6 2.4±0.0009e-3 2.1±0.02 421.6 7.1±0.009e4 3.0±0.005e-3 42.5±0.1 333.1 
3196 1.7±0.05e6 3.3±0.001e-3 1.9±0.06 300.2 2.6±0.04e5 3.9±0.01e-3 15.3±0.2 253.8 








Figure 5-20. Chemical Structures of Best of Large Molecule Series Compounds. 
A: Best ADEP4 analogs with sub nM affinities and longer residence time on ClpP. 






TSA-Based Primary Screening Results 
 
 
TSA-Fragment Screening Results  
 
Most fragments being small in size form weaker interactions within binding 
pockets on the protein surface and are often screened at high molar concentrations 
(within solubility limits) to generate a measurable response. Depending on the topology 
of the binding surface and physiochemical properties of fragments (i.e. size, cLogP), a 
same fragment can bind with some degree of with promiscuity to multiple proteins, 
although many fragments exhibit specificity in their binding behavior. Since TSA assay 
cannot distinguish between specific or nonspecific binders, the resulting hit rates are 
often high. To overcome this limitation, three orthogonal proteins were simultaneous 
screened along with wild type ClpP using same set of fragments. The underlying 
objectives of the combined screening study were multifold. First objective was 
identification of fragments with selective binding exclusive to ClpP and to orthogonal 
proteins. Second objective was identification of binders with promiscuous binding 
activity toward all four proteins. Third objective was identification of those fragments 
which upon interaction, decrease the stability of the protein. In addition to wild type 
ClpP, purified HPPK and 2 variants of DHPS protein from Staph aureus and Bacillus 
anthraces were individually optimized in a pilot study prior to fragment screening for 
buffer conditions as well as for respective positive control responses as per optimization 
strategy described in chapter 3. The DHPS and HPPK required presence of sod. 
Pyrophosphate and ATP respectively for binding functionality and therefore the TSA 
assay was ran under conditions of with or without respective additives. 
 
The collected data was evaluated as per data optimization procedure described in 
chapter 3 and assay performance was assessed by measuring melting temperature of 
negative and positive controls from day to day and plate to plate basis. All positive 
controls (1999 for ClpP, 1532 for DHPS variants and 1988, 6-TG for HPPK) were highly 
reproducible with respective shifts on day to day and plate to plate basis (Appendix D 
Figure D-1A, B, C, D) suggesting successful screening. The binding fragments were 
identified using a cut off based on baseline response (& SEM) and results hits were 
segregated into positive hits which cause increase (right shift of individual melt curve) in 
melting temperature of the protein as “stabilizers” and negative hits which cause 
corresponding decrease (left shift of individual melt curve) in melting temperature of 
protein as “Destabilizers”. Further the hits were segregated into two additional categories 
of “unique” binders representing unique responses (positive or negative) to one protein 
and “promiscuous” binders representing multiple responses (positive or negative) to at 
least more than protein. In general there were more hits in any of the above categories for 
DHPS or HPPK proteins compared to ClpP protein. The underlying factors behind this 
observation were superior tolerance to high concentration of test compounds, proper 
sigmoidal melt profile of ClpP compared to other proteins. Additionally edge effects 
from pin tool based drugging contributed to slight upward shifts in ∆Tm values in 
corresponding wells on each plate, resulting in generation of false positives. To account 




fragments screened 439 fragments (~10% of collection) identified as “promiscuous 
Stabilizers” (Figure 5-21A) due to positive binding above respective cut offs, to more 
than one protein. For ClpP protein 51 fragments (1.2% of collection) displayed 
promiscuous stabilizer behavior whereas only 6 fragments (0.14% of collection) were 
identified as unique stabilizers (Figure 5-21B, green circles) exclusive to ClpP. For 
small sized fragments binding to more than protein was expected, therefore 57 positively 
binding fragments in both categories (unique and promiscuous) were selected for follow-
up repeat conformation as well as orthogonal validation on FP and SPR assays. 
 
Of all fragments screened, 402 fragments (9.4% of collection) were found to 
destabilize (Figure 5-21A, bottom left quadrant) more than one protein with greater 
than -2 degrees. The destabilization activity of certain fragments could stems from 
denaturation of proteins after interactions with aggregates at high molar concentration or 
due to optical artifacts from fragments with overlapping emission spectra to SYPRO 
Orange(TM) dye. Similar to positive hits, the number of negatives hits was higher for 
DHPS and HPPK compared to ClpP protein. For ClpP protein 50 fragments (1.8 % of 
collection) displayed promiscuous destabilizer behavior whereas 63 fragments (1.5% of 
collection) were identified as unique destabilizers exclusive to ClpP. The fragments with 
destabilizing effects on ClpP protein were omitted from fragment collection on SPR 




TSA-3 Point Pharmacophore Collection (3PP) Screening Results 
 
The RO3 complaint 3PP collection was assembled based on molecular binding 
patterns observed from binding of earlier hits to ClpP and the fragments were screened at 
~0.5-1 mM molar concentrations to match earlier screening of larger set of fragments. 
The performance of assay controls was optimum (Appendix D Figure D-1F) with good 
reproducibility across tested 3 plates. Of 750 fragments, 11 fragments (1.5% of 
collection) exhibited positive shift above 1 degree in melting temperature whereas 50 
fragments (6% of collection) exhibited negative shifts greater than -2 degree. The 
positive hits (Figure 5-22A) were selected for follow-up experiments for conformation 
and orthogonal validation. 
 
 
TSA-FDA Collection Screening Results 
 
To explore the chemical space of ClpP binding pocket further a collection 
(Selleck’s) of 1134 FDA collection #2 approved drugs were screened. The FDA 
collection consists of larger diversity in compounds size from fragment alike to large 
molecules (MW range 60-1400 Da), of which many representative compounds did not 
followed either rule of three or rule of five guidelines. To assess assay performance 
DMSO only wells and titration of positive control 1999 (ADEP4) were added to assay 







Figure 5-21. Primary Screening Results from ClpP TSA Assay on Fragment 
Collection. 
A: Overlay of dot plots showing differential positive and negative melt curve shift (∆Tm) 
from unique or promiscuous binding stabilizer and destabilizer hits from parallel 
screening of same fragment collection against 3 orthogonal proteins (HPPK, Sa-DHPS, 
Ba-DHPS). 
B: Collective overlay of dot plot showing differential positive melt curve shift (∆Tm) of 
binding stabilizer hits (green circles) and negative melt curve shift from binding 
destabilizer hits at respective cut offs from parallel TSA screening of same fragment 








Figure 5-22. Primary Screening Results from ClpP TSA Assay on 3 Point 
Pharmacophore Fragment Collection and FDA Collection. 
A: Dot plot showing differential positive melt curve shift (∆Tm) of ClpP binding 
stabilizer hits (green circles) at 1 degree cutoff (red dots) and negative melt curve shift 
from ClpP binding destabilizer hits at -2 degree cut off (black dots) from TSA screening 
of 3 point pharmacophore collection. 
B: Dot plot showing differential positive melt curve shift (∆Tm) of ClpP binding 
stabilizer hits (green circles) at 1 degree cutoff (red dots), false positives (red circles) 
with >10 degree positive shift and negative melt curve shift from ClpP binding 






consistent (Appendix D Figure D-1E) across from one plate to other. The choice of 
screening the FDA collection at lower concentration compared to fragment screening 
concentration range was instrumental in lowering number of false positives. Of total 1134 
compounds screened, 116 (~10% of collection) were destabilizers with greater than -2 
degree shift in melting temperature of ClpP, whereas 24 fragments (2.2% of collection) 
exhibited positive shift in melting temperature above selected cutoff at 1 degree. Of 24 
positive hits (Figure 5-22B, green circles), 5 compounds (red circles) exhibited unusual 
> 10 degree shift which was indicative of potential false positives likely from 
fluorescence interference in emission spectra of SYPRO Orange(TM). Given the FDA 
collection housed compounds much larger than fragments, the molecular weight of these 
hits was between 400-1000 Da, therefore generation of larger shifts in melting 
temperature was a distinct possibility. To test the hypothesis further these hits were 
included along with remaining hits for follow-up experiments. 
 
 
FP-Based Primary Screening Results 
 
 
FP-Fragment Screening Results 
 
All fragments were screened at final concentration ranging between 0.5 to 1mM 
to generate observable FP probe displacement. A subset of 1222 fragments from Life and 
Enimine collections were screened first followed by Maybridge subset of 1823 fragments 
(year 2013) and lastly solubility curated Maybridge subset of 582 fragments along with 
Infarmtik subset of 992 fragments. As seen in Appendix D Figure D-2 overall Z score 
for entire fragment screening was between 0.76-0.92 suggesting high assay robustness, 
the average signal window >170 mP units suggesting excellent signal separation between 
baseline or maximum signal and highly reproducible displacement curves (IC50 ~6-8 µM) 
from positive control 2378 across the plates ran on different days. 
 
The Figure 5-23A shows pooled screening results normalized to baseline 
response of zero probe displacement from retrospectively combined screening results 
with all fragments (from Maybridge) subsets pooled into one larger (Maybridge) set and 
other subsets shown as per vendor. The hit cut off (Figure 5-23A, red serial dots) based 
on spread of baseline response and was kept between 25-35 % of probe displacement 
compared to 100% probe displacement by 2378. At individual subset level (per vendor) 
the hits rate from combined Maybridge set was were 0.54 % (13 fragments) of which 3 
fragments displaced FP probe more than 50%. For Life fragment subset, the hit rate was 
at 1.74% (17 fragments) of which 2 fragments displaced FP probe more than 50%. The 
hit rate for Enimine collection was 1.2% (3 fragments) whereas the hit rate for Infarmtik 
collection was at 0.3 % with just 3 hits below hit cut off. The overall hit rate was 0.84% 
with 36 initial hits from entire fragment collection of 4270 fragments, of which only 4 








Figure 5-23. Primary Screening Results from ClpP FP Assay on Fragments, 
Federal Drug Administration (FDA) Collection #1, 2 and Malaria Collection. 
A: Dot plot showing normalized % probe 6 displacement of 4400 Fragment collection 
sorted by vendor (blue dots) and hits (green circles) along with false positive hits (red 
circles) below 75% cutoff. 
B: Dot plot showing normalized % probe 6 displacement of 750 fragments from 3 point 
pharmacophore collection (blue dots) and hits (green circles) below 75% cutoff. 
C: Dot plot showing normalized % probe 6 displacement of 409 compounds from 
Malaria collection (blue dots) and hits (green circles) below 75% cutoff. 
D-F: Dot plot showing normalized % probe 6 displacement of 2125 compounds from 
FDA #1, 2 collection (blue dots) and hits (green circles) along with false positive hits (red 






FP-3 Point Pharmacophore Collection (3PP) Screening Results 
 
The 3 point pharmacophore collection of 750 fragments was screened at 
concentration ranges matching TSA assay at ~0.5-1 mM. The assay exhibited excellent 
reproducibility (Z score >0.80) along with repeatability of positive control 2378 
(Appendix D Figure D-3A). At hit rate of 0.53 % only 4 fragments were found to be 
exhibit % displacement higher than cut off (Figure 5-23B) of which 2 controls had % 
displacement below 50 % cutoff. 
 
 
FP-FDA Collection Screening Results 
 
The structurally unique FDA collection #1 of 991 compounds and FDA #2 
collection of 1134 compounds was screened for displacement of FP probe at low 
concentrations (100-200 µM final), matching the TSA assay. Similar to other FP screens, 
the FP control 2378 exhibited excellent reproducibility (Z` >0.85) with consistent IC50 
values across different plates (Appendix D Figure D-3B). The hit rates were very low 
with FDA collection #1 at 0.8% (8 out of 991) whereas the hit rate for FDA collection # 2 
was at 0.6% (7 out of 1134). All primary screening hits with >50% displacement (Figure 
5-23D, F, red circles) and hits with >25 % displacement (green circles) were selected for 
a follow up dose response and orthogonal validations experiments. 
 
 
FP-Bioactives #1 and Malaria Collection 
 
The bioactive collection #1 with 6786 compounds was screened on FP assay at 
concentration matching FDA collections (~200 µM) as the compound representation 
(type & MW) was quite similar. The bioactive collection #2 which housed 1831 
structurally unique compounds compared to bioactive collection # 1, was screened (FP 
validation, Chapter 4) along with Malaria collection with 510 compounds. As shown in 
Appendix D Figure D-3C, E the positive control 2378 exhibited excellent 
reproducibility across the screen plates (26) and overall the assay performance was very 
robust (Z`> 0.8)) with average signal window at 163 mP. The hit rate (Figure 5-24A, 
green circles) of bioactive # 1 collection was slightly higher at 1.2 % (102 hits) due to 
presence of multiple duplicate compounds spread across the screening plates. Presence of 
highly fluorescent compounds within collection was yet another contributing factor 
toward higher hit rate as such compounds often appeared to be very strong hits (Figure 
5-24A, red circles) but were false positives in real. Similar to assay performance on 
bioactive collection #1, the bioactive collection #2 assay performance was robust 
(discussed in Chapter 3). The hit rate of bioactive collection #2 was at 1.1% (20 hits) 









Figure 5-24. Primary Screening Results from ClpP FP Assay on Bioactives# 1 and 
Lead Like Collection. 
A: Dot plot showing normalized % probe 6 displacement of 6786 Bioactive compound 
collection #1 (blue dots) and hits (green circles) along with false positive hits (red circles) 
below 75% cutoff. 
B: Dot plot showing normalized % probe 6 displacement of 10040 Lead like compound 
collection (blue dots) and hits (green circles) along with false positive hits (red circles) 






FP-Lead Like Collection 
 
The screening concentration for lead like collection with 10041 compounds was 
kept in the range of 200-500 µM, by altering the amount of compound added across 32 
screening plates. The FP controls 2378 was titrated in dose response to all screening 
plates to measure assay performance during screen. The control 2378 displaced the bound 
FP probe with excellent reproducibility (n=62) with average IC50 at 7.7±0.08 µM 
(Appendix D Figure D-3D, E, F)) and overall assay performance was very robust 
(Z`>0.83) with signal window >200mP across the entire screen. The hit rate was at 0.46% 
with 43 hits (Figure 5-24B, green circles). All hits including two hits with >50% probe 
displacement (red circles) were selected for later stage orthogonal testing. 
 
 
SPR-Based Primary Screening Results 
 
 
SPR-Fragment Screening Results 
 
The screening of entire 4270 fragment collection was performed in a narrow 
screening concentration range of 150-200 µM. The 519 fragments which were identified 
as promiscuous destabilizers on multiple proteins in TSA assay, were removed from the 
fragment collection to avoid potential inactivation of ligand on the surface. The 
remaining collection (3751) was split into 14 daughter plates to accommodate the assay 
run time of ~24 hours per plate. To help improve selection of ClpP specific hits, an 
orthogonal protein (HadAB) was immobilized in parallel to ClpP. The Figure 5-25A 
shows the combined dot plots for ClpP from entire fragment screen. At hit rate of 3.8 %, 
142 hits (out of 3751) identified with >40% response (green serial dots) compared to 
fragment (positive) control (Red serial dots). The consistency of control response 
highlights the excellent performance of SPR assay performance across different plates 
ran on different days. The higher hit rate (of 3.8%) for SPR assays was rather expected 
due to higher chances of fragments to bind specifically (or even nonspecifically) to a 
multimeric (14mer) protein-protein interaction target (ClpP) with large surface area 
spread across multiple binding pockets. 
 
 
SPR-3 Point Pharmacophore (3PP) Collection Screening Results 
 
The observation from earlier SPR screening of larger fragment collection, were 
implemented for screening of 750 fragments from 3 point pharmacophore collection. The 
performance of fragment (positive) control was very consistent (Figure 5-25B) across 
multiple injections suggesting robust assay performance. Of 750 fragments, 21 fragments 
(hit rate 2.8%) with response greater than 40% of fragment control were identified as hits 








Figure 5-25. Primary Screening Results from ClpP SPR Assay on Fragment 
Collection. 
A: Dot plot showing normalized response of 3700 fragments (blue dots) and responses of 
hits above cutoff (green dotted line) compared to highly reproducible response from 
positive fragment control (red dots). 
B: Dot plot showing normalized response of 750 fragments (blue dots) from 3 point 
pharmacophore collection and responses of hits above cutoff (green dotted line) 






Characterization of Primary Screening Hits and Orthogonal Validation 
 
 
Curation of Primary Screening Hits 
 
More than 26300 compounds were screened in combination on FP, TSA, and SPR 
assays in a single point format from diverse collections including fragments, lead like, 
FDA and bioactive libraries. Based on the hit selection criteria (Figure 5-4) discussed 
above, a total of 446 primary hits at a cumulative hit rate of 1.70 % were selected for 
dose response tests. Due to overlap of certain screening collections (such as bioactives/ 
FDA #1, 2), many compounds were independently identified as duplicate hits either on 
same assay or multiple assays. The raw data from FP and TSA assay was rigorously 
analyzed to identify false positives and trouble compounds known PAINS (Pan Assay 
Interference Compounds) or aggregators which could potentially destabilize the ClpP 
protein especially for chip based SPR assays. From FP and TSA screens, multiple false 
positive signal generating compound (highly fluorescent) were identified for 
retrospective differentiation of true hits on a dose response format. Similarly from TSA 
screens, the compounds with negative shift (promiscuous or unique ClpP destabilizers) 
were identified and removed from final hit list. 
 
The core idea was to screen all hits on three different assays (FP, TSA, and SPR) 
to complement limitations of one assay with another and to provide orthogonal validation 
of hit response on at least two separate assays. Based on the earlier observations , it was 
distinctly possible that a false positive compound could appear as real hit by exhibiting 
the concentration dependent dose response by virtue of being highly fluorescent on 
labeled assays (i.e. FP, FI, TSA etc.). Therefore more emphasis was put toward finding 
validated hits which showed response on both labeled and unlabeled assays (SPR). The 
characterization of primary hits was carried out strategically by sorting the compounds on 
basis of their stock concentration as well as compound type with end goal to adjust to 
screening requirements on different assays and sensitivity of SPR assays. The formatting 
of the primary hits into 22 stock plates was performed with 14 point (1:2) dilutions series 
for each compound. Since the available volume per compound was very limited (5-10uL/ 
well), the characterization studies were based on reagent requirements per assay and were 
carried out in at least duplicate or triplicate on FP, TSA, enzymatic and SPR assay (in 
that order). Based on the observation of partial activity or incomplete curves from 
fragments the characterization on enzymatic assay was limited to lead like or higher 
molecular weight compounds only. The stock concentrations of the test compounds 
ranged from 100mM to < 5mM, therefore to meet the different screening concentration 
range requirements of each assay, different volumes (in nL) of were pin transferred (in 
384 well format) using liquid handing robots while staying below the respective DMSO 
tolerance limit per assay. The respective characterization controls for each method were 
hand prepared before the respective assay run to ensure robust assay performance. 
 
For sensitive SPR assay the screening concentration requirements of fragments 
was kept much lower (~100-200 µM) than FP or TSA (0.5-1 mM) assays. The 




would need to be screened at much lower concentration (20-50 µM) than fragments in 
order to avoid concentration dependent artifacts. Therefore for SPR-based 
characterization, all primary hits were tested in duplicate by manually segregating the hits 
into two broad pools as the fragments sized hits (MW range 100-350 Da) which included 
Maybridge, Enimine, Life, Infarmtik collections and as larger size hits (MW range 350-
1000 Da) which included hits from Malaria, FDA, bioactive and lead like collections. 
The respective compounds were manually cherry picked from dose response plates and 




Characterization of Primary Hits on TSA Assay  
 
The dose response experiments on TSA assay were carried out by altering the 
final concentration based on molecular weight of the compounds. For low molecular 
weight compounds the final screening concentration was kept high up to milli molar 
range and for high molecular weight compounds the final concentrations were lowered 
(200-500 µM) accordingly. The SJ000773156-4 (ICG-001) which was validated as a real 
hit during FP assay optimization (Chapter 3) and ADEP4 analog 2378 were used as 
main controls for positive shift upon binding by two structurally different compounds. 
The Appendix D Figure D-4A, B shows dose dependent (concentration increases, left to 
right) large increase in melting temperature of the ClpP upon binding, as an indicative of 
assay functionality. Since the individual concentration range per compound was different, 
the maximum shift at a constant concentration (∆Tmax) analysis could not be applied to all 
test compounds. Instead the wells with maximum shift (∆Tm,
 oC) within each dose 
response series were identified based on the DMSO only Tm values. Of all compounds 
tested, 94 unique compounds had positive shift (Appendix D Table D-4) greater than cut 
off criteria of 1 degree of which 15 compounds had ∆Tm in range of > 10 degrees. A shift 
of > 10 degree is rather unusual for most compounds except compounds with high 
affinity and indicates potentially false positives from likely spectral interference of 
SYPRO Orange(TM) dye. Of 15, 14 compounds with > 10 degree shift were found to be 
false positives as indicated by saturation of raw signal and reported ∆Tm values were 
found to be an erroneously generated by data fitting algorithm. The Figure 5-26 shows 
the segregation of validated hits 20 hits with low (∆Tm 1-2 degree), 20 hits with medium 




Characterization of Primary Hits on FP Assay 
 
All primary screening hits were tested for dose dependent displacement of FP 
probe in a competition format experiments to determine their displacement potency (IC50 
values) relative to positive controls 2378 and 1999. Similar to TSA assay, the screening 
concentrations for the ClpP site specific FP assay were kept high for low molecular 







Figure 5-26. Characterization of Screening Hits on ClpP TSA Assay. 
A-B: Positive shift in range of 4-10 degree in melting temperature of ClpP by screening 
hits compared to negative control (DMSO). 
C-D: Positive shift in range of 2-4 degree in melting temperature of ClpP by screening 
hits compared to negative control (DMSO). 
E-F: Positive shift in range of 1-2 degree in melting temperature of ClpP by screening 







with higher (>350 Da) molecular weight by strategically altering the titration volume per 
assay plate. More than 20 assay plates each carrying 1:2 serial dilutions of ~ 20 
compounds, were tested on different days along with respective controls to ensure robust 
assay performance. Of all compounds tested 80 compounds displaced previously bound 
FP probe either completely or partially depending on their displacement potency and 
solubility. The validated hits were sorted based on their IC50 values and data from 16 
compounds with IC50 <100 µM pooled into Figure 5-27B, C, D to highlight compounds 
with site specific interactions with ClpP along with robust (n=14) performance by 
controls (Figure 6-27A). Further analysis of raw data revealed that 8 out of above 16 
compounds were highly fluorescent and hence likely false positives. Further cross 
examination with TSA assay suggested at least 7 out of above 8 compounds also had very 
high (>10 degree) melting temperatures confirming the observation that reported potent 
IC50 values (Appendix D Table D-4) were untrue and were result of optical interference 
across the titration series. The label free SPR assay provided final confirmation of their 
nonspecific nature as most of the compounds had sensograms with either abnormally 
high response or were completely inactive. The Appendix D Figure D-5 shows the 
partial displacement curves from second best 22 compounds with estimated IC50 values 
between 100-500 µM along with robust controls performance. 
 
 
Characterization of Primary Hits on Enzymatic Assay 
 
To determine ClpP activation potential in vitro, the degradation (emitted RFU) of 
Bodipy-FL ß-casein substrate by ClpP treated with primary hit compounds (in dose 
response format), was monitored and % activation compared to positive controls 
ADEP4/2378. To establish that the earlier observations of partial activity of fragments 
toward ClpP resulting in incomplete EC50 curves, was a function of lower affinity of 
fragments rather than their sub-stoichiometric concentrations, multiple assay plates with 
fragment hits were tested at saturating concentrations. The excellent DMSO tolerance (up 
to 5% v/v) of the enzymatic assay, allowed testing of plates with fragment sized hits, at 
concentrations up to 1mM however no improvement in activity of fragments was noticed. 
It was possible that a low affinity fragment with confirmed binding to ClpP may not 
activate the ClpP sufficiently to exhibit a measurable activity on enzymatic assay. 
Therefore further testing on enzymatic assay on fragments hits was not performed. 
Further unlike TSA and FP assay, the enzymatic assay was not very informative in 
identification of false positives, likely due to difference of peak spectra of false positive 
from Bodipy-FL fluorophore. Of all false positives identified on FP and TSA assays only 
one compound displayed borderline activity on enzymatic assay. A total of 198 
compounds were tested on enzymatic assay in dose response format at concentrations 
proportional to their molecular weight or orthogonally estimated affinity. Of all tested 
only 22 compounds (Appendix D Table D-4) exhibited ClpP activation in the range of 
≥20 to ≤75 % of positive controls. The Figure 5-28A, B shows the selected 9 compounds 
with % activation greater than 30 % of positive controls. Of above 9 validated hits, 4 
compounds had % activation >50% of ADEP4 with only 1 (of 4) compound 








Figure 5-27. Characterization of Screening Hits (Set 1) on ClpP FP Assay. 
A: Complete displacement (normalized) of previously bound probe 6 by positive controls 
(2378, 1999) for set 1 of higher affinity screening hits. 
B-D: Displacement of previously bound probe 6 by screening hits (from bioactive, lead 
like and fragment collections) with estimated displacement potency (IC50) in the range of 







Figure 5-28. Characterization of Screening Hits on ClpP Enzymatic Assay. 
A: A total of 9 fragment hits were found to activate ClpP to greater than 20% cutoff 
based on positive control ADEP4 activity at 100%. 






with estimated EC50 at 22.2±2.2 µM. This finding was quite interesting given this 
compound despite being a fragment, activated ClpP to an extent comparable (>75%) to 
high affinity large molecules. 
 
 
Characterization of Primary Hits on SPR Assay 
 
All primary screening hits (446), regardless of their activity on earlier FP, thermal 
shift, enzymatic assays, were tested on label free SPR assays to further differentiate false 
positives from real hits. Unlike other assays, the test compounds could not be pin 
transferred to SPR assay plates as accuracy of pin tool (at %CV close to 10%) was not 
high enough to avoid DMSO mismatch issues. Due to high sensitivity of SPR assays to 
variations in final DMSO %, an additional daughter set (1/10th dilution where 
appropriate) of stock plates was created to increase the final pipetting volume to µL 
(from nL) to accurately transfer test compounds to SPR assay plates. All hit validation 
experiments on SPR were carried out in duplicate by using the dispersion based kinetic 
injection method (oneStep). The primary hits were manually segregated based on their 
molecular weight into sets of 30-40 compounds and compounds with lower molecular 
weight were injected first followed by higher molecular weight compounds. The test 
concentrations were manually adjusted proportionally to molecular weight of the test 
compounds and injection order was randomized to lower the probability of carry over 
effects. The SPR as a binding assay cannot differentiate between ClpP binders specific to 
ADEP4 binding pockets or compounds binding allosterically to sites adjacent to ADEP4 
binding pocket or within catalytic chamber. This was specifically true for small sized 
fragments (MW ≤300 Da) which represented bulk (>70%) of primary screening hits 
tested on SPR assay. The affinities of fragments are often low (0.1-1 mM) and with fast 
on / fast off kinetics, therefore the kinetic analysis of hits with positive response was 
carried by fitting data to affinity model which assumes fast (instant) dissociation rate of 
the compound. The hits with measurable off rate were marked for later stage analysis on 
simple (ka/kd) models to determine binding kinetics. 
 
To determine potential selectivity of hits to ClpP, the HClpP was immobilized in 
parallel to ClpP at matching high ligand densities. However the HClpP was less than 
ideal control due to its structural similarity to ClpP and lower proportional functionality 
on Chip surface following immobilization. The small sized fragments hits were expected 
to bind to both proteins with no apparent selectivity or with low molar affinity, however 
it was possible to differentiate selectivity of larger compounds on basis of their binding 
kinetics assuming equal functionality of both proteins over time. Further in absence of 
structural evidence on mode of binding of certain hits to HClpP (and to ClpP), the fitting 
of data to a particular model was difficult. Therefore determination of affinity (KD) rather 
than kinetics (on/ off rates) for HClpP binders was based on simple 1:1 affinity model 
(assumes fast off rate) although HClpP is known to exhibit binding complexity similar to 
ClpP. Overall the functionality of immobilized ClpP was much superior to HClpP 
although both proteins tend to lose up to 30% functionality (over time) following 
immobilization. Correspondingly the ClpP data was more uniform and fitted the selected 




primary hits was evaluated on ClpP and only hits with ClpP affinity ≤100µM (& ≥3x 
HClpP affinity) were contrasted for selectivity toward ClpP. The Appendix D Figure D-
6B, C, D shows the sensograms for fragment control 3027 binding to ClpP (Blue curve) 
and HClpP (Green curve), tested on different days. As expected of typical fragments, the 
3027 was nonspecific in its interactions with both proteins (slightly more to HClpP) with 
weaker affinities in the range of 200-400 µM and fast (instant) off rates. Of all 
compounds tested (Appendix D Figure D-6A), 16% (71) were completely inactive, 1% 
(4) were excluded (sticky/ precipitated), 7% (31) were nonspecific with abnormally high 
response, 48 % (214) displayed upside down sensograms and ~28% (129) had proper 
response. 
 
To observe if label free SPR assay can distinguish the earlier identified (TSA and 
FP hits) false positives from genuine hits, their sensogram profiles were compared to 
positive control response. Of all 14 compounds 3 were inactive and 11 compounds had 
response 2-3 fold higher than control (indicative of nonspecific binding), thus verifying 
their identity as false positives. The most of the compounds with inverse sensograms 
were fragments, which appeared to interact nonspecifically with reference surface 
(without ligand) more than surface with ligand (ClpP). As a result the sensograms were 
expectedly inverse due to subtraction of signal from reference surface from surface with 
ligand during affinity measurements. While it was possible that some of the compounds 
might have binding interactions with ClpP (while most were inactive), their accurate 
identification was not possible unless assay conditions were significantly altered to 
reduce their nonspecific binding to reference surfaces. Additionally it was possible that 
some of the inactive or nonspecific compound exacerbated the nonspecific binding 
during assay run. Therefore further analysis of such compounds was ceased. About half 
(14%) of compounds with proper SPR response were found to be unique to SPR assay 
only, whereas remaining half were active in one or more orthogonal assays. The Figures 
5-29, -30, and -31 highlights the compounds with best fit sensograms to affinity model 
(up to mM KD range) along with multiple repeat sensograms of weak affinity fragment 
control 3027 (Blue curves) within a narrow range suggesting overall robust SPR assay 
performance. Due to overlap of screening collections, 29 compounds were identified as 
duplicate hits of same compound with different versions. Following removal of duplicate 
compounds on SPR assay, 10 compounds were identified with estimated affinity in range 
of 1-10µM, 22 compounds with affinity in range of 10-100 µM, 36 compounds with 
affinity in range of 100-500 µM and 25 compounds with affinity > 0.5 mM. To determine 
the selectivity of validated hits with affinity ≤100 µM, their interactions with HClpP were 
evaluated by fitting the data to affinity (KD) model under the assumptions of equivalent 
ligand (HClpP) functionality as ClpP. As shown in Figure 5-32, 6 compounds with ClpP 
affinity ≥3 fold the HClpP were identified, of which 3 compounds appeared to bind ClpP 
with relatively high affinity (≤10 µM). 
 
 
Hit Validation: Collection Source Vs Primary Screening Assay 
 
All primary screening collections could be segregated into 5 distinct groups 






Figure 5-29. ClpP SPR Assay Binding Affinity Assessment: Screening Hits Set 1. 
A-H: Comparison of screening (from lead like collection) hits (set 1) with ClpP fragment 







Figure 5-30. ClpP SPR Assay Binding Affinity Assessment: Screening Hits Set 2. 
A-H: Comparison of screening hits (set 2) with ClpP fragment control (3027) to generate 









Figure 5-31. ClpP SPR Assay Binding Affinity Assessment: Screening Hits Set 3. 
A-H: Comparison of screening hits (set 3) with ClpP fragment control (3027) to generate 







Figure 5-32. ClpP SPR Assay Selectivity Assessment: Screening Hits. 
A-F: Based on selection criteria of ClpP binding affinity ≥3 fold the HClpP binding 








chemical diversity. For fragments, the primary screening hit rate (Figure 5-33A) of SPR 
assays was highest followed by TSA and FP (in that order) and the trend continued for 
dose response experiments (Figure 5-33B). Of all 279 fragments tested, 3 fragments 
were reconfirmed on all three assays while 4 additional fragments were found to be 
common hits between two assays. The lead like collection of 10041 compound was only 
screened on FP assay and of 43 initial hits (Figure 5-34A, B), 14 were found to be repeat 
hits already identified among bioactive group hits. Of remaining 29 hits, only 1 hit each 
was reconfirmed on FP, TSA and SPR assays while 4 unique hits exhibited decent 
activity on enzymatic assay. Next at hit rate of 1.3%, 109 FP assay hits were identified 
from bioactive collection and 30 hits were found to cross validate on all three assays 
(Figure 5-35B). Notably only two hits were found to be common all four assays, one of 
which was compound 3421 (ICG-001) which was validated as novel ClpP activator 
(Chapter 3). The second hit with activity on all four assays was unattractive from lead 
expansion standpoint due to its rather large size (MW >1400 Da) and perhaps fluorescent 
nature. In addition to above hits, 30 additional hits were common in combination of two 
assays. The FDA collection which was primarily screened by FP and TSA assays, had 27 
hits of which 3 hits (Figure 5-36B) were found to reconfirm the activity on FP, TSA and 
SPR assays, in addition to just 1 hit common between FP and enzymatic assay. Lastly the 
malaria collection had just 7 hits from FP screen and only 1 hit (Figure 5-37B) was 
found to validate between SPR and FP assays. 
 
 
Hit Distribution: Collection Source Vs Characterization Assay 
 
In total 446 primary hits were identified from screening of >26300 unique 
compounds on three assays. Most hits from FP, SPR and TSA assays were reconfirmed 
either exclusively on one particular assay or in combination of 2 or more assays. The 
distribution of common (& unique) hits between assays was complex with 38 hits 
common between two assays, 14 hits common between three assays and only 2 hits 
common to all four assays. A number of hits (20) were identified as false positives 
between the assays of which 2/3rd came from FP / TSA assay and remaining 1/3rd from 
SPR assay. 
 
Of 446 unique primary hits, 276 (61%) came from fragment collection (Figure  
5-38A), followed by 110 (24%) from bioactive collection. The number of hits exclusive 
to TSA, FP, Enzymatic and SPR were 24, 9, 10, and 64 respectively. The number of hits 
from lead like and FDA collections was much lower at 30 (7%) and 28 (6%) respectively 
and hit representation from Malaria collection was lowest with 8 (2%) hits. The higher hit 
rate from fragment collection was likely due to screening of fragment collection on three 
assays which resulted in additional hits whereas lead like, bioactives, FDA and Malaria 
collection were largely screened by FP assay. Further it was also possible that many 
fragments were nonspecific hits. Additional contributing factor was overlap of many 
compounds in lead like, FDA collections with bioactive collections, as a result many 
duplicate hits were identified more than once. Comparing the number of compounds 







Figure 5-33. Hit Validation: Fragments Collection. 
A-B: Out of 5020 total fragments screen on FP, SPR and TSA assay, 22 hits were 
validated on dose response experiments of which 3 hits were common between TSA, 







Figure 5-34. Hit Validation: Lead Like Collection. 
A-B: The 10041 lead like compounds were screened on FP assay and out of 43 initial hits 
29 unique hits were tested for dose response. The enzymatic assay had 4 unique hits and 







Figure 5-35. Hit Validation: Bioactive Collection. 
A-B: Screening of 8618 Bioactive compounds FP assay yielded 109 initial hits out of 









Figure 5-36. Hit Validation: FDA Collection. 
A-B: Screening of 2125 FDA compounds by FP assay and 1134 by TSA assay yielded 19 








Figure 5-37. Hit Validation: Malaria Collection. 
A-B: FP screening of 409 compounds from malaria collection yielded 5 hits including 








Figure 5-38. Hit Distribution: Collection Source Vs Characterization Assay. 
A: Distribution of 446 primary screening hits based on screening collection with largest 
share from fragments screened primarily by SPR and TSA (inset). 
B: Distribution of 446 hits based on screening assay and their dose response confirmation 








lower than SPR and TSA both of which cannot distinguish between specific or allosteric 
(or even nonspecific) binders . This observation is further reflected in lower proportion 
(18%) of fragment hits (Figure 6-38A, sub circle) identified in FP assay compared to 
SPR (57%) and TSA (25%). Further the orthogonal validation analysis (Figure 5-38B) of 
individual screening assays suggested both ClpP SPR and TSA assay identified unique 
hits most of which reconfirmed on respective assays while their orthogonal validation 
correlation was low. None of the TSA hits exhibited activity on ClpP enzymatic assay 
while about 20% were reconfirmed on SPR and FP assays each. The SPR assay hits were 
largely fragments and expectedly only few hits (<3%) showed activity on FP or 
enzymatic assays, while 30% had activity on TSA assay. For FP hits, the orthogonal 
validation was evenly spread between SPR, TSA and FP assay at ~30% while about 9% 
of FP hits exhibited functional activity on ClpP enzymatic assay. The proportionally 
higher enzymatic assay activity of FP hits and higher cross validation rate on other assays 
(SPR, TSA) is indicative of superior quality of FP hits. 
 
 
Molecular Characteristics: Validated Hits 
 
The evaluation of molecular properties of validated hits (Appendix D Figure  
D-7) indicated that >83% (151) of the hits were complaint to Lipinski’s RO5 guidelines 
of which 126 hits had ligand efficiency >0.2. However most of ligand efficient hits had 
rather weak assay activity, therefore avoid missing active hits with molecular properties 
outside RO5 criteria a filter criteria of SPR affinity <50 µM, TSA ∆Tm <10 degree, FP 
IC50 <100 µM and Enzymatic % activation >30 %, was applied. Overall no particular 
correlation between hits with best activity and hits with best efficiency was observed. 
Therefore the final selection of the best 35 hits for next stage X-ray crystallography, 
antibacterial activity was based on a combination of criteria such as structural novelty, 
chemical tractability, highest ligand efficiency, highest binding affinity (by SPR), cross 
validation on two or more assays and enzymatic assay activity. 
 
 
Assay Correlations, Selectivity and Efficiency Matrices 
 
The respective activity parameters (IC50, EC50, ∆Tm, KD) for each assay on small 
and large molecule series were compared to determine correlation between assays. Due to 
difference of measurement scales between assays and unavailable data for every 
compound, direct comparison of one assay to another is difficult from accuracy 
standpoint. Among the ClpP assays the SPR is the robust method to determine binding 
affinities, therefore respective affinity parameters of all compounds were contrasted 
against SPR generated KD values. The Figure 5-39 showcases the distribution of 
respective affinity and ligand efficiency parameters, sorted by small molecules series (#1: 
Blue, #2 Green) or large molecules (Red) and by compliance to RO5 filter (Pass: circle, 
Fail: Square). Both FP and enzymatic assay (Figure 5-39A) exhibited excellent 
correlation and as a general trend, all active compounds on FP assay were also active on 







Figure 5-39. Assay Correlations Trends between ClpP Screening Assays. 
A-F: Excellent correlation between ClpP SPR, TSA, FP and enzymatic assay on large 
molecules (pink), small molecule series 1 (blue) and series 2 (green) marked by pass 






large molecules series were different, a strong correlation can be seen between TSA, 
Enzymatic, FP and SPR assays. All compounds with high affinity on SPR had strong 
activity on each orthogonal assay. Closer inspection of selected best compounds per 
assay suggested that the correlation between SPR vs enzymatic assay was stronger than 
SPR vs FP assay due to limited resolution power of FP assay (assay cap~3µM). The SPR 
assay correlated with TSA assay quite well, a trend also observed during primary 
screening of fragment collections. Overall the affinity values for large molecules were 
understandably higher in general for any given assay and the small molecules series #2 
compounds were better than series #1 compounds in every aspect. 
 
Next the ligand efficiency parameters were compared between each series. The 
LE values (>0.3) pertain more to fragments as a measure of their efficiency as starting 
point for hit to lead optimization. Since all compounds in small or large molecules series 
were larger (and more complex), the LE values (Figure 5-39C) were expectedly lower 
than LE cutoff values (>0.3 Kcal Mol-1). To assess the druggability of lead compounds 
LiPE (Ligand Lipophilicity efficiency or LLE) is a better criteria (>5 for a nanomolar 
binder) as it accounts for added lipophilicity during compound optimization. More than 
60 large molecules series compounds with SPR KD values < 400 nM had LiPE score >5, 
while none of small molecule series compound exhibited equivalent lipophilic efficiency. 
However with LiPE score at 2.56, and high affinity (800nM), the small molecule 3471 
shadows the large molecules series and is a very promising lead toward development of 
non-peptidic small molecules activator of ClpP. Lastly both FP and TSA were not so 
useful toward assessment of selectivity of a particular binder toward ClpP. Due to 
structural similarity of HClpP to ClpP, most compounds interacted with both proteins to 
similar extent or less than 10 fold on a given criteria. On the other hand enzymatic and 
SPR assays highlighted the selectivity to a much better extent with many compounds 
exhibiting selectivity (in activation or binding to ClpP) >10 fold. In particular on rates of 






The Figure 5-40 highlights the molecular weight based distribution of best 35 
unique compounds following the selection criteria. Of 35 final hits, 31 were complaint to 
RO5 guidelines and 4 were non-complaint. Further 18 out of above 31 hits had ligand 
efficiency >0.3, suggesting higher chances of optimization of reconfirmed hits toward 
desired pharmacological properties. In particular hits with polar surface area below 60Å 
and cLogP values ≤4, had reasonable probability of good permeability across the cell 
membranes. About 21 out of 35 compounds were fragments with MW<300 Da, 5 
compounds were lead like (MW<350 Da), and 9 compounds were drug like (MW>350 








Figure 5-40. Best of ClpP Screening Hits. 
Collection of 35 best ClpP screening hits arranged based on their molecular weight, for 











Overview of Dissertation Goals 
 
The overall goal of my dissertation research was to enable development of 
advanced ClpP specific screening methods and apply this toward discovery of novel 
scaffolds for lead expansion. The main aims of the dissertation were development of FP, 
TSA and SPR as primary screening assays (Aim 1) for identification of tractable hits, 
optimization of enzymatic (functional) activity assay (Aim 2) and SPR-based kinetic 
characterization assay (Aim 3) to determine binding affinity, kinetics, and selectivity of 
ClpP activators. Through these aims the objectives were (a) comparative analysis of in 
vitro assay performance such as enzymatic activity, selectivity, Kinetic rates, and Affinity 
constants; (b) Identification of novel scaffolds with ClpP activation potential; (c) Ranking 
of compounds for development using fragment, lead like and large molecule starting 
points. 
 
All dissertation goals were successfully met (Chapter 2, 3, 4) with optimization 
of thermal shift, FP, and SPR assays as primary screening assays. The primary screening 
of diverse collections was carried out on S.aureus ClpP only. The dose dependent 
evaluation of screening hits and characterization of small/.large molecules series 
compounds was carried out on S.aureus ClpP along with their selectivity assessment on 
HClpP, on all of the above assays. The ultimate aim was to identify novel chemical 
matter, improve selectivity and potency of leads generated from screens and continuous 
integration of lead molecules into central aim of development of ClpP activators with 
desirable efficacy. To this light more than 26300 unique compounds were screened on 
FP, TSA and SPR assay along with >500 compounds synthesized in house as part of 
small /large molecule optimization series. The best of the small and large molecules 
series compounds were identified along with 35 new chemical entities. The evaluation for 
their antibacterial activity against a panel of gram positive pathogens including drug 
resistant clinical strains and ClpP knockout strain, crystallographic determination of 
binding pose along with cytotoxicity assessment on representative cell lines was ongoing 
at the time of writing. The assay results on antibacterial activity, in vitro ADME 
properties, in vivo efficacy (PK/PD) of selective leads warrants a separate discussion and 
is beyond the scope of this dissertation. The resulting leads are expected to have decent 
antibacterial (MIC) activity, high enzymatic activity, superior binding affinity and slow 
dissociation kinetics along with desirable ligand efficiency parameters (LE, LiPE) for 
their next stage advancement. The key learning lessons from ClpP screening campaign 
are summed up below. 
 
 
Multiple Orthogonal Screening Strategy-A Logical Step Forward 
 
Drug discovery is an iterative and highly complex process which relies on 




screening logistics and hit to lead selection strategies. For the proteins with high yield 
and good stability such as ClpP, a plethora of biophysical or biochemical methods can be 
applied for discovery of initial hits and their characterization. Such techniques offer high 
quality information on structure of binding pocket, mode of ligand interaction, binding 
kinetics, or thermodynamics and are suitable for primary screening as well as late stage 
characterization purposes. Standalone no one method is absolute in terms of information 
content and at very best offers a partial snapshot of full picture. Each method comes with 
its own unique requirements, advantages and limitations, therefore successful 
implementation of such techniques depends on their applicability, throughput, and 
information content. The essence of having independent biophysical and biochemical 
assays is to validate hits based on accurate functional activity or binding kinetics, and to 
complement short comings of one assay system with merits of other assay system. The 
SPR and ITC are the gold standards for measuring binding affinity, kinetics and 
thermodynamics, the successful implementation of these techniques is protein specific 
and many times, quite challenging. Therefore a bottleneck existed in hit selection or lead 
expansion process due to required expertise, expense and difficulty of implementing 
ITC/SPR experiments with a reasonable throughput to achieve desired pace of ClpP 
discovery process. This is where TSA finds its space as a rapid screening method to 
curate and select best performing compounds for further validation. Multiple research 
reports combine melting temperatures with thermodynamic parameters obtained on 
DSC/ITC or Kinetic parameters obtained from SPR or with potency (IC50/Ki) 
calculations446,254,447,448. The inclusion of thermal shift data to other orthogonal methods 




Outlook on ClpP FP, TSA, Enzymatic and SPR Assay 
 
The ClpP FP, TSA, and SPR assays were configured in high throughput screening 
format to detect potential ClpP binders. Although above assays can be broadly put in one 






On a relative scale the information content of SPR assay was highest among FP 
and TSA assays, in terms of providing information on kinetic rates beside affinity. For 
both large and small molecule series the comparison of binding kinetics and residence 
time was incremental toward generating their rankings. The SPR assay outshined in the 
detection of low affinity fragment binders while their detection on FP/TSA assay was less 
reliable due to requirement of high screening concentrations. The TSA assay was not 
very informative in determining the binding affinities however could be used a surrogate 








The design of ClpP FP probe enabled site specific detection of ligands, an aspect 
not common with SPR or TSA assay. In theory an allosteric binder could also displace 
the bound FP probe from ADEP binding pockets however chances of a strong 
conformation shift in the binding pocket topology across assembled 14 ClpP monomers 
via allosteric modulation are quite low. Similarly a shift (positive or negative) in melting 
temperature of ClpP on TSA assay is at very best indicative of (Yes/No) ligand binding 
and no conclusions on specificity or allosteric nature of interaction can be drawn, unless 
supported by orthogonal experiments. Specifically the positive shift in melting 
temperature is proportional to affinity of the molecule, rather than its molecular weight. 
In general a low molecular weight compounds such as fragments produces much smaller 
shifts in melting temperature due to lower affinity. However the opposite is also true for 
TSA assay as a large molecule with low affinity can produce a small shift and a small 
molecule with high affinity can produce larger shift in melting temperature. 
 
 
Assay Resolution Power 
 
The resolution power of ClpP SPR assays was much superior to both FP and TSA 
assays. This was especially true for detection of low affinity fragments. The ClpP SPR 
assay uniquely identified many low affinity fragments with ligand efficiency >0.25, 
which appeared completely inactive on both FP and TSA assay. The resolution power of 
ClpP SPR assays was also evident for small or large molecules series compounds. The 
binding affinity of most potent ClpP binders was determined to between 1-25 nM range 
on SPR assays while IC50 values of same compounds on FP assay appeared to clustered 
around 3-6 µM. The resolution power of ClpP FP assay to detect compounds with both 
weak and strong binding affinity is contingent on affinity of the FP probe to ClpP. The 
resolving power of ClpP FP assay is limited at binding affinity of its probe around 3µM. 
Therefore the respective IC50 values of compounds with stronger binding affinity than FP 
probe, could not be resolved and all compounds appeared equally potent. The resolution 
power of TSA is even lower than FP assay justifying its use as primary screening assay 
rather than affinity characterization assay. This is due to lack of no apparent upper 
(maximum) limit of increase in melting temperature proportional to increase in 
concentration of the test compound. As observed from characterization of large molecule 
series on TSA, all compounds exhibited shift >10 degree and their ranking on basis of Tm 





The low hit rate of ClpP FP assay across various collections suggests that it can 
be applied to almost any collection. Likewise the ClpP TSA assay can be performed on 
diverse collections including fragments provided the screening concentrations are 
adjusted accordingly to compound type (i.e. Fragments vs large molecules). The high 




concentration requirements as result the hit rate on TSA was lower than other proteins 
screened in parallel. On a comparative scale the hit rate of ClpP SPR assay was higher 
than FP and TSA assays, in part due to likely nonspecific interactions of test compounds 
with reference sensor chip or ClpP protein itself. The loss of up to 30% ClpP 
functionality upon immobilization on sensor chip was yet another limiting (& 
contributing) factor toward increasing chances of nonspecific interactions further. 
However care must be exercised before assigning an interaction as nonspecific by 
comparing its response to a control of similar molecular weight and test concentration. It 
is possible that a binder on SPR assay may not activate ClpP or displace FP probe and 
may very well be a genuine allosteric binder to ADEP binding pockets or binds within 
catalytic chamber of ClpP. Despite the limitation the ClpP SPR was applicable to wide 
range of screening collections as long as the final concentrations were adjusted 
proportional to their molecular mass. 
 
 
Ease of Screening 
 
From ease of screening stand point the ClpP FP assay was the most high 
throughput assay among SPR and TSA. The mix and read format of FP assay enabled 
screening of large collections at a rapid pace. As observed during screening of 4270 
member fragment collection against ClpP the assay run time was less than 6 hours on FP 
assay compared to 15 days on SPR and 45 days on TSA. The excellent stability and 
robustness of ClpP FP assay, was very convenient toward screening large number of 
assay plates without reproducibility issues. On the other hand the high resolution power 
of SPR assays and ability to determine binding kinetics in high throughput manner comes 
at the cost of higher level of strategic planning in protein immobilizations, test 
concentrations and balancing of buffer components. The assay setup for TSA was 
minimalistic but the overall throughput was limited by machine output as most RT-PCR 
instruments can run one plate (96 or 384 well plate) at a time. Further in the wake of 
dedicated data processing algorithms (i.e. Pipeline Pilot scripts) the data processing can 





Finally both ClpP FP and TSA assays were prone to false positives especially 
from highly fluorescent compounds with spectral overlap to respective fluorophores. A 
number of highly fluorescent compounds were found to be strong hits on both assays 
during primary screening and subsequent dose response experiments. This limitation was 
complemented by label free ClpP SPR assay in which the above false positives were 







Outlook on Screening Logistics and Hit Selection Process 
 
 
Hit Reproducibility and Validation 
 
Depending on type of compound collection (natural products or fragments), 
during initial stages it is better to select most promising compounds based on activity 
parameters (i.e. binding affinity) on two or more assays or ligand efficiency in case of 
fragments. This determination relies on type and precision of detection method while 
taking in account limitations of each assay. Next replicability of primary hits should be 
based on quality of sigmoidal dose response curves with clearly defined top and bottom 
and hill slope between 0.5-1.8 unless the target exhibits cooperatively or complex binding 
behavior. The replicability of initial hits however does not mean their reproducibility. 
The reproducibility of the hit is based on determination of similar response on orthogonal 
assays or with change of assay conditions. A genuine hit is both replicable as well as 
reproducible. A compound with promiscuous behavior could very well display sigmoidal 
response proportional to its concentration gradient in dose response experiments. For 
example the detection of doxorubicin derivatives (Chapter 3) in the primary FP-based 
screening of bioactive collection was a result of optical interference (inner filter effects) 
in excitation/emission spectra of the ClpP FP probe. The non- specificity or promiscuity 
was not detected in the follow-up dose response experiments curves as it generated 
proper sigmoidal curve response similar to positive controls. The doxorubicin derivatives 
were later found to be nonspecific on orthogonal assays such as label free SPR where 
optical interference was not a possibility. Therefore to ensure the reproducibility of the 
hits, orthogonal testing should be carried out on preferably on resynthesized hits with 
highest purity. This practice ensures proper hit validation and reduces the chances of false 
hits from a promiscuous contaminant. 
 
 
Detection of Promiscuity 
 
Promiscuity of the compounds if unresolved in the beginning states of drug 
discovery could create a significant road block in hit to lead progression. The hallmark of 
promiscuous compounds is their identification as a hit against multiple orthogonal 
targets449. As observed during ClpP TSA fragment screen, close to 10% of the fragment 
collection were found to bind with positive Tm shift to 4 completely different proteins 
although fragments being small in size, can bind to multiple proteins with some degree of 
promiscuity. On the similar note, yet another 9-10% of collection was found to exhibit 
negative Tm shifts suggesting their potential to inactivate or destabilize the target. 
Omitting such fragments from fragment collections dramatically improved the SPR assay 
performance suggesting perhaps such fragments should be removed from collection to 
avoid target inactivation. The route to determination of promiscuity is rather a 
treacherous due to its resemblance to a rather desired feature of polypharmacology 
(modulation of multiple targets with one drug)450. Often therapeutic efficacy of drugs is 
linked to ability of the drugs to engage multiple targets451, however from hit selection or 




A study based on analysis of physiochemical properties of preclinical compounds linked 
higher occurrence of nonspecific toxicity via off target binding by promiscuous 
compounds with higher lipophilicity (logP >3) and lower total polar surface area (<75Å), 
a measure of polarity115. According to Silver, the promiscuously of the compounds is the 
one of the main reasons of failure of antibacterial drug discovery efforts beside lack of 
scaffold diversity26. While it is true for fragments to exhibit binding to multiple targets by 
virtue of their small size, the promiscuity of lead like compounds poses significant risk of 
nonspecific toxicity or off target effects. Therefore appropriate filters such as PAINs 
filters or filters for physiochemical properties descriptors should be incorporated at early 






The concentration of the screening collection has direct influence on observed hit 
rates with more nonspecific hits arising from artifacts of higher concentrations. The 
uneven concentration of ClpP screening collections was one of the biggest hurdles and 
required time consuming manual adjustments to match optimal screening concentration 
requirements per assay. The Hit rates for a given detection method vary from target to 
target depending on assaybility of the target, therefore a pilot screen using representative 
sets of compounds should be carried before actual primary screen, ideally at two different 
concentrations to determine non-specificity (or rather promiscuity) of hits as well as 
influence of concentration on hit rates. If necessary, the concentration of the screening 
collection should be lowered to ensure optimal hit rates. For example ClpP and cBak 
proteins were determined to be fit for TSA assay with structurally compact ClpP 
generating proper sigmoidal denaturation profiles and slightly disordered cBak protein 
with shallow denaturation profiles. The corresponding hit rate of a fragment collection (at 




Moving Forward-A Path for Hit to Lead Progression 
 
The Process of moving validated ClpP Hits to pharmacologically optimal leads 
would require balancing of multiple parameters such as affinity/potency, Kinetics, 
thermodynamics, lipophilicity, solubility, and key ADME properties. First it is imperative 
that the kinetics and thermodynamic aspects of binding of ligands are prioritized in 
addition to focusing on binding affinity or potency of the ligand to ClpP. The potency is a 
broad and complex matric with nonlinear intricate contributions from kinetic and 
thermodynamic forces and at atomic level the potency of ligand is linked to its overall 
free energy of binding286,452,446. Overall most of the leads have been reported to be 
enthalpically driven rather than with entropy, thus it is important to distinguish the 
thermodynamics of ligand binding which may become obscured if potency alone is 
considered as key driver of lead progression453,454. Therefore inclusion of 




progression453,454. Second, the thermodynamics of ligand binding has direct impact on 
kinetics of binding. It is well known that decrease in temperature also slows down the 
kinetics and vice versa. From kinetics standpoint the dissociation rate at a given 
temperature is of special significance as compounds with slower off rates (or longer 
residence time) have been suggested to be superior in terms of duration of their 
pharmacological effect420,455,456. It is entirely possible that two compounds with similar 
potency (KD= kd/ka) can have different association (ka) and dissociation rates (kd). Thus it 
is also important to combine kinetics with thermodynamics to get more accurate picture 
of ligand affinity. Third aspect of hit to lead expansion is to focus on ligand efficiency 
parameters (LE/LLE) as a sole potency driven lead optimization often leads to higher rate 
of attrition at later stages due to inevitable increase in molecular mass121,122. This is due to 
apparent increase in molecular complexity as a result of addition of functional groups to 
drive potency, upsets the balance of pharmacological properties, causing higher degree of 
attrition in lead candidates during clinical stages124. The concept of ligand efficiency 
normalizes the potency of the compounds against its molecular weight by suggesting 
change of potency on a log scale (10 fold) for the maximum change in free energy per 
non hydrogen atom120,116. Therefore for two compounds with same potency, the 
efficiency of compound with lower number of non- hydrogen atoms (i.e. lower molecular 
mass) would be higher and such compound should be prioritized for lead selection. 
Therefore keeping the molecular size of the leads in check is the right strategy to lead 
optimization. It is important to use the ligand efficiency as guiding criteria during lead 
optimization so to retain the optimal physical properties while improving potency. This 
can be achieved with help of structural information to identify key binding interactions 
during lead optimization process. 
 
 
Assay Implementation Strategy 
 
The successful implementation of such complementation strategy is based on 
assay throughput, susceptibility to artifacts, and information content. The observations 
from ClpP screening campaign can be directly translated to target other proteins of 
interest. For initial primary screening stage, implementation two completely different 
assays is a much better strategy than implementation of assays with similar mode of 
detection. For ClpP protein the combination of site specific (with label) FP assay with 
highly sensitive (label free) SPR binding assays was much more informative than FP and 
TSA (both labeled with lower detection limits) or TSA and SPR assays (both non site 
specific). Further all fluorophore labeled assays (FP, TSA, Enzymatic) are prone to 
artifacts from spectral interference to some extent, therefore implementation of label free, 
SPR or ITC assays is critical to complement the above limitation in addition to providing 
critical binding kinetics and thermodynamics data. On the same note, none of the above 
assays can provide structural information on binding mode of ligands therefore early 
implementation of X-ray crystallography is critical to success of hit to lead campaign. 
Lastly the test concentrations should to be adjusted according to type of collection and 
assay detection limits. For example the ClpP enzymatic assay was found to be of little use 
during primary screening as well as initial dose response testing of low affinity 




screening concentrations should be in high molar in contrast to SPR where test 
concentrations should be lower (due to high sensitivity). 
 
 
Prospects of Validated Hits 
 
A structural similarity search of primary screening ClpP hits indicated presence of 
multiple compounds with high structural (Tanimoto filter >0.8) similarity. In particular 
the compound 24 existed in multiple variants (i.e. compound 27, 28) and exhibited strong 
activity on FP and TSA assays. On label free SPR assay, compound 24 exhibits 
aggregator compound behavior with higher response than normal control while no 
activity was observed on enzymatic assay. At this stage it is possible that compound 24 is 
a false positive with potential spectral interference with fluorophores on FP and TSA 
assays. Other notable compounds with structural similarity are compound 2,6,14, and 19. 
Among the unique hits most of the compounds are fragments or are more lead/drug like, 
an aspect which highlights their potential for lead optimization while retaining desired 
pharmacological properties. 
 
As per the recent survey of approved drugs, most marketed antibacterial drugs are 
larger (MW in range of 400-700 Da), have lower cLogP values (more hydrophilic) and 
most do not follow the Lipinski guidelines strictly12. The ADEP series compounds also 
do not obey RO5 guidelines and consequently their pharmacological properties are poor, 
yet ADEPs are the most potent natural product activators of ClpP discovered so far. 
Further ClpP is a protein-protein interaction target from drug discovery stand point, with 
shallow binding pockets with large surface area for interactions with its natural partners. 
Therefore it may be asserted that to modulate ClpP activity, the initial ClpP lead 
compounds perhaps need to be larger in size or more complex than average lead 
compounds or fragments. 
 
The compound 23 is a bioactive compound with anti-inflammatory activity and 
compound 24 is a yet another bioactive compound with 5-HTS serotonin receptor 
antagonistic activity. The compound 29 is a potent epigenetic multi-pathway (HDAC, 
HER2 and EGFR) inhibitor whereas compound 31 (brand name Sorafenib), 32 and 35 are 
inhibitor of multiple kinases (BRAF, KIT, VEGFR-2, Rho) involved in oncogenic 
(angiogenesis) pathways. The identification of compounds with existing therapeutic 
applications, as ClpP binder (or Activator) is rather an unprecedented and potentially 
unique discovery. The identification and validation of compound 34 (generic name ICG-
001) a known ß-Catenin Wnt pathway inhibitor, as a ClpP activator presents a strong 
testimony to above observations. Initially identified during validation of FP assay 
(Chapter 4), compound 34 was found to activate ClpP in manner similar to ADEPs and 
was the lead compound for expansion of non peptidic small molecule series #2. The 
compound 34 generated a high resolution crystal structure with ClpP with an 
unprecedented binding pose mimicking ß-turn interactions of IGF-L loops of ClpP 
chaperons. At the time of writing, the antibacterial activity of above hits on gram 
positives, structural information on their binding pose within ClpP pockets and mode of 




represent a cache of novel scaffolds with measurable activity toward ClpP and hold 




Anticipated Challenges and Future Directions 
 
For above ClpP leads molecules to be able to effectively compete with natural 
ligands (ClpA/X chaperons) in vivo, their binding affinity would need to be increased on 
a log scale while maintaining key interactions as well as ligand efficiency. First the 
presence of multiple binding pockets on ClpP, along with allosteric and cooperative 
binding interactions, is quite a challenge toward achieving high potency of ligands. With 
key binding interactions spread over a large area, the targeting of ClpP binding pockets 
with efficacy would require the leads to be larger to efficiently mimic natural substrates 
which are often much larger proteins. Further to maintain oral bioavailability and to 
maintain low clearance it is important to lower the molecular weight of the leads and 
move away from peptidic core to avoid endogenous degradation or rapid metabolism of 
peptide bonds. Therefore key physicochemical properties of leads (size, lipophilicity, 
polar surface area etc.) would needs to be maintained while improving potency otherwise 
the risk of lead attrition would be high. In this light the small molecules or fragment 
based modulators represent an important alternative to resist rapid metabolism and 
clearance. In order to progress the ClpP leads must be efficient binders and should 
possess optimal physiochemical properties151. Among the desired pharmacological 
properties are smaller molecular size, optimal balance of solubility, permeability, 
hydrophobicity, and oral bioavailability. The reproducibility of oral bioavailability from 
animal models to humans is another issue which could be resolved to some extent with 
synthesis of inactive form (pro-drugs) of drugs to aid their solubility and permeability.  
From drug design prospective, the ideal ClpP modulators are non-covalent, reversible, 
and with non-competitive mode of action (kinetics), however, design of such modulators 
is quite challenging. 
 
The hits discovered in HTS or FBDD campaigns are mostly irreversible covalent 
binders which is contrary to desired reversible covalent inhibitors to reduce the risk of 
side effects during duration of therapy due to potential antigenicity of covalently 
modified proteins457,146,458,459. Further the competitor ligands require their effective doses 
to be higher than natural substrates , thus the risk of toxicity may become higher457. 
Therefore development of allosteric modulators may be a better approach however the 
achieving desired potency may be a significant challenge. Additionally another major 
hurdle is selectivity of ClpP modulators due to presence of close structural and functional 
homologs across the species. In absence of structural selectivity, the unwanted 
modulation (off target effects) of such homolog is a distinct possibility. However 
prevalence, cellular location, structural or functional similarity at molecular level and 
ease of access to human homologs by a potential antibiotic are important aspects which 
support discovery of antibiotics against bacterial targets with possibility a human 
homolog. Successful targeting of bacterial ribosomes by multiple antibiotics is one such 










In conclusion the combination of site specific ClpP FP assay with SPR assays 
serves as best approach to identify the potential ClpP binders from diverse collections 
including fragments. The route to increase the resolving power of current FP assay is via 
increase in ADEP core solubility and affinity of the FP probe to ClpP. Perhaps the best 
alternative is to move away from ADEP core to an alternative far red shifted (emission 
wavelength >600nm) ClpP probe with high binding affinity (in nM range). The label free 
nature of SPR can be of great use in accurate quantification of binding affinity of such FP 
probes to ClpP. The thermal shift assay can be used as third orthogonal method to 
validate hits from primary or secondary screens. Further the TSA can save both time and 
resources by Identification of best screening conditions as well to identification of 
compounds with issues such as high fluorescence, aggregation and destabilization 
potential prior to large scale screening. The best utility of enzymatic assays is toward 
functionality (ClpP % activation) based ranking of lead compounds with high binding 
affinity compared to low affinity compounds where ClpP enzymatic assay was observed 
to have limited utility due partial enzymatic activity of such ClpP binders (i.e. fragments). 
Additionally the higher resolution power of SPR assays is instrumental toward further 
improving ranking of high affinity ClpP binders based on their off rates or residence 
time. The combination of enzymatic assay and SPR assays is best toward determination 
of selectivity of ClpP binders against human homolog hClpP. 
 
Finally the cross validation of compounds from large and small molecules series 
highlights the best compounds with higher potential toward improvement of in-vivo 
efficacy and pharmacological profiles compared to parent ADEP4 . The identification of 
ICG-001 and its development into more potent analogs with antibacterial activity is an 
important step toward identification of alternative non-peptidic small molecules based 
ClpP activators. Further the structural information generated from crystallography studies 
on above molecules is instrumental toward improvement of guiding ongoing SAR studies 
of ADEP analogs. At final hit rate of 0.13% the identification of 35 new chemical entities 
with cross validated ClpP activity represents cache of novel scaffolds for exploratory 
studies on ClpP binding sites. Depending on outcome of ongoing X-ray crystallography, 
pharmacological profiling, antibacterial activity and in vivo efficacy studies, at least 2-3 
leads with high in-vitro activity and ligand efficiency are expected to become the 
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Figure A-1. Experimental Scheme of Thermal Shift Assay. 
The thermal shift assay can be configured in ligand screening (blue lines) and hit 
validation (orange lines) format. The raw data is processed through data fitting 








Figure A-2. Experimental Scheme of ClpP Enzymatic Assay. 
To the master mix 1 at room temperature ,test compounds (blue lines) and controls 
(orange lines) are pin transferred before addition of master mix 2 (kept at 4 degree) ti 
initiate the digestion of BODIPY-FL labeled ß-casein. The raw data is processed through 











Figure B-1. Experimental Scheme of ClpP Fluorescence Polarization Assay. 
To the master mix containing probe and protein is incubated at room temperature for 1 
hour and test compounds (blue lines) and controls (orange lines) are pin transferred, 
followed by 2 hours of incubation at room temperature conditions. The raw data is 








Figure B-2. Structures of FP Probe 1-6 and Positive Controls. 
A to F: Chemical structures of FP probe 1-6. 
G: Chemical Structures of ADEP4 analogs (19-26), Small molecule controls (27, 28), 






Table B-1. Displacement Potency and Enzymatic Activity Data on FP Probes, 
Controls and Hit Compound. 
 
Compound # FP-IC50±SEM (µM) ß-Casein-EC50±SEM 
(µM) 
Probe 1 16.2±1.8 -- 
Probe 2 79.1±18.9 -- 
Probe 3 116.6±11.5 -- 
Probe 4 124.02±14.2 -- 
Probe 5 226.2±9.7 -- 
Probe 6 3.8±0.1 -- 
19 0.0±0.0 0.0±0.0 
20 >200±0.0 >200±0.0 
21 0.0±0.0 0.0±0.0 
22 0.0±0.0 0.0±0.0 
23 13.9±0.4 3.1±0.2 
24 >200±0.0 >200±0.0 
25 10.6±0.5 1.7±0.2 
26 6.4±0.3 0.5±0.0 
ADEP4 5.9±0.3 0.3±0.0 
7 8.5±0.3 2.4±0.2 








Figure B-3. Estimation of Isothermal Titration Calorimetery (ITC)-Based Binding 
Affinity and Enzymatic Assay-Based ClpP Activation Potential of Probe 6, 
Compound 7 and ADEP4. 
A: ITC-based estimation of Probe 6 binding affinity to ClpP. 
B: ITC-based estimation of Compound 7 binding affinity to ClpP. 
C: ITC-based estimation of ADEP4 binding affinity to ClpP. 
D: Loss of Enzymatic Activity of Compound 7 (red) compared to ADEP4 (Blue). 
E: Activation of ClpP by Probe 6 in manner similar to Compound 7 and ADEP4 in gel 








Figure B-4. Assessment of Probe 6 (2591) Displacement Potency by Positive 
Control Compound 7 (2378), and ADEP4 (1999); Correlation of FP Assay to 
Enzymatic Assay; and Assessment of Probe 6 Performance under High Throughput 
Screening Conditions. 
A: Estimation of miniaturization potential of FP assay via Probe 6 displacement by 
positive controls under different volumes. 
B: Robust correlation of ClpP FP assay to ClpP enzymatic assay. 
C: Estimation of compound 7 displacement potency compared to negative control 
(DMSO) in high throughput screening format. 








Figure B-5. Assessment of Probe 6 Reproducibility, and Day-to-Day/Plate-to-Plate 
Performance under High Throughput Conditions. 
A: Estimation of signal window, Z score, Signal to background /noise ratio of 
miniaturized FP assay. 
B: Robust performance of FP assay from day to day/ plate to plate basis. 
C: Estimation of compound 7 displacement potency compared to negative control during 
screening of bioactive collection. 











Figure C-1. Experimental Scheme of ClpP Surface Plasmon Resonance (SPR) 
Assay. 
The sensor chip is conditioned and normalized to 100% DMSO response following its 
selection based on suitable attachment chemistry. The test compounds, controls are hand 
prepared in 1.0X buffer to match the DMSO % of running buffer. The binding response 
of test compounds are measured by injecting the compounds using variety of injection 








Figure C-2. Conditioning and Hydration of Sensor Chips. 
A: Dip response of freshly installed sensor Chip prior (1) to conditioning; during DMSO 
normalization (2); after DMSO normalization (3); after ligand immobilization (4). 
B: Sensor response from buffer injections on channel 1 (red) prior to hydration 
procedure. 
C: Sensor response from buffer injections on channel 1 (red) after hydration procedure. 








Figure C-3. High Throughput Screening Requirements on SPR Assay. 
A: Theoretical immobilization levels for fragments based on desired maximum response 
(Rmax). 
B: Theoretical immobilization levels for ligands based on desired Rmax of 100 RU. 
C: Scattered plot of uneven stock concentrations in a typical fragment collection. 
D: Desired range (100-150µM) of screening concentration for optimal fragment 
response. 
E-G: Structure of fragment (3027), small molecule (2795) and large molecule (2378) 








Figure C-4. Typical Fragment Screening Issues on SPR Assay. 
A: Optimum response of fragments (grey), fragment control (green) and functionality 
control (blue). 
B: Optimum response on scatter plot from fragments screen (multicolored), fragment 
control (3027) and functionality control (2378). 
C: Binding response on scatter plot from fragments screen with nonspecific fragments, 
suboptimum fragment control (3027) and functionality control (2378). 
D: Uneven response of fragments (grey) with carry over and DMSO mismatch issues. 
E: Problematic responses on scatter plot from fragments screen (multicolored) with sever 
DMSO mismatch issues, diminished fragment control (green) response. 
F: Binding response on scatter plot from fragments screen with sticky fragments severely 
reducing functionality of ClpP as seen by diminished response from fragment control 





APPENDIX D. CHAPTER 5 SUPPLEMENTAL FIGURES AND TABLES 
 
 
Table D-1. Results of Thermal Shift and SPR Screening of Virtual Collection of 
95 Compounds. 
 
Compound # ClpP Tm±SEM 
(oC) 




1 45.4±0.1 0.1 0.2 
2 45.0±0.1 -0.2 1.4 
3 45.3±0.1 0.1 3.8 
4 45.0±0.1 -0.2 2.7 
5 45.2±0.1 0.0 5.6 
6 43.6±0.2 -1.6 3.4 
7 44.5±0.1 -0.8 -12.1 
8 45.3±0.1 0.1 1.6 
9 45.1±0.1 -0.1 2.7 
10 44.8±0.1 -0.4 -0.0 
11 44.7±0.1 -0.6 0.5 
12 45.2±0.1 0.0 2.6 
13 45.3±0.1 0.0 2.2 
14 45.3±0.1 0.1 3.07 
15 44.7±0.1 -0.5 -11.8 
16 44.6±0.1 -0.7 -3.8 
17 45.0±0.1 -0.3 1.6 
18 44.7±0.1 -0.5 2.5 
19 44.6±0.1 -0.6 5.2 
20 45.7±0.2 0.5 22.0 
21 59.6±0.1 14.4 2.4 
22 44.9±0.1 -0.4 -2.8 
23 44.4±0.1 -0.8 -5.4 
24 58.5±0.1 13.2 -3.4 
25 44.8±0.1 -0.4 -6.5 
26 44.8±0.1 -0.4 4.1 
27 44.7±0.1 -0.5 1.7 
29 44.9±0.3 -0.3 6.0 
30 44.5±0.1 -0.7 3.9 
31 44.8±0.1 -0.5 0.4 
32 44.7±0.1 -0.5 -10.4 






Table D-1. (Continued). 
 
Compound # ClpP Tm±SEM 
(oC) 
ClpP ∆ Tm (oC) SPR Response 
(RU) 
34 44.9±0.1 -0.3 5.9 
35 44.5±0.1 -0.8 3.1 
36 44.5±0.1 -0.7 4.4 
37 44.6±0.1 -0.6 5.0 
38 44.5±0.1 -0.7 3.5 
39 44.6±0.1 -0.6 -33.7 
40 42.8±0.2 -2.4 -10.9 
41 44.1±0.1 -1.1 -0.6 
42 0.0±0.0 0.0 4.5 
43 44.9±0.1 -0.3 2.3 
44 43.8±0.1 -1.5 3.2 
45 0.0±0.0 0.0 0.2 
46 44.6±0.1 -0.7 3.8 
47 45.0±0.1 -0.3 -0.3 
48 44.7±0.1 -0.5 -9.8 
49 44.5±0.1 -0.7 -4.3 
50 44.5±0.1 -0.7 0.7 
51 44.8±0.1 -0.4 0.0 
52 46.1±0.1 0.8 0.0 
53 45.0±0.1 -0.2 3.7 
54 45.2±0.1 0.0 -0.7 
55 0.0±0.0 0.0 0.0 
56 44.1±0.1 -1.1 0.0 
57 45.6±0.1 0.4 -1.9 
58 45.1±0.1 -0.1 -1.2 
59 43.8±0.1 -1.5 -12.5 
60 44.9±0.1 -0.3 0.2 
61 45.0±0.1 -0.2 -1.2 
62 45.2±0.1 0.0 -2.9 
63 44.6±0.1 -0.7 -1.5 
64 44.7±0.1 -0.5 -1.3 
65 44.7±0.1 -0.5 -1.2 
66 44.6±0.1 -0.6 2.6 
67 44.9±0.1 -0.4 -30.6 
68 43.1±0.1 -2.1 -3.1 
69 44.7±0.1 -0.5 0.7 
70 44.2±0.1 -1.0 1.3 
71 44.0±0.1 -1.2 3.3 






Table D-1. (Continued). 
 
Compound # ClpP Tm±SEM 
(oC) 
ClpP ∆ Tm (oC) SPR Response 
(RU) 
73 44.8±0.1 -0.5 2.1 
74 45.1±0.1 -0.2 0.4 
75 45.0±0.1 -0.3 -11.4 
76 44.4±0.1 -0.8 0.0 
77 44.1±0.1 -1.1 -0.2 
78 44.2±0.1 -1.0 5.7 
79 44.1±0.1 -1.1 0.0 
80 48.4±0.1 3.1 0.0 
81 44.0±0.1 -1.2 -6.0 
82 44.3±0.1 -0.9 2.7 
83 44.9±0.1 -0.3 -0.2 
84 44.5±0.1 -0.7 1.0 
85 44.9±0.1 -0.3 -0.5 
86 44.6±0.1 -0.6 -9.1 
87 44.8±0.1 -0.4 -1.6 
88 44.7±0.1 -0.5 -2.3 
89 44.7±0.1 -0.4 -1.2 
90 44.9±0.1 -0.2 5.8 
91 45.1±0.1 -0.1 -0.1 
92 45.1±0.1 -0.1 1.1 
93 45.1±0.1 -0.1 0.3 
94 45.1±0.1 -0.1 -14.1 








































2163 1 0.5 3.3 250.0±0.0 113.9±6.3 0.0±0.0 250.0±0.0 60.4±1.6 163.8±7.6 244.9±0.0 
2164 1 2.8 13.0 161.5±10.3 8.9±0.6 22.6±1.1 228.4±22.4 88.6±3.8 5.8±0.6 430.9±0.2 
2165 1 0.8 0.2 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2166 1 0.1 9.0 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2167 1 0.0 1.7 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2168 1 0.0 1.0 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2169 1 0.4 0.4 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2316 1 0.2 0.5 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2317 1 0.1 0.2 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2318 1 0.0 0.0 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2332 1 0.0 0.0 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2426 1 0.0 1.7 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 381.4±0.1 
2427 1 0.0 12.1 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 536.9±0.4 
2481 1 0.0 12.1 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2482 1 0.0 12.1 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2565 1 8.1 21.4 140.9±5.1 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 337.9±0.1 
2566 1 12.0 2.9 23.1±1.2 100.6±4.5 0.0±0.0 250.0±0.0 78.0±3.1 2.3±0.6 631.3±0.3 








































2599 1 3.5 14.2 12.6±1.8 30.9±4.2 41.7±1.6 29.6±2.5 80.2±1.5 0.7±0.0 138.9±0.0 
2600 1 3.8 8.7 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 82.8±1.9 62.3±1.9 399.4±0.1 
2601 1 1.1 2.9 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 1323.0±0.0 
2602 1 14.7 19.9 22.8±1.8 0.0±0.0 34.8±0.7 75.9±2.9 79.5±2.6 3.7±0 128.9±0.0 
2603 1 16.7 20.1 15.4±1.1 0.0±0.0 32.9±1.3 54.7±4.4 82.7±1.3 2.9±0.1 43.9±0.0 
2618 1 1.3 0.4 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2619 1 2.0 0.2 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2621 1 1.5 12.1 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 29.1±1.1 150.0±10.5 519.7±0.2 
2622 1 5.4 0.0 250.0±0.0 0.0±0.0 15.5±1.2 104.53±1 102.5±3.7 3.9±0.3 296.6±0.1 
2623 1 13.8 0.0 32.4±4.0 0.0±0.0 37.9±1.8 37.7±3.6 106.6±2.2 2.3±0.1 119.5±0.0 
2624 1 3.0 13.6 500.0±0.0 34.8±1.7 0.0±0.0 250.0±0.0 95.7±3.1 19.7±1.2 1717.0±0.0 
2625 1 0.0 0.6 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2626 1 0.0 0.4 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2627 1 0.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2628 1 0.0 0.7 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2629 1 0.1 0.8 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2630 1 0.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 








































2656 1 0.0 0.9 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2657 1 0.0 0.2 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2669 1 0.2 0.2 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 1803.4±0.0 
2670 1 0.0 11.6 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 1363±0.0 
2671 1 0.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 223.7±0.0 
2672 1 0.0 2.1 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2701 1 1.7 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 74.8±3.9 44.8±4.3 607.7±0.4 
2702 1 0.5 3.7 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 68.8±2.5 83.3±5.7 1378.8±0.0 
2703 1 0.6 3.2 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 58.7±3.2 50.2±4.5 1349.6±0.0 
2705 1 1.0 1.3 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 69.7±3.9 76.7±8.0 992.6±0.8 
2706 1 2.2 1.1 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 66.7±4.4 93.1±10.0 861.2±0.5 
2707 1 0.5 0.9 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2708 1 0.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2709 1 0.0 1.5 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2710 1 0.0 12.1 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 66.1±3.7 7.5±0.0 341.4±0.1 
2711 1 0.0 7.9 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 53.2±2.2 70.5±4.8 795.3±0.2 
2720 1 0.4 2.9 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 35.1±2.3 102.4±9.9 1148.8±0.0 








































2723 1 1.1 14.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 76.9±2.0 31.3±0.9 666.2±0.2 
2757 1 6.5 12.1 47.2±3.8 20.7±0.6 22.9±1.9 96.9±11.8 83.5±3.9 3.7±0.3 326.9±0.1 
2758 1 7.8 15.9 36.5±1.0 11.4±0.7 27.6±2.7 95.7±17.9 78.0±3.1 2.3±0.6 181.3±0.0 
2759 1 1.7 12.1 121.9±3.0 19.7±1.5 0.0±0.0 250.0±0.0 88.4±3.7 9.8±0.7 530.2±0.2 
2760 1 3.3 13.4 247±15.3 6.1±0.3 0.0±0.0 250.0±0.0 85.9±2.8 2.7±0.2 740.1±0.4 
2794 1 0.2 20.2 77.4±3.1 0.0±0.0 32.8±2.4 84.9±16.8 115.6±1.6 1.0±0.0 627.1±0.2 
2758 1 7.8 15.9 36.5±1.0 11.4±0.7 27.7±2.7 95.7±17.9 78.0±3.1 2.3±0.6 181.3±0.0 
2759 1 1.7 12.1 121.9±3.0 19.7±1.5 0.0±0.0 250.0±0.0 88.4±3.7 9.8±0.7 530.2±0.2 
2760 1 3.3 13.4 247±15.3 6.1±0.3 0.0±0.0 250.0±0.0 85.9±2.8 2.7±0.2 740.1±0.4 
2794 1 0.2 20.2 77.4±3.1 0.0±0.0 32.8±2.4 84.8±16.8 115.6±1.6 0.9±0.0 627.1±0.2 
2795 1 6.0 18.4 21.1±1.9 7.2±0.67 50.9±2.1 7.1±0.8 92.4±3.1 0.9±16.9 21.9±0.0 
2796 1 0.5 0.0 6.2±0.5 5.8±0.5 51.3±1.6 9.1±0.7 85.9±2.6 0.7±0.1 27.4±0.1 
2797 1 0.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 74.7±1.16 4.4±0.1 310.2±0.1 
2805 1 0.0 5.2 20.9±0.8 5.7±0.63 35.6±1.2 40.2±2.6 91.9±1.9 0.5±0.0 148.1±0.0 
2806 1 0.0 12.1 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2815 1 4.7 0.0 500.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 109±4.1 1.3±0.1 0.0±0.0 








































2821 1 0.0 5.6 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 1010.6±0.0 
2822 1 2.6 9.8 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 692.9±0.4 
2830 1 0.0 0.0 27.4±1.2 0.0±0.0 39.8±1.2 14.7±0.9 63.6±1.7 0.5±0 61.0±0.0 
2831 1 7.6 14.9 26.5±1.2 4.6±0.49 36.9±0.9 8.9±0.5 68.7±1.1 0.3±0.0 86.9±0.0 
2832 1 4.1 0.0 26.0±1.4 9.9±0.5 36.4±1.4 48.1±3.9 66.8±2.3 0.8±0.1 197.2±0.1 
2856 1 5.1 12.1 183.4±44.5 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 262.1±0.1 
2857 1 0.0 1.1 158.7±20.4 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2860 1 0.0 12.1 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2861 1 0.0 1.7 250.0±0.0 12.1±0.6 0.0±0.0 250.0±0.0 60.0±2.7 3.7±0.5 1072.7±0.0 
2878 1 1.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2879 1 3.9 12.1 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 1016.3±0.0 
2880 1 4.2 12.1 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2881 1 15.1 20.2 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 32.9±0.0 
2882 1 13.5 21.0 50.9±2.4 7.5±0.4 35.1±1.9 52.1±6.2 82.6±2.2 2.1±0.1 115.4±0.0 
2883 1 12.8 21.2 97.7±7.5 21.5±2.1 35.9±0.5 48.2±1.2 107.9±5.9 3.1±0.4 252.2±0.1 
2884 1 13.9 18.7 54.4±2.9 28.7±1.5 23.4±0.7 61.8±3.7 84.4±2.7 5.9±0.3 111.8±0.0 








































2908 1 0.0 0.6 250.0±0.0 500.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2909 1 0.0 0.0 250.0±0.0 500.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2915 1 0.0 5.2 250.0±0.0 44.5±13 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2923 1 0.2 8.6 250.0±0.0 500.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2924 1 0.0 5.1 250.0±0.0 63.9±6.4 0.0±0.0 250.0±0.0 89.1±2.2 36.2±1.6 0.0±0.0 
2925 1 4.4 17.6 250.0±0.0 170.3±12.1 0.0±0.0 250.0±0.0 76.9±1.7 101±3.5 236.9±0.0 
2929 1 0.0 15.4 250.0±0.0 29.6±2.17 0.0±0.0 250.0±0.0 79.7±0.7 3.5±0.0 245.1±0.0 
2930 1 0.0 0.0 500.0±0.0 10.2±0.4 0.0±0.0 250.0±0.0 104.5±2.6 5.7±0.2 55.3±0.0 
2931 1 8.3 12.1 500.0±0.0 8.5±0.7 0.0±0.0 250.0±0.0 108.9±1.9 4.2±0.1 155.6±0.0 
2932 1 6.6 15.9 166.5±9.1 26.1±2.1 16.8±1.3 85.9±12.5 96.8±4.4 8.1±0.6 233.0±0.1 
2933 1 0.0 0.0 247.6±23.6 17.6±1.0 12.5±0.7 109.2±9.4 84.0±4.5 11.9±1.4 0.0±0.0 
2934 1 0.0 12.1 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2935 1 0.0 0.0 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
2947 1 0.0 15.2 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 192.6±0.1 
2948 1 0.0 14.0 192.8±43.5 8.7±0.3 0.0±0.0 250.0±0.0 67.2±0.6 1.72±0.0 200.1±0.0 
2949 1 0.0 11.7 116±19.5 10.7±0.4 0.0±0.0 250.0±0.0 71.5±3.5 3.1±0.3 268.2±0.1 








































2951 1 0.0 0.0 74.4±13.5 7.7±0.4 13.0±0.5 59.3±3.6 75.8±1.8 1.9±0.1 99.8±0.0 
2952 1 0.0 4.3 102.1±20.2 8.0±0.5 12.1±0.6 61.9±5.5 78.9±1.7 2±0.1 0.0±0.0 
2974 1 13.7 18.9 250.0±0.0 28.9±3.2 0.0±0.0 250.0±0.0 70.4±0.6 4.95±0.1 67.2±0.0 
2975 1 6.8 17.6 110±5.3 17.7±1.3 27.8±1.0 119.5±4.9 97.6±3.3 7.3±0.4 187.8±0.1 
2976 1 5.2 14.7 155.4±10.1 14.2±1.0 20.8±2.8 64.0±16.4 77.8±1.2 3.3±0.1 220.4±0.1 
2977 1 4.2 13.9 180.1±13.1 12.9±1.0 0.0±0.0 250.0±0.0 92.4±1.6 3.7±0.1 227.3±0.1 
2978 1 7.8 14.8 166.7±11.7 13.1±0.9 35.2±4.1 122.6±5 93.7±2.3 3.9±0.2 135.3±0.0 
2979 1 7.6 14.4 121.1±6.3 13.7±0.9 27.3±1.5 121.6±7.9 76.2±3.1 3.5±0.3 170.5±0.0 
2980 1 8.9 19.4 112.8±5.3 20.3±1.4 30.5±1.3 118.1±6.8 91.9±2.7 7.2±0.4 264.0±0.1 
2994 1 4.8 11.5 41.2±1.3 3.2±0.2 42.8±3.9 13.5±4.0 92.9±2.4 1.8±0.1 0.0±0.0 
3017 1 1.0 0.0 49.5±3.5 7.7±0.2 24.6±0.7 44.4±2.9 81.3±5.7 0.2±0.0 0.0±0.0 
3018 1 0.0 0.0 128.3±6.2 6.6±0.5 40.9±1.2 90.0±5.8 127.8±2.9 0.8±0.0 1025±0.0 
3019 1 2.6 12.7 250.0±0.0 10.6±0.8 0.0±0.0 250.0±0.0 101.5±2.7 1.7±0.1 1811±0.0 
3020 1 0.0 0.0 127±7.1 6.6±0.4 20.8±0.4 84.2±2.8 79.4±2.6 0.2±0.0 400.6±0.1 
3027 1 0.0 0.0 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3037 1 0.0 0.3 250.0±0.0 34.3±1.5 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 








































3039 1 0.0 0.0 250.0±0.0 42.7±4.2 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3040 1 0.0 0.2 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3041 1 0.0 12.1 250.0±0.0 142.8±20.5 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3042 1 0.1 1.0 250.0±0.0 106.7±28.7 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3068 1 0.0 0.0 250.0±0.0 11.7±0.7 0.0±0.0 250.0±0.0 74.6±0.6 3.1±0.0 0.0±0.0 
3069 1 0.0 1.5 250.0±0.0 12.0±0.2 0.0±0.0 250.0±0.0 83.4±3.1 2.5±0.2 0.0±0.0 
3070 1 0.0 0.9 250.0±0.0 11.2±0.4 0.0±0.0 250.0±0.0 88.9±4.0 1.8±0.1 0.0±0.0 
3071 1 0.0 0.6 250.0±0.0 500.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3072 1 0.0 0.2 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 1360.8±0.0 
3073 1 0.0 0.1 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 2542.0±0.0 
3074 1 0.0 12.1 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3076 1 0.3 0.0 250.0±0.0 250.0±0.0 26.2±2.2 131.3±15.2 0.0±0.0 250.0±0.0 0.0±0.0 
3078 1 0.0 0.3 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3079 1 0.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3080 1 0.0 0.2 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3081 1 0.0 0.5 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 








































3083 1 0.0 0.2 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3084 1 0.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3085 1 0.0 12.1 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3086 1 0.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3087 1 0.0 0.0 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3104 1 0.0 0.0 250.0±0.0 250.0±0.0 18.1±0.8 135.2±15.7 0.0±0.0 250.0±0.0 0.0±0.0 
3105 1 0.0 0.0 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3106 1 0.0 0.0 250.0±0.0 250.0±0.0 24.7±0.8 166.4±13.7 0.0±0.0 250.0±0.0 0.0±0.0 
3107 1 0.2 0.0 250.0±0.0 250.0±0.0 45.5±1.5 217.1±15.8 0.0±0.0 250.0±0.0 0.0±0.0 
3108 1 0.0 0.5 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3109 1 0.0 0.0 250.0±0.0 250.0±0.0 29.3±2.2 122.6±19.1 0.0±0.0 250.0±0.0 0.0±0.0 
3110 1 0.0 12.1 250.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 
3162 1 5.6 15.6 250.0±0.0 0.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 250.0±0.0 81.2±0.0 
3378 1 5.6 15.6 38.5±3.5 3.2±0.3 37.9±1.9 39.8±4.9 53.1±2.6 0.5±0.1 37.1±0.0 
3379 1 2.6 9.6 30.6±1.6 3.5±0.3 26.5±1.1 33.8±3.0 54.3±2.4 0.5±0.0 48.1±0.0 
3380 1 2.1 7.6 82.4±3.1 5.3±0.3 32.2±5.8 179.7±60.1 58.9±2.8 2.2±0.1 159.1±0.0 








































3076 1 0.3 0.0 250.0±0.0 250.0±0.0 26.2±2.2 131.3±15.2 0.0±0.0 250.0±0.0 0.0±0.0 
3454 2 9.8 7.6 27.3±3.2 7.1±0.8 50.44±3.05 3.4±0.7 0.0±0.0 200.0±0.0 3.8±0.0 
3455 2 3.0 4.5 43.5±2.6 17.4±1.8 0.0±0.0 200.0±0.0 20±0.6 14.0±0.9 0.0±0.0 
3456 2 12.1 5.9 49.1±3.5 14.5±3.3 0.0±0.0 200.0±0.0 36.1±1.9 17.0±2.5 595.6±0.0 
3457 2 6.4 2.4 60.2±10.5 27.4±3.9 0.0±0.0 200.0±0.0 64.3±1.7 4.0±0.3 9.2±0.0 
3459 2 11.8 7.1 200.0±0.0 14.2±0.9 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 2.9±0.0 
3460 2 0.7 1.0 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 
3461 2 1.0 1.8 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 540.9±0.0 
3469 2 8.7 4.3 23.2±1.1 21.9±1.6 57.6±2.6 8.7±0.9 88.5±2.2 19.1±0.9 5.3±0.0 
3470 2 8.1 3.5 25.1±1.6 27.9±1.7 49.1±2.5 7.0±1.0 60.6±2.7 26.9±3.6 11.1±0.0 
3471 2 13.8 9.3 8.5±0.3 8.1±1.1 65.8±1.5 2.6±0.2 104.6±0.8 8.3±0.1 1.2±0.0 
3472 2 4.6 9.6 67.8±6.4 16.2±1.7 69.6±3.2 14.2±1.5 96.3±4.2 9.4±0.7 106.9±0.0 
3477 2 0.1 5.6 200.0±0.0 44.4±3.3 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 422.4±0.0 
3478 2 0.0 12.1 200.0±0.0 22.7±1.8 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 474.1±0.0 
3479 2 0.0 1.2 200.0±0.0 27.4±1.6 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 772.4±0.0 
3480 2 0.0 0.3 200.0±0.0 137.2±11.8 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 682.4±0.0 








































3492 2 0.1 0.0 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 873.3±0.0 
3493 2 0.4 0.5 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 360.7±0.0 
3494 2 0.0 0.4 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 654.54±0.0 
3496 2 2.7 0.2 135.3±24.2 161.8±21.3 46.3±3.4 7.6±1.6 0.0±0.0 200.0±0.0 12.2±0.0 
3497 2 2.7 0.0 15.4±0.8 44.4±2.4 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 57.8±0.0 
3498 2 9.4 1.6 43.2±2.4 56.8±2.9 60.9±1.9 5.3±0.6 0.0±0.0 200.0±0.0 13.4±0.0 
3499 2 14.6 8.2 200.0±0.0 200.0±0.0 60.2±3.1 14.5±2.2 80.4±5.9 62.6±9.2 0.0±0.0 
3506 2 0.0 0.0 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 186.6±0.0 
3507 2 0.2 0.7 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 249.3±0.0 
3508 2 0.2 1.2 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 221.4±0.0 
3515 2 16.7 11.9 19.9±1.5 25.5±1.3 57.0±1.7 9.2±0.7 78.1±2.3 25.8±1.4 27.2±0.0 
3516 2 13.6 12.1 10.1±0.6 10.1±0.5 53.4±1.3 1.9±0.2 85.0±3.6 8.7±0.8 22.2±0.0 
3517 2 18.5 7.7 19.1±1.1 71.0±2.9 63.9±3.8 5.9±1.1 0.0±0.0 200.0±0.0 41.6±0.1 
3518 2 16.0 4.2 42.1±2.2 169.3±6.5 63.7±3.4 15.5±2.5 0.0±0.0 200.0±0.0 41.8±0.0 
3519 2 16.0 9.0 18.7±0.7 32.9±2.2 59.4±3.1 7.8±1.2 77.0±5.1 31.6±4.9 22.3±0.4 
3520 2 20.3 13.6 17.9±0.8 25.4±1.1 59.0±1.2 4.2±0.3 91.1±7.9 24.2±4.5 12.9±0.0 








































3522 2 15.0 3.7 51.7±1.6 200.0±0.0 63.0±2.6 18.5±2.5 0.0±0.0 200.0±0.0 51.6±0.2 
3525 2 0.8 0.3 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 86.5±0.0 
3526 2 0.3 0.0 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 236.2±0.0 
3530 2 10.2 2.6 13.8±0.5 30.6±1.4 61.4±2.6 3.9±0.4 0.0±0.0 200.0±0.0 2.9±0.0 











































1999 25.4 13.2 5.6±0.3 4.2±0.1 100.1±5.2 0.3±0.1 100.1±2.5 0.4±0.03 1.56E+05 6.62E-03 0.04±0.7 
2378 12.3 0.0 7.1±0.4 28.2±1.9 89.9±3.9 5.9±0.8 72.2±2.3 141.9±6.2 1.65E+05 5.13E-01 3.1±0.02 
2420 10.3 0.1 8.6±0.4 7.6±0.3 55.8±1.6 4.4±0.3 59.2±2.1 12.4±0.67 2.64E+05 8.12E-01 3.1±0.0 
2421 0.9 0.0 250.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2428 17.4 1.4 6.2±0.4 4.3±0.1 66.0±1.1 1.2±0.1 53.2±2.4 20.8±1.68 1.56E+05 2.49E-01 1.6±0.0 
2476 0.0 0.0 0.0±0.0 0.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2477 3.8 3.1 22.6±1.1 8.8±0.6 0.0±0.0 200.0±0.0 96±3.9 0.9±0.11 0.0±0.0 0.0±0.0 0.0±0.0 
2540 23.1 4.9 7.7±0.3 9.1±0.8 86.6±1.4 0.6±0.0 85.1±0.9 1±0.02 5.00E+03 1.33E-03 0.27±2.0 
2541 21.3 3.0 9.2±0.5 2.3±0.1 72.3±1.8 1.5±0.1 71.8±1.5 9.4±0.32 0.0±0.0 0.0±0.0 0.0±0.0 
2542 4.8 0.6 27.6±2.5 0.0±0.0 83.9±1.3 5.4±0.2 82.2±0.8 10.2±0.14 0.0±0.0 0.0±0.0 0.0±0.0 
2543 23.4 8.7 32.3±2.1 2.4±0.2 75.4±1.9 1.5±0.1 88.3±0.6 2±0.03 0.0±0.0 0.0±0.0 0.0±0.0 
2544 20.7 3.7 27.4±1.7 2.7±0.2 73.2±1.8 0.8±0.1 84.8±1.9 2.4±0.12 0.0±0.0 0.0±0.0 0.0±0.0 
2545 10.6 0.0 129.0±11.3 0.0±0.0 76.1±1.4 1.6±0.1 27.4±1 12.6±0.61 0.0±0.0 0.0±0.0 0.0±0.0 
2546 20.2 1.8 16.3±0.8 2.4±0.1 59.2±0.9 1.3±0.1 74±3.4 11.5±0.8 1.26E+05 5.55E-02 0.44±0.0 
2547 18.9 1.4 25.3±2.2 2.5±0.1 61.1±1.2 1.0±0.1 52.8±2 7.7±0.5 0.0±0.0 0.0±0.0 0.0±0.0 
2556 2.3 0.1 11.6±0.8 0.0±0.0 71.8±0.8 0.9±0.0 70±0.9 3.4±0.06 0.0±0.0 0.0±0.0 0.0±0.0 
2557 16.2 1.8 4.5±0.3 3.0±0.3 73.3±0.9 1.0±0.0 83.8±1.8 2.7±0.09 0.0±0.0 0.0±0.0 0.0±0.0 











































2559 9.6 0.0 7.1±0.5 40.1±1.1 64.6±3.5 5.3±0.9 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2610 2.2 13.2 17.0±1.4 78.7±14.4 47.2±0.8 17.1±0.7 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2612 16.7 1.9 5.0±0.4 17.4±1.3 83.3±2.8 1.3±0.2 92.6±3.7 2.3±0.21 0.0±0.0 0.0±0.0 0.0±0.0 
2613 9.1 0.0 11.5±0.9 5.7±0.3 94.0±18.9 13.0±10.2 100.6±10.9 32.2±6.51 0.0±0.0 0.0±0.0 0.0±0.0 
2614 8.6 0.0 45.9±2.9 11.3±0.3 83.4±0.7 1.0±0.0 69.5±2 3.5±0.13 0.0±0.0 0.0±0.0 0.0±0.0 
2615 0.8 0.0 36.5±3.3 250.0±0.0 68.0±3.9 49.1±4.7 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2635 0.7 0.0 11.1±0.5 61.9±2.6 73.6±1.8 1.7±0.2 61.6±1.6 30.3±1.46 0.0±0.0 0.0±0.0 0.0±0.0 
2639 19.3 5.8 12.7±1.0 4.5±0.3 70.8±1.8 0.4±0.0 83.2±1.8 0.4±0.03 0.0±0.0 0.0±0.0 0.0±0.0 
2640 19.8 1.4 8.0±0.4 11.4±0.4 61.5±1.8 1.3±0.1 74±2 9.3±0.56 2.91E+05 9.50E-02 0.3±0.0 
2641 7.6 0.5 7.1±0.3 5.5±0.2 101.0±1.7 0.4±0.0 84.8±3.6 2.4±0.18 3.42E+03 7.48E-03 2.19±0.01 
2642 21.1 3.7 8.0±0.6 1.8±0.1 67.2±4.7 0.2±0.2 90.7±3.3 2.3±0.31 0.0±0.0 0.0±0.0 0.0±0.0 
2643 16.5 0.9 3.3±0.2 3.4±0.2 63.4±2.4 0.9±0.2 86.1±2.9 4.5±0.36 4.56E+04 1.60E-01 3.5±0.0 
2679 9.3 0.0 11.8±0.7 7.7±0.4 79.6±1.4 10.2±0.4 74.2±2 51.2±2.03 0.0±0.0 0.0±0.0 0.0±0.0 
2680 18.9 2.8 9.2±0.4 3.6±0.2 82.5±1.5 0.9±0.1 85.8±1.7 1.9±0.07 6.63E+04 9.80E-02 1.5±0.01 
2681 24.2 7.7 13.6±0.9 11±0.9 83.7±1.5 0.7±0.0 91.7±0.8 1.1±0.02 0.0±0.0 0.0±0.0 0.0±0.0 
2683 28.2 3.3 8.6±0.5 6.1±0.1 91.9±1.1 0.7±0.0 86.1±1.2 0.7±0.02 3.02E+04 3.11E-02 1.0±0.0 
2684 21.9 6.4 8.6±0.6 9.4±0.4 70.8±2.2 0.8±0.1 82.4±2.1 1.7±0.08 2.40E+05 3.36E-01 1.4±0.01 










































2691 14.7 0.0 6.7±0.5 2.4±0.2 72.2±2.2 0.4±0.0 96.3±2.3 0.4±0.03 0.0±0.0 0.0±0.0 0.0±0.0 
2714 14.7 0.0 16.3±0.6 6.2±0.3 55.4±0.9 6.1±0.2 59.9±2.7 31.3±2.51 4.92E+04 4.87E-02 0.9±0.0 
2715 24.4 8.5 5.2±0.3 3.0±0.1 81.3±1.3 0.7±0.0 86.2±1.6 1.2±0.04 2.03E+04 1.88E-02 0.9±0.0 
2716 16.0 2.9 6.4±0.4 2.3±0.2 79.3±2.4 1.3±0.1 80.4±2.3 2.2±0.11 0.0±0.0 0.0±0.0 0.0±0.0 
2717 21.4 4.9 8.6±0.5 2.6±0.1 73.9±4.2 0.4±0.1 69.4±2.8 1.1±0.1 0.0±0.0 0.0±0.0 0.0±0.0 
2718 22.2 7.5 5.8±0.2 3.9±0.2 84.5±1.3 0.7±0.0 90±1.4 2.2±0.08 4.09E+05 1.27E-02 0.03±0.0 
2719 26.0 18.6 6.2±0.3 4.8±0.1 116.5±2.7 0.5±0.0 99.5±1.2 0.4±0.01 4.60E+04 3.20E-02 0.69±3.0 
2726 22.5 14.2 8.4±0.2 6.5±0.2 101.9±1.4 0.8±0.0 78.3±0.9 0.5±0.01 1.08E+04 1.14E-02 1.05±0.0 
2747 22.0 4.0 7.1±0.4 2.3±0.0 82.0±1.1 0.8±0.0 63.4±6 2.3±0.4 0.0±0.0 0.0±0.0 0.0±0.0 
2748 11.7 1.6 14.6±0.5 4.1±0.2 90.9±2.2 8.4±0.5 102±4.6 6.9±0.6 0.0±0.0 0.0±0.0 0.0±0.0 
2749 8.2 0.0 19.5±0.5 30.8±1.1 120.6±1.2 13.9±0.3 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2775 21.2 9.7 8.3±0.6 5.6±0.1 93.5±2.4 0.6±0.0 83.9±1.1 0.7±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2776 19.7 10.9 7.2±0.4 6.5±0.2 94.2±1.9 1.1±0.1 82.9±2.3 0.5±0.0 2.16E+04 1.26E-02 0.6±0.0 
2777 23.9 14.4 5.6±0.3 4.9±0.0 105.4±1.6 0.5±0.0 69.7±2.2 0.4±0.0 7.34E+05 5.93E-03 0.008 
2778 25.1 11.3 5.7±0.3 4.5±0.1 97.6±2.2 0.5±0.0 76.1±3.9 0.5±0.1 0.0±0.0 0.0±0.0 0.0±0.0 
2779 21.0 8.1 6.0±0.3 5.1±0.2 102.2±4.7 0.6±0.1 80.6±2.7 0.8±0.1 7.57E+03 4.80E-03 0.635±2 
2814 14.5 0.6 11.6±0.3 13.8±0.3 97.8±2.5 3.1±0.3 83.2±1.4 39.9±1.2 2.78E+05 1.37E-01 0.5±0.0 










































2837 27.4 15.8 8.9±0.3 5.4±0.4 112.2±3.4 0.5±0.0 73.7±2.9 0.4±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2848 22.4 12.7 8.9±0.3 5.0±0.1 105.4±1.6 0.6±0.0 72.3±0.9 0.5±0.0 5.4E+05 8.21E-03 0.02±0.0 
2849 23.6 11.0 8.2±0.3 2.9±0.1 112±1.3 0.5±0.0 77.6±2.9 0.4±0.0 1.2E+06 2.76E-03 0.002±0.0 
2850 22.7 9.5 7.7±0.2 2.3±0.1 103.2±2.1 0.5±0.0 81.8±3.2 0.3±0.0 2.4E+04 5.03E-02 2.1±0.0 
2851 25.1 10.1 5.6±0.2 3.4±0.2 117.1±3.4 0.4±0.0 87.1±3 0.3±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2852 22.9 11.1 5.9±0.2 6.9±0.9 121.5±9.2 0.4±0.1 87.3±2.7 0.3±0.0 1.3E+05 1.43E-01 1.1±0.0 
2853 23.5 10.2 4.0±0.1 4.5±0.2 125.3±2.1 0.3±0.0 92.9±3.8 0.6±0.0 6.9E+04 9.31E-02 1.3±0.0 
2867 24.1 11.7 5.8±0.3 4.4±0.1 90.6±1.8 0.4±0.0 82.9±2.2 0.5±0.0 1.7E+06 1.81E-02 0.01±0.0 
2868 26.2 11.4 7.0±0.4 5.4±0.4 92.6±1.3 0.4±0.0 89.1±2.4 0.5±0.0 1.3E+04 2.54E-03 0.2±0.0 
2869 24.0 10.1 5.6±0.3 4.2±0.1 92.3±1.3 0.4±0.0 81.3±1.7 0.6±0.0 7.9E+05 5.99E-03 0.01±0.0 
2870 26.4 10.7 6.1±0.4 4.9±0.2 94.0±0.9 0.3±0.0 92.2±1.9 0.4±0.0 1.7E+04 5.87E-03 0.349±8 
2871 24.5 11.3 6.6±0.4 5.3±0.5 91.2±1.5 0.3±0.0 84.7±2 0.6±0.0 6.6E+05 7.77E-03 0.01±0.0 
2872 26.4 12.8 7.0±0.4 4.6±0.4 95.3±0.9 0.2±0.0 87.8±1.5 0.4±0.0 1.8E+04 2.31E-03 0.1±0.0 
2873 24.8 10.8 6.4±0.5 5.0±0.3 94.5±1.6 0.2±0.0 95.7±1.4 0.4±0.0 1.2E+06 4.67E-03 0.004±0.0 
2903 27.2 11.2 6.52±0.3 4.9±0.1 88.9±2.0 0.5±0.0 78.5±1.9 0.4±0.0 1.9E+05 4.27E-03 0.022±0.1 
2904 26.3 11.8 9.0±0.4 7.1±0.3 89.2±1.7 0.4±0.0 71.2±1.3 0.5±0.0 3.4E+04 4.47E-03 0.13±0.2 
2905 29.3 14.7 12.6±0.7 6.9±0.3 97.9±0.8 0.3±0.0 73.4±3.1 0.4±0.1 0.0±0.0 0.0±0.0 0.0±0.0 










































2907 29.3 14.7 7.1±0.2 5.8±0.1 94.9±2.3 0.3±0.0 90.5±0.6 0.5±0.0 1.28E+05 3.49E-03 0.027±0.1 
2910 19.9 6.5 6.6±0.2 5.9±0.3 98.5±2.0 0.4±0.0 88.1±1.5 1.5±0.1 7.20E+05 2.8E+00 3.9±0.2 
2911 22.7 7.4 6.8±0.3 6.9±0.2 109.4±1.5 0.3±0.0 90.2±2.3 0.8±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2912 22.6 13.0 6.6±0.2 5.5±0.1 84.9±1.4 0.5±0.0 91.2±2.5 0.6±0.0 3.39E+03 3.22E-03 0.95±3.0 
2913 17.9 6.6 4.6±0.2 4.2±0.2 89.8±2.1 0.3±0.0 91.6±1.3 1.1±0.0 1.80E+05 9.89E-02 0.5±0.0 
2914 25.1 16.4 4.9±0.2 1.6±0.1 106.7±2.0 0.3±0.0 103.1±1.2 0.4±0.0 4.11E+05 6.82E-03 0.02±0.0 
2920 20.3 3.8 7.2±0.3 5.3±0.2 81.8±2.0 0.8±0.1 94.2±2.2 2.4±0.1 2.17E+05 9.54E-03 0.044±0.3 
2921 27.9 11.0 7.1±0.2 5.7±0.2 84.4±0.5 0.4±0.0 76.1±1.1 0.7±0.0 4.72E+05 3.89E-03 0.01±0.0 
2922 20.6 9.8 8.1±0.3 6.0±0.3 81.6±1.3 0.6±0.0 86.4±1.2 0.8±0.0 2.52E+03 6.38E-03 2.53±0.02 
2926 11.1 2.9 12.7±0.2 6.7±0.2 64.4±1.5 2.3±0.2 70.4±1.9 4.1±0.2 0.0±0.0 0.0±0.0 0.0±0.0 
2927 18.2 10.6 7.7±0.2 5.4±0.1 82.5±1.5 0.9±0.1 82.4±1.2 0.6±0.0 7.62E+05 1.09E-01 0.14±0.0 
2928 11.9 5.4 9.7±0.3 6.2±0.2 72.1±1.2 2.5±0.1 74±0.9 1.1±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
2954 15.4 3.6 13.7±0.7 11.5±0.8 88.6±0.8 1.8±0.1 80.8±1.2 17.5±0.5 0.0±0.0 0.0±0.0 0.0±0.0 
2965 28.7 16.2 200.0±0.0 200.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 250.0±0.0 1.97E+06 2.38E-03 0.001±0.0 
2966 29.5 16.5 6.8±0.3 6.4±0.4 91.2±0.9 0.5±0.0 69.2±0.9 1.1±0.0 4.33E+04 2.63E-03 0.1±0.0 
2967 29.0 15.2 6.9±0.3 5.9±0.3 88.3±2.5 0.5±0.0 61.8±1.4 1.3±0.1 4.27E+04 4.33E-03 0.1±0.0 
2968 27.9 10.6 7.0±0.3 5.7±0.3 86.5±1.0 0.5±0.0 68.8±1.3 1.9±0.1 3.36E+05 3.61E-03 0.01±0.0 










































2995 25.3 6.8 5.7±0.34 7.6±0.3 74±0.9 0.7±0.0 91.3±1.6 1.3±0.1 0±0 0±0 0±0 
2996 27.0 8.7 4.8±0.3 3.8±0.2 84.4±0.7 0.3±0.0 81.2±2.8 0.5±0.0 4.26E+05 3.39E-03 0.01±0.0 
2999 26.6 10.8 4.9±0.4 4.1±0.2 82.8±1.3 0.4±0.0 72.8±1.6 0.4±0.0 4.66E+04 2.64E-03 0.06±0.0 
3000 24.3 11.5 4.3±0.2 3.5±0.2 83.8±0.7 0.3±0.0 78.7±1.7 0.4±0.0 1.38E+04 7.96E-03 0.579±8 
3001 0.1 0.0 6.2±0.3 4.7±0.2 72.0±2.4 0.4±0.0 63.6±3.6 1.0±0.1 0.0±0.0 0.0±0.0 0.0±0.0 
3012 26.7 6.6 7.4±0.3 6.5±0.2 71.6±0.7 0.6±0.0 82.7±2.3 1.2±0.1 6.61E+05 4.66E-03 0.01±0.02 
3015 19.2 3.6 7.2±0.3 7.1±0.4 78.2±1.0 0.7±0.1 80.3±1.9 3.4±0.2 6.46E+05 1.69E-02 0.026±0.3 
3023 24.8 8.0 7.0±0.3 6.1±0.3 0.0±0.0 200.0±0.0 82.7±1.8 1.2±0.1 4.38E+06 1.40E-02 0.003±0.0 
3025 14.5 1.1 6.6±0.2 6.1±0.3 0.0±0.0 200.0±0.0 75.7±2.6 12.5±0.9 7.29E+05 1.73E-01 0.24±0.0 
3089 23.9 9.5 5.9±0.3 3.3±0.3 84.1±0.9 0.3±0.0 92.7±2.5 1.5±0.1 7.23E+05 1.91E-02 0.03±0.0 
3090 29.5 19.7 7.1±0.3 2.3±0.2 95.3±2.0 0.2±0.0 95.4±1.7 0.3±0.0 8.93E+05 5.88E-03 0.01±0.0 
3091 28.8 15.2 9.6±0.6 2.4±0.2 82.7±1.9 0.2±0.0 75±3.3 0.3±6.2 4.19E+04 4.54E-03 0.108±2.0 
3092 22.5 6.6 11.1±0.4 3.8±0.3 70.9±1.6 0.8±0.0 83.1±2.1 1.3±0.1 3.11E+05 1.77E-02 0.06±0.0 
3093 27.0 11.2 6.5±0.3 2.8±0.2 64.8±1.9 0.2±0.0 62.7±1.4 0.3±0.0 2.17E+04 3.26E-03 0.15±0.7 
3094 3.4 0.2 7.7±0.5 7.2±0.4 84.9±1.1 0.5±0.0 0.0±0.0 0.0±0.0 1.33E+04 3.62E-03 0.272±1.0 
3111 25.0 13.8 3.3±0.2 250.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3112 8.5 4.2 7.9±0.4 5.5±0.3 81.5±2.2 0.4±0.0 60.4±1.8 0.4±0.3 0.0±0.0 0.0±0.0 0.0±0.0 










































3120 28.9 15.4 7.2±0.3 5.2±0.5 91.1±0.7 0.4±0.0 89.8±1.2 0.7±0.0 6.93E+05 3.14E-03 0.004±0.0 
3130 27.9 16.1 6.9±0.3 5.1±0.4 80.9±1.3 0.5±0.0 72.8±2 0.5±0.1 1.33E+05 5.28E-03 0.039±0.1 
3131 27.6 14.2 7.5±0.3 5.1±0.5 84.9±0.9 0.5±0.0 80.7±2 0.6±0.0 2.20E+05 4.78E-03 0.02±0.03 
3132 26.7 10.9 6.3±0.4 4.2±0.4 85.2±0.9 0.4±0.0 81.6±1.1 0.6±0.0 6.24E+05 4.38E-03 0.01±0.0 
3133 28.3 13.7 7.4±0.5 4.7±0.4 80.8±1.4 0.3±0.0 63.4±1.9 0.4±9.7 6.49E+04 2.15E-03 0.03±0.0 
3134 0.0 12.7 7.2±0.3 5.1±0.4 82.6±0.6 0.4±0.0 65.5±0.8 0.5±0.0 6.25E+04 3.55E-03 0.06±0.0 
3135 26.3 10.6 13.5±0.6 10.3±0.7 85.1±0.9 1.1±0.0 85.9±1.7 1.4±0.1 0.0±0.0 0.0±0.0 0.0±0.0 
3136 27.7 12.2 8.9±0.5 6.3±0.4 85.6±1.4 0.4±0.0 73.7±1.6 0.6±0.0 1.46E+05 3.31E-03 0.022±0.3 
3173 24.9 6.9 7.2±0.5 2.5±0.2 75.6±1.5 0.4±0.0 83.5±1.2 1.2±0.1 9.32E+05 6.61E-03 0.01±0.0 
3174 21.8 4.4 6.5±0.5 250.0±0.0 68.9±2.3 0.5±0.1 95.9±0.8 3±0.1 1.09E+06 4.07E-02 0.04±0.0 
3175 25.1 6.8 7.7±0.5 2.7±0.1 72.4±1.9 0.4±0.0 80.1±1.3 1.9±0.1 2.21E+06 9.26E-03 0.004±0.0 
3176 28.6 12.3 7.5±0.6 0.0±0.0 87.3±1.1 0.3±0.0 76.2±0.6 0.4±0.0 2.63E+06 2.94E-03 0.001±0.0 
3177 23.1 0.7 8.2±0.7 0.0±0.0 81.9±1.2 0.5±0.0 69.4±3 1.0±0.1 2.41E+04 3.70E-03 0.15±0.0 
3178 24.7 11.6 7.5±0.5 2.0±0.1 73.2±0.9 0.4±0.0 45.3±1.4 0.5±0.0 1.80E+04 9.67E-03 0.54±0.0 
3179 22.1 3.2 8.8±0.4 3.9±0.3 71.6±0.9 0.9±0.0 57.4±3.6 4.4±0.5 1.10E+04 1.01E-02 0.91±0.0 
3180 23.0 7.7 8.5±0.3 0.0±0.0 85.3±1.2 0.6±0.0 92.4±1 1.2±0.0 5.00E+05 6.04E-03 0.012±0.0 
3192 25.6 11.7 9.2±0.4 0.0±0.0 84.7±0.9 0.7±0.0 92.9±1.2 0.9±0.0 1.96E+05 2.56E-03 0.013±0.0 










































3194 24.6 9.8 4.3±0.2 2.4±0.1 77.5±1.3 0.4±0.0 100.1±1.4 0.7±0.0 6.13E+05 7.14E-03 0.011±0.0 
3195 19.4 0.2 7.5±0.3 4.3±0.2 88.7±1.5 0.5±0.0 69.6±0.6 12.8±0.2 1.33E+06 6.17E-02 0.05±0.5 
3196 27.8 12.6 3.2±0.2 2.1±0.1 0.0±0.0 200.0±0.0 0.0±0.0 0.0±0.0 7.29E+05 3.30E-03 0.004±0.0 
3197 28.4 16.6 4.1±0.3 2.2±0.1 0.0±0.0 200.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3319 13.5 0.2 11.1±0.5 11.5±0.5 93.1±2.8 1.5±0.2 69.2±1.3 17.4±0.6 3.21E+05 4.62E-02 0.14±0.0 
3320 3.7 0.0 36±1.4 107±3.8 73.1±5.1 16.8±3.5 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3321 8.5 0.0 11.7±0.3 44±1.1 79.3±1.9 4.2±0.4 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3322 16.5 0.6 5.5±0.2 6.4±0.3 103.8±3.1 0.7±0.1 80.9±2.7 7.9±0.7 2.24E+05 4.78E-02 0.213±0.9 
3329 26.0 13.3 6.6±0.3 2.1±0.2 79.8±1.8 0.4±0.0 55.2±2.4 0.2±0.0 1.47E+04 2.48E-03 0.17.0±0.7 
3330 23.9 5.9 6.4±0.4 2.9±0.1 77.9±1.7 0.4±0.0 84.3±1.5 0.8±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3331 29.2 15.8 7.3±0.4 2.4±0.2 87.1±1.6 0.4±0.0 75.5±3.6 0.2±0.0 8.75E+04 2.84E-03 0.03±0.0 
3343 11.3 0.0 11.7±0.4 11.4±0.3 80.2±1.3 2.8±0.2 77.9±4.3 29.5±3.3 0.0±0.0 0.0±0.0 0.0±0.0 
3348 25.5 12.4 4.4±0.4 3.1±0.2 79.9±1.3 0.3±0.0 49±1.7 0.4±0.0 5.21E+04 1.91E-02 0.366±0.7 
3349 26.0 14.5 2.9±0.2 2.4±0.1 70.9±2.2 0.2±0.0 47.5±2 0.3±0.2 2.50E+04 4.62E-03 0.185±0.7 
3350 15.4 13.2 2.6±0.2 1.9±0.1 83.8±2.1 0.3±0.0 51.2±3.2 0.4±0.1 8.26E+03 5.99E-03 0.726±3.0 
3351 23.6 11.6 3.5±0.1 2.9±0.1 67.0±1.1 0.3±0.0 44.5±2.6 0.5±18.9 1.16E+04 1.07E-03 0.092±1.0 
3352 20.5 8.9 5.4±0.2 3.6±0.2 77.9±3.3 1.1±0.2 69.9±1.5 1.1±0.1 0.0±0.0 0.0±0.0 0.0±0.0 










































3356 14.1 0.2 4.2±0.2 7.9±0.2 79.6±1.6 1.3±0.1 92.2±2.6 26.5±1.4 4.42E+04 1.51E-01 3.41±0.0 
3357 8.1 0.4 11.1±5.9 17.5±2.5 41.0±2.6 1.7±0.3 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3358 25.6 14.1 4.6±0.2 3.4±0.1 70.4±1.9 0.4±0.0 0.0±0.0 250.0±0.0 1.33E+04 1.02E-02 0.77±10 
3366 6.5 1.7 21.8±3.7 9.2±2.0 44.6±9.8 1.1±0.6 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3367 6.2 0.0 14±2.5 250.0±0.0 35.1±3.2 5.6±1.3 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3368 0.1 0.0 351±30 250.0±0.0 0.0±0.0 200.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3369 0.9 0.0 27.3±1.1 186±7.7 0.0±0.0 200.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3371 26.8 11.7 3.7±0.2 3.3±0.2 77.8±1.6 0.3±0.0 56.8±1 0.5±0.0 1.05E+06 8.15E-03 0.01±0.07 
3373 26.3 10.8 3.4±0.2 2.6±0.8 80.6±1.0 0.3±0.0 56.3±2.9 0.5±20.6 8.44E+05 5.75E-03 0.01±0.1 
3377 21.2 9.2 6.02±0.3 4.1±0.2 80.4±1.2 0.8±0.0 52.7±1.9 0.7±0.1 1.32E+04 2.88E-03 0.218 
3414 23.4 10.0 16.3±0.8 13.2±0.6 78.4±2.3 1.5±0.1 41.5±1.1 2.0±0.2 0.0±0.0 0.0±0.0 0.0±0.0 
3415 13.8 1.2 5.2±0.2 5.3±0.1 66.7±2.7 1.4±0.2 41.6±1.2 4.3±0.2 2.05E+03 1.50E-03 0.73±0.0 
3416 19.3 3.5 8.1±0.2 7.4±0.3 78.5±2.5 1.3±0.1 50.6±1.4 3.6±0.2 9.24E+05 6.85E-03 0.01±0.04 
3417 22.2 5.6 5.5±0.2 4.6±0.2 86.8±2.0 0.6±0.1 101.8±4 9.0±0.7 1.68E+06 1.71E-02 0.01±0.1 
3418 16.7 1.2 6.0±0.2 6.9±0.2 78.3±1.4 2.7±0.2 62.3±2 12.5±0.6 3.33E+05 6.98E-02 0.21±0.0 
3419 24.2 5.8 5.9±0.3 3.9±0.2 76.4±2.6 0.4±0.0 55.5±2.7 0.9±0.1 0.0±0.0 0.0±0.0 0.0±0.0 
3423 11.9 5.1 5.1±0.3 3.8±0.2 71.3±2.2 0.9±0.1 42.2±1 1.1±0.1 1.04E+05 1.74E-01 1.68±0.0 










































3425 20.5 7.9 5.3±0.3 4.4±0.2 71.0±1.4 0.4±0.0 51.9±1.2 0.6±0.0 1.24E+05 1.77E-02 0.14±0.0 
3426 11.0 0.5 6.1±0.3 7.0±0.3 70.2±1.8 2.5±0.2 40.7±2.5 6.6±0.8 1.50E+06 1.99E-01 0.13±0.0 
3427 13.1 0.9 5.1±0.2 3.9±0.1 59.8±1.3 0.9±0.1 46.4±1.6 3.8±0.3 0.0±0.0 0.0±0.0 0.0±0.0 
3428 13.9 10.6 4.4±0.2 3.5±0.1 64.1±1.4 0.5±0.0 35.4±1.1 0.5±32.4 0.0±0.0 0.0±0.0 0.0±0.0 
3429 10.6 5.5 7.4±0.9 2.8±0.1 43.8±1.4 1.3±0.1 34.8±0.6 1.4±0.1 0.0±0.0 0.0±0.0 0.0±0.0 
3430 22.8 13.9 4.5±0.3 3.4±0.1 69.9±1.5 0.4±0.0 47.4±1.7 0.4±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3431 10.1 0.3 7.8±0.3 7.5±0.2 54.8±1.0 4.3±0.2 39.8±1.2 18.9±1.2 0.0±0.0 0.0±0.0 0.0±0.0 
3432 12.7 9.3 4.4±0.2 3.5±0.1 58.6±1.8 1.3±0.1 41.1±0.9 0.9±20.3 1.94E+05 1.64E-01 0.84±0.0 
3433 8.2 2.6 6.6±0.7 3.9±0.1 43.5±1.6 3.7±0.3 27.9±1 3.8±0.3 0.0±0.0 0.0±0.0 0.0±0.0 
3434 19.4 8.9 4.3±0.3 3.5±0.1 62.9±0.9 0.5±0.0 51.1±1.6 0.5±0.0 2.76E+05 9.94E-01 0.003±0.0 
3449 8.3 0.0 7.8±0.3 18.6±0.9 0.0±0.0 200.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3450 0.0 0.0 271.0±27.9 261.0±8.0 0.0±0.0 200.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3451 20.3 5.7 4.5±0.2 3.7±0.1 73.8±2.9 0.4±0.1 76.7±3.1 1.3±0.1 1.22E+05 1.44E-02 0.12±1.0 
3452 16.8 4.6 4.2±0.2 3.5±0.1 74.1±2.4 0.7±0.1 72.8±1.5 1.3±0.1 2.33E+03 9.44E-04 0.41±0.0 
3453 2.1 0.0 37.3±1.8 2395.0±5.0 0.0±0.0 200.0±0.0 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3483 23.1 4.8 3.6±0.2 3.0±0.1 89.6±3.0 0.3±0.0 112.9±6.7 1.6±0.2 2.67E+05 8.91E-03 0.03±0.07 
3484 19.5 5.9 3.7±0.2 2.8±0.1 79.0±1.9 0.4±0.0 65.6±2.4 0.6±0.1 8.78E+04 1.84E-02 0.21±1.0 










































3486 25.3 9.5 3.4±0.2 2.6±0.1 84.2±2.2 0.2±0.0 86.4±3 0.4±0.0 1.56E+05 8.42E-03 0.05±0.2 
3487 23.4 3.9 3.9±0.2 3.6±0.1 86.8±1.4 0.4±0.0 106.3±2.5 1.7±0.1 2.12E+05 8.70E-03 0.04±0.1 
3488 25.1 7.3 3.2±0.2 2.4±0.1 84.9±2.3 0.2±0.0 96±3.7 0.8±0.1 2.38E+05 8.65E-03 0.04±0.07 
3489 19.5 6.4 1.9±0.1 1.5±0.1 69.9±3.9 0.3±0.1 67.5±2 0.7±0.1 6.62E+04 5.77E-02 0.87±3 
3490 22.5 8.6 3.2±0.2 2.3±0.1 78.9±2.4 0.2±0.0 67.2±3.3 0.3±0.0 8.82E+04 9.53E-03 0.11±0.9 
3495 25.1 9.2 30.6±2.4 1.8±0.1 81.8±1.4 0.2±0.0 73.3±1.2 0.3±0.0 1.67E+05 8.29E-03 0.05±0.9 
3500 25.9 8.4 2.9±0.2 1.9±0.1 85.8±1.9 0.2±0.0 88.8±1.7 0.3±0.0 2.15E+05 8.73E-03 0.04±0.1 
3501 25.9 10.5 2.3±0.2 1.7±0.2 90.4±3.1 0.3±0.0 57.8±1.4 0.2±0.0 1.63E+05 9.73E-03 0.06±0.1 
3509 8.4 13.2 11.9±2.4 10.1±1.5 44.5±3.4 1.3±0.3 0.0±0.0 250.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
3510 25.8 6.9 3.1±0.3 1.7±0.1 88.2±2.4 0.1±0.0 84.8±1.6 0.3±0.0 2.15E+05 3.78E-03 0.02±0.04 
3512 24.5 13.2 4.8±0.3 4.0±0.2 85.5±1.7 0.4±0.0 52.6±2.1 0.4±0.0 0.0±0.0 0.0±0.0 0.0±0.0 








Figure D-1. Reproducibility of TSA during Fragment Screening. 
A: Excellent reproducibility of ClpP positive and negative controls on day to day/ plate to 
plate basis. 
B: Excellent reproducibility of positive and negative controls on HPPK protein screened 
under two different conditions on day to day/ plate to plate basis. 
C: Excellent reproducibility of positive and negative controls on Sa-DHPS protein 
screened under two different conditions on day to day/ plate to plate basis. 
D: Excellent reproducibility of positive and negative controls on Ba-DHPS protein 
screened under two different conditions on day to day/ plate to plate basis. 
E: Performance of positive and negative controls on ClpP protein during screening of 
FDA collection. 









Figure D-2. Reproducibility of ClpP FP Assay During Fragment Screening (Set 1). 
A-F: Excellent reproducibility of positive control 2378 and wide dynamic range of ClpP 
FP assay indicated by high signal window between maximum signal and baseline during 








Figure D-3. Reproducibility of FP Assay across Screening Collections (Set 2). 
A-D: Excellent reproducibility (Z` >0.8) of positive control 2378 mediated complete 
displacement of previously bound probe 6 (2591) during screening of 3 point 
pharmacophore, bioactives, FDA, and lead like compound collections. 
E-F: High signal window between maximum signal and baseline suggested wide 








Figure D-4. Comparison of Dose Response of Novel ClpP Hit and Positive Control 
(2378). 
A: Novel small molecule hit (SJ000773156-4 or ICG001) exhibited positive shift in melt 
curve. 






Table D-4. Characterization of Primary Screening Hits on Multiple Orthogonal Assays. 
 


















SJ000285395-1 124.2 0.4 2.8 0.0±0.0 351.9±58.8 23±0 0.8 3.1 Pass Bioactive FP 
SJ000287348-1 146.2 1.0 0.0 28.9±0.03 45.6±1.04 37±0 0.6 3.5 Pass Bioactive FP 
SJ000804941-1 161.2 1.5 3.2 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Malaria SPR 
SJ000572754-1 164.2 1.7 0.0 1800±0.02 0.0±0.0 0±0 0.3 1.1 Pass Fragment SPR 
SJ000804355-1 165.2 1.1 1.1 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment TSA 
SJ000288069-2 168.2 1.0 0.0 0.0±0.0 267.8±19.9 22±0 0.4 2.6 Pass Bioactive FP 
SJ000822378-1 182.6 0.9 1.5 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment TSA 
SJ000288205-2 184.2 1.8 0.0 0.0±0.0 44.4±9.9 0±0 0.4 2.6 Pass Bioactive FP 
SJ000805483-1 184.2 2.6 0.0 1171±0.0 0.0±0.0 0±0 0.3 0.4 Pass Fragment SPR 
SJ000805354-1 185.2 0.5 0.0 0.0±0.0 762.1±82.5 0±0 0.4 2.6 Pass Fragment TSA 
SJ000804677-1 192.0 1.6 1.1 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment SPR 
SJ000822221-1 194.2 2.6 0.0 8.9±0.02 0.0±0.0 0±0 0.5 2.5 Pass Fragment SPR 
SJ000804721-1 195.1 0.6 24.8 0.0±0.0 523.7±217.4 0±0 0.3 2.7 Pass Fragment SPR 
SJ000805616-1 197.7 1.3 3.6 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment SPR 
SJ000572946-1 198.7 2.8 0.0 74.2±0.1 0.0±0.0 0±0 0.5 1.4 Pass Fragment SPR 
SJ000804225-1 199.3 1.6 5.5 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment TSA 
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SJ000804573-1 203.2 1.3 5.8 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment SPR 
SJ000287018-1 204.6 0.1 0.0 0.0±0.0 206.3±23.7 0±0 0.4 3.6 Pass Bioactive FP 
SJ000572737-1 206.3 2.5 0.0 1422.0±0.0 0.0±0.0 0±0 0.3 0.3 Pass Fragment SPR 
SJ000572441-1 206.3 1.3 0.0 388.0±1.0 951.7±101.9 0±0 0.3 2.1 Pass Fragment FP 
SJ000804779-1 207.7 1.8 1.8 823.0±1.0 0.0±0.0 0±0 0.3 1.3 Pass Fragment TSA 
SJ000572241-1 208.1 0.4 0.0 0.0±0.0 0.0±0.0 21±0 0.0 0.0 Pass Fragment FP 
SJ000822369-1 209.6 1.0 0.0 161.1±0.06 0.0±0.0 0±0 0.4 2.8 Pass Fragment FP 
SJ000822310-1 212.3 2.9 0.0 555.6±0.3 0.0±0.0 0±0 0.3 0.4 Pass Fragment SPR 
SJ000804271-1 214.3 2.1 0.0 751.1±0.5 0.0±0.0 0±0 0.3 1.1 Pass Fragment FP 
SJ000029652-2 223.3 2.1 0.0 498.5±0.4 0.0±0.0 0±0 0.3 1.2 Pass Fragment FP 
SJ000286396-1 224.3 3.0 0.0 13.6±0.04 0.0±0.0 22±0 0.4 1.9 Pass Bioactive FP 
SJ000848387-1 226.6 2.7 2.3 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment SPR 
SJ000822218-1 230.3 2.3 0.0 1762.0±0.0 0.0±0.0 0±0 0.2 0.5 Pass Fragment SPR 
SJ000572350-1 231.2 2.3 1.9 301.2±0.2 0.0±0.0 0±0 0.3 1.3 Pass Fragment TSA 
SJ000848459-1 231.2 1.9 0.0 329.0±0.1 0.0±0.0 0±0 0.3 1.6 Pass Fragment FP 
SJ000572935-1 231.3 1.8 1.2 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment TSA 
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SJ000572961-1 234.3 3.4 0.0 232.2±0.1 0.0±0.0 0±0 0.3 0.3 Pass Fragment SPR 
SJ000848575-1 236.2 2.5 0.0 355.1±0.4 0.0±0.0 0±0 0.3 1.0 Pass Fragment SPR 
SJ000822075-1 236.3 2.8 0.0 0.0±0.0 0.0±0.0 23±0 0.0 0.0 Pass Fragment SPR 
SJ000848525-1 240.2 3.0 0.0 363.0±0.2 0.0±0.0 0±0 0.3 0.4 Pass Fragment FP 
SJ000246486-2 242.3 3.0 0.0 2434.0±0.0 0.0±0.0 0±0 0.2 -0.3 Pass Fragment FP 
SJ000053618-2 244.3 2.0 6.6 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment SPR 
SJ000544295-2 245.7 2.7 2.7 0.0±0.0 756.6±101.0 0±0 0.3 0.5 Pass Fragment FP 
SJ000285653-3 246.8 0.3 1.4 0.0±0.0 430.4±66.3 0±0 0.3 3.1 Pass Bioactive FP 
SJ000285450-3 247.0 2.7 0.0 794.9±0.6 0.0±0.0 0±0 0.3 0.5 Pass Fragment SPR 
SJ000248843-2 250.3 2.9 0.0 515.2±0.3 0.0±0.0 0±0 0.3 0.4 Pass Fragment FP 
SJ000241593-1 251.3 1.9 0.0 129.1±0.04 0.0±0.0 0±0 0.3 2.0 Pass Lead Like FP 
SJ000821916-1 252.3 2.9 0.0 293.2±0.08 0.0±0.0 0±0 0.3 0.7 Pass Fragment SPR 
SJ000804902-1 255.1 2.8 1.5 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment TSA 
SJ000848557-1 255.2 2.8 2.4 266.1±0.7 779.2±125.3 0±0 0.3 0.8 Pass Fragment FP 
SJ000848533-1 256.2 2.2 1.3 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Fragment SPR 
SJ000848583-1 258.2 2.9 0.0 1796.0±0.0 0.0±0.0 0±0 0.2 0.0 Pass Fragment FP 
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SJ000572446-1 260.7 2.6 0.0 127.9±0.05 0.0±0.0 0±0 0.3 1.3 Pass Fragment SPR 
SJ000483069-2 264.3 2.2 0.0 58.1±0.03 0.0±0.0 0±0 0.3 2.1 Pass Fragment SPR 
SJ000241618-1 265.4 2.2 0.0 403.5±0.2 0.0±0.0 0±0 0.3 1.2 Pass Lead Like FP 
SJ000094801-1 266.7 3.1 0.0 81.2±0.03 0.0±0.0 0±0 0.3 1.0 Pass Lead Like FP 
SJ000572741-2 267.3 2.9 18.0 722.0±0.3 0.0±0.0 0±0 0.2 0.3 Pass Lead Like FP 
SJ000319812-2 268.3 2.4 0.0 790.2±0.5 0.0±0.0 0±0 0.2 0.8 Pass Fragment SPR 
SJ000007458-1 270.3 2.7 0.0 463.5±0.2 0.0±0.0 0±0 0.2 0.7 Pass Lead Like FP 
SJ000259333-1 272.3 1.3 0.0 105.7±0.1 0.0±0.0 0±0 0.3 2.7 Pass Lead Like FP 
SJ000236697-1 273.2 2.4 0.0 0.0±0.0 0.0±0.0 70±0 0.0 0.0 Pass Lead Like FP 
SJ000572940-1 273.7 1.9 0.0 466.9±0.5 0.0±0.0 0±0 0.2 1.5 Pass Fragment FP 
SJ000220528-1 275.1 2.6 0.0 0.0±0.0 14.7±0.8 0±0 0.4 2.3 Pass Lead Like FP 
SJ000280899-2 275.8 3.0 0.0 32.4±0.1 0.0±0.0 0±0 0.4 1.5 Pass Fragment SPR 
SJ000331085-1 276.3 2.6 0.0 681.8±0.9 0.0±0.0 0±0 0.2 0.6 Pass Lead Like FP 
SJ000572306-1 277.3 2.7 0.0 104.2±0.1 0.0±0.0 0±0 0.3 1.3 Pass Fragment FP 
SJ000822065-1 280.3 1.9 0.0 132.3±0.1 0.0±0.0 0±0 0.3 1.9 Pass Fragment SPR 
SJ000572555-1 280.3 2.8 0.0 1231.0±0.0 0.0±0.0 0±0 0.2 0.2 Pass Fragment FP 
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SJ000522764-1 280.8 1.7 0.0 0.0±0.0 23.23±3.2 0±0 0.4 3.0 Pass Malaria FP 
SJ000319683-2 282.3 2.7 0.0 1040.0±0.0 0.0±0.0 0±0 0.2 0.3 Pass Fragment SPR 
SJ000021818-2 282.3 4.1 0.0 231.9±0.1 0.0±0.0 0±0 0.2 -0.4 Pass Bioactive FP 
SJ000246339-1 285.3 3.4 0.0 0.0±0.0 0.0±0.0 73.4 0.0 0.0 Pass Lead Like FP 
SJ000312209-2 288.3 2.4 16.2 0.0±0.0 51.34±2.1 24±0 0.3 1.9 Pass Bioactive FP 
SJ000088386-1 288.3 3.0 0.0 351.6±0.3 0.0±0.0 0±0 0.2 0.4 Pass Lead Like FP 
SJ000048554-2 288.3 2.4 0.0 291.2±0.2 235.6±14.3 0±0 0.2 1.2 Pass Lead Like FP 
SJ000236721-1 289.7 2.9 0.0 0.0±0.0 0.0±0.0 70±0 0.0 0.0 Pass Lead Like FP 
SJ000008919-2 289.7 2.5 0.0 507.1±0.3 0.0±0.0 0±0 0.2 0.8 Pass Lead Like FP 
SJ000246332-1 290.3 2.9 0.0 0.0±0.0 0.0±0.0 20±0 0.0 0.0 Pass Lead Like FP 
SJ000270672-2 294.3 2.8 0.0 1456.0±0.0 0.0±0.0 0±0 0.2 0.1 Pass Fragment FP 
SJ000572180-1 294.4 3.2 6.5 100.9±0.1 603.3±69.1 0±0 0.2 0.9 Pass Fragment FP 
SJ000245340-2 294.8 2.9 0.0 65.1±0.07 0.0±0.0 23±0 0.3 1.4 Pass Fragment FP 
SJ000805236-1 295.2 3.2 0.0 413.7±0.2 0.0±0.0 25±0 0.2 0.2 Pass Fragment FP 
SJ000179499-1 295.3 1.3 0.0 602±0.9 0.0±0.0 0±0 0.2 1.9 Pass Lead Like FP 
SJ000572729-1 296.3 2.3 0.0 0.0±0.0 0.0±0.0 39±0 0.0 0.0 Pass Fragment FP 
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SJ000288277-2 297.3 1.8 2.7 0.0±0.0 53.8±2.2 0±0 0.3 2.5 Pass Bioactive FP 
SJ000270677-2 298.3 2.5 0.0 666.1±0.4 0.0±0.0 0±0 0.2 0.7 Pass Fragment FP 
SJ000364590-1 298.7 6.3 2.8 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Fail Fragment TSA 
SJ000287450-3 298.9 3.7 7.2 1041.0±0.0 161.8±7.8 0±0 0.4 2.3 Pass Bioactive FP 
SJ000287450-1 298.9 3.7 4.9 0.0±0.0 284.1±26.7 0±0 0.2 -0.1 Pass Bioactive FP 
SJ000285346-5 301.9 3.7 1.6 0.0±0.0 378.4±102.8 0±0 0.2 -0.2 Pass Bioactive FP 
SJ000565173-6 310.8 4.1 3.4 0.0±0.0 530.9±62.0 0±0 0.2 -0.7 Pass FDA TSA 
SJ000285960-5 310.9 4.4 1.4 0.0±0.0 422.1±51.4 0±0 0.2 -0.9 Pass Bioactive FP 
SJ000285960-1 310.9 4.4 3.9 0.0±0.0 285.0±26.5 0±0 0.2 -0.8 Pass Bioactive FP 
SJ000285960-3 310.9 4.4 1.7 32.6±0.1 383.9±65.9 0±0 0.3 0.1 Pass Bioactive FP 
SJ000285642-1 312.9 3.7 3.3 0.0±0.0 273.3±18.2 0±0 0.2 -0.1 Pass Bioactive FP 
SJ000285642-5 312.9 3.7 2.4 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Bioactive FP 
SJ000285642-2 312.9 3.7 3.9 14.8±0.02 438.8±51.4 0±0 0.3 1.1 Pass Bioactive FP 
SJ000285800-5 312.9 4.4 1.1 245.4±0.1 0.0±0.0 0±0 0.2 -0.7 Pass Bioactive FP 
SJ000285642-10 312.9 3.7 4.4 0.0±0.0 409.7±26.4 0±0 0.2 -0.3 Pass FDA TSA 
SJ000572353-1 317.3 3.3 0.0 142.8±0.1 0.0±0.0 0±0 0.3 0.6 Pass Fragment SPR 
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SJ000285707-1 318.9 4.6 1.2 0.0±0.0 374.5±70.3 0±0 0.2 -1.1 Pass Bioactive FP 
SJ000285644-1 319.0 4.3 2.5 36.8±0.05 0.0±0.0 0±0 0.3 0.2 Pass Bioactive FP 
SJ000286204-5 319.9 3.9 1.9 187.2±0.1 0.0±0.0 0±0 0.3 -0.1 Pass Bioactive FP 
SJ000287180-9 322.8 4.6 7.6 4.5±0.01 0.0±0.0 0±0 0.3 0.7 Pass Bioactive FP 
SJ000287180-1 322.9 4.6 0.0 0.0±0.0 178.3±11.9 0±0 0.2 -0.8 Pass Bioactive TSA 
SJ000287180-3 322.9 4.6 10.5 0.0±0.0 76.54±3.3 0±0 0.3 -0.4 Pass Bioactive FP 
SJ000287180-10 322.9 4.6 4.6 0.0±0.0 107.8±6.4 0±0 0.2 -0.6 Pass FDA TSA 
SJ000014680-1 326.4 3.0 0.0 45.6±0.1 0.0±0.0 0±0 0.3 1.4 Pass Fragment TSA 
SJ000287970-2 327.7 3.9 1.4 67.6±0.1 330.2±47.5 0±0 0.3 0.3 Pass Bioactive FP 
SJ000288324-1 341.8 4.1 5.2 23.4±0.04 202.5±27.1 0±0 0.3 0.6 Pass Bioactive FP 
SJ000285765-1 348.0 4.8 4.2 131.9±0.1 223.9±17.9 0±0 0.2 -0.8 Fail Bioactive FP 
SJ000288210-2 351.8 3.0 0.0 0.0±0.0 0.0±0.0 24±0 0.0 0.0 Pass Bioactive FP 
SJ000581136-1 352.4 2.9 0.0 0.0±0.0 0.0±0.0 24±0 0.0 0.0 Pass Bioactive FP 
SJ000285707-5 354.4 4.6 2.6 0.0±0.0 376.6±46.2 0±0 0.2 -1.1 Pass Bioactive FP 
SJ000285707-14 354.4 4.6 1.9 4.4±0.1 373.5±25.5 0±0 0.3 0.7 Pass FDA TSA 
SJ000286240-2 355.4 2.9 0.0 1120.0±0.0 0.0±0.0 0±0 0.2 0.1 Pass Bioactive FP 
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SJ000285479-4 382.9 5.0 4.1 0.0±0.0 355.4±90.3 0±0 0.2 -1.5 Pass Bioactive FP 
SJ000285479-1 382.9 5.0 3.8 96.1±0.1 189.0±37.1 0±0 0.2 -0.9 Pass Bioactive FP 
SJ000285479-9 382.9 5.0 4.1 0.0±0.0 135.2±17.3 0±0 0.2 -1.1 Pass FDA TSA 
SJ000287170-3 387.9 4.9 0.0 64.0±0.1 561.6±125.6 0±0 0.2 -0.6 Fail Bioactive FP 
SJ000561952-1 392.8 3.6 0.0 0.0±0.0 319.9±28.4 57±0 0.2 0.0 Pass Bioactive FP 
SJ000286016-3 404.0 4.2 1.9 13.8±0.03 421.2±62.9 0±0 0.2 0.7 Pass Bioactive FP 
SJ000286016-1 404.0 4.2 2.9 0.0±0.0 222.7±19.8 0±0 0.2 -0.5 Pass Bioactive FP 
SJ000285610-5 406.0 5.6 4.8 0.9±0.01 297.6±52.5 0±0 0.3 0.5 Fail Bioactive FP 
SJ000285610-1 406.0 5.6 4.0 0.0±0.0 279.5±36.4 0±0 0.2 -1.9 Fail Bioactive FP 
SJ000285610-3 406.0 5.6 2.0 0.0±0.0 371.2±38.0 0±0 0.2 -2.0 Fail Bioactive FP 
SJ000285610-11 406.1 5.6 2.0 0.0±0.0 304.6±39.1 0±0 0.2 -2.0 Fail FDA TSA 
SJ000285383-1 407.5 4.8 11.9 0.0±0.0 74.7±6.5 0±0 0.3 -0.6 Pass Bioactive FP 
SJ000285383-3 407.5 4.8 1.6 21.8±0.02 332.7±55.6 0±0 0.3 -0.1 Pass Bioactive FP 
SJ000285383-2 407.5 4.8 1.1 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass Bioactive FP 
SJ000285955-1 408.5 4.1 2.8 173.4±0.03 305.2±14.9 0±0 0.2 -0.3 Pass Bioactive FP 
SJ000285955-2 408.5 4.1 2.6 0.0±0.0 344.9±50.9 0±0 0.2 -0.6 Pass Bioactive FP 
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SJ000783705-7 434.5 4.2 0.0 21.7±0.04 0.0±0.0 0±0 0.2 0.5 Fail Bioactive FP 
SJ000573075-1 438.5 2.8 0.0 3.8±0.01 0.0±0.0 0±0 0.2 2.7 Pass Bioactive FP 
SJ000285488-2 446.5 4.3 4.0 4.1±0.01 574.1±149.7 0±0 0.4 1.2 Pass Bioactive FP 
SJ000784210-1 451.5 3.5 0.0 164.9±0.1 0.0±0.0 0±0 0.2 0.3 Pass Malaria FP 
SJ000571310-1 460.5 4.3 0.0 396.5±0.2 0.0±0.0 0±0 0.1 -0.8 Pass Malaria FP 
SJ000312350-1 464.8 4.2 0.0 0.0±0.0 98.4±31.2 0±0 0.2 -0.1 Pass Bioactive FP 
SJ000573048-2 466.8 4.3 1.1 0.0±0.0 324.0±239.2 0±0 0.2 -0.7 Pass Bioactive FP 
SJ000286006-6 467.0 3.4 14.5 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass FDA TSA 
SJ000567502-1 476.9 4.8 0.0 0.0±0.0 470.0±113 0±0 0.1 -1.4 Pass Malaria FP 
SJ000286185-5 478.4 5.0 4.7 0.0±0.0 220.4±25.7 0±0 0.2 -1.2 Pass Bioactive FP 
SJ000286185-8 478.4 5.0 0.0 0.0±0.0 0.0±0.0 22±0 0.0 0.0 Pass FDA FP 
SJ000286185-2 478.4 5.0 2.9 2.6±0.01 428.7±75.4 0±0 0.3 0.7 Pass Bioactive FP 
SJ000286185-13 478.5 5.0 3.9 0.0±0.0 311.4±26.3 0±0 0.2 -1.4 Pass FDA TSA 
SJ000784292-7 482.8 4.3 0.0 0.0±0.0 44.4±7.9 0±0 0.2 0.1 Pass FDA FP 
SJ000557732-2 484.9 4.5 0.0 1308.0±0.0 353.3±128.6 0±0 0.1 -1.5 Pass Malaria FP 
SJ000287362-1 507.6 0.6 1.8 0.0±0.0 354.2±43.7 0±0 0.1 2.9 Fail Bioactive FP 
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SJ000286134-1 508.5 4.4 2.2 51.3±0.1 157.4±11.7 0±0 0.2 -0.1 Pass Bioactive FP 
SJ000784314-5 515.6 3.1 0.0 197.6±0.7 0.0±0.0 0±0 0.1 0.6 Fail Bioactive FP 
SJ000855472-1 517.5 5.1 0.0 240.3±0.5 0.0±0.0 0±0 0.1 -1.4 Fail Bioactive FP 
SJ000518953-3 518.6 3.7 1.1 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Pass FDA TSA 
SJ000285820-6 521.0 3.9 3.9 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Fail FDA TSA 
SJ000287925-4 532.9 1.2 0.0 0.0±0.0 44.5±2.1 42±0.0 0.2 3.2 Pass FDA FP 
SJ000287503-1 538.6 5.2 7.5 36.4±0.02 187.5±9.1 0±0 0.2 -0.6 Fail Bioactive FP 
SJ000773156-4 548.6 4.4 7.6 16.7±0.01 0.0±0.0 9.7±0 0.2 0.4 Fail Bioactive FP 
SJ000285549-1 562.1 4.7 4.8 0.0±0.0 167.7±9.9 0±0 0.2 -0.9 Pass Bioactive FP 
SJ000855366-2 563.6 3.4 19.1 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Fail FDA TSA 
SJ000000857-6 579.0 0.2 0.0 0.0±0.0 9.1±1.4 40±0 0.2 4.9 Fail Bioactive FP 
SJ000287448-3 591.7 5.3 19.1 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Fail FDA TSA 
SJ000285549-5 602.1 4.7 4.7 0.0±0.0 209.9±17.3 0±0 0.2 -1.0 Pass Bioactive FP 
SJ000285549-11 602.1 4.7 5.5 2.4±0.04 205.8±13.6 0±0 0.3 0.9 Pass FDA TSA 
SJ000573222-1 606.0 3.1 0.0 6.3±0.01 140.8±11.7 0±0 0.2 2.1 Fail Bioactive FP 
SJ000286069-6 610.7 6.3 14.1 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Fail FDA TSA 
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SJ000285441-1 622.5 -3.4 14.0 0.0±0.0 8.9±1.1 0±0 0.2 8.4 Fail Bioactive FP 
SJ000855147-1 627.6 1.5 0.0 274.0±1.0 0.0±0.0 0±0 0.1 2.1 Fail Bioactive FP 
SJ000803698-2 638.8 5.5 0.0 152.6±0.8 0.0±0.0 0±0 0.1 -1.6 Fail Bioactive FP 
SJ000784317-3 679.8 1.6 10.1 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Fail FDA TSA 
SJ000285323-2 752.7 4.0 14.0 0.0±0.0 16.1±1.4 0±0 0.2 0.8 Fail Bioactive FP 
SJ000285323-1 752.7 4.0 14.0 0.0±0.0 25.6±3.0 0±0 0.2 0.6 Fail Bioactive FP 
SJ000285323-3 752.7 4.0 14.0 0.0±0.0 21.2±1.3 0±0 0.2 0.7 Fail Bioactive FP 
SJ000287711-2 840.1 0.2 0.0 683±2.0 198.7±60.9 0±0 0.1 3.0 Fail Bioactive FP 
SJ000829693-4 1211.4 -3.1 2.9 24.3±0.1 0.0±0.0 0±0 0.1 7.8 Fail FDA TSA 
SJ000287301-4 1251.5 -6.7 0.9 0.0±0.0 0.0±0.0 0±0 0.0 0.0 Fail FDA TSA 








Figure D-5 Characterization of Screening Hits (Set 2) on ClpP FP Assay. 
A: Complete displacement (normalized) of previously bound probe 6 by positive controls 
(2378, 1999) for set 2 of lower affinity screening hits. 
B-D: Displacement of previously bound probe 6 by screening hits with estimated 








Figure D-6. Distribution of Sensograms Shapes from Primary Screening Hits. 
A: Analysis of analyte responses in terms of their sensogram shapes to determine validity 
of their ClpP binding interaction responses. 








Figure D-7. Molecular Characteristics of Validated Primary Screening Hits. 
A-F: Comparison of ligand efficiency parameters LiPE, LE, hydrophobicity parameter 
cLogP, and polar surface area against molecular weight of validated hits sorted on basis 
of collection source and pass/fail to Lipinski’s’ rule of five guidelines to gauge molecular 
characteristics of validated hits. 
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